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Abstract
Chapter One gives an introduction to the biological importance of HDACs and in
particular of HDAC8. It discusses the structural features of the HDAC proteins,
the different structural classes of inhibitors that have been reported and the isoform
selectivity profiles of different inhibitors. The evaluation of a fluorogenic N -Boc-
protected acetyl-lysine substrate in comparison to a commercially available acetyl-
lysine containing tetrapeptide is also discussed and its suitability for inhibition assays
is demonstrated.
The synthesis and evaluation of eight 1st generation α-amino amide HDAC8 in-
hibitors is described in Chapter Two. These inhibitiors were inspired by a literature
compound utilizing a novel zinc-binding α-amino amide group. The deversity in
the inhibitors was envisaged to explore the chemical space around this novel zinc-
binding group into two of the major structural features of HDAC8, the substrate
tunnel and the acetate release pocket.
Nineteen 2nd generation α-amino amide HDAC8 inhibitors were designed as a result
of the HDAC8 inhibition assays of the 1st generation compounds. Chapter Three
discusses the design, synthesis and biological activity of these compounds. The
results of HDAC8 inhibition assays are rationalised using manual docking of the
inhibitors into an HDAC8 crystal structure. Through calculation of binding energies
investigation is carried out into the contribution of each feature of the compound to
the overall potency of the molecule. A potential beneficial HDAC8-inhibitor contact
is revealed, though no 2nd generation inhibitors show potencies that are similar to
that of the lead compound.
Following the hypothesised interactions observed in manual docking of the most
potent inhibitors from the 2nd generation of compounds, a 3rd and final round of
α-amino amide inhibitors was designed and synthesised. These compounds extend
the isoindoline scaffold of the lead compound in an attempt to form extra con-
tacts with a specific and conserved asartate residue in a flexible loop at the mouth
of substrate tunnel of the enzyme. In Chapter Four, two routes to obtain a sub-
stituted isoindoline ring system are evaluated and the synthesis of six substituted
isoindolines is described, these isoindolines were coupled to generate α-amino amide
HDAC8 inhibitors which were of comparable potency to the lead compound. Two
of these novel compounds show improved potency compared to the lead compound,
demonstrating the importance of the key hydrogen bonding interaction and validat-
ing the hypothesis that introduction of a hydrogen bond acceptor results in improved
potency. An exploratory nuclear magnetic resonance spectroscopy inhibitor bind-
5
ing experiment is also described which demonstrates the potential for investigations
using this technique in the future.
Chapter Five describes all the experimental procedures which were followed in the
biological evaluation of inhibitors and synthesis of inhibitors including physical and
spectroscopic characterisation of all the synthesised compounds and intermediates.
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1 Introduction
1.1 Histone Deacetylases
1.1.1 Acetylation as a post translational modification
Once considered a post translational modification (PTM) unique to histones, ly-
sine acetylation is now accepted as a common and proteome wide PTM and may
rival phosphorylation in its importance in the cell1. A high throughput mass spec-
trometry based study has concluded that there are at least 3600 lysine acetylation
sites on 1700 individual proteins in the human proteome2. The covalent addition
of a negatively charged acetate group (CH3COO
−) to a positively charged lysine
sidechain neutralises it (Figure 1.1). This results in a loss of charge-dependent in-
teractions and can act as a switch-like mechanism. This is particularly well demon-
strated in the case of lysine-rich histone tail acetylation; in their unmodified form
histone tails carry many positively charged lysine sidechains that wrap around the
negatively charged phosphate backbone of DNA and this results in compacted, tran-
scriptionally silent and repressed chromatin. Upon acetylation the positive charges
are neutralised, the DNA is released by the histone tails and the chromatin becomes
relaxed. More importantly (and now considered the major function of acetyl lysine
modifications) acetyl lysine sidechains are specifically bound by proteins containing
bromodomains such as histone acetyl transferases (HATs)3 and the BET family of
proteins4 which provide binding platforms for other proteins that modify chromatin
structure or facilitate transcription5.
When functioning as a switch-like modification, acetylation exists in a state of
17
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Figure 1.1: Acetylation and deacetylation of sidechains.
equilibrium, under constant turnover by histone acetyl-transferase (HAT) and his-
tone deacetylase (HDAC) enzymes. Pulse-chase experiments have measured histone
turnover rates with two categories of halflives, 1-5 minutes and 30-60 minutes6. The
equilibrium between the specific HAT and HDAC activities at a site determines the
acetylation state as sensed by a cell, which results in a functional response. Due to
the relatively fast turnover rate and wide distribution of acetylation modifications
among critical functional processes, the disruption of acetylation and/or deacetyla-
tion activity (either by dysregulation, dysfunction or inhibition of HATs or HDACs)
can have severe impacts on the fate of a cell.
1.1.2 HDAC Classification
The classical HDAC enzyme family comprises 11 enzymes divided into three phy-
logenetic classes (Figure 1.2b). Class I HDACs (HDAC1, HDAC2, HDAC3 and
HDAC8) share homology with the yeast protein RPD37; these proteins contain a
single structured catalytic domain with a short C-terminal tail with the exception
of HDAC8 which has a substantially shorter C-terminal tail than the other enzymes
in this class (Figure 1.2a). This C-terminal tail is believed to be a regulatory do-
main and determines the specificity of the HDAC in question, indeed, replacing
the HDAC1 tail with an HDAC2 sequence confers HDAC2 activity to the HDAC1
catalytic domain. HDAC1 and HDAC2 are very closely related (85% amino acid
identity8) and are often found together in multiprotein complexes including: Sin3,
nucleosome remodeling deacetylase (NuRD)9 and corepressor for element-1-silencing
transcription factor (CoREST)10. Similarly HDAC3 participates in the formation of
many complexes including the silencing mediator for retinoid and thyroid receptors
(SMRT) / nuclear receptor corepressor (N-CoR) complex11 (Table 1.1). HDAC8 is
18
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unique amongst class I HDACs in that it is catalytically active in a monomeric form,
requiring no scaffold proteins or complexes to participate in deacetylation reactions
other than its acetylated substrate.
Class II HDACs consist of HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 (which oc-
curs in three splice variants12) and HDAC10. They share homology with the yeast
histone deacetylase-A (HDA1) protein, are much larger than their class I counter-
parts through inclusion of additional regulation and localisation domains13. Numer-
ous interacting proteins and complexes have been identified that contain Class II
HDACs including some shared with Class I HDACs such as N-CoR and SMRT14.
Class II HDACs are further divided into class IIa HDACs with a single catalytic
domain (HDAC4, HDAC5, HDAC7 and HDAC9) and class IIb proteins (HDAC6
and HDAC10) which have two catalytic domains, HDAC6 possesses two active cat-
alytic domains which have different functions15 and HDAC10 has a second partial
catalytic domain (Figure 1.2a).
HDAC11 is the sole member of class IV and remains largely mysterious as limited
research has been carried out to characterise it. HDAC11 contains some primary
sequence features and activity that identify it as an HDAC but simultaneously lacks
sufficient homology to either RPD3 or HDA1 to be included in either class I or II
enzymes. HDAC11, like all HDACs except HDAC8, functions as part of a protein
complex, one example of which is the survival of motor neuron (SMN) complex16.
Class III HDAC enzymes are non-classical HDACs which require NAD+ for activity;
they are not related structurally to class I, II and IV HDACs and are known as
sirtuins because of their homology to the yeast SIR2 protein7.
Interestingly, HDAC8 appears to have diverged from the HDAC family faster than
other HADC. The evolutionary distance between the human and zebrafish HDAC8
enzymes is similar to the human and Drosophila melanogaster evolutionary distances
seen for other class I enzymes17. This rapid evolution is a feature that is often a result
of substantial functional specialisation.
19
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(a)
(b)
Figure 1.2: a)Domain architecture of Human HDAC family members (adapted from17)
and b)Phylogenetic relationships within the human HDAC proteins HDRP
= HDAC related protein (not to scale)7
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1.1.3 HDAC Expression
Different members of the HDAC family are required in various cell types, cellular
compartments, stages of the cell cycle and development and the expression of dif-
ferent HDAC isoforms consequently varies accordingly. The serial analysis of gene
expression (SAGE) data for HDAC1, HDAC2, HDAC3, HDAC5, HDAC6, HDAC7
and HDAC10 suggest that they are generally expressed in all tissues examined7. The
remaining HDACs are differentially expressed throughout different cell types13.
Of the class I HDACs, HDAC1 and HDAC2 are exclusively detected in the nucleus,
whereas HDAC3 and HDAC8 are detected both in the nuclear and cytoplasmic
cellular compartments18. All class II HDACs have been detected in cytoplasmic
and nuclear fractions and also have been detected shuttling between the two; this
shuttling may be part of their function and/or regulation19,20.
Conflicting data exists for the tissue distribution of HDAC8. When first charac-
terised, low HDAC8 mRNA levels were detected in all tissues tested and very low
HDAC8 mRNA levels were detected in smooth muscle (<1% of actin mRNA lev-
els)21. Using immunofluorescence and immunoprecipitation HDAC8 was reported to
be exclusively nuclear in NIH3T3 and HEK293 cells22. Subsequently HDAC8 has
been seen to localise to the cytoplasmic and nuclear compartments in NIH3T3 and
skin fibroblast cells23 and also to the cytoskeletal fraction of smooth muscle cells24.
HDAC8 expression in nervous tissues is also the subject of debate. Some groups have
reported high HDAC8 levels in the brain and pancreas25 whereas others detected
no expression in nervous tissues of the brain, spinal chord and periphery23. All this
conflicting evidence suggests that numerous factors contribute to the expression of
HDAC8 (e.g. stress levels, culture conditions, the stage of the cell cycle and the cell
type)26.
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1.1.4 Roles of HDACs
HDACs are involved in a vast array of overlapping cellular systems from metabolic
regulation and cell proliferation to cell fate determination and motility. Some HDAC
functions are redundant and can be compensated for by other HDACs while other
HDAC functions are unique and specific to a single isoform. Their mechanisms of
action are also numerous, including binding partner proteins in a protective man-
ner, providing a scaffold for other protein interactions, recruitment of transcription
factors and enzymatic deacetylation of substrate proteins. HDACs are often only
characterised in disease settings because their specific roles are fundamentally in-
volved in so many intertwined and complicated aspects of cellular life. An overview
of some HDAC interaction partners and substrates is shown in Table 1.1, these nu-
merouse functions are manifested by the many different phenotypes that result from
the knockout of each inividual HDAC.
Mouse knockouts of HDAC1, HDAC2, HDAC3, HDAC4, HDAC7 and HDAC8 are
lethal in the embryonic or perinatal stages whereas HDAC5, HDAC6, HDAC9 and
HDAC11 knockout mice are viable but have defects affecting the development of var-
ious tissues, HDAC10 has yet to be sucessfully knocked out of the mouse genome27–38.
These studies show that each HDAC plays a highly significant role within the cell
and has at least one non-redundant functions which it has evolved to perform.
Many HDACs are of particular interest due to observed correlations between high ex-
pression levels in tumours and disease progression/prognosis39. All 11 Zn2+dependent
HDACs have been linked to at least one process which leads to metastatic cancer39,40
and many have been detected at above normal expression levels in various cancers.
When the first non-histone substrates for HDACs were identified in 2000, and
HDAC1 was shown to deacetylate p5358,59, the functional roles of HDACs were
greatly expanded as the possibility of other non-histone HDAC substrates became
a reality. 1750 acetylated proteins have now been identified by mass spectrometry
which show a change in acetylation upon treatment with HDAC inhibitors2. The
number of potential HDAC substrates is therefore huge and acetylation has been
suggested to rival phosphorylation in importance in the cell1, since very few sub-
22
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Table 1.1: HDAC interaction partners and types (adapted from ref. [39])
Class HDAC interaction type target references
I
1, 2 active complex Sin3, NuRd, CoREST 8,41
1,2,3
pathway induction HIF, VEGF 42–44
pathway suppression
NFκB, mTOR, BRCA2
&RAD51
11,43
3 active complex N-CoR-SMRT 45
1
transcriptional repression p21 & p27 27
substrate AMPK,p53 46,47
8
substrate ERR-α,HSP20,SMC3 48–50
inhibition Otx2 & Lhx1 36
repression p53 (mutant only) 51
degradation protection hEST1B 52
interaction
α-actin, SMMHC,
Inv(16), α-SMA
23,24,53
4,5,7
regulatory AMPK 46
transcriptional inhibition MEF2 7,19,54
IIa
4
substrate GCMa, GATA-1, Hp-1 39
interaction ANKRA, RFXANK 39
5
substrate Smad7, HP-1, GCMa 39
interaction REA, estrogen receptor 39
7
substrate FLAG1 and 2 39
interaction HIF-1α, Bcl-6 39
9
substrate ATDC 55
interaction FOX3P 39
IIb
6,10 substrate HSP90 39,44,56
6 substrate tubulin 57
IV 11
interaction HDAC6? 39
active complex SMN 16
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strates have been identified as targets for specific HDACs, it is now a goal in the
field to assign specific acetylation targets to each HDAC isoform.
Most class I HDACs substrate specificity is determined by the composition of their
quarternary complex through assembly with specific proteins and many inhibitors
have been shown to have differential inhibiton depending on the complex compo-
sition60. HDAC8 is the only class I HDAC to show deacetylase activity without
additional cofactors.
The observations of HDACs acting as scaffolding proteins through co-localisation
without enzymatic activity gives rise to the possibility that their active site need not
necessarily be the target of an inhibitor, an interaction-blocking inhibitor may not
affect binding of certain substrates but may affect complex formation or regulation
of activity. It may be possible to inhibit the catalytic and scaffolding functions of an
HDAC independently, allowing even more intricate dissection of HDAC roles within
the cell as well as more specifically targeted therapies.
Just as the importance for HDACs grew when the vast number of non-histone sub-
strates was discovered, so their importance may grow again as there is a possibility
that HDAC activity is not restricted to acetyl-lysine residues. HDAC3 has recently
been shown to have some activity towards crotylated lysine residues61 and a NAD+
dependent deacetylase SIRT5 is a lysine demalonylase and desuccinylase62.
While these reports show no such activity for HDAC8 they suggest that HDAC
substrates other than acetyl-lysines are potentially physiologically relevant. The
ubiquitous role that HDACs play within cells in many cellular systems suggests
that HDACs may also provide therapeutic targets in the treatment of many more
widespread diseases than just cancer. These include treatments for sickle cell
anaemia63, α1-antitrypsin deficiency64, cyctic fibrosis65, chronic pain66, inflamatory
disorders67, anthrax poisoning68, malaria69, HIV70 and neurodegenerative diseases
such as Alzheimer’s and Parkinson’s71 to name a few. In a non-disease setting,
HDAC inhibition shows promise as a congnitive enhancer72 and has been shown to
improve the efficiency of stem-cell reprogramming73.
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1.1.5 The role of HDAC8
When originally discovered, HDAC8 was reported to have activity on the core histone
proteins H2A/H2B, H3 and H4 in vitro when overexpressed21,22,74. Supporting this
observation, hyperacetylation of histones H3 and H4 was detected when HDAC8 was
inactivated by protein kinase A (PKA) phosphorylation75 . However many studies
since have observed that removal of HDAC8 activity by inhibition or knockdown
results in no global change in histone acetylation in a cellular context76,77. HDAC8
is likely therefore to have a residual activity towards histones but this activity is
only seen when overexpressed and has no significance in a physiological context. It
would be interesting to know if HDAC8 shows activity towards histones in HDAC8-
overexpressing neuroblastoma cell lines, as this has not been investigated.
HDAC8 in neuroblastoma
HDAC8 expression (but not that of other HDAC) is highly correlated with the
progression of, and is a prognostic indicator in juvenile neuroblastoma76. Neurob-
lastoma, a cancer which arises from neural crest cells (NCCs), accounts for 7-10%
of all pediatric cancers and 15% of all pediatric cancer deaths in patients <15 years
old78,79. HDAC8 knockdown and selective HDAC8 inhibition with PCI-34051 (1) in
neuroblastoma cell lines causes terminal differentiation76, suggesting that an HDAC8
specific inhibitor could be a very powerful therapeutic treatment for cases of neurob-
lastoma. The NCCs from which neuroblastoma arises are precursor cells that gen-
erate the skull and some nervous tissues, consequently knockout of HDAC8 causes
newborn mice to die within hours of birth with severe defects in cranial tissues
causing brain herniation (Figure 1.3)36.
HDAC8 and p53
HDAC8 also plays a crucial role in the induction of the p53 tumour suppressor
through the HoxA5 transcription factor. p53 is known as the “guardian of the
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Figure 1.3: Reconstruced skulls from micro-CT scans of wild type (left) and HDAC8
knockout (right) mice (From ref[36]).
genome” and is very important in oncology, its tumour suppressor function is mu-
tated in over 50% of all cancers allowing unchecked proliferation of these cells80.
HDAC8 (but not HDAC1, HDAC2 or HDAC3) knockdown in a variety of cancer
cell lines lead to a reduction in p53 pre-mRNA expression levels. Importantly this
effect was only seen in cells with a mutant p53 gene, disruption of HDAC8 activity
by specific inhibition or knockdown triggered defects in proliferation of cells with a
mutant but not wild type p5351. This result is important as it offers HDAC8 as a
potential “personalised medicine”-type therapeutic target in many cancers with mu-
tant p53 that would be specific for cancerous cells and not affect p53 levels healthy
cells. In addition HDAC8 inhibitors may have negligable or negative effect in cancers
without mutant p53.
1.2 Structural Features of HDAC8
Rational design of an HDAC selective inhibitor requires knowledge of the structural
features of the target, specifically the features that separate it from other similar
proteins. These are the features which will be useful in our drug design process.
The HDAC8 protein is a single 42 kDa α/β domain comprising 8 β-strands sand-
wiched by 12 α-helices. It has a high loop content which is typical of promiscuous
proteins81, approximately half its residues are involved in secondary structure ele-
ments; the other half form the 9 loops which cap the top of the enzyme to form the
substrate recognition surfaces and 11A˚ substrate binding tunnel82.
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HDAC8 is structurally unique within class I HDACs - it lacks a 50-111 amino acid
C-terminal domain found in other class I HDACs which is used in enzyme recruit-
ment (a switch of HDAC1 and HDAC2 tails imparts HDAC1 activity to HDAC2)
it also contains an L2 loop which is 2 residues shorter than is found in other class
I HDACs82. With the exception of HDAC8 and HDAC11, HDACs have regulatory
sequences in addition to the catalytic deacetylase domain, these sequences regulate
HDAC activity through recruitment to different complexes or subcellular compart-
ments as well as PTMs such as summoylation83 and phosphorylation75. HDAC8
however, contains very little extraneous sequence in addition to the catalytic domain
although a nuclear localisation sequence has been determined through bioinformatic
analysis22.
Fluor de Lys - HDAC8
Tyr100
Asp101
Figure 1.4: Structure of HDAC8 in complex with the Fluor-de-Lys substrate 2 showing
interactions with Tyr100 and Asp101 (sticks) on the L2 loop (green) and
water molecules mediating hydrogen bonds (small red spheres). PDB:2V5X.
Figure 1.4 shows a peptide substrate-bound HDAC8 structure. Asp101 is conserved
throughout class I, II and IV HDACs, as part of the long L2 loop (missing from many
inhibitor bound structures) forms three hydrogen bonds to the peptide backbone,
and appears to lock the substrate in place84. Mutations at this position result in
a dramatic loss of activity suggesting that this is the functional role of Asp101 in
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vivo. Further interactions of Asp101 and the L2 loop are mediated by a network of
water molecules in the structure which may or may not occur under physiological
conditions as the crystal contacts occur in this region within the assymetric unit
(Figure 1.4)85.
X-ray structures have also been solved for the deacetylase domains of HDAC286,
HDAC387, HDAC488 and HDAC789 in complex with various ligands and cofactors.
Comparison of these structures with HDAC8 structures highlights that these iso-
forms have a narrower substrate tunnel than HDAC8. HDAC8 also seems to have
an additional“sub-pocket”within the substrate channel which has already been used
as an HDAC8 specific feature in the“design”of a small molecule selective inhibitor90.
This wide tunnel and sub-pocket are important features that will need consideration
in the design of HDAC8 selective inhibitors.
1.2.1 HDAC8 flexibility
Loop flexibility
Each of the 32 human HDAC8 structures deposited in the Protein Databank (PDB)
are in complex with an inhibitor or substrate mimic (except a single subunit in
one structure which is likely an artefact of crystal packing). Protein crystallisation
occurs more readily with rigid proteins and crystallisation of proteins with flexible
regions is often only possible after the flexible regions have been removed, either
by proteolytic cleavage or genetic alteration91, or by the addition of a ligand that
stabilises a conformation that is suceptible to crystallisation. The lack of ligand-free
structures suggests that HDAC8 is a dynamic and flexible protein and as such can
only be crystallised when rigidified by the presence of a binding partner. When
HDAC8 structures are compared, the backbone does not vary significantly within
secondary structure elements but in some of the loop regions, especially the L1
and L2 substrate binding loops, there is a great deal of conformational flexibility
displayed82(Figure 1.5). Interactions between these two loops are thought to have
an effect on the activity by affecting substrate binding92. Electron density for the L2
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loop is seen in structures with ligands that can donate hydrogen bonds to Asp101,
this interaction rigidifies the loop enabling higher occupancy in the crystal and as a
result electron density in the structure. Figure 1.5 shows a selection of L1 and L2
loops, the postion of Tyr100 demonstrates that even when the Asp101 rigidifying
interaction is present, significant flexibility in the L2 loop remains to the extent of
the formation of a helix in some structures (Cyan in Figure 1.5). Additionally in
many structures parts of the L2 loop still lack density. Two distinct conformations
of the L1 loop are also visible.
L1
L2
Asp101
Tyr100
Figure 1.5: Five sections of structures which have electron density for the L2 loop.
Asp101 and Tyr 100 are shown as sticks. PDB codes: beige - 1T64, yel-
low - 1W22, green - 2V5W, cyan - 2V5X, purple - 3RQD.
As the HDAC8 L2 loop is two residues shorter than the L2 loop in other class I
HDACs it is quite possible that different amounts of flexibility in the L2 loop is a
region of HDAC8 that could be exploited in the design of HDAC8 specific inhibitors.
The flexibility within the loop could also mean that targeting of an inhibitor to the
L2 loop could potentially be easy as the loop may be able to flex a small amount in
order to accommodate the interaction.
Core flexibility
An HDAC8 structure bound to the HDAC inhibitor (HDACi) trichostatin-A (TSA,
3) shows a second inverted TSA molecule extending into the hydrophobic core of
the protein (Figure 1.6a)82. A more recent HDAC8-TSA structure does not contain
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this second TSA molecule93 and therefore the cavity in which it binds is a transient
feature of this dynamic protein. Though the cavity may possibly be a crystallisation
artefact and therefore not physiologically relevant, it does demonstrate that the core
of HDAC8 is flexible enough to assume such conformations. The existence of this
second cavity may provide an opportunity for the design of inhibitors which can
extend into this transient cavity or alternatively do not bind to the active site26.
(a) (b)
Met274
Tyr306
Trp141
Phe152
Phe208
His180
CRA-A
Figure 1.6: The flexibility of the HDAC8 substrate tunnel demonstrated by 4 structures
with different ligands: (a) HDAC8-TSA (3) structure with a second inverted
inhibitor in a separate ligand binding cavity, (b) substrate binding pockets
of HDAC8 complexed with α-amino amide 4 (teal), Vorinostat (5, grey),
TSA (3, blue) and CRA-A (6, yellow balls and sticks).
Substrate tunnel flexibility
The structure of HDAC8 with another HDACi, CRA-A (6) bound reveals a move-
ment of Phe152 which ususally packs against Met274 (Not shown in ). Molecular
modelling and docking reinforce these data and show that the HDAC8 tunnel has
a high degree of flexibility94. Phe152 in particular has been seen to assume many
different orientations within the substrate binding pocket to accommodate different
ligands of different sizes (see Figure 1.6b). The movement of this residue is thought
to open an HDAC8 specific “sub-pocket” that has been targeted previously in the
design of an HDAC8 selective inhibitor90. Fatkins and co-workers demonstrated that
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in addition to an acetylated p53 peptide, HDAC8 is able to turnover an analogous
thioacetylated p53 peptide which HDAC1 and HDAC2 were unable to do95. This
provides evidence that despite the highly conserved nature of the catalytic pocket,
the HDAC8 catalytic pocket has features that allow it to be more flexible than other
HDACs and permits accommodation of the larger sulphur atom in thioacteyl-lysine.
HDAC8 has a dynamic nature that only allows crystallisation with a ligand, the
resulting in the rearrangement of residues can create a potential second cavity for
ligand binding. It also shows a propensity for structural rearrangement of the sub-
strate tunnel to accommodate wide ligands and has many structures with variable
conformations of loops involved with substrate and inhibitor binding. This increased
flexibility of HDAC8 over other class I HDAC isoforms is a major feature of HDAC8
that I hope to be able to exploit in the design of HDAC8 selective inhibitors.
1.2.2 Catalytic mechanism
Generally, recombinant HDAC8 when purified under normal conditions has a Zn2+
ion at its catalytic centre, this is coordinated by Asp178, His180 and Asp267. The
catalytic Zn2+ ion and His142 (acting as a general base) activates a water molecule
for nucleophilic attack on the carbonyl group of the substrate. Tyr306, His142,
His143 and Zn2+ act to stabilise a tetrahedral intermediate through hydrogen bond-
ing and His143 (acting as a general acid - general base catalyst) then protonates the
lysine leaving group completing the hydrolysis96 (See Figure 1.7).
Knowledge of the chemistry that occurs within an enzyme can help in the design of
inhibitors as enzymes often have evolved to function by stabilising a transition state
of a reaction, this can enable very efficient binding of transition state analogues that
cannot complete the intended enzymatic reaction. To some extent this has been
achieved in HDACi with trifluromethylketone analogues of existing hydroxamic acid
inhibitors showing improved HDAC8 potency97. An HDAC4 structure (2VQJ) shows
that when trifluoromethylketones bind to the HDAC active site they hydrate to a
gem-diol which is stabilised by residues in the active site88.
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Figure 1.7: Proposed mechanism for HDAC catalysis. The active site transition metal ion
of HDAC8 (Zn2+ or Fe2+) and general base His143 promote the nucleophilic
attack of a metal-bound water molecule at the metal-coordinated C=O group
of the acetyl-L-lysine substrate. The oxyanion of the tetrahedral intermediate
and its flanking transition states are stabilized by metal coordination as well
as hydrogen bond interactions with Tyr306, His143, and His142. His143
serves as a general acid catalyst to facilitate the collapse of the tetrahedral
intermediate to form acetate and L-lysine after an intervening proton transfer
(possibly mediated by His143), Figure taken from ref.[96].
1.3 Regulation of HDAC8
Included in the functions of HDACs is the regulation of many other proteins either
through direct acetylation or through scaffolding interactions. HDACs in-turn are
regulated through a number of different processes at many levels, from transcrip-
tional repression to a variety of PTMs. Elucidation of the function and mechanism
of action of these regulating modifications could help in understanding which parts
of the protein are flexible and amenable to activity altering structural changes. With
this knowledge more effective rational drug design can be undertaken by targeting
naturally occuring regulatory systems. Elevated HDAC8 expression is correlated
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with advanced disease progression and is a negative prognostic indicator for patients
with neuroblastoma76. Direct transcriptional control of HDAC8 has been demon-
strated by SOX4, a direct target gene of FRA-2 which causes elevated expression of
HDAC8 in adult T-cell leukemia/lymphoma98.
1.3.1 Regulation of subcellular location
Substrate availability, and subsequent activity of an enzyme, can vary greatly de-
pending on cellular compartment. Unlike HDAC1, HDAC2 and HDAC3, which are
exclusively nuclear proteins, HDAC8 is often detected outside the nucleus24,53. It
follows therefore that HDAC8 has non-nuclear substrates and/or interaction part-
ners. 14-3-3 proteins are chaperones which bind some phosphorylated proteins (such
as transcription factors) and translocate them into the nucleus; HDAC4, HDAC5
and HDAC7 have been identified as targets that are shuttled in this way99. HDAC8
has a nuclear localisation sequence7 and may also shuttle between the nucleus and
cytoplasm in a similar fashion as it has been observed as both phosphorylated and
non-phosphorylated forms within cells100.
Unlike all other HDACs (with the exception of HDAC11), HDAC8 has no regu-
latory sequences or domains outside its core catalytic domain. The lack of these
additional sequences and domains in HDAC8 suggests a more promiscuous func-
tionality as these additional domains and sequences are a major part of selectivity
in HDACs by enabling their recruitment to complexes and stabilise and strengthen
protein-protein interactions. Redundancies and compensatory mechanisms in many
signalling pathways also make substrate detection difficult as observed effects may
not be as a direct result of HDAC8 action but a knock-on effect. Currently it
is unknown what mechanisms regulate the subcellular location of HDAC8, under-
standing of these mechanisms may provide new directions for HDAC8 inhibition,
perhaps even through indirect inhibition or activation of the HDAC8-interacting
protein which regulates subcellular location.
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1.3.2 Post translational modifications
Phosphorylation of HDAC1 and HDAC2 by casein kinase II (CK2) is an activating
PTM which promotes incorporation into active complexes such as mSin3A and CoR-
EST8,41, conversely, phosphorylation of HDAC8 has a downregulating effect. Despite
having 19 predicted possible phosphorylation sites, HDAC8 is only observed to be
phosphorylated at one site, Ser39, both in vitro and in vivo. Ser39 phosphorylation
is only performed by cyclic adenosine monophosphate (cAMP) dependent protein
kinase A (PKA) and HDAC8 is the only HDAC with a PKA phosphorylation mo-
tif100. Ser39 is conserved in HDAC8 but not found in other HDACs and so this
inactivation by PKA is unique to HDAC8.
Ser39 is located 21A˚ from the catalytic centre of HDAC8, the inhibition there-
fore, cannot be a result of a simple blocking of catalysis or substrate binding. As
with many other PTMs, the regulation is most likely achieved through an allosteric
effect. Ser39 lies in a hydrophobic pocket so its phosphorylation may cause a struc-
tural rearrangement of the protein due to the additional charge imparted by the
phosphate82. A possible explanation for the regulation involves Arg37, the acetate
release “gatekeeper”101. Ser39 sits on the same α-helix as Arg37 (see Figure 1.8) and
phosphorylation may “shut the gate”, thereby inhibiting subsequent deacetylation
reactions. Molecular dynamics simulations of HDAC8 suggest that Arg37 forms a
barrier with backbone carbonyl groups restricting the access of water to the active
site and the escape of acetate101.
Fifteen HDAC8 interacting proteins have been identified using a bacterial two-hybrid
experiment; of which, six required HDAC8 phosphorylation52. This strongly implies
that phosphorylation is key to some HDAC8 protein-protein interactions whether
the phosphorylation is of HDAC8 itself or of the interacting protein. If the structural
basis for this inhibition was well understood it may aid in targeting of an inhibitor
that binds a stable, rigid conformation of HDAC8, possibly in a non competitive
manner.
Acetylation and glycosylation are also possible HDAC8 regulatory mechanisms. The
NetNGlyc 1.0 server identifies two potential glycosylation sites but does not predict
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Arg37
Ser39
K+
Zn2+
4
Figure 1.8: HDAC8-4 structure, two bound K+, the catalytic Zn2+, Ser39 and Arg37,
which are all important in HDAC8 regulation are shown.
glycosylation of either site102. HDAC1 has two acetylation sites in the catalytic
domain which inhibit activity towards histones103. One of these sites is conserved in
HDAC8 and is close to the inhibitory monovalent cation binding site104 (see Section
1.3.4), this has been suggested to be one possible mode of HDAC8 regulation but
has yet to be tested26. PTMs within HDACs can play an important part in drug
binding, a PTM can have a dramatic effect on the protein structure and could affect a
drug binding region by completely abolishing binding or conversely cause structural
change that facilitates drug binding. For example if an inhibitor could be designed
to stabilise the conformation of phospho-HDAC8 through binding in this region it
would be a non-competitive and highly selective HDACi.
1.3.3 Activation by small molecules
All known HDACi are competitive inhibitors which block access to the active site.
Recently N -acetylthioureas have been shown to function as activators of HDAC8105.
This was determined to be through a 5-fold increase in kcat and lowering of the KM
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by increasing the power of aromatic stacking interactions which help to bind the
substrate to the mouth of substrate tunnel (determined by docking simulations).
In a physiological context some small molecule metabolites have also been found to
stimulate HDAC1 and HDAC2 activity in a very specific manner such as coenzyme A
derivatives and NADPH (but not NADP+, NADH or NAD+)106. Inositol phosphates
have been shown to have a role in the regulation of HDAC1, HDAC2 and HDAC3, in
particular, recent structures reveal the structural basis for this regulation whereby
inositol phosphates mediate the formation of the HDAC complexes HDAC1-MTA1107
and HDAC3-NcoR287. Inositol phosphates and other metabolites do not have an
effect on HDAC8 but these types of protein-protein contact mediating molecule
sites may prove useful if they are discovered on HDAC8 in future by identyfying
sites that can be targeted in the design of inhibitors. These sorts of molecules may
be useful in diseases correlated with low HDAC activity (eg. HDAC1 and HDAC3
in metastatic melanoma108) where an increase in HDAC activity may be beneficial
to a patient.
1.3.4 Regulation by cations
Divalent and monovalent metal ions have been shown to have an effect on HDAC8
activity, they modulate the kinetics of catalysis but also possibly regulate activity
through other mechanisms which are not fully understood.
The catalytic Zn2+ in recombinantly expressed HDAC8 has been successfully ex-
changed with Co2+, Fe2+, Ni2+ and Mn2+109. Fe2+ containing HDAC8 has catalytic
efficiency 2.8-fold greater than HDAC8-Zn2+. It is possible that HDAC8 may exist
naturally as a mixture of Fe2+ and Zn2+ bound enzyme as the approximate KD val-
ues of both ions for HDAC8 (5-400 pM vs 0.2-6 µM respectively) are in the region
of the estimated cellular concentrations (5-400pM vs 0.2-0.6 µM respectively)110.
Due to difficulties expressing large amounts of other HDACs detailed analysis of the
potential active site metal ions has not been undertaken. Cellular concentrations
of Zn2+ can change significantly in response to oxidative111,112 and metal toxicity
stresses113, HDAC8 activity may be regulated in part through these ionic fluxes.
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In all HDAC8 crystal structures, two monovalent cations (MVC) are bound (see
Figure 1.8) which have been demonstrated to have different functions. Binding
at one site is activating114 while the other is an inhibiting104. With peak activity
occuring around the cellular concentrations of K+ (typically 139 mM115) it is possible
that binding of fluctuations in K+ concentration is a in vivo inhibitor of HDAC8.
These sites are conserved across class I and class II HDACs so this mechanism of
regulation may not be unique to HDAC8104
HDAC8 activity is likely regulated by a combination of processes: concentrations of
intracellular Zn2+, Fe2+, K+ and Na+, phosphorylation of Ser39 by PKA (which is
itself activated by a number of different pathways) and interactions with proteins to
localise HDAC8 with substrates, binding partners or to a cellular compartment.
1.4 HDAC inhibitors
1.4.1 Effects of HDAC inhibitors
HDACs play a broad range of roles in many cellular pathways; many cancers and
disease processes have been linked with overactive HDAC activity, HDACs have
become an attractive target for researchers wishing to affect or halt these diseases
by HDAC inhibition. A wealth of literature on HDACi has been generated over the
last 20 years, but despite the drive to create HDACi that are applicable in human
clinical settings only four HDACi are approved for use in human patients (with many
in clinical trials).
One of the major features of HDACi treatments is their selectivity for cancerous
cells. An expression profiling study has shown that, in artificially transformed cells
from a number of tissue origins, over 4200 genes are differentially expressed upon
treatment with non selective inhibitors Vorinostat (5) and Romidepsin (7)116. Gene
ontology annotations and pathway analysis revealed that many of these genes are
Bcl-2 family members which regulate the intrinsic apoptotic response116.
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Class I selective HDACi seem to have the same toxicity profile as non-selective in-
hibitors suggesting that the effects of non-selective HDAC inhibition arise primarily
from class I HDAC inhibition117. Preliminary clinical trial results are promising for a
number of non-selective HDACi in leukemias and also in solid cancers when HDACi
are used as part of a combination therapy. Patients do however, suffer from a wide
range of undesirable side effects which have been attributed to the non-selectivity
of these inhibitors. These side effects include fatigue, nausea, vomiting, diarrhoea,
thrombocytopenia, and neutropenia117. These effects can be partially understood
by taking into account the key role that HDACs play in the regulation of chro-
matin structure and expression of a huge number of proteins as well as the many
non-histone HDAC substrates and interaction partners that have been reported (see
Section 1.1.4). Currently the main goal in the field of HDACi research is to achieve
isoform-selectivity, with an HDACi which is specific for one isoform it is hoped that
side effects will be greatly reduced and efficacy in a clinical setting increased.
Trichostatin-A (TSA, 3) is produced by Streptomyces hygroscopicus initially identi-
fied only as an antifungal it is now known to be a pan-HDACi118. Another historical
inhibitor of HDACs is valproic acid (8), a prescribed treatment for bipolar disor-
ders and some epilepsy conditions119, it has numerous targets within the cell, of
which one set are HDACs with IC50 in the medium to high µM range. The HDAC
inhibitory effects of valproic acid are also potential therapies for HIV120, and vari-
ous cancers121. Despite decades of research in the development of HDACi, very few
have sucessfully exited clinical trials, often failing due to poor pharmacokinetics and
high toxicity. Four HDACi are FDA approved for treatment of different cancers:
Vorinostat (5)122 and Romidepsin(7)123 for refractory cutaneous T-cell lymphoma,
Beleodaq/Belinostat (9) for relapsed or refractory peripheral T-cell lymphoma124
and Farydak/Panobinostat (10) for multiple myeloma. At least 13 HDACi (in-
cluding Vorinostat and Romidepsin) are currently in one (or more) clinical trials11.
Because of the considerable side effects, the four approved HDACi are used mostly
in combination therapies for advanced stage and relapsing patients.
Many groups report conflicting data for the inhibitory activity of some of the more
widely used inhibitors. For example, the theyl ketone apicidin has been reported
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to have IC50 vs. HDAC4 = 5 nM
125 and >10000 nM by another group126 (see
Table 1.2). The differences are likely due to the format of the assay used, but
nevertheless the large discrepancy is concerning.
The disruption of HDAC containing complexes by HDACi may be a mechanism of
inhibition as significiant as direct inhibition of catalytic activity. As mentioned in
Section 1.1.4 HDACs often form parts of complexes as both active enymes and as
scaffolding proteins which bring together other enzyme-substrate partners such as
methylases, phosphatases/kinases (Table 1.1). TSA (3) was found to disrupt such
interactions in complexes containing HDAC1, HDAC6 and HDAC10 with phos-
phatases127. This type of inhibiton leads to HDACi affecting pathways where acety-
lation is not an active process and exacberates the need for specific inhibitors that
discriminate between individual isoforms and potentially even different functions of
a single isoform.
1.4.2 Structure of HDAC inhibitors
All known HDAC inhibitors directly block access of the substrate to the active
site and are as such, competitive inhibitors. HDACi are generally composed of
three modules; a zinc binding group (ZBG), an aliphatic substrate tunnel binding
group (STBG) which mimics the aliphatic chain of the native lysine substrate and
a cap-group which interacts with the mouth and top surface of the HDAC (See
Figure 1.9). Owing to the high sequence homology surrounding the active site any
inhibitor selectivity is typically presumed to require modifications of the cap-group.
The exterior of the protein to which the cap-group binds determines the cognate
substrate specificity in vivo should therefore be the most differentially targetable
structural feature of the protein.
The zinc binding group
The key feature of all HDACi is the ZBG with the exception of a couple of re-
ports134,151. Many different chemical compounds have been reported to bind zinc
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Table 1.2: HDACi activities against the different HDACs (IC50 in nM). References:
a[128], b[129], c [130], d[131],e[113],
f [132], g[77], h[133], i[134], j[135], k[126], l[136], m[137], i[138], n[139], o[140], p[141], q[142],r[143], s[144], t[145]
u[146], v[90], w[147],x[148],y[149]
Class I Class II Class IV
HDAC 1 2
3
(+NCoR2) 8 4 5 6 7 9 10 11
TSA (3) 0.23a 0.76a 0.58a 1100
b
25c 12
d 16d 13d 22d 38d 7a 15d
Vorinostat (5) 63e 40e 29e 2000
f
400g
16g
>10000h 33
e 1
i
0.013j
>17000h 107k 40g 362 d
Entinostat(11)h
45 j
300l
250
130j
400h
8l
>10000 >10000 >10000 13000 >10000 505k NR NR
Mocetinostat (12)m 150 290 1660 >10000 >10000 >10000 >10000 >10000 NR NR >590
Apicidin (13)k
>10000
22c
120
43k
1.5i
29c
43
760c
>10000
5n NR
123i
>10000c >10000 >10000 NR NR
Romidepsin(7)o 6700 1500 18 >50000 >50000 NR
12
200p >50000 >50000 NR NR
Romidepsin(7)(reduced)o 5.3 3.9 5.3 26 470 NR 330 3200 1200 NR
Tubacin (14)q
1400
995f 6270 1270
1270
6300f 17300 3350
4
142f 9700 4310 3710 3790
Rocilinostat(15) r 58 48 51 100 7000 5000 4.7 1400 >10000 NR >10000
Cpd-60 (16)s 4 11 3 1020 >30000 18000 2 >30000 >30000 NR NR
LMK-235 (17)t 320 881 NR 1278 11.9 4.22 55.7 NR 12.78 NR 852
A8B4 (18)u 3600 15000 25 NR NR NR NR NR NR NR NR
Cpd2 (19)v >100000 NR NR 14000 NR NR >100000 NR NR NR NR
Cpd6 (20)v >100000 NR NR 300 NR NR 55000 NR NR NR NR
4w 1700 3900 NR 90 NR NR >30000 NR NR NR NR
PCI-34051 (1)g 4000 >50000 >50000 10 NR NR 2900 NR NR 13000 NR
NCC149(21)x 38000 >100000 68000 70 44000 NR 24000 NR NR NR NR
Farydaky
Belinostaty
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Figure 1.9: Two non-selective HDACi TSA - 3118 and Vorinostat - 5150 and four HDAC8
selective inhibitors PCI-34051 - 177, cpd6 - 2090, SB-379278A - 22136, and
4147
including: thiols, carboxylic acids, barbituric acids, phosphonic acids, thiadiazoles
sulfodiimes thiadiazines, hydroxamic acids, reverse hydroxamic acids, α-pyrones, 2-
thiopyrones, 3-hydroxypyridin-2-ones hydroxypyridine-2-thiones carbamylphospho-
nates, hydroxyureas, hydrazides, aminomethylbenzimidazoles, dipicolylamines, β-
lactams and squaric acids152
The ZBG in HDACi are typically hydroxamic acids, benzamides and carboxylic
acids (examples in Figure 1.10). Other ZBG found in HDACi include: ethyl ke-
tones153, amides154, thiolates, epoxide, imidazole-2-thione77, mercaptoacetamide155,
hydroxypyridine-2-thione156, oxime amide96, trifluoromethylketone157, trifluoromethy-
loxadiazole158 and silanediol97.
Coordination of Zn2+ ions within the protein structures in the protein databank
(PDB) repository is most commonly tetrahedral (65% of crystal structures and 98%
of NMR structures) and occasionally trigonal bipyramidal/square pyramidal (15%
of crystal structures and <1% NMR structures)159. The catalytic Zn2+ ion within
HDACs is coordinated by two aspartate and one histidine residues. Therefore one
(or possibly two) coordinating bonds to HDACi are available. Crystal structures
of HDAC8 display both monodentate coordination (Figure 1.11a) with the thiolate
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Figure 1.10: Examples of HDACi with Zn2+ binding groups common in HDACi: hy-
droxamic acid - Vorinostat , carboxylic acid - valproic acid, cyclic tetrapep-
tides with ketone - apicidin, thiolate - Romidepsin (intracellularly reduced),
epoxide - trapoxin and benzamide - Entinostat.
inhibitor derived from Largazole (24), and bidentate coordination (Figure 1.11b)
with the hydroxamic inhibitor Vorinostat (5).
Carboxylic acids
Carboxylic acid HDACi are very weak inhibitors (Valproate (8) IC50 = 128 µM
for HDAC2160) for this reason they are used at very high concentrations and are
known to bind many other targets in addition to HDACs. Valproate is a prescribed
treatment for bipolar disorders and some epilepsy conditions119 and is also a po-
tential treatment for HIV120, and various cancers121. Carboxylic acid analogues of
hydroxamic acid inhibitors are occasionally used as inactive control compounds15.
Hydroxamic acids
Hydroxamic acids are strong binders of Zn2+ and so provide significant potency to
HDACi. They also however have many disadvantages such as off-target binding, in
particular it has been shown that an analogue of 1 that does not inhibit HDAC8
displays the same neuroprotective characteristics as 1161. These off target effects
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Figure 1.11: HDAC8 Zn2+ ion chelated by HDAC inhibitors with two coordination ge-
ometries (a) monodentate with Largazole 24 derived thiolate inhibitor and
(b) bidentate with hydroxamic acid inhibitor Vorinostat 5
have resulted in a search for a suitable equally potent ZBG which allows for greater
selectivity to soecific HDACs.
Hydroxamic acids display poor pharmacokinetics in the clinic and are known to
rapidly hydrolyse to give hydroxylamine and carboxylic acids162. As a result hy-
droxamic acid based HDACi have a fairly short half-life within the body (<100 min
in cats)163 and high doses are required as a result. Additionally it is thought that
the hydroxamic acid group (present in the majority of HDACi) chelates catalytic
Zn2+ ions in other zinc dependent protease enzymes such as matrix metalloprotease
proteins causing “off-target” inhibition that contributes to the side effects of non
selective HDACi164.
Hydroxamic acids are promiscuous metal ion chelators; Sc+, Y3+, La3+165, Al3+
Fe3+, Fe2+, Co2+, Co3+, Cu2+, Zn2+166, Ni2+167 and V(IV), V(V)168 have all been
reported to form hydroxamate complexes. Importantly the stability of hydroxamic
acid complexes suggest that Zn2+ is not their prefered ion, (Fe2+ ≫ Cu2+ > Ni2+
≈ Zn2+)169. Hydroxamic acids are present in siderophores such as ferrichrome which
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is synthesised by bacteria and secreted to scavenge iron from the environment, the
iron-bound molecules are then imported into the cell to deliver its iron cargo170.
Hydroxamic acids are found in some drugs such as the ibuprofen prodrug Ibuproxam
where hydrolysis of the hydroxamic acid is required to release the active drug, and
Bufexamac, a cyclooxygenase (COX) inhibitor used as an antinflamatory (now with-
drawn due to allergic reactions)60. Interestingly Bufexamac has also been shown to
be an HDAC6 and HDAC10 specific inhibitor , COX is an haeme Fe2+ containing
enzyme, and it is therefore possible that if Bufexamac inhibits HDACs that COX
enzymes may contribute to the off-target effects of HDACi. Hydroxamic acids have
also been seen to be antioxidants, posessing radical scavenging activity171
Trifluoromethylketones
Trifluoromethylketone (TMFO) inhibitors of HDACs have fairly recently been re-
ported172 but have long been known as inhibitors of other metalloproteases173. The
trifluorinated group withdraws electrons, increasing the tendency of the group to add
a nucleophile such as water to become hydrated157. In this way a gem-diol is formed
which was hyphthesised to mimic the transition state in the HDAC catalytic centre
and so is highly stable and tightly bound. A structure of the catalytic domain of
HDAC4 bound to a TMFO inhibitor has been solved which subsequently confirmed
the hydration of the inhibitor, the tetrahedral state is stabilised within the catalytic
site by two histidine residues and a hydrogen bond to a backbone amide via a water
molecule88.
This observation prompted synthesis of trifluoromethyl ketone inhibitors, many
of which showed improved inhibition against various HDAC isoforms61. Trifluo-
romethylketone analogues of Vorinostat (5), valproic acid (8) and butyric acid (25)
HDACi have been synthesised and were found to be very potent (pan-)HDACi97; in
this report silanediol was also found to be a promising potential ZBG.
Benzamides
Benzamides provide a bidentate coordination with Zn2+ within HDACs. Figure
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1.12a shows an HDAC2 bound with benzamide inhibitor (26) clearly showing Zn2+
coordination (interatomic distances ≤2.6 A˚) bonds from lone pairs on the amide
oxygen and the aniline nitrogen. The amide oxygen is further stabilised through a
hydrogen bond (2.7 A˚ distance) to Tyr308 (equivalent to Tyr306 in HDAC8).
The benzamide Entinostat (11) (Figure 1.12b) has shown good promise in phase
II and phase III clinical trials174. Mocetinostat (12) is another benzamide class
inhibitor137 which is in phase II trials for various lymphomas. It shows selectivity
for class I HDACs especialy for HDAC1 and HDAC2 with IC50 values of 150±20 and
290±80 nM for HDAC1 and HDAC2 respecitvely but IC50 >10 µM for HDAC8 (see
Table 1.2). This suggests that some feature of the HDAC8 ligand binding surface
cannot accommodate the benzamide ZBG making it unsuitable for HDAC8 selective
inhibitors.
(a)
His183
Asp269
r3
(b)
O
O
HN
O
HN
NH2
S
N
O
O
HN
O
HN
NH2
N
NH2
NH
O
HN
N
N
N
12 11 26
Figure 1.12: (a) Co-ordination of 4-(2-thiophenyl)benzamide 26 in the active site of
HDAC2175, and (b) three benzamide HDACi, Mocetinostat (12), Entinos-
tat (11) and the 4-(2-thiophenyl) substituted 26.
Entinostat analogues with substituents at the 4-postion on the anilide ring (para to
the aniline) have been shown to have an increased affinity to HDAC1 and HDAC2.
For example a >5-fold lower IC50 (0.02 µM and 0.1 µM) against HDAC1 and HDAC2
was measured with a 4-(2-thiophenyl) substituent (26) compared to with unsubsti-
tuted Entinostat (11, 0.54 µM and 0.5 µM)176.
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The cap-group (cyclic peptides/depsipiptides)
Very few of the current collection of clinical HDACi display any degree of isoform
selectivity. As the HDAC substrate tunnel is relatively narrow, very few HDACi
deviate from standard HDACi architecture (hydroxamic acid ZBG with aliphatic
linker), the remaining unit of the HDACi from which selectivity can be achieved
is therefore the cap-group. The cap-group interacts with the surface of the HDAC
near to the entrance to the substrate tunnel and it is thought that if selectivity is
to be achieved, it will be achieved through modification of the cap-group to provide
interactions that are unique to an individual HDAC isoform. Sadly however, while
many inhibitors show class selectivity few display convincing isoform selectivity.
Tubacin(14 in Figure 1.13), a fungal hydroxamic acid metabolite is one example
of an HDACi which does display HDAC6 selectivity that stems from its has an
extensive cap-group94.
O
NH
HO O
HN
O OH
S
N O
O
14
Figure 1.13: Structure of HDAC6 selective inhibitor tubacin.
Cyclic peptides and depsipeptides (peptides with an alteration such as an ester in
place of an amide) are compounds which have extensive cap-groups that form the
majority of the interaction surface with the protein by binding to the surface of
the HDAC near the entrance of the substrate tunnel177. Most inhibitors of this type
retain a ZBG of sorts (often a thiol) attached to a“pendant sidechain”which extends
into the substrate tunnel and coordinates Zn2+93. Some Largazole (24) analogues
have been synthesised that have an altered HDAC selectivity profile arising from
different ZBG such as hydroxamic acids and benzamides135. The use of a large cap
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group has allowed for the development of an increasingly diverse array of novel zinc
binding groups.
The depsipeptide Romidepsin (7) is approved for treament of CTCL. It is a prodrug
whose disulfide bond is reduced intracellularly, this reduction releases a thiol group
which becomes the ZBG178. The exclusively intracellular reduction avoids unwanted
inhibition of matrix metalloproteases which primarily act in the oxidising environ-
ment outside the cell179. Thailandepsins are related to Romidepsin and are class I
(except HDAC8) selective inhibitors180
Vaidya et al. studied HDAC inhibitors without a Zn2+ coordinating hydroxamic
acid moiety and suggested that the zinc-chelating moiety with hydroxamic acid
group were more potent inhibitors than that of other moieties such as methyl esters
and t-Bu esters that do not coordinate but rather form weaker Zn2+ interactions134.
A cyclic tetrapeptide has recently been developed which has no zinc chelating group,
it has sub-µM potency against class I HDACs (HDAC8 was not tested) exclusively
through interactions with the substrate binding surface of HDACs151. This inhibitor
is interesting as the lack 0of a ZBG may allow it to have fewer side effects than the
traditional hydroxamic acid inhibitors.
Trapoxin (23) is a natural fungal cyclic tetrapeptide product which is the only
known irriversible inhibitior of HDACs; trapoxin treated HDAC remained inactive
after dialysis against drug-free buffer181. Reduction of the epoxide ZBG lead to
complete abolishment of inhibition implying the epoxide group binds covalently to
HDAC.
A significant hindrance in studying HDAC inhibition by these cyclic peptides/depsi-
peptides is the low synthetic efficiency which prevents synthesis of many analogues,
though some “one compound-one bead”methods are being utilised by some labs182,
and this may improve throughput of screening cyclic peptides.
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1.4.3 HDAC8 selective inhibitors
Many HDAC functions described have been identified through inhibition, knockdown
or knockout of a single HDAC isoform, these functions are unaffected by disruption
of other HDAC isoforms and so are thought to be non-redundant and unique to
that particular HDAC. When these functions are altered and are involved with a
specific disease, selective inhibition of a single HDAC isoform may prove a powerful
treatment for that disease. Wider non-specific inhibition of HDACs affects multiple
cellular systems causing widespread effects. Through the development of selective
inhibitors, specific problematic cellular pathways can be targeted and disrupted.
Having isoform specific HDAC inhibitors will also greatly benefit the scientific com-
munity by allowing dissection of the individual HDAC functions.
Four compounds that have been reported as potent and selective HDAC8 inhibitors
(1, 20, 21 and 4) are shown in Figure 1.14. One feature shared by these inhibitors is
the presence of an aromatic group near to the ZBG. Non selective HDAC inhibitors
such as Vorinostat (5) and TSA (3) generally have long-chained aliphatic linkers
between the ZBG and cap-group. Analysis of crystal structures shows that this
aromatic group causes a rearrangement of substrate tunnel lining residues which
allows accommodation of this aromatic ring and some stacking interactions with
Phe152, possibly with Phe208 also.
The movement of Phe152 was originally seen in a crystal structure of HDAC8 com-
plexed with CRA-A82. The hydroxamate cpd6 (20) was designed to target the hy-
drophobic sub-pocket that is opened up by this movement90. Later crystallographic
evidence points to the movement of Phe152 being due to an energetically favourable
edge to face stacking effect rather than hydrophobic effects147.
Another common feature amongst HDAC8 selective inhibitors is their unusually
short length. As discussed above, other selective HDACi achieve specificity through
modification of the cap-group (such as the HDAC6 selective inhibitor tubacin (14)).
It seems that some HDAC8 selective inhibitors however, achieve specificity mainly
through the linker region. Three potent HDAC8 selective inhibitors do not extend
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Figure 1.14: Non-specific HDACi Vorinostat - 5150, HDAC1/2 selective cpd-60 - 16144,
HDAC4/5 selective LMK235 - 17, HDAC6 selective Rocilinostat - 15 and
HDAC8 selective hydroxamic acids: PCI-34051 - 177, cpd6 - 2090, C149 -
21 and A8B4 - 18148 and α-amino amide 4147.
out of the substrate binding tunnel and as such, their specificity must arise from the
interactions within HDAC8 rather than on the exterior surface (Figure 1.14).
PCI-34051 (1), NCC149 (21) and A8B4 (18) (Figure 1.14), are all potent HDAC8
selective inhibitor (>400-fold potency vs other class I HDACs) which do have a
cap-group. Studies have shown PCI-34051 to be a potential therapeutic for neurob-
lastoma76 and T-cell (but not B-cell) lymphomas by triggering caspase-dependent
apoptosis via phospholipase Cγ1 signalling, leading to mitochondrial cytochrome C
release77, a more metabolically stable analogue of PCI-34051 (of undisclosed struc-
ture) is reported to reduce neuroblastoma growth in mouse models183. While they
are promising potential HDAC8 selective inhibitors, PCI-34051 (and likely its stable
analogue), NCC149 and A8B4 still conform to the canonical modular HDACi struc-
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ture with a hydroxamic acid ZBG, they are likely to cause some side effects due to
the binding many off-target proteins that arises from the hydroxamic acid ZBG.
SB-379278A (22, Figure 1.14) is a small inhibitor which inhibits HDAC8 with an
IC50 5˜00 nM and has undetectable inhibition of HDAC1 and HDAC3
136, no other
reports have been published on the binding of SB-379278A to other HDACs so it is
difficult to draw any further conclusions. The presence of two aromatic rings does,
however, reinforce the suggestion that an aromatic linker group can provide some
HDAC8 selectivity. SB-379278A is a non-hydroxamate inhibitor, its mode of binding
is not reported but is likely to be through the lone pair on the sulfur atom.
Lead compound 4
Unusually a novel α-amino amide ZBG confers significant potency as a sub-unit of
an HDAC8-selective inhibitor (4, (Figure 1.14)147. With reported IC50 values of 1.7,
3.9, >30 and 0.09 µM for class I HDACs HDAC1, HDAC2, HDAC6 and HDAC8
respectively, 4 shows an 18-fold selectivity for HDAC8 over other class I HDACs
(Table 1.2). This compound must therefore provide some HDAC-inhibitor inter-
actions which can be established uniquely in HDAC8 over other HDACs in class
I. Since class I enzymes are the most structurally similar to each other this selec-
tivity is assumed to extend to class II and IV HDACs also. The HDAC8-4 struc-
ture should guide investigation of the interactions147. Interactions between α-amino
amide inhibitor 4 and HDAC8 can be seen in Figure 1.15. The substrate tunnel
is occupied by an isoindoline unit which makes aromatic edge to face stacking in-
teractions with Phe152 and Phe208 with edge-to-centre distances of 3.6 and 3.7 A˚
respectively. Hydrophobic interactions are made with the remaining substrate tun-
nel lining sidechains (Met274 and Tyr306, Figure 1.15b). These interactions are
permitted because of the linear structure of isoindoline which is only obtained when
an amide is present at the nitrogen (Figure 1.15c), without the amide delocalising
the lone pair of electrons the nitrogen atom is tetrahedral, creating a kink in the
molecule.
The coordination of the catalytic Zn2+ ion by the α-amino amide ZBG is novel; Zn2+
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Figure 1.15: Interactions of 4 with HDAC8 from the structure (PDB:3SFH147). (a)
an overview of the inhibitor binding site (b) interactions within the sub-
strate tunnel (c) Energy minimised structures of 1-(isoindolin-2-yl)ethan-
1-one (green carbon atoms) and N -methylisoindoline (cyan carbon atoms)
(d) tetrahedral Zn2+ coordination interactions for HDAC8-4.
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coordinating bonds are made with the sidechains of Asp267 (2.0 A˚), Asp178 (2.0 A˚)
and His180 (2.3 A˚), a fourth coordinating bond is provided by the lone pair of the
α-amino nitrogen of the inhibitor (2.3 A˚, Figure 1.15d). These four coordinating
bonds sit in a preferable pseudo-tetrahedral geometry159. The amide oxygen appears
to be fairly close to the Zn2+ ion but at 3.0 A˚ the distance suggests no coordina-
tion is occurring159(contradicting the report describing 4147), the geometry of the
coordination would be distorted if the oxygen was coodinating Zn2+. Additional
analysis of the electron density map (not shown) indicates that the amide oxygen
is involved strongly in a hydrogen bonding interaction via a water molecule to the
backbone nitrogen of Gly305 (visible in Figure 1.15d). This Zn2+coordination dif-
fers from hydroxamate inhibitor binding which is through oxygen lone pairs of the
hydroxamate resulting in penta-coordinate square pyrimidal geometry around the
Zn2+ (see Section 1.4.2).
The acetate release pocket binding group (ARBG) is a second feature of 4 which
makes it unique among HDAC8 inhibitors. This chlorine substituted phenyl ring
is seen to occupy a large pocket behind the catalytic ion. It is hypothesised that
cleaved acetate is released into this pocket and subsequently exits the protein directly
through a channel that is regulated by Arg37. Arg37 is known to be a key regu-
lator of acetate by mediation of acetate release101,184. This pocket is much smaller
and narrower in other HDAC8 structures due to a rotation of Tyr306 and Trp141
sidechains which restrict the channel (Figure 1.16) in the case of HDAC8-6 (CRA-A)
the acetate release pocket is not connected at all to the substrate tunnel.
HDAC2 has been crystallised with a benzamide inhibitor 2886, this inhibitor includes
an ARBG, though inhibition of HDAC8 was not reported for this inhibitor, a crystal
structure alignment reveals that the positioning of the 28 ARBG in the HDAC8
structure would result in a steric clash with Trp141 which is Leu144 in HDAC2
(Figure 1.17a). Additionally no benzamides have yet been reported which inhibit
HDAC8 so this inhibitor is highly unlikely to be a potent HDAC8 inhibitor
The HDAC8-4 crystal structure shows many interactions within the acetate release
pocket. Parallel displaced aromatic stacking occurs between the dichlorophenyl
group of the inhibitor with Trp141 (4.0 A˚ center-center, Figure 1.17b). As men-
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Figure 1.16: (a) Narrow internal cavities of HDAC8 when bound with substrate (b) much
larger cavity opened up by α-amino amide inhibitor 4.
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Figure 1.17: (a) Aligned crystal structures of HDAC8-4 (teal) and HDAC2-28, a phenyl-
benzamide inhibitor (red) (b) acetate release pocket interactions, carbons
1 and 2 of the aromatic ring are labeled.
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tioned above, Trp at this position is unique to HDAC8 and so likely provides one
mechanism for the selectivity of 4 for HDAC8.
The other interactions within the ARBG are between the two aryl chlorine sub-
stituents (Figure 1.17b). To understand the two aryl chlorine-protein interactions a
modern interpretation of the distribution of electrons around an aryl chlorine atom
is necessary. Historically chlorine was considered an electronegative atom which
aquires a δ−ve charge as a result of its electronegativity when covalently bonded to
a carbon atom (since carbon is less electronegative) as seen in Figure 1.18b. This
was thought to give chlorine a general Lewis base-like character. However density
functional theory (DFT) models reveal that there is anisotropy of electrons sur-
rounding the chlorine which leads to a doughnut shaped distribution of electrons
about the atom and a “σ-hole” of electrons in the middle resulting in a δ+ve charge
(Figure 1.18b)185. As a result, for interactions which occur roughly perpendicular to
the C-Cl bond, the Cl atom appears to act as a Lewis base, but along the axis of
the bond however the σ-hole in the electron density can act as a Lewis acid - this
phenomenon is known as halogen bonding185.
(a) (b)
Figure 1.18: Electro-surface potential representations of a halogen substituted aromatic
ring, the colour gradient from cyan to red represents the electrostatic poten-
tial mapped onto the electron isodensity surface. (a) The traditional view
of a halogen as an electron donating Lewis base and (b) the more modern
view of an aryl halogen that can also act as an electron receiving Lewis acid
(taken from ref.[185]).
The chlorine at position 4 on the ring makes contact with the electrophilic sidechain
of Arg37 which is side-on and therefore sees the Cl to have Lewis base character
(Figure 1.17b). The chlorine at position 2 of the ring however is end-on with the
backbone carbonyl oxygen of Gly140, the sigma hole of δ+ve charge can therefore
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make a halogen bond with the lone pair on the oxygen atom. These two opposite
types of interactions are important in the stable filling of the acetate release pocket
and an α-amino amide analogue with a single chlorine substitution was reported to
have >2-fold higher IC50
147.
The presence of halogen bonding between HDAC8 and α-amino amide 4 makes con-
ventional small molecule docking alorithms ineffective at finding the lowest energy
binding pose for inhibitor 4. This is because these docking algorithms use a scoring
function that calculates interactions by considering each atom as a point charge.
Representing with a point charge is not a correct approximation in the case of aryl
halogen atoms due their electronic anisotropy. Recently however a scoring function
has been described that can accurately replicate the σ-hole required for halogen
bonding186.
1.5 HDAC Activity assays
1.5.1 Cellular assays
The study of HDACs and their inhibition requires tools and techniques to monitor
their activity. In a cellular context this usually comes in the form of detection
of acetylation epitopes such as histone tails by Western blot. This is useful for
investigations on the functions of HDACs when one isoform is knocked down or
inhibited. Since over 1700 proteins are known to be deacetylated2 detection of
acetylation levels is a very rudimentary technique that may not detect a vast number
of acetylation sites due to non-uniform affinity of anti-acetyl antibodies to different
acetylation sites. Also cellular techniques cannot isolate individual HDAC functions
since complex compensatory mechanisms exist and can cause knock-on effects. In an
oncology setting the effect of HDACi on cancer cell lines is assessed much the same
as other potential anticancer drugs, for example: flow cytometry, colony forming
and migration assays.
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1.5.2 in vitro Assays
No high affinity substrates (KM >100µM) are currently available for use in in vitro
assays, this is primariy because information about the in vivo sequence specificity
of HDAC8 is scarce.
Radiolabelling assays are an old technique used to monitor HDAC activity. Histone
tails are labelled by chemically peracetylating histone tail peptides with 3H-labelled
acetate187. After purification by high performance liquid chromatography (HPLC)
these can be used as an HDAC substrate. Following incubation with HDACs the
hydrolysed acetate can be separated from the reaction mixture by extraction into
organic solvent and the amount of radioactive acetate quantified through scintilation
counting. This technique only quantifies HDAC activity against histone tails and so
has very limited scope given the numerous non-histone HDAC substrates, especially
when considering evaluation of a specific inhibitor.
Fluorescence based HDAC assays utilising the amino methyl coumarin (AMC) flu-
orophore are however the most common technique used to assess HDAC activity
and screen for inhibition due to their ease, speed and need for small amounts of
enzyme. At the most basic level, the assay substrate MAL (27) consists of an
aminomethylcoumarin (AMC) fluorophore conjugated to an acetylated N -Boc-lysine
residue. Figure 1.19 shows the steps occurring during the assay, deacetylation of the
substrate renders the lysine-AMC peptide bond suceptible to hydrolysis by trypsin
which is added as part of a developer solution, cleavage of the AMC fluorophore is
detected as an increase in fluoresence at 460 nm188. Because this is a small, single
residue substrate, its KM is very high (at ∼20 mM for HDAC8, see Section 1.6).
In a mass spectrometry based assay, HDAC8 was shown to have activity on histone
H4 tail peptides, although only a longer 11 residue sequence from the H4 tail (Lys8-
Arg19) produced detectable deacetylation189. This suggests that distal regions of
the substrate contribute to binding of and deacetylation by HDAC8. Similar exper-
iments have shown a fragment of the p53 tail (residues 372-389) can be a substrate
for HDAC8, albeit a very poor one190.
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Figure 1.19: Steps occuring the an MAL-HDAC assay, HDAC activity removes an acetyl
group from MAL (27) which makes the deacetylated substrate suitable for
tryptic hydrolysis releasing the AMC fluorophore in the developer step.
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Figure 1.20: HDAC8-Fluor-de-Lys structure with aromatic stacking interactions being
shared between two HDAC8 monomers and two Fluor-de-Lys substrate
molecules
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A further sequence specificity study, showed the preference of HDAC8 substrates
to have Arg at the -1 position and Phe at the +1 position191. This preference of
HDAC8 substrates to have an aromatic residue at the +1 position is supported by the
sequence of an HDAC8 optimised assay substrate (Fluor-de-Lys, 2). The Fluor-de-
Lys substrate consists of an ArgHisLys(Ac)Lys(Ac) tetrapeptide sequence identified
from the p53 tail with a C-terminal aromatic AMC reporter (at the +1 position),
the inclusion of the extra ArgHisLys(Ac) sequence lowers the KM to 1.5 mM
192
from ∼20 mM for the MAL substrate (see Section 1.6 in results). In the absence
of the aromatic AMC fluorophore however, HDAC8 is unable to deacetylate the
Fluor-de-Lys substrate191. A structure has been solved of inactive HDAC8 mutants
with the Fluor-de-Lys substrate Figure 1.20. In these structures the aromatic AMC
fluorophore can be seen to clearly form aromatic ring stacking interactions with
Tyr10085 Figure 1.20. These fluorescent substrates are a useful tool in the laboratory
for HDAC activity and inhibition assays but do not provide insight into bonafide in
vivo substrates of HDAC8.
The catalytic efficiency (KM/kcat) of HDAC8 is very low (7500 M
−1s−1 with the
Fluor-de-Lys substrate109) in comparison to other homologous enzymes such as
HDAC1 (which are on the order of 105 M−1s−1 with a Ac-GlyAlaLys-AMC HDAC1
optimised substrate)193, and is far from the diffusion limited rate seen in other
enzymes of up to 1.5 x 1010 M−1s−1194. Binding partners such as scaffolds or co-
activators may play a role in increasing binding affinity and positioning of substrates
(and therefore reducing their KM and increasing the kcat in vivo).
Development of specific HDAC inhibitors requires a tool to detect activity of single
isoforms in isolation. To this end purified individual HDAC isoforms are obtained,
either recombinantly expressed or immunoprecipitated from cell cultures and studied
in vitro.
Modifications have been made to the fluorescence based HDAC assays to improve
affinity195, to allow detection of inhibition by highly fluorescent inhibitors by derivati-
sation of deacetylated product196 and both improved affinity and derivatisation of
products95. A continuous protease coupled assay has also been developed that pro-
vides a more efficient method for measurement of reaction rates197. A thioaectylated
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lysine peptide has been described as a novel HDAC8 specific assay substrate which
quantifies released thioacetate using Elmann’s reagent (5,5’-dithiobis(2-nitrobenzoate))95.
Some direct detection HDACi-binding assays have used techniques such as fluores-
cence resonance energy transfer (FRET) to, or fluorescence polarisation/anisotropy
of, internal tryptophan residues. These techniques suffer from low signal to noise due
to the fact that many inhibitors (eg. Vorinostat, 5 and TSA, 3) do not have fluores-
cent groups. Fluorescent analogues are therefore required which sometimes quench
the internal tryptophan fluorescence198. Given the known positive effect of coumarin
on the binding of the in vitro HDAC substrate Fluor-de-Lys84, a fluorescent probe
was designed adding an AMC fluorophore to Vorinostat (5). The fluorescence of the
probe is quenched when bound to HDAC but is detectable when it is free in solution.
Displacement of the probe by a competitive HDACi can therefore be detected as an
increase in fluorescence. This technique also allows the detection of kon and koff
rates of HDACi.
1.6 Preliminary Assessment of Substrate Km
values
Having a cost-effective and reliable assay for measuring HDAC8 activity is crucial
for exploring many inhibitors. To remove reliance on a commercially available en-
zymatic assay using the Fluor-de-Lys HDAC8 specific tetrapeptide-fluorophore sub-
strate (which costs ∼£70 per 96 well plate), an acetylated lysine substrate (MAL,
27) was used consisting of N -Boc-acetyl-lysine fluorophore (Figure 1.22). Enzymatic
assays using the Fluor-de-Lys and the MAL substrates were compared in order to
ensure suitability of the non-specific MAL substrate to assay inhibition of HDAC8.
The Michaelis-Menten constant (KM) is a measure of the binding affinity of an
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enzyme-substrate interaction and is the substrate concentration ([S]) at which the
initial steady state rate (v0) is half the maximum rate of the enzyme (Vmax/2).
v0 ≃
Vmax[S]
KM + [S]
=
[S]
KM + [S]
E0kcat (1.1)
Acurate calculation of KM generally requires substrate concentrations both smaller
than and larger than KM . When [S]≪KM , the term
[S]
KM+[S]
≃ [S]
KM
therefore:
v0 =
kcat
KM
E0[S] (1.2)
and a plot of V0 against [S] is linear with a slope of E0 kcat/KM . As E0 is known it
is possible to extract (kcat/KM) but not kcat or KM individually.
Kinetic parameters for the deacetylation of the Fluor-de-Lys substrate by HDAC8
were determined by Gantt and colleagues109. They measured the kcat to be 0.9 s
−1
and the KM to be 1100 µM. Calculation of the KM for MAL requires measurement of
the steady-state initial reaction rate (V0) at a number of concentrations of substrate
including concentrations on the order of KM or above. The MAL substrate however,
is not suffficiently soluble in aqueous solutions so the calculation of KM cannot be
achieved. However, the ratio kcat/KM can be measured by plotting V0 against [S]
(Figure 1.21d) as described above.
Measurement of the kcat/KM was performed for both fluorescent substrates using
HDAC8 purified from recombinant E.coli. Fluorescence values were converted into
deacetylated substrate concentrations by reference to a standard curve. This refer-
ence is the same for each substrate as the fluorophore product released during the
developer step is the same for both substrates.
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Figure 1.21: Comparison of Fluor-de-Lys and MAL assay substrates in HDAC8 actitivity
assay using 400 nM HDAC8. (a) Initial rate of reaction at 30 µM (blue) and
60 µM (red) Fluor-de-Lys substrate, (b) Rate of reaction vs. Fluor-de-Lys
concentration, (c) initial rate of reaction at 50 µM (blue) 100 µM (red), 200
µM (green), 300 µM (purple) and 400 µM (cyan) MAL substrate, and (d)
initial rate of reaction vs. MAL concentration.
Reaction rates for the Fluor-de-Lys substrate were measured using 3 timepoints (5,
20 and 30 min) using substrate concentration of 30 µM and 60 µM (Figure 1.21a).
Reaction rates for the MAL substrate were measured at 5 timepoints (15, 30, 45,
60 and 90 mins) using substrate concentrations of 50, 100, 200, 300 and 400 µM.
The reaction rates were calculated and plotted against the substrate concentration
to give kcat/KM (Figure 1.21b & 1.21b). In both cases the resultant plot is linear,
indicating that KM ≫[S].
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kcat/KM=235 M
−1 s−1 for the Fluor-de-Lys substrate, whereas the kcat/KM for the
MAL substrate, is 17 M−1s−1. If it is assumed that the kcat is the same for the two
substrates since the deacetylation reaction within the enzyme does not change, then
the Km of the MAL substrate is ∼14 times larger than that of Fluor-de-Lys, about
20 mM.
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Figure 1.22: The commercially available Fluor-de-Lys substrate and the MAL HDAC
substrate. Acetyl groups in red indicated are cleaved upon HDAC activity.
Scissors indicate peptide bond that is hydrolysed by trypsin after deacety-
lation.
With competitive inhibition present the apparent KM is modified to incorporate the
fraction of total enzyme that is bound by inhibitor KappM = KM(1 +
[I]
Ki
) (Equation
1.3).
v0 =
E0kcat[S]
KM(1 +
[I]
Ki
) + [S]
(1.3)
Again when [S]≪KM
v0 =
[S]
KM(1 +
[I]
Ki
)
E0kcat (1.4)
Therefore v0 can be used as a good measure of Ki as it is proportional to
1
1+ [I]
ki
, it can
be used to calculate Ki as when [I] = Ki, v0 =
1
1+
[I]
ki
= 1
2
. A plot of v0 vs. log[I] gives
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a sigmoidal curve wherefrom Ki can be determined and any differences in KM do
not matter when investigating the inhibition of the enzyme as the Ki is still reported
accurately (see Figure 1.23). The MAL substrate is therefore a suitable substrate
for the present work as it reports accurately the relative HDAC8 activity.
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Figure 1.23: Simulated activity assays of an enzyme with 3 inhibitors, IC50 = 10 nM
(orange), 100 nM (purple) and 1 µM (green), kcat = 3 s
−1, KM = 100 mM,
E0 = 100 nM, [S] = 200 µM.
1.7 Summary
Acetylation is a major post translational modification found in over 1700 proteins
within the cell, and at least 3600 acetylation sites in total that are differentially
acetylated upon treatment with HDACi2. The ubiquity of the 11 Zn2+ depedent
HDACs across a wide range of cellular pathways and processes demonstrates their
importance in life. They perform many more functions than their name suggests.
In addition to deacetylating histone tails, they deacetylate non-histone proteins,
both cytosolic and nuclear. Further to their role as catalytic hydrolases HDACs
also mediate interactions with other proteins within multiprotein complexes. Often
these complexes enable regulation of activity and substrate specificity of a particular
HDAC isoform.
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A great number of disease states have been linked to changes in regulation of expres-
sion (or activity) of particular HDAC isoforms or HDAC binding partner. For this
reason HDACs have been major targets for the development of therapeutic treat-
ments for decades with four HDACi currently approved for the treatment of certain
cancers. The search for effective HDACi therapies has been hampered by the severe
side effects caused by HDACi. These side effects are so bad that HDACi are only
used in late stage cancers which have resisted previous chemotherapy. These side
effects are partly a consequence of the non-isoform selectivity of HDACi meaning
that all 11 Zn2+ dependent HDACs are targeted in a non-selective manner. The side
effects are also partly due to the promiscuous metal binding hydroxamic acid ZBG
found in the majority of HDACs which are known to bind other metalloproteins.
To reduce side effects associated with HDACi therapies selective HDACi must be
found that can specifically target individual HDAC isoforms, additionally the selec-
tive HDACi should also utilise a ZBG that does not bind proteins other than HDACs
as the hydroxamic acids that are currently used do.
The search for isoform selective HDACi has predominantly been through modifica-
tion of the surface binding cap-group. This is because the internal core of the protein
is thought to be fairly invariant between isoforms whereas the surface residues show
a great deal less conservation. To some degreee this direction of research has been
successful, many class selective inhibitors have been reported and some of these class
selective HDAC inhibitors are showing promise in clinical trials.
The significance of HDAC8 within the cell is becoming more apparent as more of its
functions are discovered. With roles in development of the skull, p53 expression and
chromatid separation, HDAC8 functions both as a deacetylase and as a scaffold,
facilitating the co-localisation of other proteins. HDAC8 has been shown to play
a significant role in certain types of cancer, specifically in neuroblastoma which
accounts for 15% of all pediatric cancer deaths. It has been shown that abolishing
HDAC8 activity in these cancers leads to cell cycle arrest, terminal differentiation
and apoptosis.
Despite its class I classification HDAC8 is evolutionarily divergent from HDAC1,
HDAC2, and HDAC3 and is poorly inhibited by class I specific inhibitors as a
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result. It follows that those same features of HDAC8 that make it poorly inhibited
by class I inhibitors should be able to be targeted to create highly selective HDAC8
inhibitors.
There is a great deal of structural information about HDAC8 to be gained from
the 32 structures deposited in the PDB, ligands are bound in all these structures
suggesting that HDAC8 is a flexible and dynamic protein in its ligand-free form.
Certain key residues within the substrate binding tunnel and ligand binding L1 and
L2 loops assume multiple conformations depending on the bound ligand, further
demonstrating the dynamic nature of the protein which is thought to be significantly
greater than other class I HDACs. The residues lining the substrate tunnel are
thought to be more rigid in other HDACs and the L2 ligand binding loop is two
residues shorter which may alter its dynamic characteristics.
HDACi have been reported which show selectivity, however these selective inhibitors
are either relatively low affinity (SB-379278A, 22) or retain the undesirable hydrox-
amic acid ZBG (PCI-34051, 1 and cpd6 20). There is a definite need for a potent
non-hydroxamic acid HDAC8 selective inhibitor.
An HDAC8 selective inhibitor 4 has been reported which utilises a novel α-amino
amide ZBG, showing 18-fold selectivity for HDAC8 over other class I HDACs. A
second novel property of this inhibitor compared to other HDAC8 inhibitors is the
presence of a group which occupies the acetate release pocket. This inhibitor lacks
a cap-group and so its HDAC8 selectivity must arise from the properties of the
substrate tunnel and acetate release pocket which provide interactions to this unique
inhibitor. Little information exists about α-amino amide HDACi and so it is an ideal
lead compound for rational design to improve its potency.
A commonly used flourogenic assay substrate is a suitable for assessment of inhibitor
potency against HDAC8. Both the commercially available Fluor-de-Lyssubstrate
and the “in-house” synthesised MAL substrate are equally suitable as they both
report the relative activity of HDAC8 and show Michaelis-Menten kinteics, this
makes for easy calculation of the inhibitor dissociation constants, and therefore
good comparisons between inhibitors can be obtained.
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1.8 Project goals
Since the initial publication of 4 in 2011 no other groups have explored the potential
of an α-amino amide HDACi. There is therefore a significant degree of chemical
space to be explored around this novel ZBG. The main focus of this study is to
investigate compounds based on this α-amino amide ZBG through sucessive rounds
of synthesis and measurements of HDAC8 inhibition.
The contribution of the ARBG to binding and potential chemical variability within
the acetate release pocket was to be explored through synthesis of analogues. Also
the ability of the substrate tunnel to accommodate alternate STBG and to iden-
tify important interactions could potentially be exploited was to be investigated.
This was to be achieved by systematic substitution of the synthetically challenging
isoindoline group with other aromatic groups.
Through relating the potency of an inhibitor to manual docking results, rationali-
sation of the effects of each STBG substitution was planned. Through this ratio-
nalisation, properties/groups/interactions that are beneficial in an α-amino amide
HDAC8 inhibitor would be identified as well as those which are detrimental to
HDAC8 binding. A similar method was to be used to assess the importance of the
2,4-aryl substitution within the ARBG.
The final goal was to combine all the knowledge gained through exploration of the
chemical space within the STBG and ARBG, and apply this knowledge to rationally
design and synthesise a selective α-amino amide HDAC8 inhibitor with improved
potency for HDAC8 compared to lead compound 4.
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2 1st generation α-amino amide
HDAC8 inhibitors - variation in
ARBG and STBG
2.1 Introduction
Numerous HDAC inhibitors have been reported, they are all competitive inhibitors
which share a common modular structure: A zinc binding group (ZBG) which co-
ordinates the catalytic divalent zinc ion deep within the enzyme at the active site; a
substrate tunnel binding group (STBG) which is a linker that occupies the substrate
binding tunnel, extending from the ZBG to the surface of the HDAC and mimick-
ing the aliphatic region of the natural acetyl-lysine substrate; and a cap-group that
extends out of the substrate tunnel and interacts with the surface of the HDAC (see
Section 1.4.2).
The 11 zinc-dependent HDACs have distinct roles within the cell and therefore
have different substrates and interaction partners that modulate their activity and
specificity2. The four FDA approved HDAC inhibitors (HDACi) (for treatment of
cutaneous T-cell lyphoma, peripheral T-cell lymphoma and more recently multiple
myeloma199) have a poor selectivity profile, inhibiting all HDAC isoforms in a non-
selective manner. Non-selective inhibition of HDACs is not well tollerated within the
body, it causes a wide range of severe adverse side effects, this is due to the diverse
roles in many important cellular processes and signalling pathways that HDACs play.
Non-selective HDAC inhibition therefore, causes massive cellular stress as all these
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(a) (b)
Figure 2.1: Structures of HDAC8 in complex with (a) Vorinostat (5) and (b) lead com-
pound 4, carbon atoms of inhibitors are coloured according to the modular
HDACi structure, ZBG - orange, STBG - yellow, cap-group - cyan and ARBG
magenta.
processes and pathways are perturbed simultaneously200. These severe side effects
lower the benefit-risk profile of non-selective HDACi and as such, they are only used
as second and third line treatments when the cancer is non-responsive or becomes
resistant to other treatments.
To date it is assumed that the natural substrate of all HDACs is a protein (or
peptide) with an exposed acetylated lysine, although HDAC3 has been shown to
have some activity towards crotonylated lysine61 (lysine crotonylation is a fairly
recently discovered histone modification201). Differences in activity and substrate
specificity therefore rely on the sequence and context of the acetylated lysine. This
would be due to interactions between the substrate and the surface of the enzyme,
especially within the residues around the mouth of the substrate tunnel. As a result
of this assumption the major focus in inhibitor research has been to vary and modify
the selective cap-group in order to create isoform specific interactions.
HDAC inhibitors nearly all share a common zinc binding group (ZBG) - the hydrox-
amic acid. Hydroxamic acids pose a large hurdle to the sucessful development of
HDACi into effective therapies, the largest of which is the promiscuity of binding.
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These compounds are known to bind to many metalloproteins such as matrix met-
alloproteases which cause many off-target effects which manifest as yet further side
effects.
In 2011 an HDAC8 selective inhibitor was reported which deviates from the standard
modular structure discussed in 1.4.3. The ZBG of 4 is a novel α-amino amide zinc
binding group, does not have a cap-group but instead has an acetate release pocket
binding group (ARBG) which extends into a hypothesised acetate release cham-
ber147. In order to investigate this novel zinc binding group discovered by Whitehead
et al. a series of compounds was synthesised, altering both the ARBG and STBG
which were not part of the the α-amino amide ZBG.
2.2 1st generation α-amino amide inhibitor
synthesis
The synthetic route to lead compound 4 is shown in Scheme 2.1, this is an effective
2 step route from commercially available starting materials and was adopted for the
synthesis of all α-amino amides in this study. The route consists of two steps, a 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) activated amide
coupling of N -Boc-(R)-2,4-dichlorophenylalanine with isoindoline followed by an
acidic cleavage of the N -Boc protecting group to yield the product as a hydrochloride
salt147.
Cl Cl
NHO
N
H
O O
Cl Cl
NH2.HClO
N
+
OH
Cl Cl
NHO
N
O
OEDC.HCl, DIPEA
DMF, HOBt
HCl
Et2O
29 30 31 4
Scheme 2.1: Route to α-amino amide salt 4 as described in the literature147.
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2.2.1 The amide coupling reaction
The mechanism of the amide coupling that was utilised is shown in Scheme 2.2.
The reaction proceeds through abstraction of the carboxylic acid proton by a lone
pair from the imide followed by the attack of the oxygen on the resultant imide
carbocation to form an O-acylisourea. At this point the O-acylisourea can rearrange
and racemise to form an unreactive N -acylisoura, this rearrangement is slow and
can be avoided by the addition of a nucleophile (HOBt) which attacks fast but yet
generates an intermediate which retains enough reactivity to couple with the amine
and form the amide with a stereocentre conserved from the starting material, this
fast step additionally helps to reduce side-product formation202. The choice of EDC
over other carbodiimide coupling agents such as dicyclohexylcarbodiimide (DCC) or
diisopropylcarbodiimide (DIC), was taken because of the solubility of the resulting
urea, which in the case of EDC is a water soluble urea, allowing its removal with an
aqueous workup.
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Scheme 2.2: Generalised mechanism for EDC activated amide coupling with HOBt
Initially 7 analogues of the lead compound 4 (shown in Table 2.1) were synthesised
and their tested for HDAC8 inhibition. These analogues focused on variation of
the groups either side of the α-amino amide ZBG (the STBG and ARBG). The
variation in STBG and ARBG was achieved by changing the N -Boc amino acid
or the amine being coupled. Following N -Boc deprotection the desired compounds
were successfully synthesised with good purity ( >95%).
70
1st Generation Inhibitors Simon O.R. Greenwood
2.2.2 Amide coupling to generate N -Boc-α-amino amides
To investigate the effect of alterations in the STBG and ARBG the lead compound
4 and 7 analogues were synthesised with either phenyl, p-hydroxyphenyl or 2,4-
dichlorophenyl ARBG and a selection of different STBGs (Table 2.1).
Table 2.1: Synthetic yields in the production of 4 and initial analogues with preliminary
structural variations in the STBG and ARBG
STBG
ARBG
N N
N
N
N
N
Coupling 48% 32 57% 33 64% 34 50% 35
Deprotect 92% 36 85% 37 75% 38 98% 39
N
OH
N
OH
N
ClCl
N
ClCl
Coupling 52% 40 32% 41 76% 31 68% 42
Deprotect 61% 43 70% 44 87% 4 48% 45
In order to confirm that the reaction was indeed proceeding without racemisation,
four α-amino amides (36, 37, 43 and 44) were synthesised with their corresponding
enantiomers (46, 47, 48 and 49 respectively) equal and opposite [α]D measurements
were recorded (see Table 2.2).
2.2.3 N -Boc deprotection of α-amino amides and their isola-
tion
Synthesis of N -Boc protected α-amino amides allows facile transformation to the
desired final product, an α-amino amide salt through the removal of the Boc group.
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Table 2.2: [α]D measurements of matching enantiomers.
NH2.HCl
N
O NH2.HCl
N
O NH2.HCl
N
O NH2.HCl
N
O
[α]D -30.4° 36 +33.0° 46 -7.8° 37 +7.2° 47
NH2.HCl
N
O
OH
NH2.HCl
N
O
OH
NH2.HCl
N
O
OH
NH2.HCl
N
O
OH
[α]D 34.9° 43 +32.4° 48 -9.0° 44 +12.1° 49
Removal of the Boc protecting group proceeded with ease requiring only a short
treatment with ethereal hydrogen chloride (generally <2 h). The N -Boc-α-amino
amides 32 and 50 were sucessfully deprotected following the procedure used in
literature147 to synthesise the lead compound 4. Similar treatment with ethereal
hydrogen chloride afforded α-amino amide salts 36 and 46 in excellent yields (>90
%).
N -Boc protected α-amino amide 47 has been N -Boc-deprotected previously via a
similar method using trifluoroacetic acid in DCM. Following a basic workup the
amine of 47 was obtained as an oil203. Solid compounds are more stable and easier
to handle, in this case it was therefore desirable to obtain the hydrochloride salt for
this final product (and all future cases). The oil was dissolved in diethyl ether then
treated with ethereal hydrochloric acid to precipitate the insoluble hydrochloride
salt.
In contrast to the easily isolable salts 36 and 46, the hygroscopic nature of the
analogues 37 and 47 (which have tetrahydroisoquinolyl STBGs) caused difficulties
in isolation. Upon evaporation of the solvent from the ethereal suspension of 37 the
white precipitate turned into a colourless oil with an apparent >100% yield. The
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NMR spectrum of the salt revealed complete N -Boc deprotection but also contained
a large water peak. It was therefore determined that these hydrochloride salts were
hygroscopic and that the ethereal hydrochloric acid had a small amount of water
which remained as the diethyl ether evaporated and was subsequently absorbed by
the salt turning it into an oil. This was confirmed when trituration of the oil with
dry diethyl ether to remove water did give a small amount of white hydrochloride
salt.
N
O NH2.HCl
N
O NH2.HCl
N
O NH2.HCl
N
O NH2.HCl
36 46 37 47
Figure 2.2: The non-hygroscopic (36, 46) and the very hygroscopic (37, 47) N -Boc-α-
amino amide salts.
The salt 37 was so hygroscopic that the initial solid obtained after vacuum filtra-
tion became an oil within 5 seconds. The filtration of the hydrochloride salts was
further complicated by the latent enthalpy of evaporation of diethyl ether. As the
diethyl ether evaporates it cools the surrounding glassware and atmospheric water
condenses on the surfaces which is absorbed by the filtered product. This problem
was overcome by the use of gravity filtration over diethyl ether heated to reflux.
The filter paper was then moved quickly to a warm drying cupboard to prevent
the cooling of the surfaces and the resultant condensation and absorption of atmo-
spheric water into the salt. Different levels of hygroscopicity were encountered for
various other salts and so gravity filtration over boiling diethyl ether was utilised in
the isolation of all subsequent salts. The solid salts were kept in a desiccator and
were exposed as little as possible to open atmosphere. Yields for the deprotection
of N -Boc α-amino amides can therefore only be taken as approximate due to the
unknown level of hygroscopiscity for every individual hydrochloride salt.
A stronger N -Boc deprotection strategy was required for α-amino amides 40 and 51
(Figure 2.3) with phenol ARBGs. After a 16 h treatment with ethereal hydrochloric
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N
O NH
OO
OH
N
O NH
OO
OH
40 51
Figure 2.3: The α-amino amides 40 & 51 which require HCl bubbling through an ethe-
real solution.
acid some starting material was present (as determined by TLC), and was still
present after a further 2 h at reflux. A modified deprotection strategy attempted
which conveniently also avoids the use of slightly wet ethereal hydrochloric acid.
Hydrogen chloride is bubbled through a dry ethereal solution of the N -Boc-α-amino
amide deprotecting it and forming an insoluble hydrochloride salt which can be
collected by filtration as described above.
2.3 1st Generation α-amino amide inhibition assay
results
Inital efforts of this study were aimed at the investigation of the chemical variability
of the novel inhibitor 4 through alteration of both the STBG and ARBG components
whilst keeping the α-amino amide ZBG constant.
Initially exploration of the ARBG and STBG was undertaken separately to assess
the possible routes to improve the potency and selectivity of the lead compound
4. Relative initial steady-state rates collected for inhibition of HDAC8 by lead
compound 4 are shown in Figure 2.4. The lead compound 4 has a measured IC50
of 206 ±51 nM which corresponds to a ki of 204 ±50 nM using the Cheng-Prusoff
equation (Equation 2.1)204, in this case because the KM of the MAL substrate (17
mM) is 85 times that of the substrate concentration ([S]=200 µM), [S]
KM
is small
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and Ki values are very close to IC50 values. The binding energy of 4 to HDAC8 is
calculated using Gibbs free energy of binding equation (Equation 2.2).
Ki =
IC50
1 + [S]
KM
(2.1)
∆Gbinding = −RTlnKi (2.2)
The IC50 obtained for 4 differs slightly from the literature reported value of 90
nM147. Values reported for other inhibitors against HDAC8 can vary greatly - for
example Vorinostat (5) has reported IC50 values between 49 nM
205 and 2185 nM206.
Additionally the precise assay conditions and error values are not reported in the
literature and so conclusions about this discrepancy cannot be made. Here assay
conditions were kept consistent where possible and comparisons between inhibitors
are therefore possible here.
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Figure 2.4: Experimental data points recorded for 20 HDAC8-4 inhibition assays. Dif-
ferent symbols represent data from independent repeats. Fitted line is a
calculated inhibiton curve for IC50 = 210 nM, the average calculated for 4
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2.3.1 Changes to the 2,4-dichlorophenyl ARBG
The ARBG is a key part of the novelty of the α-amino amide class of HDACi. The
primary interaction in this pocket is an aromatic stacking interaction with Trp141.
Trp141 is unique to HDAC8 with leucine present at this position in other class 1
HDACs (Figure 2.5). The interaction with Trp141 is therefore highly likely to be
contributing to the specificity of 4 for HDAC8.
Q Q  D I A V N W A G G  H H A   S E A S G F C Y V N D I V L A I L E L L K Y
R Q Q T D M A V N W A G G L H H A K K S E A S G F C Y V N D I V L A I L E L L K Y
N K I C D I A I N W A G G L H H A K K F E A S G F C Y V N D I V I G I L E L L K Y
E L K N G F A V V R P P G - H H A E E S T P M G F C Y F N S V A V A A K L L Q Q R
E L K N G F A I I R P P G - H H A E E S T A M G F C F F N S V A I T A K L L Q Q K
E I R N G M A I I R P P G - H H A Q H S L M D G Y C M F N H V A V A A R Y A Q Q K
E L K N G F A V V R P P G - H H A D H S T A M G F C F F N S V A I A C R Q L Q Q Q
D G M C K V A I N W S G G W H H A K K D E A S G F C Y L N D A V L G I L R L R R K
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Figure 2.5: Alignment of all 11 human HDAC enzymes showing the unique Trp141 found
in HDAC8 (performed using Mafft alignment algorithm within Jalview soft-
ware).
From the HDAC8-4 structure, interactions can be seen between HDAC8 and the
chlorine atoms (see Figure 2.7a). The electronic anispotropy about the chlorine
atom at position 4 results in a δ−ve region facilitating an interaction with the positive
Arg37 sidechain. Halogen substitutents on aromatic rings have also been reported
to make “halogen-bonds” to backbone carbonyl oxygen atoms, hydroxyl groups, car-
boxylate groups and pi surfaces of sidechains that can all act as electron donating
Lewis bases (Figure 2.6b, discussed in Section 1.4.3)185. In the HDAC8-4 structure
the chlorine atom at position 2 on the aromatic ring is 3.4 A˚ from the peptide back-
bone oxygen atom of Gly140, suggesting that there is an interaction between these
two atoms.
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Figure 2.6: (a) Two reported α-amino amide HDAC8 selective inhibitors, and (b, left)
Traditional assumption of the halogen as a Lewis base (electron donor) with
a predominantly isotropic electron distribution on the cap, (b, right) descrip-
tion highlighting the anisotropy of the electron density on the halogen. The
color gradient from cyan to red represents the electrostatic potential mapped
onto the electron isodensity surface(from [185]).
(a)
Gly140
Trp141
Ile34
Arg37
(b)
Tyr306
Met274
Phe152
Phe208
Phe207
Figure 2.7: HDAC8-ligand interactions in (a) the ARBG, and (b) the STBG as observed
in the published structure147.
To explore the effect of the chlorinated aromatic unit, compounds were synthesised
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with different ARBG as compared to the 2,4-dichlorophenyl group found in the lead
compound 4.
Phenyl ARBG
To determine the contribution of the chlorine substitutions to the binding of 4,
α-amino amide inhibitor 36 was synthesised with an unsubstituted phenyl ARBG
(Table 2.3). All other protein-ligand interactions should be maintained as this vari-
ation is a removal of two chlorines rather than addition to the group. The only
exception to this would be if the chlorine interactions cause a significant confor-
mational change in the protein which alters other binding surfaces in an allosteric
fashion.
Table 2.3: A selection of compounds synthesised to explore the possibility of varying
the ARBG and STBG and their associated IC50 (full results are presented in
Table 2.4).
NH2.HCl
N
O NH2.HCl
N
O
NH2.HCl
N
O
OH
NH2.HCl
N
O
OH
N
O
NH2.HCl
ClCl
NH2.HCl
N
O
ClCl
36 37 43 44 4 45
IC50
/µM
1.15
±0.18
10.7
±0.86
4.28
±1.56
21.0
±6.52
0.21
±0.04
2.06
±0.51
∆Gb
/kcal
mol−1
-8.43
± 0.16
-7.1
± 0.08
-8.24
± 0.36
-6.63
± 0.31
-9.48
± 0.18
-8.07
±0.25
The unsubstituted ARBG containing α-amino amide inhibitor 36 has a 5-fold higher
IC50 value than the corresponding 2,4-dichlorophenyl ARBG containing inhibitor
4 (1.15 ±0.18 µM vs. 0.21 ±0.04 µM). Using Equations 2.1 and 2.2 which con-
vert an IC50 value to a binding energy, this correlates to a binding energy loss of
about 1 kcal mol−1 which occurs as a result of the loss of the two chlorine sub-
stituents (Table 2.3). To confirm this result, two more compounds were synthesised,
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both with a tetrahydroisoquinoline substrate binding group. Compound 37 with
a unsubstituted phenyl ARBG had an IC50 5-fold higher than the corresponding
2,4-dichlorophenyl substituted inhibitor 45, again this energy loss corresponds to
a reduction in binding energy of ∼ 1 kcal mol−1 indicating that the presence of
the chlorine substitutions provides ∼ 1 kcal mol−1 to the binding energy of the
lead compound 4 (see Figure 2.9). Allosteric effects are unlikely to contribute 1
kcal mol−1 to binding energies as the ∆∆Gbinding is the same when both isoindoline
and tetrahydroisoquinoline STBG are present, therefore interactions involving the
ARBG aromatic substituents as well as the the pi-stacking with Trp141 are required
for tight binding.
(a)
Trp141
Ile34
Arg37
(b)
Trp141
Ile34
Arg37
Figure 2.8: (a) Two aligned structures of HDAC8 bound to the literature α-amino amide
inhibitors 4 (teal) and 52 (olive), and (b) manual docking of p-hydroxyphenyl
ARBG containing α-amino amide 43 into HADC8-4 structure.
p-Hydroxyphenyl ARBG
Hydroxyl groups posess a lone pair of electrons and a very polar oxygen-hydrogen
bond which makes them good hydrogen bond donors and acceptors and also Lewis
bases. To explore the possibility of modifying the interaction between the Arg37
sidechain and a hydroxyl group, compound 43was synthesised with a p-hydroxyphenyl
ARBG. Manual docking of 43 into the HDAC8 structure shows that the lone pair
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can be positioned in such a way as to interact with the positively charged Arg37
sidechain (Figure 2.8b). The acetate release pocket is most-likely large enough to
accommodate a hydroxyl group being only slightly larger than a Cl atom.
The compound with a p-hydroxyphenyl ARBG (43) showed a reduction in binding
energy of 1.86 ±0.40 kcal mol−1 compared to its 2,4-dichlorophenyl ARBG con-
taining counterpart (4)(Table 2.3). Again this result was confirmed through the
synthesis of another compound, both with a tetrahydroisoquinoline STBG. The p-
hydroxyphenyl ARBG containing inhibitor (44) has a binding energy of -6.63 ±0.31
kcal mol−1, 1.44 ±0.41 kcal mol−1 smaller than the corresponding 2,4-dichlorophenyl
ARBG containing inhibitor (45). This loss in binding energy is close to the loss in
binding energy seen when the 2,4-dichlorophenyl group is replaced with an unsub-
stituted phenyl ARBG (36→43, Figure 2.9, ∼1 kcal mol−1). The presence of the
p-hydroxyphenyl group in the acetate release pocket does not re-establish interac-
tions with the acetate release pocket, in fact there is possibly a small negative effect
due to the p-hydroxyphenyl ARBG, possibly because of the electron-withdrawing
effect of the oxygen affecting aromatic stacking with Trp141.
From these explorations of the ARBG, it appears that the 2,4-dichloro unit cannot
be readily improved upon. From now on, the focus will be on exploration and
optimisation of the STBG.
2.3.2 Changes to the STBG
Alternative aromatic ringed systems to isoindoline were explored as STBG, which
would enable a more diverse series of inhibitors to be easily constructed. Such alter-
ations include tetrahydroisoquinoline as discussed above (Section 2.3.1). Aromatic
stacking interactions between inhibitor 4 and Phe152 and Phe208 are present (Figure
2.7b). These two residues have previously been mutated to all other natural amino
acids in HDAC1 and were proved to be essential for activity (although a Phe208Tyr
substitution partially restored some activity)207. To confirm the importance of these
two residues in HDAC8 I performed site directed mutagenesis, recombinantly ex-
pressed and purified HDAC8 containg Phe152Ala and Phe208Ala mutations. No
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N
O NH2.HCl
N
O NH2.HCl
OH
N
O NH2.HCl
N
O NH2.HCl
OH
1.86
±0.40
1.44
±0.39
1.37
±0.18
0.99
±0.48
N
O NH2.HCl
N
O NH2.HCl
1.01
±0.26
ClCl
Cl Cl
1.05
±0.24
1.41
±0.31
4
45
36
37
43
44
Figure 2.9: Losses in binding energy between 1st generation α-amino amide HDAC8i.
Horizontal arrows represent ARBG changes, vertical arrows represent
changes in STBG. Values on arrows are ∆∆Gbinding values in kcal mol
−1.
activity was detected in the mutants using the MAL substrate (results not shown).
This confirms the importance of these two aromatic interactions to the binding of
substrate in HDAC8.
Comparison of HDAC8 crystal structures in complex with various inhibitors shows
the aromatic ring of Phe152 is able to assume many orientations in order to ac-
commodate different ligands (Figure 2.10a82). The structural flexibility of Phe152 is
such that a difference in positioning is observed even between the structures of two
similar α-amino amide inhibitors reported (Figure 2.6a147).
Figure 2.10a highlights the structural flexibility of Phe152 that lines the substrate
tunnel of HDAC8, with a hydroxamate inhibitor CRA-A (6). The Phe152 sidechain
can swing up to reveal a “subpocket” which is thought to be a feature unique to
HDAC8. Two “linkerless” HDAC8 specific inhibitors (19 & 53, Figure 2.10b) have
been reported which are thought to utilise this subpocket to confer HDAC8 se-
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lectivity (53 IC50 = 0.7 µM) over HDAC1 (IC50 >100 µM) and HDAC6 (IC50 =
55 µM)90(though crystal structures have not been solved with these ligands which
prove this). As discussed earlier in Section 1.4.3, aromatic T-stacking interactions
are formed between Phe152 which is perpendicular to the substrate tunnel and the
isoindoline STBG (Figure 2.7b).
The position of Phe152 when bound to the non-specific HDAC inhibitor Vorinostat
(5), grey in Figure 2.10a) is flat against the substrate tunnel. It is possible that the
ability of Phe152 to rotate is unique to HDAC8 and is a feature that can be targeted
for the synthesis of HDAC8 selective inhibitors. The crystal structure shown in 2.10a
has a rotated Phe152 sidechain, but the selectivity profile for this inhibitor has not
been reported and so no inferences can be made in this case.
(a)
Phe152
Phe208
Met274
Trp141
Tyr306
(b)
OHN
OH
OHN
OH
OHN
OH
N
O
H
N
O
N
H
O
H
N
O
OH
N
O
NH2.HCl
ClCl53
19
6
5
4
Figure 2.10: (a) HDAC8-4 (teal, 4 not shown) and HDAC8-Vorinostat (5, grey, not
shown) structures superimposed onto the HDAC8-CRA-A (yellow, 6) struc-
ture, and (b) Two “linkerless” HDAC8 inhibitors 53 and 19 which show
selectivity for HDAC8 over HDAC1 and HDAC690, Vorinostat (5, CRA-A
(6) and lead compound 4.
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Tetrahydroisoquinoline STBG
As discussed in Section 4.1, isoindoline is a fairly unstable molecule and substi-
tutions around it require formation of the isoindoline system after installation of
a substituent at the position desired. Tetrahydroisoquinoline was tested as a po-
tential substitute for the isoindoline STBG as it is more stable and more readily
substituted. It was hoped that due to the known flexibility of the HDAC8 substrate
channel that the non-planar asymmetrical tetrahydroisoquinoline STBG would be
accommodated without a large decrease in potency. If the binding affinity remained
high then then modifications could be made to the tetrahydroisoquinoline system to
try and introduce more interactions with the protein and improve binding affinity
as a result.
The tetrahydroisoquinoline STBG can adopt one of two conformations and one of
two different rotamers due to the planar amide system (Figure 2.11b). The nitrogen
is sp3 hybridised, but as the lone pair is delocalised into the amide bond the bond-
ing around the nitrogen is effectively trigonal-planar. This causes the two adjacent
methylene groups to be in plane with the amide bond. The remaining methylene
group can assume one of two conformations, forming a more boat-like structure
(Figure 2.11c) or a more chair like structure (Figure 2.11d). Both these conforma-
tions are non-planar and may cause steric clashes with the substrate channel. In
addition to the non-planarity of tetrahydroisoquinoline it is also asymmetrical, the
isoindoline STBG of the lead compound 4 is symmetrical about the amide bond
(see Figure 2.11a). This asymmetry introduces an additional kink in the molecule
causing possible steric clashes with the wall of the substrate tunnel.
Tetrahydroisoquinoline containing compounds 45, 37 and 44 discussed above in
Section 2.3.1 were assayed for HDAC8 inhibition. In all cases however, these tetrahy-
droisoquinoline STBG containing compounds with IC50 values of 2.06 ±0.51, 10.7
±0.86 and 21.3 ±6.52 µM respectively are 5 to 10-fold less potent than their isoindo-
line STBG containing counterparts (4, 36 and 43 respectively)(IC50 = 0.21 ±0.04,
1.15 ±0.18 and 4.28 ±1.56 µM), this difference equates to a loss of binding energy of
around 1.4 kcal mol−1 (Figure 2.9). Independent of ARBG, replacement of the isoin-
83
1st Generation Inhibitors Simon O.R. Greenwood
doline STBG with a tetrahydroisoquinoline STBG destabilises the HDAC8-inhibitor
interaction by ∼1.4 kcal mol−1.
(a)
NH2.HCl
N
O
ClCl
N
O
NH2.HCl
ClCl
4 45
(b)
arg
(c)
Met274
Phe152
Phe208
(d)
Met274
Phe152
Phe208
Figure 2.11: (a) Structures of α-amino amide HDAC8 inhibitors 4 and 45, (b) Overlay
of four energy minimised structures of isoquinoline STBG containing 45
(yellow, purple, grey, blue) and isoindoline STBG containing 4 (teal) (c &
d) manual docking of the 4 rotamers of 45, positioning of 4 from crystal
structure is shown for comaprison (teal).
To explain these results, tetrahydroisoquinoline containing 45 was manually docked
into the HDAC8 structure to reveal potential changes in interactions that arise from
the new STBG. It was hoped that the flexibility within the substrate tunnel would
allow for the accommodation of tetrahydroisoquinoline as a STBG, leaving the aro-
matic interactions intact. While manual docking suggests that on the whole, steric
84
1st Generation Inhibitors Simon O.R. Greenwood
Table 2.4: HDAC8 inhibition assay results for first generation compounds. Values are ±
standard deviation of >2 independent repeats (∆Gb = ∆Gbinding).
ARBG
NH2.HCl
O
STBG
ARBG STBG
IC50
/µM
∆Gb
/kcal
mol−1
ARBG STBG
IC50
/µM
∆Gb
/kcal
mol−1
36
N
1.15
±0.18
-8.43
±0.16
44
OH N
21.3
±6.52
-6.63
±0.31
37
N
10.7
±0.86
-7.1
±0.08
39
N
N 11.0
±5.98
-7.04
±0.54
38
N
N >600 >-4.6 4
ClCl N
0.21
±0.04
-9.48
±0.18
43
OH N
4.28
±1.56
-8.24
±0.36
45
ClCl N
2.06
±0.51
-8.07
±0.25
clashes should be minimal for tetrahydroisoquinoline containing 45, comparison of
4 and 45 STBGs within the substrate tunnel reveals a potentially crucial difference
between the positioning and orientation of the isoindoline and tetrahydroisoquino-
line aromatic rings (Figure 2.11). The aromatic ring for isoindoline 4 is positioned
for T-stacking interactions with Phe152 and Phe208 (Figure 2.7b), and despite the
known conformational flexibility of Phe152 which has been seen in many positions
in different structures (Figure 2.10a), it is apparent that this flexibility could not
enable aromatic stacking with tetrahydroisoquinoline 45 to be maintained. The loss
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in binding energy could therefore be caused by introduced steric clashes and/or loss
of aromatic stacking interactions
Piperazine based STBGs
With the loss of potency that results from the introduction of a tetrahydroisoquino-
line STBG, two compounds with linear and symmetrical piperazine-based STBGs
were synthesised (39 and 38) to further explore the possibility of replacing the
isoindoline STBG with an alternative, more readily modified unit.
Similar to tetrahydroisoquinoline STBGs, piperazine based STBG are also poorly
tolerated within the substrate tunnel, with IC50s of 11.0 ±5.98 µM and >600 µM
respectively both methylpiperazine 39 and phenylpiperazine 38 are poor inhibitors
(Table 2.4). When manually docked into the HDAC8-4 structure the chair confor-
mation of the piperazine ring in 39 is obvious (Figure 2.12a). In its lowest energy
conformation, as calculated by an energy minimisation performed within the pro-
gram Avogadro208, the methyl group lies in an equatorial position. This places the
methyl group in a steric clash (1.1 A˚) with Phe152 or very close (2.7 A˚) to His180
(Figure 2.12a). Manual docking of the slightly less energetically favourable axial con-
formation of the methyl piperazine STBG allows no steric clashes with the protein.
As there is a pose in which the methylpiperazine 39 can be fitted into the HDAC8
structure it is likely that the loss of potency is mainly due to the lost aromatic
stacking interactions with Phe152 and Phe208. This is confirmed by comparison to
the equivalent tetrahydroisoquinoline STBG containing compound 36 which has a
similar potency (IC50 =10.7 ±0.86 µM).
In an attempt to re-establish aromatic contacts in the region a phenyl ring was in-
troduced on to the end of the methylpiperazine STBG to make the phenylpiperazine
STBG containing 38. Addition of results in a dramatic reduction in affinity of the
inhibitor compared to 39 however. A 50-fold loss in potency is seen corresponding
to a loss in binding energy of >2.4 kcal mol−1. The geometry of phenylpiperazine
is different ot that of methylpiperazine because of the delocalisation of the pheny-
lamino nitrogen lone pair of electrons into the phenyl ring, this results in a planar
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region as opposed to the approximately tetrahedral geometry of the methyl amino
group.
(a)
Phe208
Phe152
His180
(b)
Phe208
Phe152
His180
Figure 2.12: The two rotamers of (a)38 with solvent exposed phenyl group & (b) 39
manually docked into HDAC8.
Of the two rotamers of 38 manually docked into the HDAC8 structure only one fits
without causing steric clashes with Phe152 (brown ligand in Figure 2.12b). This
conformation of 38 does not put the phenyl ring in a position to stack with any
residues at the mouth of the subtrate tunnel, instead it forces the phenyl ring to be
exposed to the solvent. This is a very energetically unfavourable interaction and is
likely the cause of the very low potency.
It is interesting that piperazine is unsuitable as a STBG as it is the STBG present
in the one other known α-amino amide (52, Figure 2.6a), this inhibitor does sit in
a slightly rotated conformation in the ARBG however (Figure 2.8a), it is possible
that the piperazine STBG is only compatible with a 3-chlorophenyl ARBG while
isoindoline STBG is only compatible with the 2,4-dichlorophenyl ARBG due to
the enforced STBG orientation governed by the identity of the ARBG. The 2,4-
dichlorophenyl ARBG was persued due to the superior reported affinity for HDAC8
of 4 (90 nM) over 52 (200 nM). Additionally 52 contains an amide on each side of
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the piperazine which would significantly alter the geometry of the piperazine group
(in a similar fashion as the aromatic ring of 38 was seen to do).
2.4 Summary of 1st generation inhibitor assay
results
Eight compounds were synthesised with various ARBGs and STBGs to investigate
the binding pocket of 4 in HDAC8; these compounds were tested for HDAC8 in-
hibition and binding energies were calculated from the measured IC50 values. A
tetrahydroisoquinoline group was tested in place of the isoindoline STBG of the
lead compound 4.
Chlorination of the ARBG was found to be essential as inhibitors with unsubstituted
phenyl ARBG lead to a ∼1 kcal mol−1 reduction in binding energy. Attempts to
re-establish a contact with Arg37 by introduction of a p-hydroxyphenyl ARBG to
act as a Lewis base resulted in a similar loss in binding energy when compared to
the 2,4-dichlorophenyl ARBG.
Replacement of the isoindoline STBG for a non-planar and asymmetric tetrahy-
droisoquinoline STBG group lead to a loss of aromatic contacts that resulted in a
>1 kcal mol−1 loss in binding energy that was independent of the ARBG present.
In order to confirm this effect two piperazine containing inhibitors were synthesised.
A similar ∼1 kcal mol−1 loss in binding energy was measured for the methylpiper-
azine inhibitor 39 indicating that the change in binding energy is due to the loss of
aromatic interactions within the substrate tunnel. Reestablishment of aromatic con-
tacts was not successful through the addition of a phenyl ring to inhibitor 39 to give
38 with a phenylpiperazine STBG. Manual docking reveals that only one rotamer of
38 fits within the substrate tunnel without steric clashes and this conformation ex-
poses the aromatic ring to the solvent which, being a higly unfavourable interaction
reduces the binding energy by > 2.4 kcal mol−1 compared to the methylpiperazine
STBG containing 39.
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The structure of HDAC8-4 shows very little room for additional variation within the
acetate release pocket. With the observed and quantified necessity for the interac-
tions between the two chlorine atoms and Gly140 and Arg37 it was decided that the
2,4-dichlorophenyl ARBG is unlikely to be improved upon within the time available
and so subsequent efforts were focussed on exploration of possible alternative groups
to occupy the substrate tunnel which is known to be flexible and contains at least
one water molecule in the HDAC8-4 structure.
The acetate release pocket lies within the core of the protein and as such there
is little room around it to perform modifications. Crystal structure with different
ligands reveal the substrate binding tunnel is able to accommodate many different
STBGs including some containing bulky and aromatic regions, in these structures
conformational change is seen within residues lining the tunnel, especially Phe152
(Figure 2.10a). As a result of these observations it was decided to attempt futher
variation of the STBG while maintaining the 2,4-dichlorophenyl ARBG of the lead
compound 4.
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3 2nd generation α-amino amide
HDAC8 inhibitors - further
variation of the STBG
3.1 Introduction
Following the discovery of the necessity to have a 2,4-dichlorophenyl ARBG a series
of 16 compounds were synthesised which retain the 2,4-dichlorophenyl ARBG from
the lead compound but contain varying STBGs. The inhibitory activity of these
compounds against HDAC8 allows us to investigate the possibiblity of introducing
an alternative STBG (Table 3.1) and also to identify different factors that are con-
tributing to binding of the inhibitor with a view to maximising the beneficial factors
and minimising the factors which are detrimental to binding.
Entropy is a measure of disorder in a system; the more disordered a system is,
the greater the entropy (the more negative the value). In small molecules a ma-
jor component of entropy is the number of conformations a molecule can exist in
and coresponds to the number of rotatable bonds within the molecule. Rotatable
bonds add to the degrees of freedom experienced by a molecule and so add to the
conformational entropy of a molecule. These factors include introducting flexibility
to and extending the length of the alkyl linker to the aromatic ring, introducing
heteroatoms to the ring, and adding various finctional groups to the STBG.
Equation 3.1 shows the relationship between binding energy (∆Gbinding), the binding
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enthalpy (∆Hbinding) and the binding entropy (∆Sbinding) where T is the absolute
temperature. ∆Sbinding is defined in Equation 3.2 where Sf and Si are the final and
initial entropy of the molecules. For ∆Gbinding to be maximised -T∆Sbinding must
be minimised (assuming minimal change in ∆Hbinding remains constant). This is
achieved if Si is minimised (as there is always a reduction in conformational entropy
upon binding). Therefore a reduction in conformational entropy of a free ligand will
result in an increase in binding energy (all other factors being constant).
∆Gbinding = ∆Hbinding − T∆Sbinding (3.1)
∆Sbinding = Sf − Si (3.2)
The STBG of α-amino amide 55 was designed to explore the contribution of confo-
mational entropy to the binding of α-amino amide HDACi. Comparison of STBGs
of 54 and 55 is shown in Figure 3.1. The STBG of α-amino amide 54 contains an
ethyl linker with two rotatable bonds, transformation of this linker into an aromatic
ring gives α-amino amide 55 creating a rigid planar carbazole system which results
in a reduction in conformational entropy of the molecule.
NH
O NH
ClCl
HN
OO
NH
O NH
ClCl
HN
OO
54 55
Figure 3.1: Comparison of the STBG of 54 and 55 with reduced conformational entropy
through the addition of an aromatic ring.
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3.2 2nd Generation α-amino amide inhibitor
synthesis
3.2.1 Synthesis of carbazole-3-amines
Many of the amines coupled for the initial series of α-amino amide HDAC8 inhibitors
were commercially sourced. Carbazole-3-amines 58 and 61 are prohibitivley expen-
sive from commercial sources (up to $540 /g). Both are easily synthesised in two
steps from carbazoles 56 and 59 (Scheme 3.1) which are significantly cheaper (∼$1
/g). Nitration of 9-ethylcarbazole (59) was initally attempted as a test reaction
and proceeded to give 60 with an impressive 99% yield. The analagous carbazole
nitration to give 57 gave a lower yield at 57%. The subsequent reduction of 57
and 60 using ammonium formate proceeded with fairly low yields of 41% and 31%
respectively. The literature describes an 80% yield for the reduction of 57 to 58
using hydrazine hydrate and a palladium catalyst209.
N N N
NO2 NH2
glacial 
AcOH
c.HNO3
NH4HCO2
10% Pd/C
MeOHR R R
R=   H
R=   Et
R= H   57%
R= Et   99%
R= H   52%
R= Et   41%
NH
O NH
ClCl
N
EDC
HOBt
R= H    36%
R= Et   46%
R
OO
56 57 58
55
59 60 61
62
29
Scheme 3.1: Route taken for synthesis of α-amino amides 55 and 62 via carbazole-3-
amines.
3.2.2 Coupling and deprotection of 2nd generation inhibitors
A general trend was seen for the yield of the coupling where sterically unhindered
amines (such as 63 and 83) were coupled with a higher yield than aniline type
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amines (such as 55 and 62) that have reduced nucleophilicty because the nitrogen
lone pair is delocalised into the aromatic system.
Many of the N -Boc-α-amino amides were not completely soluble in diethyl ether. A
small volume of dry dichloromethane was therefore added until a complete solution
was obtained before the introduction of hydrogen chloride gas. In some instances a
larger amount of DCM was required (for example in the deprotection of 63 to give 68
and 67 to give 72 which required 30 mL of a 2:1 and 1:2 mixture of diethyl ether to
DCM respectively). The additional DCM did not have an effect on the solubility of
the resultant hydrochloride salts which remained insoluble in the diethyl ether/DCM
mixture allowing filtration to proceed as before.
3.3 2nd Generation α-amino amide inhibitor assay
results
To further probe the protein-ligand interactions within the substrate tunnel a num-
ber of α-amino amide inhibitors were synthesised with the 2,4-dichlorophenyl ARBG
but various, structurally diverse STBGs. A wide range of IC50 values were measured
which provide indications as to which types of groups and linkers are favoured over
others within the substrate binding tunnel.
Overall, (1) linker length between the ZBG and aromatic group was varied from 0 to
3 methylene units, (2) linkers were rigified, (3) aromatic groups were modified with
p-methoxy and hydroxy groups and (4) a selection of heteroaromatic ring systems
were tested (Table 3.2). In total 32 α-amino amide inhibitors were synthesised and
tested for activity against HDAC8. Manual docking of inhibitors into an HDAC8
structure was performed to assess the rationale for altered potency compared to the
lead compound 4.
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Table 3.1: Synthetic yields for α-amino amide inhibitors varing in STBG only
STBG
NH
O
ClCl
O
O
STBG
NH
NH
O
NH NH NH
O
Coupling 96% 63 71% 64 51% 65 94% 66 58% 67
Deprotect 73% 68 55% 69 92% 70 63% 71 63% 72
STBG
NH
HO
NH
HN
N
NH
S
NH
Coupling 74% 73 77% 54 82% 74 54% 75 74% 76
Deprotect >100% 77 94% 78 83% 79 42% 80 82% 81
STBG
NH
NH
HN N
NH
OH
NH
Coupling 96% 82 36% 55 46% 62 - 85% 83
Deprotect 95% 84 42% 85 - 82% 95 85% 86
STBG
NH
N
NH NH
HO
HO
NH
HN
HO
Coupling 42% 87 49% 88 63% 89 72% 90
Deprotect >100% 91 >100% 92 95% 93 79% 94
95
2nd Generation Inhibitors Simon O.R. Greenwood
3.3.1 Inclusion of the ZBG
In order to test the importance of the α-amino amide ZBG a compound was syn-
thesised with a carboxylic acid in place of the amide (95). Compound 95 binds
very poorly and has the highest IC50 of those tested (410 ±190 µM)(Table 3.2).
Compound 95 has no STBG, a carboxylic acid replaces the amide of the parent
compound 4, 95 therefore lacks the α-amino amide ZBG. It is clear that the amide
contributes a significant amount to the binding since compound 81 with the α-amino
amide ZBG and only a single methyl group occupying the substrate tunnel, has a
greatly improved affinity, IC50 = 16.5±1.79 µM, and an increase in binding energy of
∼2 ± 0.47 kcal mol−1 compared to 95 (Table 3.2). Both 95 and 81 have little or no
extension into the substrate binding tunnel and demonstrate that contacts between
the STBG and substrate tunnel are essential for tight binding of α-amino amide
inhibitors. Generally compounds which provide some interactions with the HDAC8
substrate tunnel have IC50 <5 µM whereas those with obvious clashes or repulsive
interactions have IC50 >5 µM. This is in line with the generally accepted principle
that increased contact surface area between two binding partners provides increased
affinity as more interactions are able to be formed betwen the two partners210. All
other compounds contain substrate tunnel binding groups with aromatic rings that
occupy this tunnel and provide large hydrophobic surface area for interactions and
(generally) have improved binding as a result.
3.3.2 Introducing flexibility into the STBG
Removal of one of the 5-membered ring methylene groups to leave a single methylene
linker between the ZBG and aryl ring from 4 had an unexpectedly large effect on
the binding of α-amino amide inhibitor 68 (Figure 3.2). Manual docking suggests
that the positoning of the STBG aromatic ring would be slightly shifted to one side
(by 1.1 A˚) but should otherwise function as the aromatic ring of 4 does, forming
aromatic interactions with Phe152 and Phe208 (Figure 3.4a), Phe152 has been seen
in different orientations in various structures (Figure 2.10a) and so should be able
to move to accommodate the altered position of the aromatic ring.
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At -7.62 ±0.28 kcal mol−1, compound 68 with increased flexibility has a binding
energy 1.86 ±0.33 kcal mol−1 smaller than the lead compound 4 and IC50 20-fold
higher (Table 3.2). This value corresponds to the entropy loss of approximately
two rotors (0.6 - 1.0 kcal mol−1 per rotor211) which is what has been introduced by
the removal of the 5-membered ring. As a ligand binds to a protein any rotatable
bonds are fixed and the conformational entropy contained within them is lost. This
manifests as a reduction in binding energy as demonstrated by Equation 3.3. The
change in binding energy is therefore likely to be due to increased flexibility of the
free 68 wich posesses a one methylene linker with respect to 4 which has no flexibility
in its rigid isoindoline group.
∆Gbinding = ∆Hbinding − T∆Sbinding (3.3)
N
O
NH2.HCl
ClCl
NH
O
NH2.HCl
ClCl
NH
O
NH2.HCl
ClCl
NH
O
NH2.HCl
ClCl
increase linker length
 -7.62 ±0.28
kcal.mol-1
Introduce flexibility
 1.86 ±0.33
-9.48 ±0.18
kcal.mol-1
-7.95 ±0.40
kcal.mol-1
-8.09 ±0.15
kcal.mol-1
 0.33 ±0.49  0.47 ±0.31
kcal.mol-1 kcal.mol-1 kcal.mol-1
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Figure 3.2: ∆Gbinding changes of α-amino amide inhibitors with the introduction of flex-
ibility and increasing length in the STBG, red values indicate reduction in
binding energy and green values indicate gain in binding energy.
3.3.3 Addition of branched STBG
Branching in the N-amido substituent is deleterious to inhibitor binding. Two
branched STBG-containing compounds (70 and 71) were synthesised which have
IC50 values of 25.30±5.99 and 76.4±13.6 µM respectively (Table 3.2). The inclusion
of a branched methyl group in th imediate vicinity of the α-amino amide ZBG has a
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great impact on binding by introducing steric clashes. The binding of inhibitors with
these groups therefore requires an energetically unfavourable rearrangement of the
hydrophobic substrate tunnel lining residues in order to be accommodated. Manual
docking of 70 and 71 with the HDAC8-4 structure shows that steric clashes could
be occuring with Tyr306 (for 70, Figure 3.3a) and with His180 (for 71, Figure 3.3b)
of HDAC8. While the distances involved should allow these groups to be tolerated
(2.5 A˚ in the case of 70 and 2.7 A˚ in the case of 71), the large reduction in bind-
ing energy measured indicates that favourable interactions are being outweighed by
unfavourable interactions or are being disrupted. It is possible that the presence of
the methyl branching alters the positioning of the inhibitor in the pocket, distorting
the Zn2+ coordination geometry and also the STBG and ARBG positioning, thereby
disrupting many fabvourable interactions, resulting in a reduced binding energy. As
a result of this negative impact of a branched sidechain no further compounds were
synthesised with branched sidechains.
(a)
Met274
Phe208
Phe152
Tyr306
His180
(b)
Met274
Phe208
Phe152
Tyr306
His180
Figure 3.3: Manual docking poses of (a) 70, and (b) 71 in the HDAC8 structure. Po-
tential steric clashes are shown with dashed yellow lines.
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Table 3.2: Inhibition assay results for second generation α-amino amide HDAC8 in-
hibitors with varying STBG. Values are the mean of at least two independent
repeats ± standard deviation, (∆Gb = ∆Gbinding).
Cl Cl
NH2.HCl
O
STBG
STBG
IC50
/µM
∆Gb
/kcal
mol−1
STBG
IC50
/µM
∆Gb/kcal
mol−1
95 OH
410
±190
-4.81
±0.46
81 NH
16.5
±1.79
-6.79
±0.11
71
NH
25.30
±5.99
-6.53
±0.24
70
NH
76.4
±13.6
-5.84
±0.18
4
N
0.21
±0.04
-9.48
±0.18
72
NH
O 2.67
±0.46
-7.91
±0.17
68
NH
4.28
±1.22
-7.62
±0.28
69
NH
O
16.6
±3.19
-6.79
±0.19
86
NH
2.50
±0.99
-7.95
±0.40
77
NH
HO
1.25
±0.39
-8.38
±0.31
91
NH
N
3.85
±0.92
-7.69
±0.24
93
NH
HO
HO
2.07
±0.51
-8.07
±0.25
78
NH
HN 0.97
±0.34
-8.53
±0.35
92
NH
2.01
±0.31
-8.09
±0.15
94
NH
HN
HO
1.77
±0.47
-8.16
±0.27
85
NH
HN 10.5
±6.75
-7.07
±0.64
80
NH
S 3.00
±0.76
-7.84
±0.25
84 NH
8.76
±4.22
-7.18
±0.48
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3.3.4 Increasing length of the STBG
Extension of the methylene linker of 68 to a two (86) or three methylene 92 chain
(Figure 3.2) to allow more conformational flexibility slightly improves the bind-
ing affinity of the inhibitors by 0.33 ±0.49 and 0.47 ±0.31 kcal mol−1 respectively
(Table 3.2). These marginal improvements in binding energy suggest that the aro-
matic ring positioning can be improved by the greater conformational flexibility
imparted by the additional rotatable bond, allowing more optimal interactions with
Phe152 and Phe208, this is supported by manual docking of the inhibitors (Figures
3.4b & 3.5a). Inclusion of extra linker units increases the conformational entropy
of the free inhibitor but is compensated for upon binding by the more favourable
aromatic interactions.
(a)
M274
Tyr306
Phe152
Phe205
(b)
M274
Tyr306
Phe152
Phe205
Figure 3.4: (a) Comparison of lead compound 4 (teal) and manual docking of 68 (brown),
and (b) 86 (sky blue) manually docked into HDAC8 structure.
3.3.5 Introduction of hydrogen bond acceptors
A key interaction between Asp101 of HDAC8 and the peptide substrate was revealed
in the crystal structure, Asp101 is conserved throughout class I and II HDACs
and sits on the flexible L2 loop (which is often crystallographcally unresolved) and
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(a)
M274
Tyr306
Phe152
Phe205
(b)
Tyr306 Phe152
Met274
Phe208
Asp101
Figure 3.5: (a) Manual docking pose of 92 in HDAC8 and (b) HDAC8 structural overlay
with Fluor-de-Lys substrate bound and interactions highlighted with Asp101
on the L2 loop (purple).
has been shown to be essential for substrate binding84. Asp101 facilitates substrate
binding by acting as a clamp; upon association of the peptide ligand, the flexible loop
can close and Asp101 forms hydrogen bonds with the backbone amide NH groups
either side of the residue occupying the substrate tunnel (the acetylated lysine to be
de-acetylated), this locks the peptide backbone of the substrate in a cis conformation
(see Figure 3.5b), thereby reducing koff and in turn Ki (Ki = koff/kon). Asp101
and The L2 binding loop are unresolved in the 4-HDAC8 structure, this indicates
that no interactions are occuring between the L2-loop and α-amino amide inhibitor
4. It was hypothesised therefore that introducing a hydrogen bond to Asp101 from
the inhibitor would provide an improvement in affinity over inhibitors without a
hydrogen bond to Asp101.
Introduction of hydrogen bond acceptors at the distal end of the STBG has a detri-
mental effect on the binding of the inhibitor. 69 with a p-methoxy group has IC50
= 16.6 ±3.19µM, 5-fold higher than 68 with no methoxy group (IC50 = 4.28 ±0.18
µM), this equates to a binding energy difference of 0.83±0.34 kcal mol−1 (Table 3.2).
It is possible that this is due to a repulsion between the δ−ve p-methoxy oxygen and
the neagtively charged Asp101 as seen by manual docking (Figure 3.6a).
101
2nd Generation Inhibitors Simon O.R. Greenwood
(a)
M274
Tyr306
Phe152
Phe205
(b)
Tyr306 Phe152
Met274
Phe208
Asp101
(c)
NH
O
NH2.HCl
ClCl
NH
O
NH2.HCl
ClCl
O
NH
O
NH2.HCl
Cl
O
Cl
O
O
-
O
O
-
-7.62 ±0.28
kcal.mol-1
-6.79 ±0.19
kcal.mol-1
-7.91 ±0.17
kcal.mol-1
0.83 ±0.34
kcal.mol-1
1.12 ±0.26
kcal.mol-1
Asp101 Asp101
68 69 72
Figure 3.6: (a) Manual docking poses of 69, (b) 72 in the HDAC8 structure. Flexible L2
loop and Asp101 (purple) are overlaid from substrate bound structure. (c)
energy differences upon the addition of a hydrogen bond donor to Asp101,
red values indicate loss in binding energy, green values indicate increase in
binding energy. The red circles represent the distance over which Asp101
effects are seen.
Repulsion of the hydroxyl lone pair is supported by improved binding of 72 compared
to 69. Manual docking of 72, a compound with a STBG which maintains the p-
methoxy substitution but has a shortened linker was performed. In this docking the
methoxy group is 7 A˚ from Asp101 (Figure 3.6b) such that the Asp101-p-methoxy
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repulsion cannot take place. The binding energy of 72 is -7.91 ±0.17 kcal mol−1
which is 1.12 ±0.26 kcal mol−1 better than that of 69 which has a repulsive Asp101-
p-methoxy interaction (3.6c).
The p-hydroxyphenyl STBG containing 77 has two-fold lower IC50 and average
binding energy 0.4 ±0.5 kcal mol−1 better than its phenyl counterpart 86 (Figure
Table 3.2). The hydroxyl group could potentially contribute benficial contacts to
the protein-ligand interaction. Hydroxyl groups can be both hydrogen bond donors
through their hydrogen, or acceptors through the lone pair on the oxygen. Manual
docking of two possible poses of 77 into the HDAC8 structure reveals a possible
interaction with Lys33 near the entrance to the substrate tunnel, which may con-
tribute a hydrogen bond (Figure 3.7a), alternatively a hydrogen bond may be being
donated to Asp101 (Figure 3.7b). An edge to face aromatic stacking interaction
could form between the aromatic ring of the STBG and Phe152 if an interaction
were to occur between the OH of 77 and Lys33 (Figure 3.7a). Lys33 is a dynamic
residue, its Cα has been seen to move by more than 0.5 nm when different inhibitors
are bound to HDAC892.
A second hydroxyl group was introduced to assess the effect a dihydroxylated aro-
matic ring would have on the cap group interactions (93). The binding energies of
both mono- and dihydroxylated inhibitors (77 and 93) were well within the errors
of each other and so the effect of the second hydroxy group is not measureable in
this scenario (Table 3.2).
A heteroaromatic pyridine ring was tested as a cap group to see if this would
alter binding at the entrance of the substrate tunnel (91). The pKa of the 4-
methylpyridinium ion is 5.98212 and so the pyridine nitrogen atom will be deproto-
nated at pH 8.0 (the pH of the fluorescent assay192). The IC50 of 91 is 3.85 ±0.92
µM corresponding to a binding energy of -7.59 ±0.24 kcal mol−1 which is very sim-
ilar to that of the equivalent phenyl ringed inhibitor (86) so the introduction of the
piperazine ring has little to no effect on the interactions of the aromatic ring.
Indole STBG containing 78 was also considerably potent of this second generation of
α-amino amide compounds exploring the variability STBG (IC50 = 0.97 ±0.34 µM,
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(a)
Lys33
Tyr306
Met274
Phe208
Phe152
Asp101
(b)
Figure 3.7: Two manually docked poses of 77 in HDAC8-4 structure (teal) that would al-
low for 77 to be (a) a hydrogen bond acceptor from Lys33 and form aromatic
stacking with Phe152, and (b) a hydrogen-bond donor to Asp101.
binding energy = -8.53 ±0.35 kcal mol−1, Table 3.2). Manual docking places the
indole NH to provide a hydrogen bond to Asp101 (Figure 3.8a) in a similar manner
as was seen for 77 above (Figure 3.7). This manual docking pose of a low energy
confomation of 78 with its Asp101 interaction also positions the six-membered aro-
matic ring for an energetically favourable T-stacking interaction with Phe152. The
suggestion that hydrogen bonding interactions to Asp101 could be promoting tight
binding in two low IC50 α-amino amide inhibitors 78 and 77 suggested that the
interaction could be exploited in the design of subsequent inhibitors. Addition of a
hydroxyl group at the 5-position of the indole group of 78 to give 94 had little to
no effect on the binding energy of 94 compared to 78 (-8.16 ±0.27 kcal mol−1 vs.
-8.53 ±0.35 kcal mol−1, Table Table 3.2).
The carbazole inhibitor 85 (Figure 3.8b) was designed with previous observations
on conformational flexibility and hydrogen bonding with Asp101 in mind. A loss in
binding energy of 1.86 ±0.33 kcal mol−1 was observed by replacement of the rigid
5-membered ring with a methylene linker (4→68). This was attributed in the most
part to increased conformational flexibility of the unbound inhibitor 68. Compounds
78, 77, 93 have methylene linkers with three rotatable bonds, but with improved
104
2nd Generation Inhibitors Simon O.R. Greenwood
(a)
Asp101
Tyr306
Met274
Phe205
Phe152
(b)
Asp101
Tyr306
Met274
Phe205
Phe152
Figure 3.8: Manual docking poses of (a) Indole 78 and (b) carbazole 85 in two amide con-
formations, cis-(yellow) and trans-(magenta) the HDAC8-4 structure (teal).
Flexible L2 loop and H-bond-donating Asp101 shown are overlaid from the
HDAC8-Fluor-de-Lys structure (purple).
binding energy over 86 due to hydrogen bonding with Asp101. This suggests that the
hydrogen bonding contribution is greater than the energy loss due to conformational
flexibility. In order to lower the conformatioal flexibility of 78 the methylene linker
was replaced with a rigid aromatic ring. It is known that the substrate tunnel can
accommodate bulky aromatic rings close to the ZBG90 as seen in Figure 2.10a.
Manual docking of carbazole 85 into the HDAC8 structure reveals the reduction
in conformational flexibility actually restricts the positioning of the hydrogen bond
donating nitrogen to being >5.0 A˚ from the Asp101 acceptor (magenta in Figure
3.8b). The less energetically favourable cis-amide (yellow in Figure 3.8b) allows the
carbazole nitrogen to approach 3.4 A˚ from Asp101, all poses of the cis-amide cause
steric clashes with Phe208. The lowering of entropy was therefore cancelled out by
the clashes introduced and the loss of hydrogen bonding with Asp101. The result
is a significant reduction in potency (IC50 = 10.5 ±6.75 µM) and in binding energy
(1.46 ±0.72 kcal mol−1), compared to indole 78.
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Figure 3.9: IC50 values of 2nd generation inhibitors with varying STBG, error bars are
SD of >2 independent repeats. corresponding R-groups are shown above the
bars.
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3.4 Summary of 2nd generation inhibitor assay
results
Second generation α-amino amide compounds were designed to explore the possible
groups which could occupy the substrate binding tunnel and be a good analogue
for the isoindoline STBG of the lead compound 4. Comparison of binding energies
and manual docking of compounds into HDAC8 structures shows that rigidity of the
STBG is essential for good binding. 4 with an isoindoline STBG remains the most
potent compound (IC50 = 210 ±40 nM). It appears that interactions with residues
in flexible loops on the exterior of the enzyme may be important in providing extra
binding contacts and therefore improved binding properties. The most potent com-
pounds (78 and 77) of this generation have low energy poses that can be manually
docked into the structure of the enzyme such that a hydrogen bond can form with
Asp101 of HDAC8 and stil form favourable aromatic stacking. The presence of hy-
drogen bonding between substrate and Asp101 is essential for substrate binding84
and this data was subsequently used to design the 3rd generation of α-amino amide
inhibitors throught the inclusion of a hydrogen bonding group to the lead compound
4 in an appropriate position to make this contact.
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4 3rd generation α-amino amide
HDAC8 inhibitors - containing
isoindoline based STBG
4.1 Introduction
Inhibition data of the 1st and 2nd generation of α-amino amide HDAC8 inhibitors
were modest (see Section 2.3 & 3.3). No increase in potency was achieved with
alternative ARBG or STBG and all compounds had IC50 values around 10 times that
of the lead compound 4 (Lit147. 90 nM). All variations of the STBG or ARBG were
shown to have a detrimental effect on the binding interactions of the α-amino amide
inhibitors synthesised with their novel ZBG. Through manual docking simulations
reasoning behind the the different degrees of inhibition of compounds with differing
STBG and ARBG was reached.
The failiure to improve upon the lead compound 4 by replacement of the ARBG
or STBG lead to the conclusion that existing inhibitor-protein binding interactions
cannot be strengthened by the alteration of the 4 core structure, therefore in order
to increase potency, new interactions must be introduced through addition to the
core structure. Analysis of the HDAC8-4 structure reveals that there is limited space
inside the protein in which to add inhibitor substituents without causing steric clash
with the protein (see Section 3.3.3). The remaining region that can be added to
must therefore be the 5 and 6 positions on the isoindoline ring which are solvent
exposed.
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(a)
Fluor de Lys - HDAC8
Tyr100
Asp101
(b)
L2 loop
Figure 4.1: (a) Interactions between HDAC8 and Fluor-de-Lys seen from the struc-
ture84. Hydrogen bonding interactions between Asp101 on the flexible L2
loop (green) and peptide backbone of the Fluor-de-Lys substrate (cyan) and
aromatic stacking of Tyr100 and the AMC fluorophore (b) The HDAC-4
structure (teal) with missing L2 loop from Fluor-de-Lys bound structure
superimposed (purple).
Figure 4.1a shows the structure of HDAC8 in complex with the Fluor-de-Lys (2)
substrate (PDB: 2V5W), hydrogen bonding interactions can be seen between Asp101
which resides on the flexible L2 loop and amide groups of the peptide backbone
within the substrate. Asp101 is known to be an essential residue for substrate
binding, mutants at this position have been measured to have three times slower
kon and 36 times faster koff as measured by surface plasmon resonance
84. The same
hydrogen bonding interactions were also been seen in crystal structures of HDAC8
in complex with 96, a hydroxamate inhibitor (PDB:2V5X)84.
In the structure of HDAC8 in complex with 4 (teal in Figure 4.1b) the L2 loop is un-
resolved147, this indicates that the L2 loop is very flexible and has no defined regular
packing in the crystaland points towards Asp101 being flexible and not involved in
binding of 4 to HDAC8. It follows that if natural substrate-like interactions could
be incorporated into 4, perhaps by the introduction of hydrogen bond donor groups,
that substrate mimicking L2-ligand binding interactions could be established and
binding characteristics of the inhibitor improved as a result.
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(a)
Asp101
5
Cα
(b)
Asp101
Figure 4.2: The crystal structure of Fluor-de-Lys substrate (purple) overlaid with (a)
HDAC8-4 crystal structure and (b) manual docking pose of 78, potential
hydrogen bonds are displayed with dashed lines
Exploration of different STBGs highlighted the possible importance of creating a
hydrogen bond between the inhibitor and Asp101 for improving binding (Section
3.3.5). In particular compound 78 was one of the tighest binding novel inhibtor,
manual docking of 78 into the substrate bound crystal structure allows the indole
nitrogen to be positioned so as to create a hydrogen bond with Asp101, this hydrogen
bonding interaction may be the reason that 78 is realtively good inhibitor compared
to others synthesised with different STBGs. Despite the improvement in binding
offered by the introduction of this hydrogen bond, even the most potent inhibitors
synthesised with a non-isoindolyl STBG (77 and 78) had binding energies ∼1 kcal
mol−1 smaller than the lead compound 4, indicating that isoindoline is the optimal
STBG for α-amino amide HDAC8 inhibitors, probably due to its linearity, planarity
and rigidity. To improve binding of isoindoline based α-amino amide inhibitors, a
series of inhibitors was designed and synthesised to introduce an interaction between
the STBG and Asp101, essentially introducing a cap-group interaction (discussed in
Section 1.4.2).
The subsequent round of α-amino amide inhibitors was designed following a close
insepction of the HDAC8-substrate and HDAC8-4 structures. When these two struc-
tures are aligned the Cα of the acetylated lysine substrate lies very close (∼0.5 A˚)
from the 5-position of the isoindoline ring of 4 (Figure 4.2). Importantly the Cα-N
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bond orientation is approximately in plane with the aromatic ring of 4, therefore a
hydrogen bond donor at the 5-postion of the aromatic ring would be in a similar
position to the amide NH and so be available to provide hydrogen bonds to Asp101
in a similar manner to the substrate. Given the known flexibility of Asp101, the in-
troduction of a hydrogen bonding interaction at the isoindoline 5-position should be
well tolerated and so improve upon the binding energy of 4. Previous reports have
described the introduction of hydrogen bond donors into inhibitors in this region
of the inhibitor resulting in improved binding characteristics and retaining HDAC8
selectivity213.
4.2 Synthesis of 3rd generation α-amino amide
inhibitors
Compounds were envisaged with groups to provide even more “substrate-like” inter-
actions; 98 & 99 with one amide group and 100 with two amide groups (all seen in
Figure 4.3). It was hoped that these compounds would have improved binding over
4 and yet would retain the selectivity of 4.
N
O NH2.HCl
ClCl
O
HN HN
R2
O
N
O NH2.HCl
ClCl
O
HN
R1R
R1=CH3,
R2=CH3
N
O NH2.HCl
ClCl
NH
O
R
R= CH3R= CH3
N
O NH2.HCl
ClCl
H2N
97 98 99 100
Figure 4.3: Structures of the mono (97, 98 & 99) and disubstituted (100) that were
designed to add “subtrate-like” interactions with Asp101 on the L2 loop of
HDAC8.
Establishment of synthetic routes to 97, 98, 99 and 100 would allow R-groups to
be added which could further extend the additional binding interactions e.g. by
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creating aromatic interactions similar to those seen between Tyr100 and the AMC
fluorophore in the HDAC8-Fluor-de-Lys structure84 (visible in Figure 4.1a). Inclu-
sion of orthogonally derivatisable groups at these two positions allows different two
different R-groups to be installed on the isoindoline system and as a result provides
a far greater scope for increasing the interaction surface between the inhibitor and
the protein, this could further increase both the potency and specificity of inhibitors
of this type.
N
H
NN
H
O O
R Br
Br
NaBH4,BF3
or BH3
Radical 
initiator
NBS
Base
R-NH2
BnBr
K2CO3
o-xylenebis-bromo-o-xyleneprotected isoindolineisoindolinephthalimide
(a) (b)
Scheme 4.1: The two routes that have been described to create an unsubstituted pro-
tected isoindoline ring system: (a) Through the reduction of phthalim-
ides214,215 and (b) the ring-closure of α,α’-dibromo-o-xylene215 R = ben-
zyl/p-tosyl.
Lead compound 4 was synthesised using the commercially available isoindoline, as
substituted isoindolines are not readily available for the synthesis of 97, 98, 99
and 100 it was necessary to synthesise substituted isoindoline rings from commer-
cially available building blocks. Two routes have been previously described for the
construction of the isoindoline ring: by the reduction of phthalimides and also by
cyclocondensation of α,α’-dibromo-o-xylenes with primary amines (Scheme 4.1). As
isoindolines are not very stable compounds, we require that the ring is substituted
before the creation of the isoindoline ring. The substitutions at the 5- and 6-positions
need to be derivatisable at a later stage to form amide groups. 5,6-Dibromination
of isoindolines has been reported using aluminium chloride and neat bromine on
1,3-dimethyl and 1,3-diethyl examples but not on 1,3-dihydro examples216,217. To be
able to orthogonally derivatise our inhibitors at a later stage two different isoindolyl-
substiuents are required. For this reason a nitro substitutuent (easily reduceable to
an amine facilitating acetylation) and a bromo substituent (allowing lithium-halogen
exchange) were chosen which would give us access to a suitable late-stage interme-
diate. With the establishment of a high yielding route to this late-stage common
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intermediate, a series of structurally diverse substituted isoindoline based α-amino
amide inhibitors can be synthesised.
4.2.1 Isoindolines from reduction of phthalimides
Synthesis of substituted phthalimides
The first four steps of the proposed route to generate disubstituted isoindolines re-
quires the generation of a disubstituted phthalimide 105a (Scheme 4.2) and are
reported as a sequence from phthalic anhydride (101) in a patent with good yields
at each step (>70%)218. At this early stage however, the literature yields could not
be obtained, over the combined steps from 101 to 103 58% was achieved compared
to the literature’s 79%. Anhydride 103 underwent nucleophilic attack with ring
opening and ring closing to give 104a with 97% yield (Lit.218 99%) and the subse-
quent nitration with 78% yield (Lit.218 98%). As a result the combined yield over
4 steps to produce 105a was 39% compared to 77% in the literature218. This is a
large loss in yield but as the starting material is inexpensive it is not prohibitively
low multigram scale production of these early intermediates is possible (5 - 10 g).
This however, is dependent on relatively good yields being obtained in later steps.
OO O
-O O-
O O OO O
Br
N
H
O O
Br
N
H
O O
O2N Br
1. NaOH
2.Br2
Br
Na+
H2SO4
HNO3
SOCl2 HCONH2
58% (2-steps)
(Lit 79%)
97%
(Lit 99%)
78%
(Lit 98%)
101 102 103 104a 105a
Scheme 4.2: Route to generate 5,6-disubstituted phthalimide 105a as described in the
literature.218
Reduction of phthalimides
Reduction of the phthalimide carbonyl groups to generate isoindoline has been re-
ported using electrolytic reduction219 as well as many reducing agents: originally
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in 1948 with LiALH4
214, more recently with borane-THF215,220 and NaBH4 and
BF3.Et2O
221.
Reduction of 4-bromophthalimide
Bromophthalimide 104a has previously been reduced in the literature using NaBH4
and BF3.Et2O with 76% yield
221 (Scheme 4.3). A lower yield of 54% was achieved
on the first attempt but no product was obtained on subsequent attempts. The liter-
ature procedure describes a lengthy workup: alkaline extraction into EtOAc, drying
and concentration of the organic layer, dilution in ether, acidification and extraction
into the aqueous layer, basification of the aqueous layer and a second alkaline extrac-
tion before drying and evaporating. As it is known that isoindolines undergo aerial
N -oxidation it is possible that the reduced isoindoline 106a is degrading during the
workup before it can be isolated with decent yield. In order to reduce the length of
time in which degradation of the product could occur, a procedure with a shortened
workup was attempted. The shortened workup consists of an alkaline extraction, a
wash with brine, drying over Na2SO4 and evaporation which did yield some crude
product to take on to the next step.
The subsequent N -Boc protection of 106a to 106d is reported with 89% yield221.
To minimise the degradation of isoindoline 106a it was decided to take the product
from the shortened workup and take it forward to be N -Boc protected without
additional purification. The N -Boc protected product 106d is easily purified by
column chromatography resulting in a 38% overall yield from 104a.
Reduction of disubstituted phthalimides
Following the low-yielding but sucessful 4-step synthesis of the disubstituted phthal-
imide 105a, the reduction to give its corresponding isoindoline 107a was pursued.
The procedure used for the disubstituted phthalimide reduction (105a to 107a) was
the same as that used for the monosubstituted analogue (104a to 106a).
When applying the NaBH4/BF3.Et2O reduction procedure to the disubstituted ph-
thalimide 105a (Scheme 4.3), the isolation of disubstituted isoindoline 107a proved
115
3rd Generation Inhibitors Simon O.R. Greenwood
N
H
O O
Br
N
H
O O
O2N Br
N
H
O2N Br
N
O2N Br
Boc
NaBH4
BF3
H2SO4
HNO3
(Boc)2O
DMAP
78% 24% (from          )
Br
N
Br
Boc
38% (2 steps)
89% (1 step)
54%
(Lit 76%)
(Boc)2O
DMAP
NaBH4
BF3.Et2O
N
H
104a
106a 106d
105a
105a
107a 107c
Scheme 4.3: Route to N -Boc protected mono- and disubstituted isoindolines
more difficult than that of monosubstituted 106a. In addition to the rapid degra-
dation of the product upon exposure to air it was also difficult to purify by column
chromatography owing to its poor solubility. Application of the above procedure
with shortened workup and direct N -Boc protection to 105a gave a yet lower yield
of 24% (compared to 38% for 106d). A total 9% yield was obtained over the initial
6 steps from the starting phthalic anhydride 101 to give 107c. This yield is not
sufficient to permit the use of this route to generate sufficient amounts of the late
stage intermediate 107c which must undergo a further 6 steps in order to reach the
target α-amino amide salt 100.
Many factors could be causing the low yield in the reduction of nitrophthalimide
105a to 107a such as a reduction in solubility of nitrophthalimide 105a compared
to unnitrated phthalimide 104a and also the solubility of any reaction intermediates.
Alternatively the presence of the electron withdrawing nitro group could be making
the carbonyl bonds more polar and therefore making the reaction proceed faster
than the un-nitrated analogue 104a thereby exposing the isoindolyl product 107a
vulnerable to degradation for longer before the reaction was worked up. Conversely,
nitro groups are highly polar and may be coordinating with the reducing agents,
interfering with them to result in a slower, or even disrupted reduction. After the
addition of BF3.Et2O to the reaction mixture, the disubstituted phthalimide 105a
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was seen to be completely consumed by TLC, therefore the reaction may be being
halted at an intermediate stage.
Attempts were made to optimise the reaction by using increased volumes of solvents
and varying the number of equivalents of NaBH4 and BF3.Et2O. Due to the fast
degradation of the product 107a, it was very difficult to tell if the reduction yield
was improved or not. Subsequent N -Boc protection and purification resulted in no
increase of final stable product 107c.
An alternative route to obtain 107c was considered by nitration of the isoindoline
106d after the reduction and protection of bromophthalimide 104a , this is not
and option however as the acidic conditions used during nitration would cleave the
N -Boc protecting group and to give the unstable isoindoline 107a .
New reagents for the reduction of disubstituted phthalimide 105a were considered.
Diborane is the species that reduces the carbonyl groups in this reaction; reduction of
phthalimide with borane THF has been reported to give isoindoline with good yield
(78%)215, the purpose of BF3.Et2O in the reaction is to react with NaBH4 generating
diborane in situ, this avoids the use of what may be a deteriorated commercial sample
of borane-THF (where titration for activity has not been carried out). I2, another
commonly used co-reagent in the generation of diborane in situ222 was tried in place
of BF3.Et2O but resulted in no increase in yield. Neumeyer first observed in 1964,
reduction of an N -(benzyl)-phthalimide is possible using LiAlH4
223. Using LiAlH4
might also prove useful by reducing the nitro group to an amine group thereby
removing the need to perform that transformation at a later stage and thereby
reduce the electron withdrawing effects of the nitro group to the reduction of 105a.
LiAlH4 reduction of an N -benzyl protected phthalimide 104b toN -benzylisoindoline
106b is not applicable in this situation however. LiAlH4 reduction was attempted on
both a monosubstituted N -benzylphthalimide 104band disubstituted N -benzylphthalimide
105b (Scheme 4.4). Both isoindolyl-products had an additional aromatic proton by
NMR spectroscopy and so were judged to have lost their bromine substituent, this
was further confirmed by mass spectrometry.
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Scheme 4.4: Failed reduction of bromophthalimides to the analogous isoindolines using
LiAlH4 due to the loss of the bromine substituent.
Alternative routes were explored to reach 107a including nitration after the reduc-
tion of the imide 104a (Scheme 4.5) this nitration however resulted in a 41% yield
and the product was difficult to handle being only sparingly soluble in MeOH and
degrading rapidly.
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H
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Br
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Br NO2
NaBH4
BF3.Et2O
HNO3
H2SO4
41%54%
(achieved once)104a
106a 107a
Scheme 4.5: Alternative route to 107a by nitration of 106a.
Other alternative routes to obtain a protected substituted isoindoline were devised
in order to avoid generating air sensitive unprotected isoindolines such as 106a and
107a. The addition of an N -protecting group both improves solubility and also the
stability of the product by removing the posibility for the aerial oxidation of the
isoindolyl product.
The introduction of an N -Boc group before the reduction is not feasible for this route
as the Boc carbonyl bond would be reduced along with the imide when generating
the isoindoline. As discussed above, N -benzylphthalimides undergo reduction to
generate N -benzylisoindolines. Also N -benzylisoindolines have been reported to
undergo debenzylation to isoindolines using hydrogen and Pd/C catalysts224. The
benzyl group was therefore chosen to be the phthalimide protecting group.
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A hybridised method was decided on using the previously tested NaBH4 / BF3.Et2O
reduction conditions and 4,5-substituted N -benzylphthalimides as starting materi-
als to give 5,6-substituted N -benzylisoindolines (numbering changes are a result of
isoindoline numbering convention).
4.2.2 Isoindolines from reduction of N -benzylphthalimides
Synthesis of N -benzylphthalimides
Scheme 4.6 shows the route to mono and disubstituted N -benzylphthalimides 104b
and 105b. The initial steps to generate bromophthalic anhydride 103 are shared
with the previously described route (Scheme 4.2). The N -benzylation of disubsti-
tuted phthalimide 105a proceeds with a good yield of 70% (Lit.218 90%). Synthesis
of N -protected bromophthalimides 104b and 104c were achieved directly from bro-
mophthalic anhydride 103 in a single step by heating at reflux in acetic acid with
the desired benzylamine. Both N -benzyl and N -(4-methoxybenzyl) protected bro-
mophthalimides were achieved with very good yields (90% and 87% respectively).
Synthesis of disubstituted N -benzylphthalimide requires of two extra steps (dis-
cussed in Section 4.2.1), 103 → 104a → 105a followed by benzylation to 105b
(Scheme 4.6) these additional steps result in a 60% loss in yield compared to the
monosubstituted N -benzylphthalimide.
Reduction of N -benzylphthalimides
Both mono and disubstituted phthalimides 104b and 105bwere sucessfully reduced
to their respective isoindolines 106b and 107b using NaBH4 and BF3.Et2O in
THF. The yield for the reduction of the disubstituted benzyl-phthalimide 105b to
107b (43%) was nearly half that of the monosubstituted N -(benzyl)-phthalimide
to 106b (82%). This loss of yield proves that the nitro group is certainly having
a dramatic effect on the reduction of the phthalimide, which was not possible to
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Scheme 4.6: Route for the synthesis of mono and disubstituted N -benzylisoindolines.
quantify previously due to the difficulties experienced in isolating the insolindoline
products (Section 4.2.1).
If the solubility of the nitro group was the cause of the poor yield when the ph-
thalimide reduction was attempted, it follows that improving the solubility of 105b
by reduction of the nitro group to a more soluble amine (to give 110 prior to its
reduction to 111) may improve the yield over these steps (Scheme 4.7).
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Scheme 4.7: Alternative routes to achieve bromo-amidoisoindolines with reduction of
nitro group prior to carbonyl reduction.
Reduction of the bromonitrophthalimide 105b proceeded with a 59% yield and the
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subsequent reduction was not explored. The extra steps required to make disubsti-
tuted phthalimide 105b mean that pursuit of optimal reducing conditions to obtain
107b were postponed in favour of sucessfully synthesising and refining the route to
mono-substituted isoindolines 98 and 99 (Figure 4.3).
The reduction of monosubstituted N -benzylphthalimide 104b to 106bwas sucessful
with respectable yields (43% over 4 steps from phthalic anhydride 101 to 106b). The
alternative cyclocondensation route to isoindoline ring formation was also attempted
for comparison purposes (discussed in Section 4.2.3 ).
N
Br
N OO
Br
NaBH4
BF3.Et2O
N
Br
+
PMB PMB PMB
104c 106c 113
Scheme 4.8: 10-pi intermediate generated during reduction of phthalimide 104b.
During purification of N -(4-methoxybenzyl)-isoindoline 106b a 10 pi electron aro-
matic system was isolated. Column chromatography purification lead to the isola-
tion of an interesting, isoindole intermediate (113). Aromaticity of a molecule is a
property that leads to unusually stable ring systems. Hu¨ckel’s rules define aromatic
ringed systems and require atoms to be arranged in one or more planar rings with a
delocalised pi electron system throughout and a number of pi electrons 4n+2 where
n is an integer. If these requirements are satisfied the molecule is aromatic. The
isoindole 113 has a lone pair on the nitrogen that is able to contribute to the delo-
calised pi electron system so the number of pi electrons is 10 (4 × double bonds + 1
× lone pair). It is therefore a non-benzenoid system but is still aromatic.
4.2.3 Isoindolines from cyclocondensation of o-xylenes
To determine the most efficient method for synthesis of monosubstituted isoindoline
systems an alternate o-xylene cyclocondensation route was tested. Monosubstituted
nitro (120) and ethylcarboxylate (119a) isoindoline systems were synthesised using
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the ring-closure route seen in Scheme 4.9. As before, the aromatic substitutions
were present before the formation of the isoindoline ring system.
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Scheme 4.9: Synthesis of N -benzylisoindolines via ring-closure of a bis-bromo-o-xylene
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Figure 4.4: An isoindoline based HDAC6 inhibitor 124225 and 4147. Green = cap-group,
blue=STBG, red = ZBG, magenta = ARBG
HDAC inhibitors have previously been reported containing isoindoline ring sys-
tems generated via the ring-closure of bis-bromo-o-xylene methyl ester 122 which
was then taken forward to generate 124225(Figure 4.4. The isoindoline containing
HDAC6 inhibitor utilises a more traditional hydroxamate ZBG that is located at
the 5-position of the isoindoline ring system225, as a result the isoindoline ring sys-
tem is inverted in the substrate tunnel with respect to the lead compound 4 which
has an α-amino amide ZBG at the 2-position. Thi compound inhibits HDAC6
only and has undetectable inhibition for all other class II and class I HDACs except
HDAC8, (IC50 = 1.3 µM for HDAC8, IC50 = 0.040 µM for HDAC6) but IC50 >50 µM
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against all other HDACs225. The inhibition of HDAC8 by this isoindoline containing
inhibitor supports the observations that the tunnel of HDAC8 is more conforma-
tionally flexible than the substrate tunnel of other class I HDACs (HDAC1, HDAC2
and HDAC3); it also suggests that positioning of the bulky isoindoline group deep
within the substrate tunnel near to the zinc binding group is possible (and possibly
preferable) as it seems also to help to impart specificity of an inhibitor to HDAC8
over the other class I HDACs.
The isoindoline system contained within the HDAC6 selective inhibitor was synthe-
sised from xylyl-methyl ester 121 (Scheme 4.9)225. Literature describes the bromi-
nation of 121 for 1.5 hours using NBS with benzoyl peroxide as a radical initiator in
carbon tetrachloride at reflux. The bis-bromo intermediate 122 was obtained after
filtration of the cooled mixture and dissolved in THF without purification. After
treatment with triethylamine, 4-methoxybenzylamine was slowly added, generat-
ing the ring through a cyclocondensation step to give 123 with a yield of 49% (2
steps)225. The same procedure, applied to the ethyl ester 115 (synthesised through
esterification of o-xylene-4-carboxylic acid 114) was applied in the synthesis of isoin-
dolines of the type 119, slightly lower than literature yields of 40% and 43% were
achieved for the N -benzyl (106b ) and N -(4-methoxybenzyl) (106c ) ethyl ester
analogues respectively.
NMR spectroscopy of bis-brominated intermediate 117 revealed that 36% starting
reactant 115 remained unbrominated, this material was therefore unavailable to par-
ticipate in the subsequent cyclo-condensation step; increased yield may be possible
if the bromination step was more efficient. Use of a fresher or alternative (i.e. azo-
bisisobutyronitrile) radical initiator may also improve the efficiency of bromination
as the benzoyl peroxide used was old.
Patents describe the route from nitro-o-xylene 116 to N -benzyl-5-nitroisoindoline
120 on a large scale (∼40 g), obtained 120 with yields of 33%226 and 22%227 in a
one-pot procedure. Both these procedures use a water/acetone solvent and sodium
carbonate as a base for the cyclocondensation step. On the smaller (5 g) scale at-
tempted in our hands an unoptimised 20% yield was achieved over the two steps
Scheme 4.9. The procedure for the bromination of methyl ester 121 however heats
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under reflux for 1.5 h225, significantly shorter than the patents describing the bromi-
nation of the nitroxylene 116 which require heating at reflux for as much as 1 day
followed by 2 further days at room temperature. The methyl ester cyclocondensation
step (122 → 123) occurs in THF after a pretreatment with triethylamine.
The cyclocondensation of 118 for the synthesis of 120 was attempted using THF
solvent and triethylamine base because difficulty was being experienced when dis-
solving anhydrous sodium carbonate (which was what was available at the time)
and the resulting reaction mixture was a thick sludge, negligible difference in yield
was observed with this alteration so triethylamine and THF were used for subse-
quent preparations as they make setting up the reaction easier. Improvement of
initial yields was observed through the very slow addition of benzylamine to the
bis-bromo intermediate (slower than 50 g benzylamine over 3 h that is described in
the patents226,227), possibly because the ring-closure reaction is fairly slow and if the
concentration of free benzylamine is too high then addition of a second benzylamine
over ring closure can occur.
N -benzylnitroisoindoline 120 is a photosensitive compound and must be kept in
the dark. Initial purification by column chromatography removed a bright yellow
impurity visible by TLC. An orange crust subsequently formed on the surface of
the sample after a number of days exposed to daylight in a sealed glass sample
vial. TLC analysis revealed that the bright yellow band had reappeared. Increase
in yield could perhaps therefore be achieved by performing the reaction in the dark
(and purification in low light conditions).
4.2.4 Summary of synthesis of the isoindoline ring system
There are various advantages and disadvantages between phthalimide reduction and
α,α’-bisbromo-o-xylene cyclocondensation in the generation of mono and disubsti-
tuted isoindoline systems. A comparison of the routes to obtain N -benzyl protected
mono- and di-substituted isoindolines is shown in Scheme 4.10.
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The xylene route
The major benefit of the cyclocondensation route to isoindolines is the short length
of the route; nitro xylene 116 → 118 → 120 in a one-pot reaction gives 120 in
only two steps with 20% yield. The carboxylic acid 114→ 115 (88%, unoptimised)
→ 117 → 119 (40% 2 steps, without isolation of the intermediate) gives the ethyl-
isoindoline carboxylate in 3 steps with 35% yield.
Ethyl carboxylate 119a is a very viscous dark brown oil. This oil is difficult to
handle, therefore subsequent reactions are difficult to set up and losses are incurred
during transfer between flasks and vials. Additionally the subsequent reactions
to install the carboxamide group are fairly low yielding at present (Section 4.2.5).
Nitroisoindoline 120 on the other hand is a bright yellow solid which (excepting its
light sensitivity) is easy to handle and undergoes subsequent steps in high yields
(Section 4.2.6). 4-Bromo-5-nitro-o-xylene has been synthesised via nitration of 4-
bromo-o-xylene with 45% yield228, but it is impossible to know how efficient the
bromination and cyclocondensation would be to form a disubstituted isoindoline
without attempting the reaction.
The phthalimide reduction route
Reduction of phthalimides to give isoindolines 106b and 106c proceeded with nearly
twice the yield of the cyclocondensation of o-xylenes (76% vs. 40%) and were
white easily purifyable solids. The route to achieve the phthalimide had a yield
of 52% (phthalic anhydride 101 →benzyl phthalimide 104b , 52% over 3 steps).
The phthalimide reduction vs. o-xylene cyclocondensation yield increase is there-
fore compensated for by the additional synthetic cost of obtaining the phthalimide.
The literature discribes the three initial steps to obtain disubstituted phthalimide
105a with significantly higher yields than were achieved (44% vs. 77%218), if the
literature could be replicated and 104a and 105b obtained with high yields this
route would be preferable for all the desired isoindolines (although mono-substituted
nitro-phthalimide reduction has not been attempted here).
Three steps are required to achieve the disubstituted phthalimide (103 → 107b ,
60% overall yield) compared to a single high yielding step for the monosubstituted
125
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Scheme 4.10: Overview of all routes to protected mono- and disubstituted isoindolines.
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phthalimide (103 → 104b , 90%). The yield for the subsequent phthalimide re-
duction is halved for the disubstituted compared to the monosubstituted example
(Scheme 4.6). Disubstituted isoindolines are however only possible using the phthal-
imide reduction route as 4-bromo-5-nitro-o-xylenes are difficult to synthesise228.
The steps to transform the bromine substitution into a carboxamide substitution
are high yielding so for monosubstituted carboxamides the phthalimide reduction
route is preferable to the o-xylene cyclocondensation route (Section 4.2.5).
4.2.5 Derivatisation of substituted isoindolines
Synthesis of N -benzylcarboxamido isoindolines
In order to obtain a series of 5 (and 5,6) -substituted isoindoline based α-amino amide
inhibitors, three late-stage N -benzylisoindoline intermediates were synthesised via
two alternative routes described in Scheme 4.11: cyclocondensation of an α-α’-bis-
bromoxylene with benzylamine (119a & 120) and reduction of a phthalimide with
NaBH4 and BF3.Et2O (106b).
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Scheme 4.11: Synthetic routes to three late-stage N -benzylisoindoline intermediates
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Synthesis of methyl carboxamido-isoindoline
Bromoisoindolines 106band 119bwere derivatised to give isoindoline-5-carboxamides
126 and 127 (Scheme 4.12). The intermediate N -methylcarboxamide 126 is a con-
vergence point for the two routes to the α-amino amide inhibitor 98 (Scheme 4.12).
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Scheme 4.12: Two routes to carboxamidoisoindolines 126 and 127 from bromo-
isoindolines 106 and ethylcarboxylates 119, and subsequent steps to
achieve the correlating α-amino amide salt 98.
Two synthetic routes to achieve 126 from 106 were explored. Direct transition from
bromo to carboxamido aromatic substituents has been reported on a 4-bromotoluene
system using a nickel acetate and phosphite coupling reaction in diglyme at 110℃229.
This procedure was attempted on the unprotected 106a but failed (Scheme 4.13).
The secondary amine within the isoindoline ring reacted to give the isoindoline-
carbaldehyde 131 (confirmed by NMR and mass spectrometry). It is possible that
had the reaction been attempted on an N -benzyl protected isoindoline that it would
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Scheme 4.13: Attempted direct transformation of bromo-aromatic to amide 128 using a
literature procedure229.
have suceeded but this route was not pursued as the alternative route proved suffi-
ciently effecitve.
With the failure of a direct transformation from bromoisoindoline 106 to isoindo-
linecarboxamide 128 an alternative method was used with a N -benzylisoindoline-
carboxylic acid inetermediate (125a in Scheme 4.12). N -Benzylbromoisoindoline
106b was successfully converted to the carboxylic acid 125a using lithium-halogen
exchange followed by the addition of carbon dioxide as a nucleophile with a good
yield of 79%. The analogous N -(4-methoxybenzyl) protected 125b was obtained
with 98% yield. Convenient purification of isoindoline carboxylic acids 125a and
125b was achieved by loading onto a silica plug in ethyl acetate, washing off impu-
rities and then eluting the product with 1% acetic acid in ethyl acetate.
Coupling of 125a with methylamine to give the N -methylcarboxamide 126a us-
ing EDC was performed under similar conditions to those used for previous amide
couplings (see Section 2.2.2) and proceeded well with 75% yield (Scheme 4.12)
From the alternative route, conversion of the ethyl ester 119b to the N -methyl-
carboxamide 126bwas performed in a sealed tube with 40% aqueous methylamine as
has been reported previously on a tetrahydroisoquinoline system230 (Scheme 4.12), a
75% yield was obtained but was difficult to repeat as methylamine is very corrosive to
the rubber seals used on the sealed tubes. This strategy is also applicable to synthesis
of other compounds with alternate R-groups which introduces the possibility of
creating addidional selective cap-group contacts.
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Synthesis of carboxamido isoindoline 127
The steps taken to synthesise the primary carboxamide 127 were similar to those
used for the synthesis of methylcarboxamide 126 (Section 4.2.5) but had a greatly
reduced yield (Scheme 4.12). Heating a mixture of concentrated aqueous ammonia
and 119b at 100 ℃ for 16 h in a sealed tube resulted in only a 26% yield of primary
amide 127 after 16 h (compared to 75% obtained for the methylcarboxamide 126).
The remaining material recovered from the reaction was the starting reactant 119b
indicating that the reaction was significantly slower.
4.2.6 Debenzylation of N -benzylisoindolines
Debenzylation ofN -benzylisoindolines was more difficult than expected. Hydrogenol-
ysis of isoindolineamine 120 has previously been reported and difficulty in the hy-
drogenolysis of the benzyl group was mentioned. Overnight hydrogenation at 50 psi
with 0.6% HCl and 20 mol% Pearlman’s catalyst was required for complete debenzy-
lation to give 134226. High pressure apparatus were not available when debenzylating
132 and at 1 atm only 51% debenzylation was achieved after 120 h (Scheme 4.14).
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Scheme 4.14: Generalised route from N -benzylisoindoline to α-amino amide salt.
Multiple variations of the standard hydrogenolysis procedure (1 Atm H2, 10% Pd/C
in EtOH or MeOH) were attempted for the debenzylation of 126b to give 128:
using 5%, 10% and 30% Pd/C, Pearlman’s catalyst (Pd(OH)2/C 20%), extending
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the time of the reaction to 72 h and also addition of 0.5% HCl to prevent poisoning
of the catalyst. All variations resulted in yields of debenzylated product 135 of ∼25
%, in these cases the remainder of the starting material was recovered after silica
column chromatography.
A 1:1 mixture of Pearlman’s catalyst and Pd/C is reported to be an effective
debenzylation strategy in cases where single catalysts are ineffective224. Efficient hy-
drogenolysis of 133 was achieved using a mixture of these two catalysts and heating
to 30℃, occured in 16-20 h under only ∼1 atm. hydrogen (supplied by a balloon) to
give 135 (>100% crude) as seen in Scheme 4.14, in future all debenzylations should
use a 1:1 mixture of pearlmans catalyst an 30% palladium on carbon.
The debenzylation of the primary carboxamido isoindoline 127 resulted in two prod-
ucts. Column chromatgraphy in 5% aqueous ammonia, 5% MeOH, 90% ethyl acetate
was required for the very polar amines, the less polar product (RF = 0.15) had an
extra methyl group present which was detected by NMR spectroscopy, peaks core-
sponding to the CH2 groups were also shifted, this indicates that the isoindoline had
been N -methylated. The more polar product (RF < 0.1) seemed to be a volatile
solid which sublimed during evaporation of the solvent. White needles were seen
in the adapter of the rotary evaporator. Sadly, due to the sublimation, significant
amounts of primary carboxamide 129 were lost and the subsequent coupling to give
137 and N -Boc deprotection to give 139 was not pursued.
Synthesis of 5-((methylamino)methyl)isoindoline α-amino amide salt 144
Synthesis of α-amino amide 144 proceeded through carboxamido isoindoline 126a
which is an intermediate in the route to 98 (Scheme 4.12). LiAlH4 reduction of the
amide 126a proceeded well to give 140 (75%) and the subsequent N -Boc protection
of the secondary amine gave 141 with an unoptimised 58% yield (Scheme 4.15).
Hydrogenolysis of the N -benzyl protecting group to isoindoline 142 (69%) permitted
coupling with amino-acid 29 to give 143 with good yield (84%) and efficient removal
of the Boc group with HCl gas bubbled through an ethereal solution of 143 resulted
in α-amino amide salt 144 (87%).
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Scheme 4.15: Synthesis of α-amino amide salt 144 through previously synthesised car-
boxamide 126a
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Synthesis of 4-aminoisoindoline α-amino amide salt 97
The preparation of α-amino amide salt 97 was achieved via 5-aminoisoindoline 134
(Scheme 4.16). Hydrogenolysis of nitro and benzyl groups ofN -benzylnitroisoindoline
120 for 120 h at 20℃ using a 10% Pd/C catalyst to afford isoindolineamine 134 in a
single step with fair yield (51%). The subsequent coupling of 134 to N -Boc-amino
acid 29 proceeded to give 136 (44%). Amide coupling gave the desired product
preferentially as the secondary amine of 134 is more reactive than the aniline (due
to the delocalisation of the nitrogen lone pair of electrons into the aromatic ring).
The removal of the Boc group with HCl (as described in Section 2.2.2) then gave
97(22%).
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NH2.HClO
N
ClH
.
H2N
N
O
ClCl
NH
H2N
O
O HClEDCHOBt
52% 44% 22%
Bn
N
H2N
Bn
N
HN
Bn
R
O
N
H
HN
R
O
N
O
ClCl
NH
HN
O
O
Cl Cl
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Scheme 4.16: Derivatisation of nitro-substituted N -benzylisoindoline to achieve amino
and acetamido substituted α-amino amide salts.
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Synthesis of 4-acetamido isoindolyl α-amino amide salts
There is a vast discrepancy between the reactivity of the 5-nitro and the N -benzyl
groups of 120 when performing palladium on carbon catalysed hydrogenolysis. N -
Benzyl-5-nitroisoindoline (120) reacted to give N -benzylisoindoline-5-amine 132
within 2 h. (89%). Only prolonged hydrogenation with multiple catalysts and
heating removed the benzyl group with acceptable efficiency (see Scheme 4.16). Se-
lective reduction of the nitro group to an amine without debenzylation to 132 is
therefore possible and permits acetylation with acid chlorides or anhydrides in the
presence of a base to give N -benzylisoindoline-acetamides with very good yields in
the majority of cases: 133 (87%), 145 (54%) and 146 (90%). Following debenzy-
lation to give isoindolines 135, 147 and 148 these isoindolines were then readily
coupled with dichlorophenylalanine 29 to give 138, 149 and 150. Following the fi-
nal deprotection step the target compounds 99, 151 and 152 were obtained (yields
given in Scheme 4.16).
4.2.7 NMR to probe rotameric energy barriers
Rotamers arise in compounds due to restricted rotation about certain bonds, which
leads to significant populations of two conformers of a molecule, a trans and cis
conformation (Figure 4.5). In the case of α-amino amide HDAC8 inhibitors such
as 99, the restriction is around the amide bond within the ZBG which has partial
double bond character due to delocalised electrons throughout the N, C and O atoms,
thus restricting rotation around the C-N bond. For 99, the two N-substituents are
symmetical (in the region of the amide bond) and so there is no energetic preference
for one conformation over the other, therefore the two conformer populations are
equal. This is manifested as equal integrations of NMR signals arising from each
conformer (Figure 4.5). At equilibrium the conformational exchange rate from trans
to cis (k1) is equal to the conformational exchange rate from cis to trans (k2), and
the equilibrium constant Kexch = k2/k1 = 1. When a rotamer isomerises the double
bond characteristics of the amide group must be overcome. The energy required to
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break this “energy barrier” is the activation energy of the isomerisation and is also
the energy of the transition state.
Cl Cl
NH2.HCl
O
N
NH
O
Cl Cl
NH2.HCl
O
N
HN
O
k1
k2
Figure 4.5: A section of the aliphatic region of NMR spectra of α-amino amide inhibitor
99 at 298 K (blue) 363 K (green) and 403 K (red)
Nuclei have different chemical shifts in each of the rotamer conformations and NMR
spectroscopy is a powerful solution state technique that can probe dynamics of
molecules. There are three “exchange regimes” catagorised by the lifetime of the
states that are interconverting:
1. τ ≫ 1/∆ν ⇒ two resonance lines at νA and νB, slow exchange region
2. τ ∼ 1/∆ν ⇒ one broad resonance line at νA + νB/2, intermediate exchange
(coalescence) region
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3. τ ≪ 1/∆ν ⇒ one narrow resonance line at νA + νB/2, fast exchange region
A molecule in “slow exchange” in NMR terms gives rise to two different NMR signals
for each nucleus as two different rotamers are present and distinct, this occurs when
a molecule has confromational lifetimes on the order of minutes. A molecule in
“fast exchange” is interconverting faster than the NMR timescale (typically 10-1000
Hz) and therefore gives rise to a time-averaged signal of the two conformations
rather than the two distinct signals observed at slow exchange. In between these
two extremes of exchange dynamics is a grey area known as intermediate exchange -
where the exchange between the two conformations is on the NMR timescale and so a
mixture of averaged signals and intermediate signals are detected - this is manifested
as line broadening of the two signals.)
The rate of interconversion of two conformations can be modulated by increasing
the number of molecules which possess the activation energy of conformational iso-
merisation, i.e. by increasing the temperature of the sample. As the temperature
increases there is a larger proportion of molecules with energy greater than or equal
to the activation energy. This leads to greater exchange and a reduced confor-
mational lifetime. If the isomerisation rate can be increased sufficiently to alter
the exchange regime, we can estimate the amount of energy required to effect the
change in exchange regimes and in turn the activation energy for the conformational
isomerisation between cis and trans.
Using the Eyring equation (Equation 4.1) from transition state theory we can rear-
range and substitute ~ and kB to obtain ∆G‡ (Equation 4.2).
A short 1H NMR temperature series was recorded on 99 to investigate the energy
barrier of the amide bond. Spectra were recorded at 298 K, 363 K (90 ℃) and 403
K (130 ℃) (Figure 4.5). At 363 K (green in Figure 4.5) rotamer peaks are clearly
visible with only slight line broadening compared to the 298 K spectrum (blue in
Figure 4.5, the difference in frequency between the two rotameric states (∆ν) is 23
Hz. Only at 403 K was coalescence of the peaks observed Figure 4.5, using these
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values in equation 4.2 we can estimate the rotameric energy barrier to be 86.5 kJ
mol−1 or 20.6 kcal mol−1.
k =
kBT
~
e−
∆G‡
RT (4.1)
∆G‡ = RT [23.76 + ln(T/k)] (4.2)
The rate of conformational isomerisation is important in an inhibitor, if it is slow
and only one conformation binds a target then the molecule will be half as potent
than if the isomerisation was fast. Binding of the correct conformation of the in-
hibitor stabilises it thereby making it energetically favoured, shifting the equilibrium
constant in favour of that binding conformation. The fraction of 99 molecules that
has the energy > 1∆G‡ at room temperature (298.15 K, ∆G‡ = 20.6 kcal mol−1)
is 7.01×10−16 or 1 in 1.4 ×1015. The rate of isomerisation is therefore slow. It
is possible that one rotameric conformation of HDAC8 inhibitor 99 has a lower ki
than the other. The inhibitor may therefore be a “slow-tight binding inhibitor” this
would mean that a pre-incubation of inhibitor and enzyme would lower the apparent
ki (k
app
i ) as measured by an HDAC8 inhibition assay.
4.3 3rd generation α-amino amide HDAC8
inhibition results
4.3.1 Addition of an amine hydrogen bond donor to inhibitor
4
Compounds with small substitutions that are potential hydrogen bond donors to
Asp101 showed improved binding characteristics compared to the unsubstituted
isoindoline containing 4. Table 4.1 shows the IC50 values measured and binding
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Table 4.1: Inhibition assay results for 3rd generation 5-substituted isoindolyl α-amino
amide HDAC8 inhibitors. IC50 values are the mean of at least two independent
repeats ± standard deviation. (∆Gb = ∆Gbinding).
Cl Cl
NH2.HCl
O
N
R
R
IC50
/nM
∆Gb/kcal
mol−1
R
IC50
/nM
∆Gb/kcal
mol−1
4 H
210
±40
-9.48
±0.18
97 NH2.HCl
130
±22
-9.77
±0.17
98
NH
O
258
±63
-9.37
±0.24
99
HN
O
101
±26
-9.93
±0.26
144
NH.HCl 176
±50
-9.59
±0.28
151
HN
O
232
±33
-9.42
±0.14
152
HN
O
259
±67
-9.35
±0.26
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energies calculated for α-amino amide inhibitors based on 4 with Asp101 hydrogen
bond donating substituents. The presence of an amino substitution at position 5 of
the isoindoline STBG of 4 allows a hydrogen bond with Asp101 to be formed (Figure
4.6a). This interaction lowered the IC50 from 210 ±40 nM (4) to 130 ±22 nM (97),
with a corresponding improvement in binding energy from -9.48 ±0.18 kcal mol−1
to -9.77 ±0.17 kcal mol−1. The hydrogen bond provided by the primary aryl-amine
is not identical to the hydrogen bond provided by the amide of the Fluor-de-Lys
substrate peptide backbone and as such the interaction of 97 with Asp101 does not
truly replicate the substrate-Asp101 interaction. In the peptide, the presence of the
carbonyl group increases the polarity of the amide nitrogen and so the hydrogen
bond to Asp101 becomes stronger than if an amine were present.
An amide substituent was therefore installed at the 5-position to make the inhibitor-
Asp101 hydrogen bonding interaction more “substrate-like”. Both 5-carboxamido
(98) and 5-acetamido (99) substitutions were tested.
(a)
Asp101
Phe152
Phe208
Met274
(b)
Asp101
Phe152
Phe208
Met274
Figure 4.6: Manual docking poses for (a) 97 and (b) 98 in the HDAC8 structure. Flexible
L2 loop and Asp101 are superimposed from HDAC8-Fluor-de-Lys structure
(purple).
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4.3.2 Addition of a amide hydrogen bond donor to inhibitor
4
The 5-Carboxamide 98 seen in Figure 4.6b has electrons from the amide group delo-
calised into the aromatic ring, the hydrogen bond-donating nitrogen must therefore
remain in the plane of the aromatic ring. In the most ideal manual docking pose
the amide is placed 4.1 A˚ from the hydrogen bond accepting Asp101 and the ori-
entation of the N-H bond is perpendicular to an ideal hydrogen bond orientation231
(Figure 4.6b). As a result of this positional and orientational restriction there is no
increase in potency of 98 over 4 (258 ±63 nM vs. 210 ±40 nM, Table 4.1). The
N -methylamine hydrochloride 144 was synthesised to enable more flexibility in the
new hydrogen bond donating cap-region compared to 98. It was hoped that with
2 rotatable bonds between the aromatic ring and the hydrogen bond donor a more
optimal positioning of the nitrogen could be achieved and that this would lead to
increased potency over 98 as shown in the manual docking pose in Figure 4.7a. A
modest but not statistically significant increase in potency is seen for 144 over 98
(176 ±50 nM vs. 258 ±63 nM). It is possible that the improved positioning of the
hydrogen bond-donating nitrogen is offset by the increase in conformational entropy
of the free ligand that comes from having two extra rotatable bonds.
5-Acetamido substituted 99 (101 ±26 nM) showed an increase in potency over the
un-substituted 4 (210 ±40 nM), similar to that of amino substituted 97 (130 ±22
nM) and corresponding energy increase of 0.45 ±0.32 kcal mol−1(Table 4.1). Manual
docking shows that the nitrogen of 99 can closely mimic the peptide backbone of the
substrate as the aryl-amide bond is superimposable with the substrate backbone.
Additionally the orientation of the amide can be orthoganal to the plane of the ring
(Figure 4.7b) so a stronger hydrogen bond can be formed compared to 98 where the
amide is restricted to being in plane with the aromatic ring (Figure 4.6b).
Following the increase in potency of 97 and 99 over 4 which was achieved by addition
of a hydrogen bond-donor, two more α-amino amide inhibitors were synthesised to
explore the possibility of adding more cap-group interactions with the surface of
HDAC8. Three aromatic residues and one hydrophobic residue (Phe152, Phe208,
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(a)
Asp101
Phe152
Phe208
Met274
(b)
Asp101
Phe152
Phe208
Met274
Figure 4.7: Manual docking poses for (a) 144 and (b) 99 in the HDAC8 structure. Flex-
ible L2 loop and Asp101 are superimposed from HDAC8-Fluor-de-Lys struc-
ture (purple).
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Figure 4.8: Experimental data points recorded for 8 HDAC8-99 inhibition assays. Dif-
ferent symbols represent data collected from independent repeats. Fitted line
is a calculated inhibiton curve for IC50 = 101 nM, the average calculated for
99.
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(a)
P 2
P 8
Met274
(b)
Asp101
Phe152
Phe208
Met274
Figure 4.9: Manual docking poses for (a) 151 and (b) 152 in the HDAC8 structure.
Flexible L2 loop and Asp101 are superimposed from HDAC8-Fluor-de-Lys
structure (purple).
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Figure 4.10: IC50 values of HDAC8 inhibitors incorporating a hydrogen bonding group,
error bars are SD of >2 independent repeats.corresponding R-groups are
shown above the bars.
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Tyr306 and Met274) form the entrance to the substrate channel. Phe152 and Phe208
are already known to create key contacts that are visible in the HDAC8-4 structure
and mutation of these residues eliminates substrate binding (results not shown & ref
[207]). The Fluor-de-Lys substrate has a 20-fold lower KM than the MAL substrate
and so there must be many more contacts available on the surface of the protein.
The extra peptide extension of the Fluor-de-Lys substrate must be responsible for
this increase in affinity. The exact contacts responsible for this increase are not
observable from the HDAC8-substrate structure however. This is because of the
face-to-face crystal packing which puts the substrate molecule in contact with a
second HDAC8 monomer and means the physiologically relevant conformation of
surface residues is unlikely to be present in the structure. These additional contacts
are contacts that could prove very useful in dramatically increasing the potency of
inhibitors and so I attempted to probe them through extension of the cap-group.
Phenylacetalamide (69) and phenylmethylacetylamide (70) isoindoline substitutions
did not improve potency of isoindoline α-amino amide inhibitor 4 against HDAC8.
(232 ±33 nM and 259 ±67 nM vs. 210 ±40 nM). Manual docking of these in-
hibitors suggested that possible interactions may occur between the cap-group aro-
matic rings and Phe208 (Figure 4.9a & b). The lack of improvement in binding over
4 suggests that the energetic contributions of any beneficial interactions (includ-
ing the hydrogen bond to Asp101) are negated by other unfavourable interactions of
the cap-group, perhaps through the exposure of hydrophobic surfaces to the aqueous
solvent. Isoindoline α-amino amide inhibitors with a small, unconjugated, hydrogen-
bond-donating substitution at the 5-position (97, 99, 144) are more potent HDAC8
inhibitors than any other HDAC inhibitors reported with this novel α-amino amide
ZBG.
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4.4 Summary of 3rd generation inhibitor assay
results
The addition of a hydrogen bond donor in these 3rd generation of α-amino amide
inhibitors lead to improved binding of non-isoindoline containing α-amino amide
inhibitors. Manual docking of these inhibitors pointed to the possibility that in-
teractions of these hydrogen bond donors with Asp101 could be responsible for the
increased potency. Non-isoindoline from the 2nd generation of inhibitors had poor
binding energies of >∼1 kcal mol−1 smaller than lead compound 4 with an isoindo-
line STBG. This was due to the loss of conformational restriction that was provided
by isoindoline rigid, planar ring system. For the 3rd generation of inhibitors it was
therefore decided to add hydrogen bond donating groups to the isoindoline group
to improve the potency by adding Asp101 H-bonding interactions while maintain-
ing the rigidity imparted by the isoindoline STBG. Hydrogen bonding groups were
added at position 5 of the isoindoline ring since this position aligns nicely with
the Cα of the Fluor-de-Lys peptide substrate, it is therefore likely to be the most
beneficial position to add a hydrogen bonding group.
5-Aminoisoindoline 97 and 5-acetamido 99 had improved potency compared to the
lead compound 4 indicating that hydrogen bonds were indeed being formed between
the amino group and Asp101. 5-carboxamido 98 did not show improved binding
compared to 4 with an unsubstituted isoindoline STBG. This is most likely due to
the orientation of the amide group which is planar with the aromatic ring since the
amide electrons are delocalised into the ring, conversely the 5-acetamido group in 99
is able to rotate and provide more favourable hydrogen bonding with Asp101 since
its electrons are not delocalised into the aromatic ring. 144 with a flexible amine
hydrogen bond donor was synthesised to provide an improved hydrogen bond with
Asp101 but did not have statistically significant improvements in binding energy
over 4, again suggesting that conformational entropy of the free ligand plays an
important part in determining the potency of α-amino amide inhibitors.
To further explore possible cap-group interactions two further 5-amido sustituted α-
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amino amide inhibitors were synthesised with additional aromatic extensions (151
and 152). Both these inhibitors had a potency comparable to lead compound 4
suggesting that any additional favourable interactions are being cancelled out by
unfavourable interactions and increased conformational entropy of the free ligand.
4.5 NMR spectroscopy of HDAC8-4 binding
Nuclear magnetic resonance (NMR) is a powerful technique that can be used to
follow protein-protein interactions or protein-ligand interactions. 1H, 13C and 15N
nuclei give rise to NMR signals, and the position of these signals in the NMR spec-
trum are specific to the environment around the nucleus. Therefore of this a change
in environment (i.e. by the proximity of a ligand) will alter the signal position,
linewidth or intensity. This makes it an ideal tool to detect binding of ligands to
proteins.
HDAC8 is 42 kDa which is large for structural studies by NMR. A uniformly 1H, 13C,
15N isotope labelled HDAC8 gives rise to many overlapping peaks (not shown) which
hampers detailed analysis . Using Transverse Relaxation Optimised Spectroscopy
(TROSY), a specialised NMR technique for investigations into large proteins, the
overlap in crowded spectra can be reduced232. Residue specific labelling can also
greatly reduce the complexity of NMR spectra as it enables detection of signals
from specifically labeled groups (or residues) against an NMR silent background233.
Using these two techniques in combination it is possible to gain some insight into
the binding of α-amino amide HDACi to HDAC8.
An exploratory NMR experiment was performed using the Ile348Val HDAC8 mutant
expressed in deuterated media with a fully deuterated amino-acid precursor (α-
ketobutyric acid-4-13C,3,3-2H2). This labelling strategy results in NMR spectra with
peaks corresponding only to the terminal methyl groups of isoleucine sidechains as
seen in Figure 4.11. HDAC8 has 25 isoleucine residues (one of which is mutated to
valine in the case of HDAC8 Ile348Val) so 24 peaks should be visible in the 1H-13C
Methyl-TROSY HMQC spectrum (purple peaks in Figure 4.11). Spectra recorded
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before and after the addition of five equivalents of α-amino amide inhibitor 4 show
a dramatic change in peak positions of residues lining or connected to the inhibitor
binding region of the protein, a result of α-amino amide inhibitor binding. Peaks
assigned to Ile34, Ile284 and Ile269 have large changes in chemical shift, while the
remaining 21 visible isoleucine peaks showed little to no change (Figure 4.11). These
data can be rationalised by insepection of the structure shown in Figures 4.12a & b.
Ile34, the most dramatically shifting peak which forms part of the acetate release
pocket, is 3.3 A˚ away from the para-chlorine of 4 in the structure. Both Ile284 and
Ile269 are >15 A˚ from 4 so do not have direct interaction with the inhibitor but
their peak shifts can be explained through allosteric effects, which eminiate from
the change in Zn2+cordination upon inhibitor binding. The remaining isoleucine
residues show little or no peak changes indicating no structural changes occur in a
large part of the protein.
(a)
Ile34
Asp178
Asp267
Ile269
Ile284
(b)
Ile269
Ile284
Leu177
Leu264
Asp178
Asp267
Ile34
H
y
d
ro
phobic region
Figure 4.12: Effects of compound 4 binding on Ile residues. a,b) Structure of HDAC8-
4, with Ile affected by addition of ligand (red sticks), Zn2+-coordinating
aspartates (magenta sticks) and Leu residues important in transmitting
change to Ile284 (teal sticks).
When substrate bound, the catalytic Zn2+ ion is penta-coordinated in square pyrami-
dal geometry by Asp178, His180, Asp267 the substrate-acetate carbonyl and a water
molecule with inter atomic distances of 2.8, 2.1, 2.0, 2.0 and 2.1 A˚ respectively84
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1H /ppm
1
3
C
/p
p
m
I34
I56
I269
I45
I284
Figure 4.11: Methyl-TROSY HMQC spectrum of deuterated δ13C1H3-Ile labelled
HDAC8 with 0 equivalents of 4 (purple) and with 5 equivalents 4 (green).
Red arrows indicate peaks that are shifted as a result of ligand binding.
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(Figure 4.13a). Zinc preferentially adopts tetrahedral coodination in proteins234 and
as such it is likely that in the absence of a ligand there is a single non-sidechain coor-
dinating contact provided by an exchangable water molecule. The lack of ligand-free
HDAC8 X-ray structures suggests that in an apo-state, the region around the ac-
tive site of HDAC8 is more flexible. The orientation of the mutated Tyr306Phe
sidechain in this structure suggests that were the hydroxyl group of the wild-type
protein present, a water-mediated coordinating bond between Tyr306 the catalytic
zinc could be made in the apo-state147 (Figure 4.13a).
The binding of the α-amino amide inhibitor causes the replacement of the suggested
exchangable water molecule for the strong coordinating bond between the Zn2+ ion
the lone pair on the amine NH2 (2.3 A˚)(Figure 4.13b), this causes the rigidification
of the local environment. The amide carbonyl of 4 contributes a weaker coordinating
interaction (3.0 A˚) but is mainly involved in hydrogen bonding to Gly305 via a water
molecule (Figure 4.13b).
(a)
His180
Asp267
Asp178
Phe306
Fluor-de-Lys
substrate
(b)
Gly305
Tyr306
His1 0
As 6
As 1
Figure 4.13: Coordintation of the catalytic Zn2+ ion found in structures with (a) sub-
strate bound square-pyrimaidal geometry (additional substrate residues and
fluorophore not shown), and (b) α-amino amide inhibitor bound tetrahedral
geometry.
NMR chemical shifts were perturbed by the addition of α-amino amide inhibitor
4. The most dramatic peak shift was that of Ile34 which is located in the acetate
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release pocket and sits 3.3 A˚ from the chlorine atom at position 4 of the ARBG
(Figure 4.12a).
The rigidification of the Zn2+ coordination is apparent from the chemical shift
changes seen in Ile269 and Ile284. Ile269 is separated from Zn2+ coordinating Asp267
by one residue. The change in Zn2+ coordinating environment propogates through
Asp267 to cause the change in chemical shift at Ile269 (Figure 4.12b). One possible
explanation to explain the peak shift of Ile284 is also the propogation of structural
changes through hydrophobic regions. Ile284 sits in a hydrophobic pocket which
also contains Leu177, a residue adjacent to Zn2+- coordinating Asp178. Alteration
of the Zn2+ coordination sphere dynamics results in a structural stiffening that pro-
pogates through the coordinating residues Asp178 and Asp267 resulting in a change
in chemical environment (and therefore peak position) of both Ile269 and Ile284
(Figure 4.12b).
The movement of the peaks in each case away from 0.8 ppm (1H dimension) and
12 ppm (13C dimension) is indicative of isoleucine residues becoming more rigid in
their conformation235. Additionally, two peaks are visible in the apo-state for Ile284
suggesting the presence of two different states, upon inhibitor binding these two
peaks merge into one peak suggesting a single conformation for this sidechain in the
ligand-bound state. This data suggests that the environment around the Zn2+ ion
is altered upon 4 binding which causes a structural rearrangement and rigidification
of the coordinating residues which is then propagated through nearby connected
residues to Ile269 and Ile284 where the changes are detected as changes in NMR
peak positions.
The shift of these peaks allows us for the first time to directly detect the binding
of an inhibitor to the HDAC8 protein using NMR. This result opens the door for
NMR based investigations into the binding of inhibitors and other molecules such
as substrates and other binding partners to HDAC8. the residues associated with
the peaks that shift in NMR titration experiments could identify residues that are
important for ligand binding and even provide detailed information about kon and
koff rates, and the specific protein-ligand interactions that contribute to them.
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Current fluorescence based techniques provide only limited information about the
binding of an inhibitor to HDAC8. Through utilisation of NMR experiments, pre-
cise kinetic rate constants can be obtained. Furthermore as NMR provides struc-
tural information about the protein, binding sites can be mapped onto the structure
and energetic contributions of individual interactions can be calculated. Various
NMR techniques have been developed that allow the detection of weak binding in-
hibitors236–238, multiple inhibitor fragments that bind different regions of a protein
have previously been linked to create an inhibitor that binds tightly to the protein239.
Lastly these experiments are independent of substrate deacetylase activity and so
can be performed on mutants with limited activity (thereby reporting the effect of
the mutation on ligand binding).
Summary
NMR investigations with selectively labeled HDAC8 showed dramatic changes in
the peak positions of certain Ile residues which can be linked to the coordination of
the catalytic Zn2+ and perturbation of the acetate release pocket upon saturation
with 4. This result opens the door for more in-depth ligand binding studies using
NMR which are not possible with other methods.
4.6 Summary of Results
The exploration of the versatility of the α-amino amide ZBG was initially performed
by altering the ARBG and the STBG. a series of 8 inhibitors was initial synthesised
using amide coupling of an N -Boc protected amino acid and an amine followed by
acidic deprotection of the N -Boc protecting group. Assessment of the inhibitory
activity of these compounds was performed using a fluorescent HDAC8 activity
assay. It was discovered that the presence of chlorine substitutions on the aryl
ARBG is essential as a ∼1 kcal mol−1 loss in energy was observed when the chloro-
substituted ARBG 4 was replaced with an unsubstituted ARBG 36 or p-hydroxy-
substituted 43. Tetrahydroisoquinoline was tested as a possible replacement for
isoindoline as a STBG because it is a more chemically versatile unit than isoindoline.
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Despite the reported flexibility of the HDAC8 substrate tunnel the additional bulk
and deviation from the linear and planar isoindoline STBG was not well tolerated
(Table 2.4).
After the initial discovery of the importance of the chlorinated aryl ARBG and
the linearity and planarity of the STBG, a second generation of α-amino amide
inhibitors were synthesised with a constant 2,4-dichlorophenyl ARBG and varying
STBG. STBGs tested included phenyl, p-methoxy, hydroxyphenyl and indole groups
with methylene linkers as well as a methyl group and a carbazole group (Table 3.2.
The most potent inhibitor from this second generation of α-amino amide inhibitors
was 5-fold less potent than the lead compound 4. However, a trend was seen that
suggested that hydrogen bonds were being donated from the inhibitor to HDAC8
with the most potent compounds being ethylindole 78 and ethyl-p-hydroxyphenyl
77. Manual docking of the inhibitors into the HDAC8 structure suggested that the
hydrogen bond acceptor was Asp101, a residue reported to be crucial for substrate
binding by forming hydrogen bonds with the backbone of the peptide-substrate84. In
addition to the beneficial effect of a hydrogen-bond donor, a negative effect was seen
with hydrogen bond acceptor groups which was reduced by shortening of the linker
chain to move the hydrogen bond acceptor away from the Asp101 residue (69→72).
Combining the observations of the initial two generations of α-amino amide in-
hibitors a third round of α-amino amide inhibitors was synthesised which added
hydrogen-bond donating groups to 5-position (the distal end) of the isoindoline.
Two synthetic routes were explored to reach substituted isoindoline ring systems.
Both these routes were sucessful but neither were optimised sufficiently to give high
yields, this could be improved with optimisation. Upon sucessful generation of the
5-substituted isoindoline ring system, a series of α-amino amide inhibitors were gen-
erated and assayed for HDAC8 inhibition.
The 5-aminoisoindolyl 97 and 5-acetamido 99 had IC50 values lower than the unsub-
stituted isoindoline inhibitor 4 with 99 having an average IC50 half that of 4 equating
to an improvement in binding energy of ∼ 0.5 kcal mol−1. 5-aminoisoindolyl 99 and
5-acetamido 97 are the most potent α-amino amide HDAC8 inhibitors that have
been reported to-date.
151
3rd Generation Inhibitors Simon O.R. Greenwood
4.7 Future work and perspectives
4.7.1 Selectivity of α-amino amide HDACi
Currently two HDAC8 inhibitors with an α-amino amide ZBG have been identified
that are more potent than any other α-amino amide inhibitors reported in the liter-
ature. While previous α-amino amide inhibitors have been reported to be selective
for HDAC8 over HDAC1, HDAC2 and HDAC6 (19 fold selectivity147), the inhibitors
reported in this study are as-yet untested against other HDAC isoforms. Inhibition
assays against the other 10 HDAC isoforms would confirm if slectivity for HDAC8
is retained for 99 compared to 4.
4.7.2 Cellular activity of compounds
Mocetinostat (12), the class I selective benzamide HDACi is in phase II clinical
trials for the treatment of lymphomas and leukemias240. It has a reported IC50 of 150
nM and 290 nM against HDAC1 and HDAC2 respectively. The current generation
of α-amino amide HDAC8 inhibitors have IC50 s as low as 101 nM, with sucessive
iterations of synthesis and activity measurements (in combination with other binding
studies), it is possible that this value will become lower. Therefore the potency of
α-amino amide HDACi is in the range of inhibitors that are currently being used as
treatments.
If compounds of this α-amino amide type are to become drug candidates then their
cellular effects need to be investigated. It is possible that the activity of an α-amino
amide based HDAC8 inhibitor in a cell would not be comparable to its activity in the
context of purified recombinant enzyme. This could be due to compensating mecha-
nisms, inability to cross the cell membrane, through metabolism of the compound or
a number of other reasons. For this reason it would be a good idea to attempt some
assays on cell lines to determine the efficacy of 4 in a more physiological setting.
From the results of these assays further rational design can be persued, e.g. if the
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compound was metabolised then knowing the metabolic products could lead to the
design of a more stable inhibitor. This has been performed with the HDAC8 selec-
tive inhibitor PCI-34051 (1) which has been modified to be more stable in plasma
for animal testing (the structure of the modified inhibitor has not been disclosed)241.
4.7.3 Expanding the cap-group interactions of 99
The design of an inhibitor with a single directed cap-group hydrogen bond interac-
tion sucessfully lowered the binding energy by ∼0.5 kcal mol−1. It stands to reason
therefore, that if additional orthoganal cap group interactions could be designed,
that the binding of the inhibitor could be further improved. HDACi exist that have
split cap groups15,242 so a second isoindoline substitution (if designed carefully) may
further improve binding to HDAC. Further investigations and manual docking of hy-
pothetical inhibitors suggests that a second cap-group substitution at position 7 of
the isoindoline ring could potentially improve binding. Previous investigations have
demonstrated that the AMC fluorophore of the Fluor-de-Lys substrate lowers the
KM dramatically due to aromatic stacking interactions with Tyr100
84, additionally
studies into the sequence specificity of HDAC8 have shown a preference for a pheny-
lalanine at the +1 position of the substrate191, finally a series of N -acetylthioureas
have been shown to bind to HDAC8 independently of substrate and improve activity
by lowering the KM of the Fluor-de-Lys substrate through aromatic interactions
105.
These three reports strongly suggest that designing an inhibitor with an aromatic
group that could form aromatic stacking interactions with Tyr100 could dramati-
cally improve binding of a ligand to HDAC8. The inclusion of this particular could
additionally increase the specificity of the α-amino amide inhibitor for HDAC8 as
this residue is not conserved among class I HDACs (being acidic residues in HDAC1,
HDAC2 and HDAC3)84. Aromatic residues are present at this position in HDAC6
(both catalytic domains) and HDAC10 but as the lead compound 4 inhibits HDAC6
very weakly147 this should not cause an issue.
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4.7.4 in silico Compound screening
To guide future chemical synthesis it would be useful to have an in silico method
for ligand screening. many reports have performed in silico screening of HDAC8
inhibitors but none of these studies considered α-amino amide type HDACi or con-
sidered the impact of halogen bonding243–246. Standard molecular docking algorithms
use a crystal structure and allow the sidechains of residues near the binding side to
be flexible, the backbone of the protein is fixed so no flexibility of the backbone
is taken into account and results are limited as a result. This technique would not
work well for the flexible HDAC8 protein, particularly as I have demonstrated above
the significance of interactions that occur between ligand and Asp101 on the highly
mobile L2 loop. The L2 loop is unresolved in the HDAC8-4 structure147 that would
be used as the basis for docking of any α-amino amide inhibitor and so the docking
would not accurately report interactions in this region even if it were modelled in as
it would be considered a rigid structure. Within the lab a large amount of all-atom
molecular dynamics (MD) data has been generated simulating HDAC8. Since this
data has been generated I think it would be a potentially very powerful dataset for
the exploration of potential inhibitors in silico.
By using multiple frames from the MD trajectory the flexibility of HDAC8 is ac-
counted for and ligands can be docked into individual rigid structures. As this
method removes the need to consider flexibility of sidechains, the docking algorithm
is a lot less computationally intensive while having the added advantage of taking
the flexibility of the full protein into account. The final dificulty in performing the
docking is replicating the halogen bonding interactions that are seen in the HDAC8-
4 structure. Standard forcefields used for molecular docking simulations consider
each atom to be a point charge and all calculations are performed under this as-
sumption. Due to the electronic anisotropy around the chlorine atoms in the ARBG
(discussed in Section 1.4.3) this assumption is not valid. One scoring function has
been described which claims to accurately replicate the effects of halogen bonding
in ligand docking186 but this has not been widely applied and rigourously tested. A
quantum mechanics-based scoring function has recently been described which may
provide a better description of the halogen bonding seen within the HDAC8-4 inter-
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action. Through docking of potential inhibitors into multiple frames of an HDAC8
MD trajectory the inherent flexibility of HDAC8 can be accounted for and does not
need to be considered during the docking, thereby reducing the time and computa-
tional power required. Using new scoring functions that replicate halogen bonding
new potential HDAC8i could be screened in silico to assess their potential value as
HDAC8i.
AM
AM
Tyr100
As 101
Tyr100
As 101
Lys-A
Lys-A
Figure 4.14: Crystal packing artefacts in the HDAC-Fluor-de-Lys substrate sctructure.
HDAC8 (purple and green) are bound with Fluor-de-Lys peptide molecules
(cyan and red respectively). The two AMC fluorophores are sandwiched
between the two Tyr100 from each monomer.
4.7.5 NMR ligand binding studies
Preliminary NMR investigations were carried out that clearly show the binding of α-
amino amide inhibitor 4 to HDAC8. NMR is known to be a very useful technique in
the investigation of protein-ligand interactions236, and can provide dynamic, residue-
specific information about protein-ligand interactions which can be used to evaluate
the ligand binding surface on the protein. This is superior to X-ray crystallography
because it is a solution state method and therefore avoids problems associated with
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crystal packing artefacts such as is seen in the HDAC8-Fluor-de-Lys structure where
2 HDAC8 monomers pack face-to-face and the aromatic stacking interactions occur
between the AMC fluorophores belonging to both HDAC8 monomers (Figure 4.14)
but also directly estimate the strength of interactions with each residue247. Kinetic
rate constants can also be calculated.
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5 Materials and Methods
5.1 HDAC8 Sample Preparation
HDAC8 was expressed and purified as described in previous reports114. Ile348Val
was kindly expressed and purified by Havva Yalinca using a C-terminal His-tagged
construct. The protein was been expressed at 21 ℃in deuterated M9 media with
13C2H3 α-ketobutyrate (60 mg/L) added 1 hr before induction by isopropyl-β-D-
thiogalactoside (IPTG). This sample was sufficiently pure for NMR after nickel
affinity purification.
The vector used for protein expression was purchased from GenScript (GenScript
USA Inc., 860 Centennial Ave., Piscataway, NJ 08854, USA) and consists of a His-
tag, NusA, TEV cleavage site and codon optimized human HDAC8. Protein concen-
trations were determined by measuring the A280 on a Biomate 3 spectrophotometer.
The extinction coefficient ε280 for HDAC8 was calculated to be 53290 M
−1cm−1 using
the ProtParam tool at http://expasy.org.
5.1.1 Site directed mutagenesis
Site directed mutatgenesis was performed using primers with optimised melting tem-
peratures of 80℃:
HDAC8 F152A f 5’- CGAAAAAAGACGAAGCCTCGGGTGCTTGTTATCTGAAT-
GATGCG -3’
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HDAC8 F152A r 5’- CGCATCATTCAGATAACAAGCACCCGAGGCTTCGTCTTTTTTCG
-3’
HDAC8 F208A f 5’- TTTCCCCGGGCTTTGCCCCGGGCACCGG -3’
HDAC8 F208A r 5’- CCGGTGCCCGGGGCAAAGCCCGGGGAAA -3’
PCR was performed using KOD-hot start polymerase (Merck) and parental DNA
was digested using DPN1 (New England Biolabs) before transformation into com-
petent DH5α E.coli. Sequences were verified by sequencing using T7 reverse primer
and a forward primer that recognises a sequence in the C-terminal of the N-terminal
NusA tag
5.1.2 Protein Purification
BL21(DE3) pET-29b+ His-NusA-HDAC8 cells were grown in LB at 37 ℃and in-
duced with 1mM isopropyl β -D-1-thiogalactopyranoside (IPTG) and ZnSO4 (200
µM) when A600= 0.6-1.0. The temperature was decreased to 23
◦C for expression
and cells were harvested after approximately 16 h.
The cells were harvested by centrifugation (4 ◦C, 15 min, 4k rpm). Cell pellets were
resuspended in lysis buffer (50 mMTris, pH 8.0, 500 mMKCl, 5 mM imidazole, 3 mM
MgCl2, 5% glycerol, 5 mM beta-mercaptoethanol, 0.25% IGEPAL) with complete
protease inhibitor, lysozyme and DNAse.
Cells were lysed using sonication and the lysate centrifuged (4 ◦C, 50 min, 18 krpm)
in a Sorvall standing centrifuge using an SS34 rotor. The lysate supernatant was
filtered (0.2 µm) and applied to a pre-equilibrated Ni-NTA column (GE Healthcare).
The column was washed with washing buffer (50 mM Tris, pH 8.0, 500 mM KCl, 5
mM imidazole, 3 mM MgCl2, 5% glycerol, 5 mM beta-mercaptoethanol) and eluted
with an imidazole gradient of 0 - 250 mM over 100 mL. HDAC8 containing elution
fractions (as determined by SDS-PAGE) were pooled, diluted twofold and dialysed
o/n at 4 ◦C against 2 L of TEV cleavage buffer (50 mM Tris, pH 8.0, 150 mM
KCl, 5 mM beta-mercaptoethanol, 5% glycerol). To remove the NusA solubility
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tag, TEV-protease was added (0.01 mg/mg protein) and incubated for 3 h at room
temperature. If at this time cleavage was not complete more protease was added
and incubation time was prolonged (e.g. o/n at 4 ◦C). The cleaved proteins were
separated by a second pass over a Ni-NTA affinity column (equilibrated with washing
buffer). The NusA solubility tag and TEV protease are retained on the column due
to the presence of a His-tag, this step also removes other protein impurities which
boun to the nickel resin and eluted in the first Ni-NTA pass. The HDAC8 containing
flowthrough was concentrated and purified by gel filtration on an S75 column (GE
Healthcare) equilibrated with gel filtration buffer (50 mM Tris pH 8.0, 150 mM KCl,
1 mM TCEP 5% glycerol), the relevant fractions were concentrated, and aliquotted
before snap-freezing in liquid nitrogen and storage at -80◦C.
5.1.3 HDAC8 fluorogenic activity Assay
The MAL substrate was kindly synthesised by Chris Matthews. As a single residue
(rather than commercial Fluor-de-Lys tetrapeptide), this substrate has a higher KM
than the Fluor-de-Lys substrate but it is cheap and easy to synthesise, the assay
is not compromised as [S] ≫ [E] is still satisfied (so Michaelis Menten conditions
are still met). The AMC fluorophore is used in both substrates so other parameters
do not need to be modified and the same standard curve can be used to quantify
deaceylation in each case.
The inhibitor was diluted to 2 - 10 mM using DMSO-d6 and the concentration
measured using NMR (see Section 5.2.2), and was diluted to the maximum stock
concentration with assay buffer: 50 mM Tris/Cl pH 8.0, 137 mM NaCl, 2.7 mM
KCl, 1 mM MgCl2, 10% Polythelene glycol (PEG) (avg. MW 8000 Da), 1 mg/mL
bovine serum albumin (BSA). New inhibitor dilutions were made from the DMSO-
d6 stock for each independent repeat. It was found that serial dilutions of inhibitor
gave more consistent results than regularly distributed dilutions. Assay buffer was
used to dilute all other stock solutions.
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Inhibition assays
To inhibitor (10 µL, 5x final concentration) in a 96 well, 1/2 area, white microtitre
plate (Corning), was added HDAC8 (15 µL 3.3x final concentration), 25 µL substrate
(2x final concentration, diluted in assay buffer) was then added and mixed using a
multichannel pipette. The deacetylation reaction was allowed to proceed for 1 h
before the addition of 50 µL developer solution (assay buffer + 2 mg/ml trypsin
and 4 µM TSA), the TSA in the developer solution was subsequently replaced with
2 µM 4 after the Ki of TSA was measured at 1.6 µM and was therefore unfit for
purpose as a reaction quenching agent. The stopped reactions were incubated at 20
℃ for 15 - 45 min (the signal was sen to be stable over this time period) and then
the fluorescence was read using a Fluostar Optima (BMG Labtech) plate reader λex
= 380 nm and λem = 460 nm.
The results of the assay were processed using a script written in MatLabr. A
baseline fluorescence value was substracted from all wells and the flourescence values
(in arbitrary fluoescence units) were normalised against an uninhibited control to
give relative fluorescence values. The data were fitted to a Michaelis-Menten model
using a non-linear regression using all points (Equation 5.1).
y =
KcatE0S
KM(1 + I/Ki) + S
/
KcatE0S
KM + S
(5.1)
Activity assays
Activity assays were performed in microcentrifuge tubes with the stated concentra-
tions of HDAC8 and substrate. At each timepoint 50 µL was removed from the
reaction tube and quenched with 50 µL developer solution in a 96 well, 1/2 area,
white microtitre plate (Corning), the plate was incubated for 15 min. Fluorescence
was subsequently measured as above and data analysed using Microsoft Excel.
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5.1.4 Manual Molecular docking
All structural figures were made using PyMOL248. Manual docking was performed
using PyMOL and Avogadro, a molecular editor208. The HDAC-4 X-ray structure
(PDB:3SFH) was downloaded from the PDB and loaded into PyMOL. The ligand (4)
was extracted and modified to make the target inhibitor in Avogadro. Atoms which
are common to both the lead compound 4 and the target were then fixed and an
energy minimisation was performed on the remaining atoms using the UFF forcefield
with steepest decent algorithm, this process was repeated multiple times if rotamers
were possible. The energy minimised ligand was loaded into the HDAC8-4 structure
with the ligand removed. The newly created bonds were rotated to position relevant
groups in appropriate positions using Pymol. The STBG was energy minimised a
second time in the same way to ensure the dihedral angles were in allowed regions
before loading into the crystal structure a final time.
5.2 NMR experiments
5.2.1 Methyl-TROSY NMR
13CH3Ile-labeled HDAC8-Ile348Val (20 µM in 50 mM potassium phosphate, 30 mM
sodium chloride, 99% D2O, pH 8.2) was mixed with 4 (10 µL, 2.4 mM in DMSO-d6)
in a Shigemi NMR tube at 25℃. Methyl-TROSY HMQC spectra were recorded on a
Varian 600MHz spectrometer before and after addition of 4. The sweepwidth in the
indirect dimension was 1800 Hz, 256 complex points were collected. The number of
measurements in the direct dimension was 1536 real points and 768 complex points,
with an acquisition time of 64 ms. The total experiment time was approximately 4
hours.
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5.2.2 NMR concentration measurements
The mass of solid obtained from the N -Boc deprotection did not reliably correlate
to the amount of α-amino amide salt present owing to the often very hygroscopic
nature of the α-amino amide hydrochloride salts (as mentioned in Section 2.2.3).
To account for this discrepency. an NMR sample was made in deuterated DMSO
and the concentration quantified using the quantint macro within the TopSpin NMR
software (kindly set up by Dr. Abil Aliev). This method uses an external sample
of a known concentration (recorded previously) to set the peak integral reference.
The concentration of a sample is calculated by defining peak integral regions and
running the macro which calibrates the scaling of the integral regions to give the
concentration in mM of that region. Because absorbed water does not contriubute
to the NMR signals of the molecule (peaks away from the water signal are used for
quantification), this method allows concentration measurement that is independent
of any water absorbed by the compound. This method also allows greater accuracy
of inhibitor concentrations within the assay as two sources or error are removed (the
weighing of the solid sample and the measuring of the solvent volume. Therefore
with this NMR concentration measurement greater confidence can be given to the
exact inhibitor concentration within the assay.
5.3 General Chemistry experimental
Chemicals were used as supplied from commerical sources, solvents used were reagent
grade, when not purchased as anhydrous, anhydrous solvents were obtained from
Anhydrous Engineering (USA) solvent systems after passing through an alumina
column. Compound homogeneity was monitored by ascending thin-layer chromatog-
raphy, performed on Merck 0.2 mm aluminum-backed silica gel 60 F254 plates and
visualized using an alkaline potassium permanganate dip or by ultraviolet light.
Flash column chromatography was performed using Merck 0.040 to 0.063 mm, 230
to 400 mesh silica gel. Evaporation refers to the removal of solvent under reduced
pressure. Hydrogen chloride was generated by the dropping of concentrated sulfuric
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acid into a flask containing sodium chloride equipped with a magnetic stirrer. Opti-
cal rotation measurements were performed on a Perkin Elmer 343 polarimeter using
a 1 mL 10 cm pathlength cell, in the stated solvent. Melting points were measured
on an electrothermal 9100 melting point aparatus. NMR spectra were recorded at
300 MHz on a Bruker AMX300 spectrometer, at 400 MHz on a Bruker AMX400, at
500 MHz on a Bruker Avance 500 spectrometer or at 600 MHz on a Bruker Avance
600 spectrometer in the stated solvent; chemical shifts are reported in δ (ppm) rel-
ative to the lock signal of the stated solvent. Infrared spectra were recorded on
a Brucker Alpha FTIR spectrometer equipped with a diamond ATR prism. Mass
spectra were recorded in the UCL mass spectrometry facility on a Finnigan MAT
900XP or a capLC-MSn Thermo Finnigan LTQ spectrometer.
note on NMR assignments: Where ambiguous, assignments have been made using
an oblique (ie. C(7)/C(9) means C(7) or C(9)), where peaks arise from more than one
nucleus the assignments are separated with a comma (ie. C(7),C(9) means C(7) and
C(9)).
5.4 Chemistry experimental procedures and
characterisation
(R)-2-Amino-3-(2,4-dichlorophenyl)-1-(isoindolin-2-yl)propan-1-one
hydrochloride (4)
N
1
2
O 3
4
NH2.HCl5
6
11
10
9
8
7
ClCl
19
1813
12
17
1615
14
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N -Boc protected amide 31 (0.15 g, 0.35 mmol) was dissolved in diethyl ether (10 mL)
and hydrogen chloride was bubbled through while stiring for 2 h. The precipitate
was filtered by gravity filtration through filter paper in a funnel that was on top
of a flask of boiling ether 4 (114 mg, 87%) as a white solid, m.p.(decomp. 175
℃); [α]25
D
c=1 methanol: -41.0°; νmax (cm
−1)3080-2680 br. (NH), 1644 (C=O);
1H NMR (500 MHz, DMSO-d6) δ ppm 8.73 (3H, br.s, H(5)), 7.55 (1H, d, J=1.4
Hz, H(10)), 7.47 (1H, d, J=8.1 Hz, H(7)/H(8)), 7.33 - 7.40 (1H, m, H(8)/H(7)), 7.19
- 7.33 (4H, m, aryl), 5.04 (1H, d, J=13.6 Hz, H(12)/H(19)), 4.51 (1H, d, J=16.0
Hz, H(19)/H(12)), 4.36 (1H, br.s, H(3)), 4.21 (1H, d, J=13.6 Hz, H(19)/H(12)), 3.17
- 3.48 (3H, m, 2H(5),H(19)/H(12));
13C NMR (126 MHz, methanol) δ ppm 166.48
C(2), 135.74, 135.16, 134.55, 133.55, 133.03, 131.64, 128.81, 127.64, 127.56, 122.98,
122.73, 52.08 C(12)/C(19), 51.68 C(3), 49.98 C(19)/C(12), 33.30 C(4); HRMS calcd for
C17H17Cl2N2O: 435.1242, found: 435.1230.
(R)-tert-Butyl (3-(2,4-dichlorophenyl)-1-(2,3-dihydro-1H-inden-2-yl)-1-
oxopropan-2-yl)carbamate (31)147
N
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2
O 3
4
NH
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To isoindoline (0.11 mL, 1.0 mmol), N -Boc-(R)-2,4-dichlorophenylalanine (344 mg,
1.0 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg, 1.0 mmol) and
anyhdrous 1-hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethylformamide (3.0
mL) was added N,N -diisopropylethylamine (1.3 mL, 7.5 mmol), the mixture was
then stirred for 20 h at 20 ℃. The solvent was evaporated, the residue was disolved
in ethyl acetate (20 mL) and washed with water (2 x 20 mL). The combined aqueous
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fractions were re-extracted with ethyl acetate (4 x 20 mL) and the combined organic
layers were washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL)
and brine (20 mL) before being dried over magnesium sulfate and evaporated. The
residue was purified by silica column chromatography (5% ethyl acetate in dichloro-
methane) to give 31 (330 mg, 76%) as a pale yellow solid, m.p. 160-162℃; [α]25
D
c=1
CHCl3 -24.7°; νmax (cm
−1): 3429 (NH), 3296 (NH), 1704 (NHC=O), 1641 (CHC=O);
1H NMR (500 MHz, chloroform-d) δ ppm 7.30 (1H, m, aryl) 7.07 - 7.27 (6H, m, aryl),
5.67 (1H, d, J=9.1 Hz, H(5)), 4.93 - 5.03 (1H, d, J=13.7 Hz, H(12)/H(19)), 4.84 - 4.92
(1H, m, H(3)), 4.72 - 4.83 (1H, d, J=15.6 Hz, H(19)/H(12)), 4.62 - 4.72 (1H, d, J=
14.8 Hz, H(19)/H(12)), 3.16 (1H, dd, J=13.6, 6.1 Hz, H(4)), 3.03 (1H, dd, J=13.6,
8.2 Hz, H(4)), 1.22 - 1.42 (9H, m, 3 x 3H(22));
13C NMR (126 MHz, chloroform-d)
δ ppm 170.22 C(2), 155.05 C(20), 135.85 C(13)/C(18), 135.80 C(13)/C(18), 135.16 C(6),
133.62, 133.14, 132.83, 129.30, 127.97, 127.74, 127.07, 122.97, 122.80, 79.88 C(21),
52.41 C(12)/C(19), 52.37 C(19)/C(12), 51.03 C(3), 36.66 C(4), 28.32 C(22); HRMS calcd
for C22H24Cl2N2O3 435.1242, found: 435.1230.
(R)-tert-Butyl(1-(isoindolin-2-yl)-1-oxo-3-phenylpropan-2-
yl)carbamate (32)249
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A literature procedure249 using triethylamine was adapted for use with N -diisopropyl-
ethylamine. To isoindoline (0.11 mL, 1.0 mmol), N -Boc-(R)-phenylalanine (265 mg,
1.0 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg, 1.0 mmol) and
anyhdrous 1-hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethylformamide (3.0
mL) was added N,N -diisopropylethylamine (1.3 mL, 7.5 mmol). The mixture was
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stirred for 16 h at 20 ℃. The solvent was evaporated, the residue was disolved in
ethyl acetate (20 mL) and washed with water (2 x 20 mL). The combined aqueous
fractions were re-extracted with ethyl acetate (2 x 20 mL) and the combined organic
layers were washed with saturated sodium hydrogen carbonate solution (2 x 20 mL)
and brine (20 mL) before being dried over magnesium sulfate and evaporated. The
residue was purified by silica column chromatography (25% ethyl acetate/hexane)
to give 32 (175 mg, 48%) as a cream solid, m.p. 156-160 ℃; 1H NMR (500 MHz,
chloroform-d) δ ppm 7.20 - 7.30 (7H, aryl), 7.15 (1H, m, aryl), 7.10 (1H, m, aryl), 5.36
(1H, d, J=9.0 Hz, H(5)), 4.88, (1H, d, J=13.8 Hz, H(12)/H(19)), 4.82 (1H, d, J=15.9
Hz, H(19)/H(12)), 4.68 - 4.77 (1H, m, H(3)), 4.63 (1H, d, J=15.9 Hz, H(19)/H(12)), 4.06
(1H, d, J=13.8 Hz, H(12)/H(19)), 2.98 - 3.10 (2H, m, 2H(4)), 1.36 - 1.44 (9H, m, 3
x 3H(22));
13C NMR (126 MHz, chloroform-d) δ ppm 170.7 C(2), 155.2 C(20), 136.4
C(13)/C(18), 136.0 C(18)/C(13), 135.8 C(6), 129.4 C(8),C(10)), 128.5 C(7),C(11), 127.8
C(15)/C(16), 127.6 C(16)/C(15), 127.1 C(17), 122.9 C(14)/C(9), 122.6 C(17)/C(14), 79.9
C(21), 53.4 C(3), 52.2 C(12)/C(19), 52.1 C(12)/C(19), 39.9 C(4), 28.4 C(22).
(R)-tert-Butyl(1-(3,4-dihydroisoquinolin-2(1H )-yl)-1-oxo-3-
phenylpropan-2-yl)carbamate (33)250
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A literature procedure250 was adapted to use DMF as a solvent. To tetrahydroiso-
quinoline (0.13 mL, 1.0 mmol), N -Boc-(R)-phenylalanine (265 mg, 1.0 mmol), 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg, 1.0 mmol) and anyhdrous 1-
hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethylformamide (3.0 mL) was added
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N,N -diisopropylethylamine (1.3 mL, 7.5 mmol), the mixture was then stirred for 16
h at 20 ℃. The solvent was evaporated, the residue was disolved in ethyl acetate
(20 mL) and washed with water (2 x 20 mL). The combined aqueous fractions were
re-extracted with ethyl acetate (2 x 20 mL) and the combined organic layers were
washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL) and brine
(20 mL) before being dried over magnesium sulfate and evaporated. The residue
was purified by silica column chromatography (25% ethyl acetate, 75% hexane) to
give 33 (207 mg, 57%) as a colourless oil, νmax (cm
−1): 4322 (NH), 3300 (NH), 1702
(NHC=O), 1635 (CHC=O); 1H NMR (500 MHz, chloroform-d, 2 rotamers) δ ppm
6.77 - 7.23 (9H, aryl), 5.48 - 5.65 (1H, m, H(5)), 4.84 - 4.98 (1H, m, H(3)), 4.68 -
4.77, 4.52 - 4.61, 4.43 - 4.52, 3.93 - 4.03 (2H, m, H(12)), 3.09 - 3.85 (2H, m, 2H(20)),
2.90 - 3.06 (1H, m, H(19)), 2.93 - 2.98 (1H, m, H(4)), 2.22 - 2.83 (2H, m, H(4),H(19)),
1.41 (9H, s, 3 x H(23));
13C NMR (126 MHz, chloroform-d, 2 rotamers) δ ppm 170.75
C(2), 170.45 C(2), 155.20 C(21), 155.17 C(21), 136.60, 136.36, 134.54, 134.12, 132.84),
132.17, 129.53, 129.38, 128.64, 128.50, 128.34, 128.29, 126.92, 126.86, 126.62, 126.57,
126.54, 126.30, 126.15, 79.64 C(22), 51.88 C(3), 51.66 C(3), 47.06 C(12), 44.55 C(12),
43.09 C(20), 40.50 C(20), 40.40 C(4), 40.24 C(4), 29.15 C(19), 28.46 C(23), 28.35 C(19).
(R)-tert-Butyl (1-oxo-3-phenyl-1-(4-phenylpiperazin-1-yl)propan-2-yl)
carbamate (34)
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To phenylpiperazine (0.16 mL, 1.0 mmol), N -Boc-(D)-phenylalanine (265 mg, 1.0
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mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg, 1.0 mmol) and
anyhdrous 1-hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethylformamide (3.0
mL) was added N,N -diisopropylethylamine (1.3 mL, 1.0 mmol), the mixture was
then stirred for 16 h at 20 ℃. The solvent was evaporated, the residue was disolved
in ethyl acetate (20 mL) and washed with water (2 x 20 mL). The combined aque-
ous fractions were re-extracted with ethyl acetate (2 x 20 mL) and the combined
organic layers were washed with saturated aqueous sodium hydrogen carbonate (2
x 20 mL) and brine (20 mL) before being dried over magnesium sulfate and evapo-
rated. The residue was purified by silica column chromatography (14% ethyl acetate
86% dichloromethane) to give 34 (307 mg, 64%) as a white solid, m.p. (decomp 170
℃); νmax (cm
−1): 3393 (NH), 3200-2500 br. (NH), 1648 (C=O);
1H NMR (500 MHz, chloroform-d) δ ppm 7.16 - 7.32 (7H, m, aryl), 6.87 (1H, t, J=7.3
Hz, aryl), 6.81 (2H, d, J=8.4 Hz, aryl), 5.62 (1H, d, J=8.8 Hz, H(5)), 4.84 - 4.94 (1H,
m, H(3)), 3.60 - 3.75 (2H, m, H(12)/H(22)), 3.39 - 3.49 (1H, m, H(12)/H(22)), 2.97 - 3.19
(4H, m, H(4),H(12)/H(22),H(13)/H(21)), 2.87 - 2.96 (2H, m, H(4),H(13)/H(21)), 2.39 - 2.50
(1H, m, H(13)/H(21)), 1.44 (9H, s, 3 x 3H(25));
13C NMR (126 MHz, chloroform-d)
δ ppm 170.20 C(2), 155.13 C(23), 150.79 C(15), 136.46 C(6), 129.65, 129.27, 128.66,
127.14, 120.61, 116.68 C(16),C(20), 79.88 C(24), 51.03 C(3), 49.32 C(13)/C(21), 49.06
C(21)/C(13), 45.46 C(12)/C(22), 41.91 C(22)/C(12), 40.57 C(4), 28.43 C(25).
(R)-tert-Butyl(1-(4-methylpiperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)-
carbamate (35)
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To N -methylpiperazine (0.11 mL, 1.0 mmol), N -Boc-(R)-phenylalanine (265 mg,
1.0 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg, 1.0 mmol) and
anyhdrous 1-hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethylformamide (3.0
mL) was added N,N -diisopropylethylamine (1.3 mL, 7.5 mmol), the mixture was
then stirred for 16 h at 20 ℃. The solvent was evaporated, the residue was disolved
in ethyl acetate (20 mL) and washed with water (2 x 20 mL). The combined aqueous
fractions were re-extracted with ethyl acetate (2 x 20 mL) and the combined organic
layers were washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL)
and brine (20 mL) before being dried over magnesium sulfate and evaporated. The
residue was purified by silica column chromatography (15% methanol 85% ethyl
acetate) to give 35 (174 mg, 50%) as a colourless oil, νmax (cm
−1): 3297 (NH), 1704
(NHC=O), 1639 (CHC=O); 1H NMR (500 MHz, chloroform-d) δ ppm 7.05 - 7.22
(5H, m, aryl), 5.60 (1H, d, J=8.7 Hz, H(5)), 4.74 (1H, m, H(3)), 3.36 - 3.55 (2H,
m, 2H(12)/2H(16)), 3.19 - 3.27 (1H, m, H(4)), 2.79 - 3.03 (3H, m, H(4),2H(16)/2H(12)),
2.15 - 2.29 (1H, m, H(13)/H(15)), 1.98 - 2.14 (5H, m, 1H(13),1H(15),3H(17)), 1.55 - 1.74
(1H, m, H(13)/H(15)), 1.32 (9H, s, 3 x 3H(20));
13C NMR (126 MHz, chloroform-d)
δ ppm 169.93 C(2), 155.07 C(18), 136.53 C(7), 129.58 C(8),C(10), 128.50 C(7)/C(11),
126.90 C(9), 79.51 C(19), 54.45 C(13),C(15), 54.34 C(13)/C(15), 50.88 C(3), 45.81 C(17),
45.35 C(5), 41.77 C(12)/C(16), 40.33 C(12)/C(16), 28.38 3C(2).
(R)-2-Amino-1-(isoindolin-2-yl)-3-phenylpropan-1-one
hydrochloride (36)
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N -Boc protected amide 32 (182 mg, 497 mmol) was dissolved in diethyl ethereal
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hydrochloric acid (10 mL, 1 M) and the mixture stirred at 20℃ for 16 h. The solvent
was evaporated to give 36 as a pale brown solid (139 mg, 92%), m.p. (decomp. 220
℃); [α]25
D
c=1 methanol -30.4°; νmax (cm
−1): 3362 (NH), 3000-2800 br. (NH), 1650
(C=O); 1H NMR (500 MHz, DMSO-d6) δ 8.71 (3H, br.s, 3H(5)), 7.15 - 7.31 (9H,
m, aryl), 4.93 (1H, d,J=14.0 Hz, H(12)/H(19)), 4.69 (1H, d, J=16.1 Hz, H(19)/H(12)),
4.50 (1H, d, J=16.1 Hz, H(19)/H(12)), 4.32 (1H, br.s, H(3)), 3.92 (1H, d, J=14.0
Hz H(12)/H(19)), 3.26 (1H, dd, J=13.2, 5.5 Hz, H(4)), 3.05 (1H, dd, J=13.2, 9.0
Hz, H(4));
13C NMR (126 MHz, DMSO-d6) δ 166.9 C(2), 135.9 C(13)/C(18)/C(6),
135.1 C(13)/C(18)/C(6), 134.8 C(13)/C(18)/C(6), 129.5 C(10),C(8), 128.6 C(7),C(11), 127.6
C(15)/C(16), 127.6 C(16)/C(15), 127.3 C(9), 123.0 C(14)/C(17), 122.6 C(17)/C(14), 52.0
C(3), 51.9 C(12)/C(19), 51.6 C(19)/C(12), 36.5 C(4); m/z: (CI+) 267 ([M-Cl]+, 21%)
175 ([M-Cl-CH2C6H5]
+, 55%), 118, ([isoindoline]+, 34%), 120 ([C8H(10)N]+, 55%),
85 (100%); HRMS calcd for C17H20N2O requires: 267.1497, found 267.1495.
(R)-2-Amino-1-(3,4-dihydroisoquinolin-2(1H )-yl)-3-phenylpropan-1-
one hydrochloride (37)
10
11
6
7
8
9
4
3
NH2.HCl
5
2
N
1
O
12
13
14
15
16
17
18
19
20
N -Boc protected amide 33 (207 mg, 54 mmol) was dissolved in ethereal hydrogen
chloride(1 M, 10 mL) and stirred at 20 ℃ for 16 h, the solvent was evaporated to
give 37 (142 mg, 85%) as a hygroscopic pale yellow solid, [α]25
D
methanol: -7.8°;
νmax (cm
−1): 3200-2500 br. (NH), 1641 (C=O); 1H NMR (500 MHz, DMSO-d6, 2
rotamers) δ ppm 8.46 (3H, br.s, 3H(5)), 6.91 - 7.36 (9H, m, aryl), 3.90 - 4.66 (2H,
m, 2H(12)), 3.50 - 3.68 (2H, m, H(3),H(20)), 3.11 - 3.24 (1H, m, H(4)), 2.91 - 3.07 (1H,
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m, H(4)), 2.54 - 2.76, 2.15 - 2.36, 1.23 - 1.36 (2H, m 2H(19));
13C NMR (126 MHz,
DMSO-d6, 2 rotamers) δ ppm 167.21 C(2), 166.90 C(2), 134.55, 134.29, 134.22, 134.07,
132.37, 132.33, 129.57, 129.47, 128.51, 128.33, 128.23, 127.27, 127.12, 126.58, 126.49,
126.43, 126.22, 126.09, 126.05, 50.37 C(3), 50.18 C(3), 46.15 C(12), 44.03 C(12), 42.52
C(20), 36.99 C(4), 36.78 C(4), 28.34 C(19), 27.58 C(19). HRMS calcd for C18H21N2O:
281.1654, found 281.1650.
(R)-2-Amino-3-phenyl-1-(4-phenylpiperazin-1-yl) propan-1-one
hydrochloride(38)
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N -Boc protected amide 34(307 mg, 0.75 mmol) was dissolved in dry diethyl ether
(10 mL). Hydrogen chloride was bubbled through the solution with vigorous stirring
for 5 h. The precipitate was filtered by gravity filtration through filter paper in
a funnel that was on top of a flask of boiling ether 38 (244 mg, 75%) as a cream
solid, m.p. (decomp. 170℃); [α]25
D
c=1 methanol: +37.3°; νmax (cm
−1): 3393 (NH),
3200-2700 br. (NH), 1648 (C=O); 1H NMR (500 MHz, DMSO-d6) δ ppm 8.65 (3H,
br.s, 3H(5)), 7.03 - 7.59 (10H, m, aryl), 3.82 - 3.84 (1H, m, H(8)), 3.57 - 3.72 (2H,
m, H(12)/H(13)/H(21)/H(22)), 3.52 (1H, br.s, H(12)/H(13)/H(21)/H(22)), 3.35 (1H, dd,
J=14.0, 6.9 Hz, H(12)/H(13)/H(21)/H(22)), 3.23 - 3.31 (1H, m, H(12)/H(13)/H(21)/H(22)),
3.20 (1H, dd, J=13.0, 5.4 Hz, H(4)), 3.04 - 3.16 (1H, m, H(12)/H(13)/H(21)/H(22)),
2.93 (1H, dd, J=13.2, 9.2 Hz, H(4)), 2.54 - 2.74 (1H, m, H(12)/H(13)/H(21)/H(22));
13C NMR (126 MHz, DMSO-d6) δ ppm 166.93 C(2), 146.01 C(15), 134.48, 129.61,
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129.44, 128.54, 127.27, 118.52 Caryl, 51.13 C(13)/C(21), 50.87 C(21)/C(13) 49.39 C(3),
43.59 C(12)/C(22), 40.29 C(22)/C(12), 36.88 C(4); HRMS calcd for C19H23N3O requires
309.1841, found 309.1837;
(R)-2-Amino-1-(4-methylpiperazin-1-yl)-3-phenylpropan-1-one
hydrochloride (39)
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N -Boc protected amide 35 (174 mg, 0.5 mmol) was dissolved in ethereal hydrogen
chloride (1 M, 10 mL) and stirred at 20 ℃ for 16 h and the solvent was evaporated.
To the residue was added saturated aqueous sodium hydrogen carbonate (20 mL)
and the solution was washed with ethyl aetate (2 x 20 mL) and extracted into
dichloromethane (3 x 30 mL) and evaporated to give the amine, 1H NMR (500
MHz, chloroform-d) δ ppm 7.07 - 7.25 (5H, m, aryl), 3.87 (1H, br.s, H(3)), 3.45 -
3.61 (2H, m, 2H(12)/2H(16)), 3.22 - 3.35 (1H, m, H(16)/ H(12)), 2.97 - 3.08 (1H, m,
H(16)/H(12)), 2.82 - 2.90 (1H, dd, J=13.1, 7.0 Hz, H(5)), 2.70 - 2.78 (1H, dd, J=13.1,
7.1 Hz, H(5)), 2.22 - 2.32 (1H, m, 13/H(15)), 2.15 - 2.19 (2H, m, H(13)/H(15)), 2.14
(3H, s, H(17)), 1.74 - 1.82 (H, m, H(13)/H(15));
13C NMR (126 MHz, DMSO-d6) δ
ppm 173.22 C(2), 137.67 C(6), 129.40 C(8),C(10), 128.63 C(7),C(11), 126.83 C(9), 54.63
C(12)/C(16), 54.50 C(12)/C(16), 52.33 C(3), 45.93 C(19), 45.08 C(13)/C(15), 43.18 C(5),
41.85 (13/C15);
The residue was dissolved in diethyl ether (5 mL) and ethereal hydrochloric acid (2
M, 5 mL) was added and the solvent was evaporated to give 39 (140 mg, 98%) as a
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cream solid, m.p. (decomp. 150 ℃); νmax (cm
−1): 3391 (NH), 1650 (C=O), 1602;
[α]25
D
c=1 methanol: -27.0°; HRMS calcd for C14H22N3O: 248.1763, found: 248.1762.
(R)-tert-Butyl (3-(4-hydroxyphenyl)-1-(isoindolin-2-yl)-1-oxopropan-2-
yl) carbamate (40)
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To isoindoline (0.11 mL, 1.0 mmol), N -Boc-(D)-tyrosine (270 mg, 1.0 mmol), 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg, 1.0 mmol) and anyhdrous 1-
hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethylformamide (3.0 mL) was added
N,N -diisopropylethylamine (1.3 mL, 7.5 mmol), the mixture was then stirred for 16
h at 20 ℃. The solvent was evaporated, the residue was disolved in ethyl acetate
(20 mL) and washed with water (2 x 20 mL). The combined aqueous fractions were
re-extracted with ethyl acetate (2 x 20 mL) and the combined organic layers were
washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL) and brine
(20 mL) before being dried over magnesium sulfate and evaporated, to give 40 (200
mg, 52%) as a white solid, m.p. 213-214 ℃; [α]25
D
c=1 Chloroform -29.8°; 1H NMR
(500 MHz, chloroform-d) δ ppm 8.11 (1H, br.s, H(20)), 7.12 - 7.23 (3H, m, aryl), 7.04
(1H, d, J=8.5 Hz, aryl), 6.74 (1H, d, J=8.5 Hz, aryl), 5.50 (1H, d, J=9.0 Hz, H(5)),
4.86 (1H, d, J=13.7 Hz, H(12)/H(19)), 4.78 (1H, d, J=16.0 Hz, H(19)/H(12)), 4.67 (1H,
s, H(3)), 4.58 (1H, d, J=16.1 Hz, H(19)/H(12)), 4.15 (1H, d, J=13.7 Hz, H(12)/H(19)),
2.96 (1H, dd, J=13.4, 8.5 Hz, H(4)), 2.89 (1H, dd, J=13.4, 6.0 Hz, H(4)), 1.39 (9H, s,
3 x H(23));
13C NMR (126 MHz, chloroform-d) δ ppm 170.96 C(2), 155.42 C(20)/C(21),
155.31 C(20)/C(21), 135.83, 135.62, 130.55 C(7),C(11), 127.84, 127.64, 127.62, 122.90,
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122.64, 115.55 C(8),C(10), 80.15 C(22), 53.51 C(3), 52.33 C(12)/C(19), 52.22 C(19)/C(12),
38.76 C(4), 28.42 C(23); HRMS calcd for C22H26N2O4: 383.1971, found: 383.1953.
(R)-tert-Butyl (1-(3,4-dihydroisoquinolin-2(1H )-yl)-3-(4-hydroxy-
phenyl)-1-oxopropan-2-yl)carbamate (41)
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To tetrahydroisoquinoline (0.11 mL, 1.0 mmol), N -Boc-(R)-tyrosine (281 mg, 1.0
mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg, 1.0 mmol) and
anyhdrous 1-hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethylformamide (3.0
mL) was added N,N -diisopropylethylamine (1.3 mL, 7.5 mmol), the mixture was
then stirred for 24 h at 20 ℃. The mixture was the diluted with ethyl acetate (20
mL) and washed with water (2 x 20 mL). The combined aqueous fractions were
re-extracted with ethyl acetate (2 x 20 mL) and the combined organic layers were
washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL) and brine
(20 mL) before being dried over magnesium sulfate and evaporated. The residue was
purified by silica column chromatography (50% ethyl aceate, 50% hexane) to give
41 (125 mg, 32%) as a white solid, m.p. 213-214℃; νmax (cm
−1): 3303 (NH), 2978,
1691 (NHC=O), 1630 (CHC=O); 1H NMR (500 MHz, chloroform-d, 2 rotamers) δ
ppm 6.80 - 7.18 (6H, m, aryl), 6.66 (1H, d, J=8.5 Hz, aryl), 6.60 (1H, d, J=8.5
Hz, aryl), 5.50 (1H, d, 8.7 Hz, H(5)), 4.84 - 4.93 (1H, m, H(3)), 4.76, 4.53 (1H, d,
J=17.2 Hz, H(12)), 4.51, 4.08 (1H, d, J=15.9 Hz, H(12)),3.76 - 3.83, 3.62 - 3.70,
3.55 - 3.62, 3.16 - 3.23 (2H, m, 2H(20)), 2.84 - 2.96 (2H, m, H(4),H(9)), 2.69 - 2.82
(2H, m, H(4),H(9)), 2.41 - 2.48 (1H, m, H(9)), 1.37 - 1.46 (9H, m, 3 x 3H(24));
13C
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NMR (126 MHz, chloroform-d, 2 rotamers) δ ppm 171.19 C(2), 170.93 C(2), 155.94
C(9)/C(22), 155.87 C(9)/C(22), 155.55 C(22)/C(9), 155.53 C(22)/C(9), 134.46, 134.07,
132.54, 132.05, 130.56 C(7),C(11), 130.47 C(7),C(11), 128.56, 128.31, 127.21, 127.03,
126.99, 126.73, 126.57, 126.44, 126.18, 115.62 C(8)/C(10) 115.52 C(8)/C(10), 80.18
C(23), 77.51 C(23), 52.09 C(3), 51.86 C(3), 47.19 C(12), 44.71 C(12), 43.20 C(20), 40.63
C(20), 39.49 C(4), 39.43 C(4), 29.12 C(19), 28.46 3C(2), 28.29 C(19); HRMS calcd for
C22H26N2O4: 397.2127, found: 397.2133.
(R)-tert-Butyl (3-(2,4-dichlorophenyl)-1-(3,4-dihydroisoquinolin-2(1H )-
yl)-1-oxopropan-2-yl)carbamate (42)
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To tetrahydroisoquinoline (0.12 mL, 1.0 mmol), N -Boc-(R)-2,4-dichlorophenylalanine
(344 mg, 1.0 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg, 1.0
mmol) and anyhdrous 1-hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethylfor-
mamide (volume mL) was added N,N -diisopropylethylamine (1.3 mL, 7.5 mmol),
the mixture was then stirred for 20 h at 20 ℃. The solvent was evaporated, the
residue was disolved in ethyl acetate (20 mL) and washed with water (2 x 20 mL).
The combined aqueous fractions were re-extracted with ethyl acetate (2 x 20 mL)
and the combined organic layers were washed with saturated aqueous sodium hy-
drogen carbonate (2 x 20 mL) and brine (20 mL) before being dried over magnesium
sulfate and evaporated. The residue was purified by silica column chromatography
(6% ethyl acetate, 94% dichloromethane) to give 42 (308 mg, 68%) as a white solid,
Mp 155-156 ℃; νmax (cm
−1): 3393 (NH), 3200-2700 br. (NH), 1648 (CHC=O); 1H
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NMR (500 MHz, chloroform-d, 2 rotamers ) δ ppm 6.87 - 7.42 (7H, m, aryl), 5.50
(1H, d, J=8.7 Hz, H(5)), 5.46 (1H, d, J=8.7 Hz, H(5)), 5.10 (1H, q, J=7.7 Hz, H(3)),
5.04 (1H, q, J=7.7 Hz, H(3)), 4.73 (1H, d, J=16.8 Hz, H(12)), 4.64 (1H, d, J=16.8 Hz,
H(12)), 4.59 (1H, d, J=16.1 Hz, H(12)), 4.50 (1H, d, J=16.1 Hz, H(12)), 4.02 - 4.10,
3.71 - 3.81, 3.50 - 3.60, 3.41 - 3.50 (2H, m, 2H(20)), 3.12 (1H, dd, J=13.4, 6.4 Hz,
H(4)), 3.02 (1H d, J=7.4 Hz, H(19)), 2.97 (1H, dd, J=13.4, 8.0 Hz, H(4)), 2.83 - 2.92
(1H, m, H(19)), 2.65 - 2.80 (1H, m, H(19)), 1.36 - 1.42, 1.28 - 1.36 (9H, s, H(23));
13C
NMR (126 MHz, chloroform-d, 2 rotamers) δ ppm 170.32 C(2), 169.92 C(2), 154.95
C(21), 135.18 C(18), 134.91 C(18)/C(19), 134.23, 133.91, 133.58, 133.53 , 133.03, 132.85,
132.77, 132.64, 131.87, 129.24, 129.11, 128.82, 128.40, 127.17, 127.00, 126.94 126.81,
126.70, 126.63, 126.49, 125.92, 79.80 C(27), 79.78 C(22), 49.48 C(3), 49.31 C(3), 47.38
C(12), 44.74 C(12), 43.23 C(20), 40.46 C(20), 37.79 C(4), 37.43 C(4), 29.41 C(19), 28.35
C(23), 28.20 C(19).
(R)-2-Amino-3-(4-hydroxyphenyl)-1-(isoindolin-2-yl)propan-1-one
hydrochloride (43)
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N -Boc protected amide 40 (100 mg, 0.26 mmol) was dissolved in dichloromethane (2
mL) and ethereal hydrochloric acid (1 M, 10 mL) was added, after 16 h the reaction
was incomplete and the mixture was heated at reflux for 4 h. The reaction was still
incomplete and was subsequently completed by bubbling of gaseous hydrochloric
acid through the solution. The solid was filtered over boiling diethyl ether and dried
to give 43 (51 mg, 61%) as a white solid, m.p. (decomp. 220 ℃); [α]25
D
: ℃ -34.9°;
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νmax (cm
−1): 3225, 3049 (NH) 1649 (C=O) 1633; 1H NMR (500 MHz, chloroform-
d) δ ppm 9.41 (1H, s, H(20)), 8.47 (3H, s, 3H(6)), 7.30 - 7.35 (1H, m, aryl), 7.26
(2H, m, aryl), 7.17 - 7.23 (1H, m, aryl), 7.04 (2H, d, J=8.4 Hz, H(7),H(11)), 6.67
(2H, d, J=8.4 Hz, H(8),H(10)), 4.92 (1H, d, J=14.0 Hz, H(12)/H(19)), 4.72 (1H, d,
J=16.2 Hz, H(19)/H(12)), 4.53 (1H, d, J=16.2 Hz, H(19)/H(12)), 4.19 - 4.31 (1H, m,
H(3)), 4.02 (1H, d, J=14.0 Hz, H(12)/H(19)), 3.06 (1H, dd, J=13.4, 6.0 Hz, H(4)), 2.94
(1H, dd, J=13.4, 7.0 Hz, H(4));
13C NMR (126 MHz, chloroform-d) δ ppm, 167.08
C(2), 156.63 C(9), 135.95,135.14, 130.41C(7)/C(11), 127.58 C(11)/C(7), 127.55, 124.53,
123.01, 122.60, 115.32 C(8),C(10), 52.24 C(3), 51.84 C(12)/C(19), 51.50 C(19)/C(12),
35.77 C(4); HRMS calcd for C17H19N2O2: 283.1447, found: 283.1449.
(R)-2-Amino-1-(3,4- dihydroisoquinolin-2(1H )-yl)-3-(4-hydroxy-
phenyl)propan-1-one hydrochloride (44)
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N -Boc protected amide 41 (125 mg, 315 mmol) was dissolved in ethereal hydrogen
chloride(1 M, 10 mL) and the mixture stirred at 20 ℃ for 16 h. The solvent was
evaporated to give 44 (74 mg, 70%) as a white solid, m.p. (decomp. 245-247 ℃);
[α]25
D
: -9.0°; νmax (cm
−1): 3197-2951 (NH), 1638 (NHC=O), 1627 (CHC=O); 1H
NMR (500 MHz, DMSO-d6, 2 rotamers) δ ppm 9.42 (1H, s, H(21)), 8.37 (3H, s,
3H(5)), 6.90 - 7.23 (6H, m, aryl), 6.66 (1H, d, J=8.2 Hz, H(8)/H(10)), 6.63 (1H, d,
J=8.2 Hz, H(8)/H(10)), 4.50 - 4.80 (1H, m, H(12)), 4.50 - 4.66 (2H, m, H(3),H(12)), 4.37
(1H, d, J=17.1 Hz, H(12)), 3.96 (1H, d, J=16.3 Hz, H(12)), 3.69 - 3.78, 3.52 - 3.65, 3.41
- 3.51 (2H, m, H(20)), 2.96 - 3.13 (2H, m, H(4),H(19)), 2.81 - 2.91 (1H, m, H(4)), 2.59 -
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2.80, 2.30 - 2.44 (2H, m, H(19));
13C NMR (126 MHz, DMSO-d6) δ ppm 167.34 C(2),
167.12 C(2), 156.69 C(9) 156.67 C(9), 134.34, 134.11, 132.48 C(13), 132.36 C(13)/C(8),
130.49 br. C(7),C(11), 128.32, 128.24, 126.64, 126.47, 126.42, 126.21, 126.14, 126.08,
124.34, 124.14, 115.29 C(8),C(10), 115.20 C(8),C(10), 50.75 C(3), 50.45 C(3), 46.08 C(12),
44.02 C(12), 42.48 C(20), 36.23 C(4), 35.95 C(4) 28.40 C(19), 27.60 C(19); HRMS calcd
for C18H21N2O2: 297.1603, found: 297.1602.
(R)-2-Amino-3-(2,4-dichlorophenyl)-1-(3,4-dihydroisoquinolin-2(1H-
yl)propan-1-one hydrochloride (45)
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N -Boc protected amide 42 (292 mg, 0.67 mmol) dissolved in ethereal hydrochloric
acid (1 M, 10 mL). After 16 h stiring at 20℃ the reaction was heated at reflux for 4
h before the solvent was evaporated to yield 45 (306 mg, 116%). νmax (cm
−1): 2865
br. (NH), 1645 (C=O), 1587; The solid was dissolved in sodium hydrogen carbonate
solution (20 mL) and extracted into ethyl acetate (2 x 20 mL), washed with brine
(20 mL) and dried over magnesium sulfate. The solvent was evaporated and the
residue purified by silica column chromatography (94% ethyl acetate, 5% methanol,
1% ammonia .880) to give the amine 45 as a yellow oil (114 mg, 48%), ethereal
hydrochloric acid (2 M, 10 mL) was added and the precipitated solid collected by
filtration The precipitate was filtered by gravity filtration through filter paper in a
funnel that was on top of a flask of boiling ether 45 as a bright yellow solid, m.p.
187-189 ℃; 1H NMR (500 MHz, DMSO-d6) δ ppm 6.84 - 7.44 (7H, m, aryl), 4.68
(1H, s, H(12)), 4.51 (1H, d, J=16.0 Hz, H(12)), 4.40 (1H, d, J=16.0 Hz, H(12)), 4.02
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- 4.23 (2H, m, H(3),H(20)), 3.59 - 3.71 (1H, m, H(20)), 3.40 - 3.54 (1H, m, H(20)),
3.00 - 3.08 (1H, m, H(4)), 2.55 - 3.09 (3H, m, H(4),2H(19));
13C NMR (126 MHz,
DMSO-d6) δ ppm 166.77 C(2), 166.29 C(2), 134.56, 134.10, 134.03, 133.84, 133.63,
133.23, 133.07, 132.97, 132.42, 131.84, 131.46, 131.10, 128.82, 128.56, 128.35, 128.17,
127.62, 127.52, 126.65, 126.55, 126.43, 126.25, 126.01, 125.72, 50.49 C(3), 50.17 C(3),
47.09 C(12), 44.74 C(12), 42.91 C(20), 40.46 C(20), 40.38 C(4), 40.03C(4), 29.47 C(19),
28.24 C(19); HRMS calcd for C18H19N2OCl2: 349.0884, found: 349.0865.
(S)-2-Amino-1-(isoindolin-2-yl)-3-phenylpropan-1-one
hydrochloride (46)249
10
11
6
7
8
9
4
3
NH2.HCl
5
2
N
1
O
19
1813
12
17
1615
14
N -Boc protected amide 50 (117 mg, 0.32 mmol) was dissolved in ethereal hydrogen
chloride(1 M, 10 mL) and the mixture stirred at 20 ℃ for 16 h. The solvent was
evaporated to give 91 (91 mg, 94%) as a cream solid, m.p. (decomp. 235 ℃). [α]25
D
methanol +33.0°; νmax (cm
−1): 3100 2700 br. (NH), 1651 (C=O); 1H NMR (500
MHz, DMSO-d6) δ ppm 8.63 (3H, br.s, 3H(5)), 7.13 - 7.36 (9H, m, aryl), 4.93 (1H, d,
J=13.9 Hz, H(12)/H(19)), 4.71 (1H, d, J=16.2 Hz, H(19)/H(12)), 4.51 (1H, d, J=16.2
Hz, H(19)/H(12)), 4.32 (1H, br.s, H(3)), 3.96 (1H, d, J=13.9 Hz, H(12)/H(19)), 3.22
(1H, dd, J=13.2, 5.5 Hz, H(4)), 3.06 (1H, dd, J=13.2, 8.7 Hz, H(4));
13C NMR (126
MHz, DMSO-d6) δ ppm 166.92 C(2), 135.90 C(13)/C(18)/C(6), 135.12 C(13)/C(18)/C(6),
134.80 C(13)/C(18)/C(6), 129.46 C(8),C(10), 128.52 C(7),C(11), 127.56 C(15)/C(16), 127.52
C(16)/C(15), 127.30 C(9), 122.98 C(14)/C(17), 122.56 C(17)/C(14), 51.96 C(3), 51.82
C(12)/C(19), 51.53 C(19)/C(12), 36.48 C(4). HRMS calcd for C17H19N2O: 267.1497,
found 267.1494.
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(S)-2-Amino-1-(3,4-dihydroisoquinolin-2(1H )-yl)-3-phenylpropan-1-
one hydrochloride (47)203
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N -Boc protected amide 153 (210 mg, 0.55 mmol) was dissolved in dichloromethane
(6.7 mL) and cooled to 0 ℃. Trifluoroacetic acid was added (0.42 mL) and the mix-
ture stirred overnight. The reaction was concentrated and the residue was dissolved
in dichloromethane (10 mL) then neutralised with saturated aqueous sodium hydro-
gen carbonate (15 mL). The aqueous phase was extracted with dichloromethane (2
x 10 ml), the combined organic layers were combined and washed with brine then
dried over magnesium sulfate and solvent evaporated to give a dark orange oil (140
mg, 91%). To obtain the hydrochloride salt the oil was dissolved in diethyl ether (3.0
mL) and ethereal hydrochloric acid was added (2 M, 3.0 mL) and the precipitate
filtered. [α]25
D
methanol: +7.2°; νmax (cm
−1): 2910-2810 br. (NH), 1644 (CHC=O);
1H NMR (600 MHz, DMSO-d6, 2 rotamers) δ ppm 8.44 (3H, br.s, 3H(5)), 6.92 -
7.34 (9H, m, aryl), 3.90 - 4.70 (2H, m, H(2)), 3.50 - 3.66 (3H, m, H(3),2H(20)), 3.14 -
3.25 (1H, m, H(4)), 2.92 - 3.05 (2H, m, H(4),H(12)), 2.89 - 3.07 (2H, m, H(14)), 2.21 -
2.79 (2H, m, H(9));
13C NMR (151 MHz, DMSO-d6, 2 rotamers) δ ppm 167.24 C(2),
166.92 C(2), 134.5, 134.28, 134.25, 134.09, 132.39, 132.35, 129.62, 129.51, 128.57,
128.40, 128.28, 127.34, 127.19, 126.64, 126.55, 126.48, 126.28, 126.13, 126.11, 50.41
C(3), 50.21 C(3), 46.17, 44.00, 42.55, 37.03 C(4), 36.81 C(4), 28.36 C(9), 27.60 C(9);
HRMS calculated for C18H20N2O+H
+: 281.1654, found: 281.1665.
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(S)-2-Amino-3-(4-hydroxyphenyl)-1-(isoindolin-2-yl)propan-1-one
hydrochloride (48)
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N -Boc protected amide 51 (153 mg, 0.48 mmol) was dissolved in ethereal hydrogen
chloride and stirred at 20 ℃ for 16 h. Dichloromethane (2.5 mL) was added and
the mixture was then heated at reflux for an additional 2 h before being filtered
The precipitate was filtered by gravity filtration through filter paper in a funnel
that was on top of a flask of boiling ether 48 (106 mg, 69%) as a cream solid, m.p.
(decomp. 250 ℃); [α]25
D
c=1 methanol: +32.4°; νmax (cm
−1): 3052 br. (NH), 1650
(C=O); 1H NMR (500 MHz, DMSO-d6) δ ppm 9.44 (1H, br.s, H(20)), 8.51 (3H, s,
3H(5)), 7.17 - 7.37 (4H, m, aryl), 7.04 (2H, d, J=8.5 Hz, H(7),H(11)), 6.67 (2H, d,
J=8.5 Hz, H(8),H(10)), 4.92 (1H, d, J=14.0 Hz, H(12)/H(19)), 4.71 (1H, d, J=16.2 Hz,
H(19)/H(12)), 4.46 - 4.57 (1H, d, J=16.2 Hz, H(19)/H(12)), 4.17 - 4.28 (1H, m, H(3)),
3.99 (1H, d, J=14.0, H(12)/H(19)), 3.07 (1H, dd, J=13.5, 5.8 Hz, H(4)), 2.94 (1H, dd,
J=13.5, 8.7 Hz, H(4));
13C NMR (126 MHz, DMSO-d6) δ ppm 167.09 C(2), 156.64
C(9), 135.95, 135.15, 130.39 C(7),C(11), 127.57, 127.54, 124.54, 123.01, 122.60, 115.32
C(8),C(10), 52.22 C(3), 51.82 C(12)/C(19), 51.51 C(19)/C(12), 35.78 C(4); HRMS calcd
for C17H19N2O2: 283.1446, found: 283.1441
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(S)-2-Amino-1-(3,4- dihydroisoquinolin-2(1H )-yl)-3-(4-
hydroxyphenyl)propan-1-one hydrochloride (49)
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N -Boc protected amide 154 (166 mg, 0.42 mmol) was dissolved in ethereal hydrogen
chloride and stirred for 24 h. Hydrogen chloride was then bubbled through the
solution with vigorous stirring for 1 h. The precipitated product was filtered over
boiling diethyl ether to give 49 (47 mg, 37%) as a white solid, m.p. (decomp. 220
℃); [α]25
D
c=1 methanol: +12.1°; νmax (cm
−1): 3199-2951 (NH), 1638 (C=O), 1623;
1H NMR (500 MHz, DMSO-d6, 2 rotamers) δ ppm 9.47, 9.40 (1H, s, H(21)), 8.38
(3H, s, 3H(5)), 6.89 - 7.25 (6H, m, aryl), 6.67 (1H, d, J=8.3 Hz, H(8),H(10)), 6.63
(1H, d, J=8.3 Hz, H(8),H(10)), 4.73 (1H, d, J=17.2 Hz, H(12)), 4.50 - 4.66 (2H, m,
H(3),H(12)), 4.36 (1H, d, J=17.2 Hz, H(12)), 3.96 (1H, d, J=16.3 Hz, H(12)), 3.68
- 3.80 (1H, m, H(20)), 3.52 - 3.62 (1H, m, H(20)), 3.33 - 3.51 (1H, m, H(20)), 2.96
- 3.15 (2H, m, H(4),H(19)), 2.80 - 2.94 (1H, m, H(4)), 2.58 - 2.78 (1H, m, H(19)),
2.29 - 2.42 (1H, m, H(19)).
13C NMR (126 MHz, DMSO-d6) δ ppm 167.34 C2,
167.12 C2, 156.69 C9, 156.67 C9, 134.34, 134.11, 132.48, 132.36, 130.49 C(7),C(11),
128.32, 128.24, 126.64, 126.47, 126.42, 126.21, 126.14, 126.08, 124.34, 124.14, 115.29
C(8),C(11), 115.20 C(8),C(11), 50.75 C(3), 50.45 C(3), 46.08 C(12), 44.02 C(12), 42.48
C(20), 40.00 C(20), 36.23 C(4), 35.95 C(4), 28.40 C(19), 27.60 C(19); HRMS calcd for
C16H21N2O2: 319.1422, measured: 319.1422.
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(S)-tert-Butyl(1-(isoindolin-2-yl)-1-oxo-3-phenylpropan-2-
yl)carbamate (50)249
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A literature procedure249 using triethylamine was adapted for use with N,N -diiso-
propylethylamine, briefly, to isoindoline (0.11 mL, 1.0 mmol), N -Boc-(S)-phenyl-
alanine (256 mg, 1.0 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (182
mg, 1.0 mmol) and anyhdrous 1-hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethyl-
formamide (3.0 mL) was added N,N -diisopropylethylamine (1.3 mL, 7.5 mmol). The
mixture was stirred for 16 h at 20 ℃ before the solvent was evaporated, the residue
was dissolved in ethyl acetate (20 mL) and washed with water (2 x 20 mL). The
combined aqueous fractions were extracted with ethyl acetate (2 x 20 mL) and the
combined organic layers were washed with saturated aqueous sodium hydrogen car-
bonate (2 x 20 mL) and brine (2 x 20 mL) before drying over magnesium sulfate.
The solvent was evaporated and the residue was purified by silica column chro-
matography (70% hexane, 30% ethyl acetate) to give 50 (117 mg, 32%) as a pale
cream solid, νmax (cm
−1): 3425 (NH), 3291 (NH), 1707 (NHC=O), 1643 (CHC=O);
1H NMR (500 MHz, chloroform-d) δ ppm 7.19 - 7.26 (m, 7H, aryl), 7.13 - 7.18
(1H, m, aryl), 7.08-7.12 (1H, m, aryl), 5.39 (1H, d, J=8.5 Hz, H(5)), 4.87 (1H, d,
J=13.6 Hz, H(12)/H(19)), 4.82 (1H, d, J=15.9 Hz, H(19)/H(12)), 4.72 (1H, m, H(3)),
4.63 (1H, d, J=15.9 Hz, H(19)/H(12)), 4.07 (1H, d, J=13.6 Hz, H(12)/H(19)), 2.94 -
3.10 (2H, m, H(4)), 1.34 - 1.49 (9H, m, 3 x 3H(22));
13C NMR (126 MHz, chloroform-
d) δ ppm 170.70 C(2), 155.23 C(20), 136.42 C(13)/C(18), 136.00 C18/13, 135.76 C(6),
129.42 C(8),C(10), 128.52 C(7),C(11), 127.78 C(15)/C(16), 127.57 C(16)/C(15), 127.05 C(9),
183
Materials and Methods Simon O.R. Greenwood
122.89 C(14)/C(17), 122.62 C(17)/C(14), 79.86 C(21), 53.44 C(12), 52.21 C(12)/C(19), 52.12
C(19)/C(12), 39.88 C(4), 28.41 C(22).
(S)-tert-Butyl(3-(4-hydroxyphenyl)-1-(isoindolin-2-yl)-1-oxopropan-2-
yl)carbamate (51)
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To isoindoline (0.11 mL, 1.0 mmol), N -Boc-(S)-tyrosine (279 mg, 1.0 mmol), 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg, 1.0 mmol) and anyhdrous 1-
hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethylformamide (3.0 mL) was added
N,N -diisopropylethylamine (1.3 mL, 7.5 mmol), the mixture was then stirred for 16
h at 20 ℃. The solvent was evaporated, the residue was disolved in ethyl acetate
(20 mL) and washed with water (2 x 20 mL). The combined aqueous fractions were
re-extracted with ethyl acetate (2 x 20 mL) and the combined organic layers were
washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL) and brine
(20 mL) before being dried over magnesium sulfate and evaporated. The residue was
purified twice by column chromatography (20% ethyl acetate in dichloromethane) to
give 51 (168 mg, 44%) as a white foam, νmax (cm
−1): 3290 (NH), 1698 (NHC=O),
1634 (CHC=O); 1H NMR (500 MHz, chloroform-d) δ ppm 7.17 - 7.25 (3H, m, aryl),
7.03 - 7.11 (3H, m, aryl), 6.71 (2H, d, J=8.4 Hz, H(8),H(10)), 5.40 (1H, d, J=8.7 Hz,
H(5)), 4.89 (1H, d, J=13.7 Hz, H(12)/H(19)), 4.81 (1H, d, J=15.9 Hz, H(19)/H(12)),
4.70 (1H, m, H(3)), 4.61 (1H, d, J=15.9 Hz, H(19)/H(12)), 4.19 (1H, d, J=13.7 Hz,
H(12)/H(19)), 2.99 (1H, dd, J=13.5, 8.4 Hz, H(4)), 2.91 (1H, dd, J=13.5, 5.8 Hz,
H(4)), 1.74 - 1.87 (1H, br.s, H(20)), 1.41 (9H, s, 3 x 3H(23));
13C NMR (126 MHz,
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chloroform-d) δ ppm 171.01 C(2), 155.46 C(22),C(10), 135.82, 135.59, 130.53 C(7),C(11),
127.83, 127.63, 127.47, 122.90, 122.64, 115.57 C(8),C(10), 80.20 C(22), 53.52 C(3), 52.34
C(12)/C(19), 52.23 C(12)/C(19), 38.73 C(4), 28.41 C(23).
(R)-tert-Butyl (R)-(1-((2-(1H -indol-3-yl)ethyl)amino)-3-(2,4-
dichlorophenyl)-1-oxopropan-2-yl)carbamate (54)
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To tryptamine (960 mg, 0.6 mmol), N -Boc-(R)-2,4-dichlorophenylalanine (201 mg,
0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109 mg, 0.6 mmol) and
anyhdrous 1-hydroxybenzotriazole (122 mg, 0.9 mmol) in dimethylformamide (3.0
mL) was added N,N -diisopropylethylamine (0.78 mL, 4.5 mmol), the mixture was
then stirred for 17 h at 20 ℃. The mixture was the diluted with ethyl acetate (20
mL) and washed with water (3 x 20 mL). The combined aqueous fractions were
re-extracted with ethyl acetate (3 x 20 mL) and the combined organic layers were
washed with dilute hydrochloric acid (1 M, 20 mL), saturated aqueous sodium hy-
drogen carbonate (2 x 20 mL) and brine (20 mL) before being dried over magnesium
sulfate and the solvent evaporated.The residue was washed with diethyl ether to give
54 (219 mg, 77%) as a white solid, m.p. 170-174℃; 1H NMR (500 MHz, chloroform-
d) δ ppm 10.74 - 10.84 (1H, br.s, H(21)), 7.52 (1H, d, J=8.0, aryl), 7.33 - 7.37 (1H, m,
aryl), 7.28 - 7.31 (1H, m, aryl), 7.15 - 7.21 (1H, m, aryl), 7.05 - 7.14 (3H, m, aryl),
6.84 - 7.00 (1H, m, aryl), 5.95 (1H, t, J=5.5 Hz, H(1)), 5.09 (1H, d, J=7.1 Hz, H(5)),
4.30 (1H, d, J=8.5 Hz, H(3)), 3.40 - 3.67 (2H, m, H(12)), 3.15 (1H, dd, J=13.9, 6.5
Hz, H(4)), 2.93 - 3.04 (1H, m, H(4)), 1.15 - 1.32 (9H, m, 3 x 3H(25));
13C NMR (126
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MHz, chloroform-d) δ ppm 173.65 C(2), 158.28 C(23), 139.41, 138.05, 136.53, 136.35,
135.39, 132.24, 130.15, 125.27, 124.98, 123.27, 122.58, 121.54, 115.60, 114.32, 83.16
C(24), 57.55 C(3), 42.84 C(12), 39.05 C(4), 31.19 3C(2), 28.05 C(25); HRMS calcd for
C24H27Cl2N3O3: 498.1327, found: 498.1323.
tert-Butyl (R)-(1-((9H -carbazol-3-yl)amino)-3-(2,4-dichlorophenyl)-1-
oxopropan-2-yl)carbamate (55)
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To 9H -carbazole-3-amine (58) (109 mg, 0.6 mmol), N -Boc-(R)-2,4-dichlorophenyl-
alanine (201 mg, 0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109
mg, 0.6 mmol) and anyhdrous 1-hydroxybenzotriazole (122 mg, 0.6 mmol) in dimethyl-
formamide (3.0 mL) was added N,N -diisopropylethylamine (0.78 mL, 4.5 mmol), the
mixture was then stirred for 16 h at 20℃. The mixture was the diluted with ethyl ac-
etate (20 mL) and washed with water (3 x 20 mL). The combined aqueous fractions
were re-extracted with ethyl acetate (3 x 20 mL) and the combined organic layers
were washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL) and
brine (20 mL) before being dried over magnesium sulfate and evaporated to give 55
(109 mg, 36%) as a white solid, m.p. 201-203℃; νmax (cm
−1): 3200-3400 (NH), 1707
(NHC=O), 1655 (CHC=O); 1H NMR (600 MHz, CD3OD-d4) δ ppm 8.02 (1H, d,
J=7.5 Hz, aryl), 7.92 (1H, d, J=7.5 Hz, aryl), 7.40 - 7.52 (2H, m, aryl), 7.34 (2H, d,
J=8.3 Hz, aryl), 7.24 - 7.30 (1H, m, aryl), 7.07 - 7.19 (3H, m, aryl), 4.52 - 4.71 (1H,
m, H(3)), 3.32 - 3.46 (1H, dd, J= 13.8, 6.8 Hz, H(4)), 3.13 - 3.25 (1H, dd, J=13.8,
186
Materials and Methods Simon O.R. Greenwood
8.7 Hz, H(4)), 1.42 (9H, s, 3 x 3H(27));
13C NMR (126 MHz, CD3OD-d4 δ ppm 172.71
C(2), 157.92 C(25), 141.30, 136.50, 135.89, 135.28, 134.54, 134.14, 130.23, 128.28,
127.00, 126.10, 124.39, 122.12, 122.05, 121.10, 120.14, 119.80, 119.24, 111.95, 80.98
C(26), 55.99 C(4), 36.38 C(3), 28.71 3C(2); HRMS calcd for C26H25Cl2N3O3: 497.1273,
found: 497.1284.
3-Nitro-9H -carbazole (57)251
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Following the proceduce used for 60, carbazole (3.68g, 22 mmol) was disolved in
glacial acetic acid (70 mL) and stirred at 60 ℃ for 30 min. The solution was cooled
to 20 ℃ and fuming nitric acid (1 mL) in glacial acetic acid (3 mL) was added
dropwise over 30 min, the reaction was then stirred for 1 h at 20 ℃ before being
poured into ice water (100 mL). The precipitate was filtered and dissolved in ethyl
acetate and concentrated before purification by column chromatography (10% ethyl
acetate 90% hexane) and then recrystallised from acetic acid to give 57 as a yellow
crystalline solid (2.76 g, 57%), m.p. 208-210 ℃ (lit.252 m.p. 215-216 ℃); νmax
(cm−1): 3399 br. (NH); 1H NMR (500 MHz, chloroform-d) δ ppm 10.01 (1H, br.s,
H(8)), 8.29 - 8.42 (2H, m, aryl), 8.09 (1H, d, J=7.9 Hz, aryl), 7.50 - 7.64 (2H, m,
H(11),H(14)), 7.22 - 7.41 (2H, m, H(12),H(13)),;
13C NMR (126 MHz, chloroform-d)
δ ppm 139.83 C(2), 133.78, 132.22, 127.78, 127.53, 122.30, 122.01, 121.35, 120.74,
118.80, 111.71
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9H -Carbazole-3-amine (58)251
NH2 1
2
3
4
5
6
7
HN8
9 10
11
12 13
14
(57) (500 mg, 2.36 mmol) and ammonium formate (743 mg, 11.8 mmol) were dis-
solved in 30 mL methanol. After 10 min stiring under N2 at 20 ℃, 10% palladium
on carbon (59 mg) was added and the suspension was heated at reflux for 16 h. The
mixture was then filtered over celite and washed with methanol. The filtrate was
neutralised with 0.1 M citric acid and extracted with ethyl acetate (3 x 30 mL). The
combined organic layers were washed with brine and dried over magnesium sulfate
before concentrating. The residue was purified by column chromatography (50%
ethyl acetate 50% hexane) to give 58 (135 mg, 31%) as a tan solid, νmax (cm
−1):
3100-3500 (NH), 2300-2700 (NH); 1H NMR (500 MHz, CD3OD) δ ppm 7.96 (1H, d,
J=7.7 Hz, aryl), 7.47 (1H, dd, J=7.8, 1.0 Hz, aryl), 7.43 (1H, d, J=8.2 Hz, aryl),
7.32 (1H, ddd, J=8.2, 7.1, 1.2 Hz, aryl), 7.10 (1H, m, J=7.5, 7.5, 0.9 Hz, aryl),
6.97 (1H, t, J=7.6 Hz, aryl), 6.78 (1H, dd, J=7.6, 1.1 Hz, aryl); HRMS calcd for
C12H11N2: 183.0922 (M+H), found: 183.0920.
3-Nitro-9-ethyl-9H -carbazole (60)
1
2
3
4
5
6
78
N
9
10
1112
13
NO2 14
15
16
To a solution of 9-ethyl-9H -carbazole (4.0 g 14 mmol) in glacial acetic acid (70
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mL) was added with stirring fuming nitric acid (1 mL) in glacial acetic acid (3 mL)
over 30 min. The mixture was stirred for 1 h at 20 ℃ before being poured into
iced water (100 mL) and stirred for 30 min, the precipitate was extracted into ethyl
acetate and purified by column chromatography (20% ethyl acetate 80% hexane) and
rectrystalised from ethyl acetate to give (60) (3.35 g, 99%), m.p. 128-130 ℃ (Lit
126-127℃253); νmax (cm
−1): 1593 (N=O); 1H NMR (500 MHz, chloroform-d) δ ppm
8.91 (1H, d, J=2.2 Hz, H(3)), 8.33 (1H, dd, J=9.0, 2.2 Hz, H(1)), 8.08 (1H, d, J=7.7
Hz, aryl), 7.56 (1H, ddd, J=8.3, 7.1, 1.2 Hz, aryl), 7.45 (1H, d, J=8.4 Hz, aryl), 7.30
- 7.37 (2H, m, aryl), 4.36 (2H, q, J=7.3 Hz, 2H(15)), 1.45 (3H, t, J=7.3 Hz, 3H(16));
13C NMR (126 MHz, chloroform-d) δ ppm 143.03, 141.19, 140.60, 127.45, 122.93,
122.64, 121.60, 121.03, 120.78, 117.28, 109.50, 107.99, 38.14 C(15), 13.84 C(16).
9-Ethyl-9H -carbazole-3-amine (61)
1
2
3
4
5
6
78
N
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NH2 14
15
16
To a solution of 3-nitro-9-ethyl-9H -carbazole (60) (400 mg, 1.66 mmol) in methanol
(20 mL) was added ammonium formate (64.3 mL, 7.9 mmol). After 10 min stirring
under nitrogen 10% palladium on carbon (40 mg) was added and the reaction mix-
ture was heated gently to reflux for 2.75 h. The catalyst was filtered through celite
and washed with methanol before neutralising with citric acid (0.2 M) and extrac-
tion into ethyl acetate (2 x 30 mL) the combined organic layers were concentrated
and purified by column chromatography (50% ethyl acetate 50% hexane) to give 61
(143 mg, 41%) as a grey solid which degraded quickly, νmax (cm
−1): 3415 br. (NH),
3342 br. (NH), 2700-2950 (NH); 1H NMR (500 MHz, chloroform-d) δ ppm 8.02 (1H,
d, J=7.7 Hz, H(3)), 7.42 - 7.50 (2H, m, aryl), 7.37 (1H, d, J=8.0 Hz, aryl), 7.14
- 7.28 (1H, m, aryl), 6.93 (1H, dd, J=8.5, 2.2 Hz, aryl), 4.31 (2H, q, J=7.2 Hz,
H(15)), 3.52 (2H, br.s, H(14)), 1.41 (3H, t, J=7.2 Hz), H(16);
13C NMR (126 MHz,
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chloroform-d) δ ppm 140.53, 138.94, 134.69, 125.54, 123.78, 122.58, 120.51, 118.13,
115.71, 109.10, 108.46, 106.51, 37.59 C(15), 13.90 C(16);
tert-Butyl (R)-(3-(2,4-dichlorophenyl)-1-((9-ethyl-9H -carbazol-3-
yl)amino)-1-oxopropan-2-yl)carbamate (62)
13
12
24
23
15
14
2217
N
16
21
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NH 1
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2
O 3
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61 (109 mg, 0.52 mmol), N -Boc-(R)-2,4-dichlorophenylalanine (201 mg, 0.6 mmol),
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109 mg, 0.6 mmol) and anyhdrous
1-hydroxybenzotriazole (122 mg, 0.6 mmol) in dimethylformamide (3.0 mL) was
added N,N -diisopropylethylamine (0.78 mL, 4.5 mmol), the mixture was then stirred
for 16 h at 20 ℃. The mixture was the diluted with ethyl acetate (20 mL) and
washed with water (3 x 20 mL). The combined aqueous fractions were re-extracted
with ethyl acetate (3 x 20 mL) and the combined organic layers were washed with
saturated aqueous sodium hydrogen carbonate (2 x 20 mL) and brine (20 mL) before
being dried over magnesium sulfate and evaporated. The residue was purified by
column chromatography (20% ethyl acetate/hexane) to give 62 (127 mg, 46%) as
a cream solid, m.p. 200-201 ℃; νmax (cm
−1): 3295 br. (NH), 1680 (NHC=O),
1651 (CHC=O); 1H NMR (600 MHz, chloroform-d) δ ppm 8.19 (1H, br.s, aryl),
7.95 (1H, br.s, aryl), 6.98 - 7.65 (8H, m, aryl), 5.49 (1H, br.s, H(1)/H(5)), 4.73 (1H,
br.s, H(5)/H(1)), 4.21 (2H, br.s, H(25)), 3.38 (1H, br.s, H(4)), 3.22 (1H, br.s, H(4)),
1.39 (9H, br.s, H(29)), 1.32 (3H, br.s, 3H(26));
13C NMR (151 MHz, chloroform-d) δ
ppm 169.50 C(2), 156.00 C(30), 140.45, 137.41, 135.24, 133.64, 133.57, 132.71, 129.50,
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129.07, 127.38, 125.93, 122.98, 122.78, 120.76, 119.69, 118.84, 113.12, 108.58, 108.50,
80.66 C(33), 55.10 C(4), 37.60 C(5)/C(28), 35.87 C(28)/C(5), 28.38 C(34),C(35),C36, 13.89
C(29); HRMS calcd for C28H29Cl2N3O3: 525.1586, found: 525.1579.
(R)-tert-Butyl (1-(benzylamino)-3-(2,4-dichlorophenyl)-1-oxopropan-2-
yl) carbamate (63)
NH
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O 3
4
NH
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To benzylamine (0.11 mL, 1.0 mmol), N -Boc-(R)-2,4-dichlorophenylalanine (330 mg,
1.0 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg, 1.0 mmol) and
anyhdrous 1-hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethylformamide (3.0
mL) was added N,N -diisopropylethylamine (1.3 mL, 7.5 mmol), the mixture was
then stirred for 18 h at 20 ℃. The mixture was the diluted with ethyl acetate (20
mL) and washed with water (3 x 20 mL). The combined aqueous fractions were
re-extracted with ethyl acetate (3 x 20 mL) and the combined organic layers were
washed with diluter hydrochloric acid (1 M, 20 mL) saturated aqueous sodium hy-
drogen carbonate (2 x 20 mL) and brine (20 mL) before being dried over magnesium
sulfate and evaporated. The residue was purified by silica column chromatography
(70% hexane 30% ethyl acetate) to give 63 (405 mg, 96%) as a white solid, m.p. 185
- 186.5 ℃; [α]25
D
c=1 Dichloromethane, +9.5°; 1H NMR (500 MHz, chloroform-d) δ
ppm 7.08 - 7.36 (8H, m, aryl), 6.44 (1H, br.s, H(1)), 5.22 (1H, d, J=8.7 Hz, H(5)),
4.41 - 4.51 (1H, m, H(3)), 4.29 - 4.40 (2H, m, H(12)), 3.15 - 3.33 (1H, m, H(4)), 2.95 -
3.15 (1H, m, H(4)), 1.21 - 1.40 (9H, m, 3 x 3H(21));
13C NMR (126 MHz, chloroform-
d) δ ppm 170.81 C(2), 155.50 C(19), 137.68 C(13), 135.10 C(6), 133.51, 133.46, 132.59,
191
Materials and Methods Simon O.R. Greenwood
129.39 C(15),C(17), 128.73 C(14),C(18), 127.69, 127.60, 127.30, 80.36 C(20), 54.53 C(3),
43.58 C(12), 35.79 C(4), 28.27 3C(2); HRMS calcd for C21H24Cl2N2O3: 445.1062,
found: 445.1051.
(R)-tert-Butyl (3-(2,4-dichlorophenyl)-1-((4-methoxybenzyl)amino)-1
-oxopropan-2-yl)carbamate (64)
NH
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To 4-methoxybenzylamine (0.13 mL, 1.0 mmol), N -Boc-(R)-2,4-dichlorophenylala-
nine (334 mg, 1.0 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg,
1.0 mmol) and anyhdrous 1-hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethyl-
formamide (3.0 mL) was added N,N -diisopropylethylamine (1.3 mL, 7.5 mmol), the
mixture was then stirred for 16 h at 30 ℃. The mixture was the diluted with ethyl
acetate (20 mL) and washed with water (3 x 20 mL). The combined aqueous frac-
tions were re-extracted with ethyl acetate (3 x 20 mL) and the combined organic
layers were washed with dilute hydrochloric acid (1 M, 20 mL), saturated aque-
ous sodium hydrogen carbonate (1 x 20 mL) and brine (20 mL) before being dried
over magnesium sulfate and evaporated. The residue was purified by silica column
chromatography (30% ethyl acetate 70% hexane) to give 64 (320 mg, 71%) as a
white solid, m.p. 175-177 ℃; 1H NMR (500 MHz, chloroform-d) δ ppm 7.34 (1H, s,
H(10)), 7.09 - 7.20 (2H, m, H(7),H(8)), 7.04 (2H, d, J=8.5 Hz, H(14),H(18)), 6.82 (2H,
d, J=8.5 Hz, H(15),H(17)), 6.22 (1H, br.s, H(1)), 5.16 (1H, d, J=6.3 Hz, H(5)), 4.42
(1H, d, J=6.3 Hz, H(3)), 4.18 - 4.35 (2H, m, 2H(12)), 3.79 (3H, s, 3H(19)), 3.21 (1H,
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m, H(4)), 3.08 (1H, m, H(4)), 1.27 (9H, s, H(22));
13C NMR (126 MHz, chloroform-d)
δ ppm 170.58 C(2), 159.14 C(16), 155.44 C(20), 135.09 C(6), 133.48, 132.58, 129.72,
129.39, 129.09 127.31, 114.12 C(15),C(17), 80.34 C(21), 55.35 C(19), 54.53 C(3), 43.11
C(12), 35.87 C(4), 28.27 3C(2); HRMS calcd for C22H26Cl2N2O4: 475.1167, found:
475.1166 (M+Na+).
tert-Butyl ((R)-3-(2,4-dichlorophenyl)-1-oxo-1-(((S)-1-phenyl-
ethyl)amino)propan-2-yl)carbamate (65)
NH
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O 3
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To (S)-1-phenylethylamine (0.13 mL, 1.0 mmol), N -Boc-(R)-2,4-dichlorophenylalanine
(334 mg, 1.0 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg, 1.0
mmol) and anyhdrous 1-hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethylfor-
mamide (3.0 mL) was added N,N -diisopropylethylamine (1.3 mL, 7.5 mmol), the
mixture was then stirred for 19 h at 20 ℃. The mixture was the diluted with ethyl
acetate (20 mL) and washed with water (3 x 20 mL). The combined aqueous frac-
tions were re-extracted with ethyl acetate (3 x 20 mL) and the combined organic
layers were washed with dilute hydrochloric acid (1 M, 20 mL) saturated aqueous
sodium hydrogen carbonate (2 x 20 mL) and brine (20 mL) before being dried
over magnesium sulfate and evaporated. The residue was purified by silica column
chromatography (20% ethyl acetate 80% hexane) to give 65 (221 mg, 51%) as a
white solid, m.p. 169-170℃; [α]25
D
c=1 dichloromethane +2.8°; 1H NMR (500 MHz,
chloroform-d) δ ppm 7.03 - 7.43 (8H, m, aryl), 6.27 (1H, br.s, H(1)), 5.12 (1H, d,
J=7.9 Hz, H(12)), 5.01 (1H, br.s, H(5)), 4.40 (1H, d,J=5.0 Hz, H(3)), 3.30 - 2.97 (2H,
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m, H(5)), 1.36 (12H, br.s, 3H(13),3 x 3H(22));
13C NMR (126 MHz, chloroform-d)
δ ppm 169.79 C(2), 155.53 C(20), 142.87 C(14), 135.13 C(6), 133.59, 133.50, 132.63,
129.39, 128.73, 127.46, 127.32 126.11, 80.42 C(21), 54.47 C(12), 49.02 C(3), 35.46
C(4), 28.26 3C(2), 21.83 C(13); HRMS calcd for for C22H26Cl2N2O3: 459.1218, found:
459.1218 (M++Na).
tert-Butyl((R)-3-(2,4- dichlorophenyl)-1-oxo-1-(((R)-1-
phenylethyl)amino)propan-2-yl)carbamate (66)
NH
1
2
O 3
4
NH
5
6
11
10
9
8
7
ClCl
12
14
19
18
17
16
15
13 20 O
O 21
2222
22
To (R)-1-phenylethylamine (0.077 mL, 0.6 mmol), N -Boc-(R)-2,4-dichlorophenyl-
alanine (201 mg, 0.6 mmol),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109
mg, 0.6 mmol) and anyhdrous 1-hydroxybenzotriazole (122 mg, 0.9 mmol) in dimethyl-
formamide (3.0 mL) was added N,N -diisopropylethylamine (0.78 mL, 4.5 mmol).
The mixture was stirred for 20 h at 20 ℃. The mixture was the diluted with ethyl
acetate (20 mL) and washed with water (3 x 20 mL). The combined aqueous frac-
tions were re-extracted with ethyl acetate (3 x 20 mL) and the combined organic
layers were washed with dilute hydrochloric acid (1 M, 2 x 20 mL) saturated aque-
ous sodium hydrogen carbonate (2 x 20 mL) and brine (20 mL) before being dried
over magnesium sulfate and evaporated. Amide 66 was obtained as a white solid
without further purification (247 mg, 94%), m.p. 178-180 ℃; [α]25
D
c=1 methanol:
+22.1°; 1H NMR (500 MHz, chloroform-d) δ ppm 6.99 - 7.18 (8H, m, aryl), 6.14 -
6.35 (1H, m, H(1)), 5.26 (1H, d, J=8.7 Hz, H(12)), 4.97 - 5.10 (1H, m, H(5)), 4.28 -
4.45 (1H, m, H(3)), 2.99 - 3.28 (2H, m, H(4)), 1.30 - 1.46 (12H, m, 3H(13),3 x 3H(22));
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13C NMR (126 MHz, chloroform-d) δ ppm 169.88 C(2), 155.48 C(20), 142.65 C(14),
135.01 C(6), 133.43, 133.36, 132.51, 129.33, 128.69, 127.45, 127.28, 126.05, 80.31
C(21), 54.56 C(3), 48.96 C(12), 35.87 C(4), 28.29 C(22), 21.84 C(13); HRMS calcd for
C22H26Cl2N2O3: 437.1399, found: 437.1384.
(R)-tert-Butyl(3-(2,4-dichlorophenyl)-1-((4-methoxyphenyl)amino)-1-
oxopropan-2-yl)carbamate (67)
NH 1
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O 3
4
NH
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To anisidine (74 mg, 0.6 mmol), N -Boc-(R)-2,4-dichlorophenylalanine (201 mg, 0.6
mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109 mg, 0.6 mmol) and
anyhdrous 1-hydroxybenzotriazole (122 mg, 0.9 mmol) in dimethylformamide (3.0
mL) was added N,N -diisopropylethylamine (0.78 mL, 4.5 mmol), the mixture was
then stirred for 16 h at 20 ℃. The mixture was the diluted with ethyl acetate (20
mL) and washed with water (3 x 20 mL). The combined aqueous fractions were
re-extracted with ethyl acetate (3 x 20 mL) and the combined organic layers were
washed with dilute hydrochloric acid (1 M, 20 mL), saturated aqueous sodium hydro-
gen carbonate (2 x 20 mL) and brine (20 mL) before being dried over magnesium
sulfate and evaporated. The residue was recrystallised (ethyl acetate/hexane) to
give 67 (154 mg, 58%) as a white solid, m.p.(decomp. 180 ℃); 1H NMR (500 MHz,
chloroform-d) δ ppm 8.08 (1H, br.s, H(1)), 7.38 (1H, s, H(10)), 7.31 (2H, d, J=8.6 Hz,
H(13),H(17)), 7.23 (1H, d, J=8.4 Hz, H(7)/H(8)), 7.15 (1H, d, J=8.4 Hz, H(8)/H(7)),
6.82 (2H, d, J=8.6 Hz, H(14),H(16)), 5.30 (1H, d, J=8.4 Hz, H(5)), 4.55 (1H, br.s,
H(3)), 3.78 (3H, s, H(18)), 3.32 (1H, m, H(4)), 3.13 (1H, m, H(4)), 1.23 - 1.42 (9H, s, 3
x 3H(21));
1H NMR (126 MHz, chloroform-d) δ ppm 169.12 C(2), 156.75 C(15)/C(19)
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155.67 C(19)/C(15), 135.14 C(6), 133.59, 133.46, 132.56, 130.41, 129.45, 127.33, 122.01
C(13),C(17), 114.20 C(14),C(16), 80.73 C(20), 55.51 C(18), 55.09 C(3), 35.53 C(4), 28.26
3C(2); HRMS calcd for for C21H24Cl2N2O4: 461.1011, found: 461.0992 M
++Na.
(R)-2-Amino-N -benzyl-3-(2,4-dichlorophenyl)propanamide
hydrochloride (68)
NH
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N -Boc protected amide 63 (210 mg, 0.5 mmol) was dissolved in dry diethyl ether
(20 mL) and dichloromethane (10 mL). Hydrogen chloride was bubbled through the
solution with vigorous stirring for 90 min. The precipitate was filtered by gravity
filtration through filter paper in a funnel that was on top of a flask of boiling ether
68 (131 mg, 73%) as a white solid, m.p. (decomp. 205 ℃); [α]25
D
c=1 methanol:
-53.5°; 1H NMR (500 MHz, DMSO-d6, 2 rotamers) δ ppm 8.96 (1H, t, J=5.8 Hz,
H(1)), 8.72 (3H, s, 3H(5)), 7.57 (1H, d, J=2.2 Hz, H(10)), 7.20 - 7.35 (5H, m, aryl),
7.02 - 7.09 (2H, m, aryl), 4.29 (1H, d, J=6.3 Hz, H(12)), 4.26 (1H, d, J=6.3 Hz,
H(12)), 4.15 (1H, d, J=5.4 Hz, H(12)), 4.12 (1H, d, J=5.3 Hz, H(12)), 4.03 (1H, br.s,
H(3)), 3.27 (1H, dd, J=13.5, 5.7 Hz, H(4)), 3.14 (1H, d, J=13.5, 9.4 Hz, H(4));
13C
NMR (126 MHz, DMSO-d6) δ ppm 167.17 C(2), 138.02 C(13), 134.68 C(6), 133.19,
132.70, 131.99, 128.78, 128.13, 127.40, 127.36, 126.91, 51.95 C(3), 42.28 C(12), 33.80
C(4); HRMS calcd for C16H17Cl2N2O: 323.0718, found: 323.0720.
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(R)-2-Amino-3-(2,4-dichlorophenyl)-N -(4-methoxybenzyl)propanamide
hydrochloride (69)
NH
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N -Boc protected amide 64 (260 mg, 0.67 mmol) was dissolved in dry diethyl ether
(20 mL) and dichloromethane (1 mL). Hydrogen chloride was bubbled through the
solution with vigorous stirring for 70 min. The precipitate was filtered by gravity
filtration through filter paper in a funnel that was on top of a flask of boiling ether
69 (123 mg, 55%) as a white solid, m.p. (decomp. 155 ℃); [α]25
D
c=1 methanol:
-55.9°; νmax (cm
−1): 3216 (NH), 2892 (NH3), 1660 (C=O);
1H NMR (500 MHz,
DMSO-d6) δ ppm 8.85 (1H, t, J=5.7 Hz, H(1)), 8.70 (3H, br.s, 3H(5)), 7.57 (1H,
s, H(10)), 7.26 - 7.34 (2H, m, H(7),H(8)), 6.96 (2H, d, J=8.5 Hz, H(14),H(18)), 6.80
(2H, d, J=8.7 Hz, H(15),H(17)), 4.21 (1H, dd, J=14.8, 6.2 Hz, H(12)), 4.04 (1H, dd,
J=14.8, 5.1 Hz, H(12)), 3.99 (1H, dd, J=9.2, 5.6 Hz, H(3)), 3.71 (3H, s, H(19)), 3.25
(1H, dd, J=13.5, 5.6 Hz, H(4)), 3.12 (1H, dd, J=13.4, 9.5 Hz, H(4));
13C NMR (126
MHz, DMSO-d6) δ ppm 166.98 C(2), 158.30 C(16), 134.64 C(6), 133.17, 132.68, 131.96,
129.92, 128.77, 128.72 C(14),C(18), 127.39, 113.52 C(15),C(17), 55.06 C(19), 51.89 C(3),
41.71 C(12), 33.81 C(4); HRMS calcd for C17H19Cl2N2O2: 353.0824, found: 353.0825.
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(R)-2-Amino-3-(2,4-dichlorophenyl)-N -((S)-1- phenylethyl)propan-
amide hydrochloride (70)
NH1
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N -Boc protected amide 65 (210 mg, 496 mmol) was dissolved in dry diethyl ether
(20 mL) and dichloromethane (5 mL). Hydrogen chloride was bubbled through the
solution with vigorous stirring for 4 h. The solvent was evaporated to give 70 (151
mg, 92%) as a cream solid, m.p.(decomp. 80 ℃); [α]25
D
c=1 methanol: -103.5°; νmax
(cm−1): 2919 (NH)3, 1659 (C=O);
1H NMR (500 MHz, DMSO-d6) δ ppm 8.82 (1H,
d, J=8.0 Hz, H(1)), 8.56 - 8.75 (3H, br.s, 3H(5)), 7.56 - 7.66 (1H, m, H(10)), 7.37 -
7.45 (2H, m, aryl), 7.24 - 7.35 (4H, m, aryl), 7.14 - 7.23 (1H, m, H(12)), 4.80 (1H,
quin, J=7.2 Hz, H(15)), 3.95 - 4.04 (1H, m, H(4)), 3.30 (1H, dd, J=13.6, 5.4 Hz,
H(5)), 3.12 (1H, dd, J=13.6, 9.5 Hz, H(5)), 1.08 - 1.13 (3H, m, H(22));
13C NMR
(126 MHz, DMSO-d6) δ ppm 166.23 C(3), 143.53 C(14), 134.78 C(6), 133.32, 132.66,
132.13, 128.69, 128.17, 127.33, 126.77, 126.23, 51.95 C(3), 48.26 C(12), 33.91 C(4),
21.96 C(13); HRMS calcd for C17H19Cl2N2O: 337.0874, found: 337.0879.
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(R)-2-Amino-3-(2,4-dichlorophenyl)-N -((R)-1- phenylethyl)propan-
amide hydrochloride (71)
NH
1
2
O 3
4
NH2.HCl
5
6
11
10
9
8
7
13Cl
12
14
19
18
17
16
15
13
N -Boc protected amide 66 (213 mg, 0.49 mmol) was dissolved in dry diethyl ether
(20 mL) and dichloromethane (1 mL). Hydrogen chloride was bubbled through the
solution with vigorous stirring for 70 min. The solvent was evaporated to give 71
(175 mg, 63%) as a white solid, m.p. 110-112 ℃; 1H NMR (500 MHz, DMSO-d6)
δ ppm 8.93 (1H, d, J=8.2 Hz, H(1)), 8.70 (3H, br.s, H(5)), 7.49 (1H, d, J=2.2 Hz,
H(10)), 7.18 - 7.30 (4H, m, aryl), 7.14 (1H, dd, J= 8.2, 2.2 Hz, H(8)), 6.92 - 7.00 (2H,
m, aryl), 4.87 (1H, quin J=7.1 Hz, H(12)), 4.05 (1H, br.s, H(3)), 3.19 (1H, dd, J=13.6,
5.5 Hz, H(4)), 3.08 (1H, dd, J=13.6, 9.8 Hz, H(4)), 1.32 (3H, d, J=7.1 Hz, H(13));
13C
NMR (126 MHz, DMSO-d6) δ ppm 166.12 C(2), 143.18 C(14), 134.54 C(6), 133.00,
132.57, 131.81, 128.71, 128.02 C(16)/C(18), 127.33, 126.66, 125.85 C(15)/C(19), 51.86
C(3), 48.02 C(12), 33.64 C(4), 22.11 C(13); HRMS calcd for C17H19Cl2N2O: 337.0874,
found: 337.0873.
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(R)-2-Amino-3-(2,4-dichlorophenyl)-N -(4-methoxyphenyl)propan-
amide hydrochloride (72)
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N -Boc protected amide 67 (111 mg, 0.30 mmol) was dissolved in dry diethyl ether
(11 mL) and dichloromethane (21 mL). Hydrogen chloride was bubbled through
the solution with vigorous stirring for 3 h. The solvent was evaporated and the
residue triturated with diethyl ether to give 72 (60 mg, 63%) as a cream solid, m.p.
decomp. 115 ℃; 1H NMR (500 MHz, DMSO-d6) δ ppm 10.52 (1H, s, H(1)), 8.59
- 8.79 (3H, s, H(5)), 7.58 (1H, d, J=2.0 Hz, H(10)), 7.46 (1H, d, J=8.4 Hz, H(7)),
7.41 (2H, d, J=9.1 Hz, H(13),H(17)), 7.35 (1H, dd, J=8.4, 2.0 Hz, H(8)), 6.87 (2H, d,
H(14),H(16)), 4.15 - 4.23 (1H, m, H(3)), 3.70 (3H, s, H(18)), 3.29 - 3.35 (1H, m, H(4)),
3.20 - 3.28 (1H, dd, J=13.4, 8.7 Hz, H(4));
13C NMR (126 MHz, DMSO-d6) δ ppm
165.55 C(2), 155.83 C(15), 134.74 C(6), 133.20, 132.73, 131.94, 130.96, 128.78, 127.36,
121.28 C(13),C(17), 113.93 C(14),C(16), 55.19 C(18), 52.65 C(3), 33.76 C(4); HRMS calcd
for C16H17Cl2N2O2: 339.0667, found: 339.0666.
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(R)-tert-Butyl (3-(2,4-dichlorophenyl)-1-((4-hydroxyphenethyl)amino)-1-
oxopropan-2-yl)carbamate (73)
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To tyramine hydrochloride (104 mg, 0.6 mmol), N -Boc-(R)-2,4-dichlorophenylalanine
(201 mg, 0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109 mg, 0.6
mmol) and anyhdrous 1-hydroxybenzotriazole (122 mg, 0.9 mmol) in dimethylfor-
mamide (3.0 mL) was added N,N -diisopropylethylamine (0.78 mL, 4.5 mmol), the
mixture was then stirred for 16 h at 20 ℃. The mixture was the diluted with ethyl
acetate (20 mL) and washed with water (3 x 20 mL). The combined aqueous frac-
tions were re-extracted with ethyl acetate (3 x 20 mL) and the combined organic
layers were washed with dilute hydrochloric acid (1 M, 20 mL), saturated aqueous
sodium hydrogen carbonate (2 x 20 mL) and brine (20 mL) before being dried over
magnesium sulfate and evaporated to give 73 (200 mg, 74%) as a white solid without
further purification, m.p. 66-68℃; [α]25
D
c=1 dichloromethane +0.4 °; 1H NMR (500
MHz, chloroform-d) δ ppm 7.30 - 7.36 (1H, s, H(10)), 7.04 - 7.19 (2H, m, H(8),H(9)),
6.91 (2H, d, J= 7.8 Hz, H(15),H(19)), 6.74 (2H, d, J=8.5 Hz, H(16),H(19)), 6.08 - 6.28
(1H, br.s, H(1)), 5.25 (1H, d, J= 9.5 Hz, H(5)), 4.35 (1H, d, J= 7.4 Hz, H(3)), 3.27 -
3.48 (2H, m, H(12)), 3.09-3.24 (1H, m, H(4)), 2.96 - 3.05 (1H, m, H(4)), 2.54 - 2.69 (2H,
m, H(13)), 1.22 - 1.40 (9H, m, 3 x 3H(24));
13C NMR (126 MHz, chloroform-d) δ ppm
170.72 C(2), 155.21 C(22), 154.65 C(17), 134.71 C(6), 133.16, 133.00, 132.09, 129.48,
129.35, 128.97, 126.85, 115.31 C(16),C(18), 80.16 C(23), 54.12 C(3), 40.66 C(12), 35.62
C(4), 34.24 C(13), 27.87 C(24); HRMS calcd for C22H26Cl2N2O4: 475.1167, found:
475.1163.
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tert-Butyl(R)-(3-(2,4-dichlorophenyl)-1-oxo-1-(piperidin-1-yl)propan-2-
yl)carbamate (74)
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To piperidine (0.59 mL, 0.6 mmol), N -Boc-(R)-2,4-dichlorophenylalanine (201 mg,
0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109 mg, 0.6 mmol) and
anyhdrous 1-hydroxybenzotriazole (122 mg, 0.6 mmol) in dimethylformamide (3.0
mL) was added N,N -diisopropylethylamine (0.78 mL, 4.5 mmol), the mixture was
then stirred for 16 h at 20 ℃. The mixture was the diluted with ethyl acetate (20
mL) and washed with water (3 x 20 mL). The combined aqueous fractions were
re-extracted with ethyl acetate (3 x 20 mL) and the combined organic layers were
washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL) and brine
(20 mL) before being dried over magnesium sulfate and evaporated to give 74 (197
mg, 82%) as a pure white solid, m.p. 104-106 ℃; νmax (cm
−1): 3290-4320 (NH),
2930 br. (NH), 1707 (NHC=O), 1628 (CHC=O); 1H NMR (500 MHz, chloroform-d)
δ ppm 7.23 - 7.35 (1H, s, H(10)), 7.03 - 7.15 (2H, m, H(7),H(8)), 5.46 - 5.59 (1H, d, J=
7.7 Hz, H(5)), 4.85 - 4.97 (1H, m, H(3)), 3.34 - 3.61 (3H, m, 2H(12),2H(16)), 3.19 - 3.33
(1H, m, H(12)/H(16)), 3.02 (1 H, dd, J=13.1, 5.0 Hz, H(4)), 2.86 (1 H, dd, J=13.1,
8.2 Hz, H(4)), 1.35 - 1.64 (6H, m, H(13),H(14),H(15)), 1.22 - 1.32 (9H, m, 3 x 3H(19));
13C NMR (126 MHz, chloroform-d) δ ppm 169.38 C(2), 154.91 C(17), 135.21 C(6),
133.36, 133.30, 132.94, 129.11, 126.84, 79.42 C(18), 48.94 C(3), 46.62 C(12)/C(16), 43.23
C(16)/C(12), 37.39 C(4), 28.27 C(19), 26.32 C(13)/C(14)/C(15), 25.48 C(15)/C(13)/C(14),
24.37 C(14)/C(15)/C(13); HRMS calcd for C19H26Cl2N2O3: 400.1320, found: 400.1310.
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(R)-tert-Butyl (3-(2,4-dichlorophenyl)-1-oxo-1-((thiophen-2-
ylmethyl)amino)propan-2-yl)carbamate (75)
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To 2-(thiophenyl)-methylamine (0.05 mL, 0.45 mmol), N -Boc-(R)-2,4-dichlorophenyl-
alanine (153 mg, 0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (82 mg,
0.45 mmol) and anyhdrous 1-hydroxybenzotriazole (91 mg, 67.5 mmol) in dimethyl-
formamide (3.0 mL) was added N,N -diisopropylethylamine (0.59 mL, 3.4 mmol),
the mixture was then stirred for 21 h at 20 ℃. The mixture was the diluted with
ethyl acetate (20 mL) and washed with water (3 x 20 mL). The combined aqueous
fractions were re-extracted with ethyl acetate (3 x 20 mL) and the combined or-
ganic layers were washed with saturated aqueous sodium hydrogen carbonate (2 x
20 mL) and brine (20 mL) before being dried over magnesium sulfate. The residue
was purified by silica chromatography (28% ethyl acetate 72% hexane) to give 75
(100 mg, 54%) as a white solid, m.p. 162-163.5 ℃; [α]25
D
c=1 methanol: +11.6°; 1H
NMR (500 MHz, chloroform-d) δ ppm 7.31 (1H, s, aryl), 7.06 - 7.19 (3H, m, aryl),
6.81 - 6.95 (2H, m, aryl), 6.64 - 6.80 (1H, m, aryl), 5.31 (1H, d, J=9.3 Hz H(1)),
4.37 - 4.61 (3H, m, H(3),2H(12)), 3.13 - 3.33 (1H, m, H(4)), 2.93 - 3.12 (1H, m, H(4)),
1.27 - 1.40 (9H, m, 3 x 3H(19));
13C NMR (126 MHz, chloroform-d) δ ppm 170.78
C(2), 155.55 C(17), 140.33, 135.08 C(6), 133.46, 133.40, 132.54, 129.34, 127.24, 126.89,
126.12, 125.25, 80.32 C(18), 54.34 C(3), 38.28 C(12), 35.75 C(4), 28.27 3C(2), ; HRMS
calcd for C19H23Cl2N2O3S: 429.0806, found: 429.0793.
203
Materials and Methods Simon O.R. Greenwood
tert-Butyl (R)-(3-(2,4-dichlorophenyl)-1-(methylamino)-1-oxopropan-2-
yl)carbamate (76)
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To methylamine (0.075 mL, 0.6 mmol), N -Boc-(R)-2,4-dichlorophenylalanine (201
mg, 0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109 mg, 0.6 mmol)
and anyhdrous 1-hydroxybenzotriazole (122 mg, 0.6 mmol) in dimethylformamide
(3.0 mL) was added N,N -diisopropylethylamine (0.78 mL, 4.5 mmol), the mixture
was then stirred for 16 h at 20 ℃. The mixture was the diluted with ethyl acetate
(20 mL) and washed with water (3 x 20 mL). The combined aqueous fractions
were re-extracted with ethyl acetate (3 x 20 mL) and the combined organic layers
were washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL) and
brine (20 mL) before being dried over magnesium sulfate and evaporated to give 76
(154 mg, 74%) as a white solid, m.p. 181-183 ℃; νmax (cm
−1): 3330 (NH), 1682
(NHC=O), 1651 (CHC=O); 1H NMR (500 MHz, chloroform-d) δ ppm 7.31 - 7.38
(1H, m, H(10)), 7.11 - 7.21 (2H, m, H(7),H(8)), 6.15 (1H, br.s, H(1)), 5.15 - 5.25 (1H, d,
J=8.2 Hz, H(5)), 4.32 - 4.43 (1H, m, H(3)), 3.15 - 3.35 (1H, m, H(4)), 2.96 - 3.08 (1H,
m, H(4)), 2.65 - 2.80 (3H, m, H(12)), 1.30 - 1.38 (9H, m, 3 x 3H(15));
13C NMR (126
MHz, chloroform-d) δ ppm 171.54 C(2), 155.46 C(13), 135.12 C(6), 133.62, 133.46,
132.48, 129.34, 127.20, 80.25 C(14), 54.47 C(3), 35.94 C(4), 28.25 3C(2), 26.28 C(12);
HRMS calcd for C15H20Cl2N2O3: 346.0851, Measured: 346.0866.
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(R)-2-Amino-3-(2,4-dichlorophenyl)-N -(4-hydroxyphenethyl)-
propanamide hydrochloride (77)
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N -Boc protected amide 73 (199 mg, 0.5 mmol) was dissolved in dry diethyl ether
(15 mL). Hydrogen chloride was bubbled through the solution with vigorous stirring
for 135 min. The precipitate was filtered by gravity filtration through filter paper
in a funnel that was on top of a flask of boiling ether 68 (219 mg, >100%) as
a hygroscopic white solid, m.p. (decomp. 100 ℃); [α]26
D
methanol: -48.0°; νmax
(cm−1): 3054 (NH3), 2918, 2848, 1663 (C=O);
1H NMR (500 MHz, DMSO-d6) δ
ppm 9.17 - 9.33 (1H, s, H(1)), 8.46 - 8.64 (4H, m, H(5),H(20)), 7.59 (1H, s, H(10)), 7.30
- 7.42 (2H, m, H(7),H(8)), 6.90 (2H, d, J= 8.4 Hz, H(16),H(18)), 6.66 (2H, d, J=8.5
Hz, H(15),H(19)), 3.87 - 4.05 (1H, m, H(3)), 3.32 - 3.41 (1H, m, H(12)), 3.15 - 3.29
(2H, m, H(4),H(12)), 3.03 - 3.14 (2H, m, H(4),H(13)), 2.37 - 2.46 (1H, m, H(13));
13C
NMR (126 MHz, DMSO-d6) δ ppm 167.08 C(2), 155.80 C(17), 134.69 C(6), 133.18,
132.74, 132.03, 129.34 C(15),C(19), 128.97, 128.77, 127.39, 115.15 C(16),C(18), 51.92
C(4), 40.69 C(12), 33.94 C(13), 33.88 C(4); HRMS calcd for C17H19Cl2N2O2: 353.0824,
found: 353.0822.
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(R)-N -(2-(1(H )-indol-3-yl)ethyl)-2-amino-3-(2,4-dichlorophenyl)-
propanamide hydrochloride (78)
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N -Boc protected amide 54 (84 mg, 0.2 mmol) was dissolved in dry diethyl ether
(5 mL) and dichloromethane (20 mL). Hydrogen chloride was bubbled through the
solution with vigorous stirring for 70 min. The solvent was evaporated to give 78
(70 mg, 94%) as a cream solid, m.p. (decomp. 120 ℃); [α]25
D
c=1 methanol: -53.4°;
1H NMR (500 MHz, DMSO-d6) δ ppm 8.50 - 8.7 (5H, m, H(1),3H(5),H(21)), 6.27 -
7.75 (9H, m, aryl), 3.81 - 4.10 (1H, m, H(3)), 3.32 - 3.39 (1H, m, H(12)), 3.16 - 3.30
(2H, m, H(4),H(12)), 3.03 - 3.15 (1H, m, H(4)), 2.60 - 2.78 (2H, m, H(13));
13C NMR
(126 MHz, DMSO-d6) δ ppm 167.08 C(2), 136.25, 134.69, 133.20, 132.69, 132.06,
128.74, 127.33, 127.01, 122.72, 120.91, 118.24, 118.03, 111.43, 111.24, 64.89 C(12),
52.00 C(3), 33.86 C(4), 24.73 C(13); HRMS calcd for C19H20Cl2N3O: 376.0983, found:
376.0979.
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(R)-2-Amino-3-(2,4-dichlorophenyl)-1-(piperidin-1-yl)propan-1-one
hydrochloride (79)
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N -Boc protected amide 74 (197 mg, 0.58 mmol) was dissolved in dry diethyl ether
(15 mL). Hydrogen chloride was bubbled through the solution with vigorous stirring
for 60 min. The precipitate was filtered by gravity filtration through filter paper in a
funnel that was on top of a flask of boiling ether 79 (139 mg, 83%) as a white solid,
m.p. 228 - 229 ℃; 1H NMR (500 MHz, DMSO-d6) δ ppm 8.57 (3H, br.s, 3H(5)),
7.57 - 7.69 (1H, s, H(10)), 7.38 - 7.47 (2H, m, H(7),H(8)), 4.47 - 4.60 (1H, m, H(3)),
3.28 - 3.46 (2H, m, H(12)/H(16)), 3.15 - 3.27 (2H, m, H(16)/H(12)), 3.01 - 3.13 (1H, m,
H(4)), 2.87 - 2.99 (1H, m, H(4)), 1.33 - 1.55 (4H, m, 2H(13),2H(15)), 1.19 - 1.33 (1H,
m, H(14)), 0.80 - 0.96 (1H, m, H(14));
13C NMR (126 MHz, DMSO-d6) δ ppm 165.87
C(2), 134.59 C(6), 133.74, 133.07, 131.67, 128.85, 127.65, 47.80 C(3), 45.97 C(12)/C(16),
42.60 C(16)/C(12), 33.94 C(4), 25.34 C(13)/C(14)/C(15), 24.90 C(14)/C(15)/C(13), 23.55
C(15)/C(13)/C(14); HRMS calcd for C14H19Cl3N2O: 301.0874, found: 301.0813.
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(R)-2-Amino-3-(2,4-dichlorophenyl)-N -(thiophen-2-ylmethyl)propan-
amide hydrochloride (80)
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N -Boc protected amide 75 (130 mg, 0.35 mmol) was dissolved in dry diethyl ether
(20 mL) and dichloromethane (2 mL). Hydrogen chloride was bubbled through the
solution with vigorous stirring for 140 min. The precipitate was filtered by gravity
filtration through filter paper in a funnel that was on top of a flask of boiling ether
80 (48 mg, 42%) as a white solid, m.p. 191-193 ℃; 1H NMR (500 MHz, DMSO-d6)
δ ppm 9.04 (1H, t, J=5.7 Hz, H(1)), 8.67 (3H, br.s, H(5)), 7.55 (1H, d, J=2.1 Hz,
aryl), 7.38 (1H, dd, J=5.1, 1.3 Hz, aryl), 7.31 (1H, d, J= 8.2 Hz, aryl), 7.25 (1H, d,
J= 8.2, 2.1 Hz, aryl), 6.92 (1H, dd, J=5.1, 3.4 Hz, aryl), 6.85 (1H, dd, J=3.4, 1.1
Hz, aryl), 4.42 (1H, dd, J=15.3, 6.0 Hz, H(12)), 4.31 (1H, dd, J=15.3, 5.4 Hz, H(12)),
3.93 - 4.02 (1H, m, H(3)), 3.24 (1H, dd, J=13.7, 5.8 Hz, H(4)), 3.11 (1H, dd, J=13.7,
9.0 Hz, H(4));
13C NMR (126 MHz, DMSO-d6) δ ppm 167.05 C(2), 140.44, 134.64,
133.10, 132.69, 131.83, 128.74, 127.32, 126.61, 126.11, 125.31, 51.80 C(3), 37.24 C(12),
33.78 C(4); HRMS calcd for C14H15Cl2N2OS: 329.0282, found: 329.0273.
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(R)-2-Amino-3-(2,4-dichlorophenyl)-N -methylpropanamide
hydrochloride (81)
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76 (154 mg, 0.44 mmol) was dissolved in dry diethyl ether (15 mL) and dichloro-
methane (5 mL). Hydrogen chloride was bubbled through the solution with vigorous
stirring for 4.5 h. The precipitate was filtered by gravity filtration through filter
paper in a funnel that was on top of a flask of boiling ether 81 (96 mg, 82%) as
a white solid, 1H NMR (500 MHz, DMSO-d6) δ ppm 8.65 (3H, br.s, 3H(6)), 8.48
(1H, q, J=4.4 Hz, H(1)), 7.57 (1H, s, H(10)), 7.33 - 7.42 (2H, s, H(7),H(8)), 3.90 (1H,
br.s, H(3)), 3.23 (1H, dd, J=13.7, 5.7 Hz, H(4)), 3.10 (1H, dd, J=13.7, 8.7 Hz, H(4)),
2.51 (3H, s, H(12));
13C NMR (126 MHz, DMSO-d6) δ ppm 167.58 C(2), 134.66 (6),
133.11, 132.64, 132.15, 128.73, 127.35, 51.99 C(4), 33.71 C(3), 25.49 C(12); HRMS
calcd for C10H13Cl2N2O: 247.0405, found: 247.0414.
tert-Butyl (R)-(3-(2,4-dichlorophenyl)-1-((2,3-dihydro-1H-inden-2-
yl)amino)-1-oxopropan-2-yl)carbamate (82)
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2-Aminoindane (0.08 mL, 0.6 mmol), N -Boc-(R)-2,4-dichlorophenylalanine (201 mg,
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0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109 mg, 0.6 mmol) and
anyhdrous 1-hydroxybenzotriazole (122 mg, 0.6 mmol) in dimethylformamide (3.0
mL) was added N,N -diisopropylethylamine (0.78 mL, 4.5 mmol), the mixture was
then stirred for 16 h at 20 ℃. The mixture was the diluted with ethyl acetate (20
mL) and washed with water (3 x 20 mL). The combined aqueous fractions were
re-extracted with ethyl acetate (3 x 20 mL) and the combined organic layers were
washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL) and brine
(20 mL) before being dried over magnesium sulfate and evaporated. The residue
was purified by column chromatography (33% ethyl acetate 66% hexane) to give
82 (57 mmol, 96%) as a white solid, m.p. 193-194 ℃; νmax (cm
−1): 3200-3400
(NH), 1684 (NHC=O), 1650 (CHC=O); 1H NMR (500 MHz, chloroform-d) δ ppm
7.31 - 7.36 (1H, m, H(10)), 7.09 - 7.24 (6H, m, aryl), 6.07 (1H, br.s, H(1)), 5.14
(1H, br.s, H(5)), 4.55 - 4.72 (1H, m, H(12)), 4.32 (1H, s, H(4)), 3.14 - 3.34 (3H, m,
H(4),H(13)/H(20)), 3.06 (1H, m, H(4)), 2.73 (1H, dd, J=16.2, 4.8 Hz, H(20)/H(13)), 2.59
(1H, dd, J=16.2, 3.8 Hz, H(20)/H(13)), 1.31 - 1.38 (9H, m, 3 x 3H(23));
13C NMR
(126 MHz, chloroform-d) δ ppm 170.45 C(2), 155.40 C(21), 140.54 C(14),C(19), 135.10
C(6), 133.54, 132.49, 129.40, 127.29, 126.90, 124.83, 124.80, 80.34 C(22), 54.48 C(12),
50.68 C(3), 39.96 C(13)/C(20), 39.94 C(20)/C(13), 35.92 C(4), 28.25 3C(2); HRMS calcd
for C23H27Cl2O3N2: 449.1399 (M+H), found: 449.1385.
tert-Butyl (R)-(3-(2,4-dichlorophenyl)-1-oxo-1-(phenethylamino)-
propan-2-yl)carbamate (83)
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To phenylethylamine (0.76 mL, 0.6 mmol), N -Boc-(R)-2,4-dichlorophenylalanine
(201 mg, 0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109 mg, 0.6
mmol) and anyhdrous 1-hydroxybenzotriazole (122 mg, 0.6 mmol) in dimethylfor-
mamide (3.0 mL) was added N,N -diisopropylethylamine (0.78 mL, 4.5 mmol), the
mixture was then stirred for 16 h at 20 ℃. The mixture was the diluted with ethyl
acetate (20 mL) and washed with water (3 x 20 mL). The combined aqueous frac-
tions were re-extracted with ethyl acetate (3 x 20 mL) and the combined organic
layers were washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL)
and brine (20 mL) before being dried over magnesium sulfate and evaporated. The
residue was purified by column chromatography (60% ethyl acetate 40% dichloro-
methane) to give 83 (117 mg, 45%) as a white solid, m.p. 169-170 ℃; νmax (cm
−1):
3338 br. (NH) 2875-3030 (NH) 1682 (NHC=O), 1654 (CHC=O); 1H NMR (500
MHz, chloroform-d) δ ppm 7.05 - 7.40 (8H, m, aryl), 5.98 (1H, t, J=6.0 Hz, H(1)),
5.12 (1H, d, J=8.5 Hz, H(5)), 4.21 - 4.44 (1H, m, H(3)), 3.30 - 3.64 (2H, m, H(12)),
3.18 (1H, dd, J=13.3, 6.7 Hz, H(4)), 2.99 (1H, dd, J=13.3, 7.9 Hz, H(4)), 2.61 - 2.82
(2H, m, H(13)), 1.25 - 1.43 (9H, m, 3 x 3H(22));
13C NMR (126 MHz, chloroform-d)
δ ppm 170.84 C(2), 155.43 C(20), 138.55 C(14), 135.17 C(6), 133.61, 133.57, 132.58,
129.44, 128.83, 128.80, 127.32, 126.78, 80.32 C(21), 54.56 C(3), 40.78 C(12), 36.12
C(13), 35.63 C(4), 28.34 3C(2); HRMS calcd for C22H27Cl2N2O3: 437.1399 (M+H),
found: 437.1385.
(R)-2-Amino-3-(2,4-dichlorophenyl)-N -(2,3-dihydro-1H-inden-2-
yl)propanamide hydrochloride (84)
NH
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N -Boc protected amide 82 (194 mg, 0.5 mmol) was dissolved in dry diethyl ether
(15 mL) and dichloromethane (10 mL). Hydrogen chloride was bubbled through the
solution with vigorous stirring for 2 h. The solvent was evaporated to give 84 (158
mg, 95%) as a cream solid, m.p. (decomp. 150℃); [α]25
D
c=1 methanol: -65.0°; νmax
(cm−1): 3199 (NH), 3019 (NH3), 3918, 2847, 2658 ;
1H NMR (500 MHz, DMSO-d6)
δ ppm 8.60 - 8.74 (4H, m, H(1),H(5)), 7.55 (1H, s, H(10)), 7.35 (2H, s, aryl), 7.01
- 7.23 (4H, m, aryl), 4.29 - 4.48 (1H, m, H(12)), 3.89 (1H, br.s, H(3)), 3.24 (1H,
dd, J=13.5, 5.3 Hz, H(4)), 3.06 - 3.15 (2H, m, H(4),H(13)/H(20)), 2.98 - 3.06 (1H,
dd, ( J)= 16.2, 7.5 Hz, H(13)/H(20)), 2.76 (1H, dd, J=16.2, 5.2 Hz, H(20)/H(13)), 2.45
(1H, dd, J=16.2, 5.2 Hz, H(20)/H(13));
13C NMR (126 MHz, DMSO-d6) δ ppm 166.86
C(2), 140.81 (14/C19), 140.79 C(19)/C(14), 134.62 C(6), 133.16, 132.64, 132.01, 128.68,
127.32, 126.42, 124.43, 124.41, 51.77 C(4)/C(12), 49.89 C(12)/C(4), 38.77 C(13)/C(20),
38.61 C(20)/C(13), 33.76 C(4);
(R)-2-Amino-N -(9H -carbazol-3-yl)-3-(2,4-dichlorophenyl)propanamide
hydro-chloride (85)
NH
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N -Boc protected amide 55 (109 mg, 0.25 mmol) was dissolved in dry diethyl ether
(15 mL). Hydrogen chloride was bubbled through the solution with vigorous stirring
for 150 min. The precipitate was filtered by gravity filtration through filter paper
in a funnel that was on top of a flask of boiling ether 85 (40 mg, 42%) as a cream
solid, 1H NMR (500 MHz, DMSO-d6) δ ppm 11.46 (1H, s, H(1)/H(16)), 10.77 (1H, s,
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H(16)/H(1)), 8.78 (3H, br.s, 3H(5)), 8.10 (1H, d, J=7.7 Hz, aryl), 7.96 (1H, d, J=7.7
Hz, aryl), 7.60 - 7.70 (1H, m, aryl), 7.33 - 7.59 (5H, m, aryl), 7.08 - 7.22 (2H, m,
aryl), 4.49 (1H, s, H(3)), 3.33 - 3.66 (2H, m, H(4));
13C NMR (126 MHz, DMSO-d6)
δ ppm 166.50 C(2), 139.28, 134.90, 133.35, 133.16, 132.88, 131.84, 128.91, 127.47,
125.87, 123.65, 122.31, 121.24, 120.31, 119.34, 118.85, 118.52, 117.63, 111.02, 52.47
C(4), 33.79 C(3); HRMS calcd for C21H17Cl2N3O: 397.0749, found: 397.0739.
(R)-2-Amino-3-(2,4-dichlorophenyl)-N -phenethylpropanamide
hydrochloride (86)
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N -Boc protected amide 83 (148 mg, 0.34 mmol) was dissolved in dry diethyl ether
(20 mL), and dichloromethane (5 mL). Hydrogen chloride was bubbled through
the solution with vigorous stirring for 2 h and the solvent was then evaporated,
trituration with dry diethyl ether gave 86 (104 mg, 85%) as a sticky white solid,
m.p. 96-97 ℃ 1H NMR (500 MHz, D2O) δ ppm 7.58 (1H, s, H(10)), 7.37 - 7.45 (2H,
m, aryl), 7.34 - 7.45 (4H, m, aryl), 7.14 - 7.25 (3H, m, aryl), 4.19 (1H, dd, J=9.5,
6.0 Hz, H(3)), 3.60 (1H, m, H(4)), 3.16 - 3.40 (3H, m, H(4),H(12)), 2.60 - 2.79 (2H, m,
H(13));
13C NMR (500 MHz, D2O) δ ppm 176.77 C(2), 147.27, 143.27, 142.77, 142.68,
142.26, 139.01, 138.04, 137.40, 137.00, 135.17, 61.45 C(3), 49.05 C(4)/C(12), 45.19
C(12)/C(4), 42.67 C(13); HRMS calcd for C17H19N2Cl2O: 337.0874 (M+H), found:
337.0870.
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tert-Butyl (R)-(3-(2,4-dichlorophenyl)-1-oxo-1-((2-(pyridin-3-yl)-
ethyl)amino)propan-2-yl)carbamate (87)
NH1
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3-(2-Aminoethyl)pyridine dihydrobromide (81 mg, 0.6 mmol), N -Boc-(R)-2,4-di-
chlorophenylalanine (201 mg, 0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbo-
diimide (109 mg, 0.6 mmol) and anyhdrous 1-hydroxybenzotriazole (122 mg, 0.6
mmol) in dimethylformamide (3.0 mL) was added N,N -diisopropylethylamine (1.0
mL, 5.7 mmol), the mixture was then stirred for 16 h at 20 ℃. The mixture was
the diluted with ethyl acetate (20 mL) and washed with water (3 x 20 mL). The
combined aqueous fractions were re-extracted with ethyl acetate (3 x 20 mL) and
the combined organic layers were washed with saturated aqueous sodium hydro-
gen carbonate (2 x 20 mL) and brine (20 mL) before being dried over magnesium
sulfate and evaporated. The residue was purified by colum chromatography (25%
ethyl acetate 75% hexane) to yeild 87 as a white solid (110 mg, 42%), m.p. 154
- 154.5 ℃; [α]26
D
chloroform: +5.9°; νmax (cm
−1): 3370 br. (NH), 2966 (NH), 1681
(NHC=O), 1650 (CHC=O); 1H NMR (500 MHz, chloroform-d) δ ppm 8.29 - 8.49
(2H, m, H(17),H(18)), 7.48 (1H, d, J=8.2 Hz, aryl), 7.29 - 7.38 (1H, m, aryl), 7.08 -
7.24 (3H, m, aryl), 6.61 (1H, t, J=6.0 Hz, H(1)), 5.33 (1H, d, J=9.0 Hz, H(5)), 4.30
- 4.41 (1H, m, H(3)), 3.44 (1H, q, J=7.0 Hz, H(12)), 3.09 - 3.30 (1H, m, H(4)), 2.93
- 3.05 (1H, m, H(4)), 2.67 - 2.81 (2H, m, H(13)), 1.26 - 1.36 (9H, m, 3 x 3H(21));
13C
NMR (126 MHz, chloroform-d) δ ppm 171.27 C(2), 155.56 C(19), 149.49 C(19), 147.47,
136.78, 135.10, 134.50, 133.53, 133.46, 132.49, 129.33, 127.18, 123.73, 80.29 C(20),
54.38 br. C(3), 40.37 C(12), 35.75 br. C(4), 32.83 C(13), 28.26 C(21); HRMS calcd for
C21H26N3Cl2O3: 438.13512, found: 438.135409.
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tert-Butyl (R)-(3-(2,4-dichlorophenyl)-1-oxo-1-((3-phenylpropyl)-
amino)propan-2-yl)carbamate (88)
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3-Phenylpropan-1-amine (85 mg, 0.6 mmol) N -Boc-(R)-2,4-dichlorophenylalanine
(201 mg, 0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109 mg, 0.6
mmol) and anyhdrous 1-hydroxybenzotriazole (122 mg, 0.6 mmol) in dimethylfor-
mamide (3.0 mL) was added N,N -diisopropylethylamine (0.78 mL, 4.5 mmol), the
mixture was then stirred for 16 h at 20 ℃. The mixture was the diluted with ethyl
acetate (20 mL) and washed with water (3 x 20 mL). The combined aqueous frac-
tions were re-extracted with ethyl acetate (3 x 20 mL) and the combined organic
layers were washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL)
and brine (20 mL) before being dried over magnesium sulfate and evaporated. The
residue was purified by colum chromatography (66% hexane 33% ethyl acetate) to
give 88 (133 mg, 49%) as a white solid, m.p. 133-133.5 ℃; 1H NMR (500 MHz,
chloroform-d) δ ppm 7.34 (1H, d, J=1.6 Hz, H(10)), 7.23 - 7.30 (2H, m, aryl), 7.15 -
7.21 (2H, m, aryl), 7.10 - 7.15 (3H, m, aryl), 6.39 (1H, br.s, H(1)), 5.31 (1H, d, J=9.1
Hz, H(5)), 4.31 - 4.46 (1H, m, H(3)), 3.14 - 3.28 (3H, m, H(4),2H(12)), 2.96 - 3.09 (1H,
m, H(4)), 2.51 - 2.63 (2H, m, H(14)), 1.68 - 1.82 (2H, m, H(13)), 1.35 (9H, br.s, 3 x
3H(23));
13C NMR (126 MHz, chloroform-d) δ ppm 171.02 C(2), 155.59 C(21), 141.32
C(14), 135.14 C(6), 133.65, 133.43, 132.61, 129.33, 128.54, 128.39, 127.19, 126.09,
80.18 C(21), 54.44 C(3), 39.21 C(15), 35.92 C(4), 33.18 C(14), 30.94 C(13), 28.31 3C(2);
HRMS calcd for C23H29Cl2N2O3 451.1556 (M+H), found 451.1552.
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tert-Butyl (R)-(3-(2,4-dichlorophenyl)-1-((3,4-dihydroxyphen-
ethyl)amino)-1-oxopropan-2-yl)carbamate (89)
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Dopamine hydrochloride (114 mg, 0.6 mmol), N -Boc-(R)-2,4-dichlorophenylalanine
(201 mg, 0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109 mg, 0.6
mmol) and anyhdrous 1-hydroxybenzotriazole (122 mg, 0.6 mmol) in dimethylfor-
mamide (3.0 mL) was added N,N -diisopropylethylamine (0.78 mL, 4.5 mmol), the
mixture was then stirred for 18 h at 20 ℃. The mixture was the diluted with ethyl
acetate (20 mL) and washed with water (3 x 20 mL). The combined aqueous frac-
tions were re-extracted with ethyl acetate (3 x 20 mL) and the combined organic
layers were washed with saturated aqueous sodium hydrogen carbonate (2 x 20
mL) and brine (20 mL) before being dried over magnesium sulfate and evaporated.
The residue was purified by colum chromatography (33% ethyl acetate 66% hexane)
to give 89 as a glassy solid (177 mg, 63%), m.p. 64-65 ℃; 1H NMR (500 MHz,
chloroform-d) δ ppm 7.29 - 7.38 (1H, s, H(10)), 7.09 - 7.14 (2H, m, H(7),H(8)), 6.76
(1H, d, J=8.0 Hz, H(15)), 6.63 (1H, s, H(19)), 6.52 (1H, br.s, H(1)), 6.46 (1H, d,
J=8.0 Hz, H(16)), 5.32 - 5.70 (1H, m, H(5)), 4.30 - 4.69 (1H, m, H(3)), 3.29 - 3.45
(2H, m, 2H(12)), 3.08 - 3.22 (1H, m, H(4)), 2.96 - 3.06 (1H, m, H(4)), 2.56 (2H, m,
H(13)), 1.29 - 1.42 (9H, m, H(24));
13C NMR (126 MHz, chloroform-d) δ ppm 171.71
(2), 155.85 C(22), 144.14 C(17)/C(18), 143.12C(18)/C(17), 135.07C(6), 133.59, 133.20,
132.40, 130.66, 129.39, 127.28, 120.77, 115.84, 115.55, 80.86 C(23), 54.60 C(3), 41.14
C(12), 35.94 C(4), 34.70 C(13), 28.25 C(24).
216
Materials and Methods Simon O.R. Greenwood
tert-Butyl (R)-(3-(2,4-dichlorophenyl)-1-((2-(6-hydroxy-2H -indol-3-
yl)ethyl)amino)-1-oxopropan-2-yl)carbamate(90)
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Serotonin hydrochloride (128 mg, 0.6 mmol) N -Boc-(R)-2,4-dichlorophenylalanine
(201 mg, 0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109 mg, 0.6
mmol) and anyhdrous 1-hydroxybenzotriazole (122 mg, 0.6 mmol) in dimethylfor-
mamide (3.0 mL) was added N,N -diisopropylethylamine (0.78 mL, 4.5 mmol), the
mixture was then stirred for 18 h at 20 ℃. The mixture was the diluted with ethyl
acetate (20 mL) and washed with water (3 x 20 mL). The combined aqueous frac-
tions were re-extracted with ethyl acetate (3 x 20 mL) and the combined organic
layers were washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL)
and brine (20 mL) before being dried over magnesium sulfate and evaporated. The
residue was purified by colum chromatography to give 90 (220 mg, 72%) as a white
solid, m.p. 85 ℃; νmax (cm
−1): 3242 (br. OH), 2866 (br. NH), 1665 (C=O); 1H
NMR (500 MHz, chloroform-d) δ ppm 8.22 (1H, br.s, H(17)), 7.27 (1H, s, aryl), 7.14
(1H, d, J=8.7 Hz, aryl), 7.01 - 7.09 (2H, m, aryl), 6.93 (1H, s, aryl), 6.76 - 6.85
(2H, m, aryl), 6.36 (1H, t, J=6.0 Hz, H(1)), 5.49 (1H, d, J=9.0 Hz, H(5)), 4.24 - 4.49
(1H, m, H(3)), 3.41 - 3.53 (1H, m, H(13)), 3.24 (1H, m, H(13)), 3.11 (1H, dd, J=13.8,
5.0 Hz, H(4)), 2.96 (1H, dd, J=13.6, 8.5 Hz, H(4)), 2.62 - 2.81 (2H, m, H(14)), 1.28
- 1.39 (9H, m, 3 x 3H(27));
13C NMR (126 MHz, chloroform-d) δ ppm 171.12 C(2),
155.77 C(25), 150.34 C(20), 135.07 C(6), 133.41, 133.31, 132.34, 131.43, 129.31, 128.11,
217
Materials and Methods Simon O.R. Greenwood
127.17, 123.15, 112.49, 112.10, 103.27, 80.73 C(26), 54.57 C(3), 40.98 C(13), 36.18 C(4),
28.30 3C(2), 25.42 C(14).
(R)-2-Amino-3-(2,4-dichlorophenyl)-N -(2-(pyridin-3-yl)ethyl)propan-
amide hydrochloride (91)
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N -Boc protected amide 87 (110 mg, 0.25 mmol) was dissolved in dry diethyl ether
(10 mL), dichloromethane (2 mL) and ethyl acetate (1 mL). Hydrogen chloride
was bubbled through the solution with vigorous stirring for 1 h. The solvent was
evaporated to give 91 (105 mg) as a damp solid, 1H NMR (600 MHz, DMSO-d) δ
ppm 8.92 (1H, s, H(19)), 8.84 (1H, t, J=5.3 Hz, H(1)), 8.79 (1H, d, J=5.5 Hz, H(17)),
8.74 (3H, br. s 3H(5)), 8.48 (1H, d, J=8.1 Hz, H(15)), 7.97 (1H, dd, J=8.1, 5.5 Hz,
H(16)), 7.55 (1H, d, J=2.1 Hz, H(10)), 7.38 (1H, d, J=8.5 Hz, H(7)), 7.34 (1H, dd,
J=8.5, 2.1 Hz, H(8)), 3.92 (1H, br.s, H(3)), 3.39 - 3.47 (1H, m, H(12)), 3.24 - 3.32 (1H,
m, H(3)), 3.18 (1H, dd, J=13.7, 6.0 Hz, H(4)), 3.07 (1H, dd, J=13.7, 8.6 Hz, H(4)),
2.81 - 2.97 (2H, m, H(13));
13C NMR (151 MHz, DMSO-d6) δ ppm 167.53 C(2), 146.45,
141.50, 139.40, 139.27, 134.65, 133.15, 132.64, 132.05, 128.75, 127.38, 126.78, 64.95
C(12), 51.93 C(3), 33.71 C(4), 31.32 C(13); HRMS calcd for C16H18N3OCl2: 338.0827
(M+H), found: 338.0822.
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(R)-2-Amino-3-(2,4-dichlorophenyl)-N -(3-phenylpropyl)propanamide
hydrochloride (92)
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N -Boc protected amide 88(100 mg, 22 mmol) was dissolved in dry diethyl ether
(15 mL), dichloromethane (0.5 mL). Hydrogen chloride was bubbled through the
solution with vigorous stirring for 2 h. The solvent was evaporated to give 92 (96
mg) , 1H NMR (600 MHz, DMSO-d6) δ ppm 8.71 (3H, br.s, 3H(5)), 8.59 (1H, s, 1),
7.57 (1H, d, J=2.0 Hz, H(10)), 7.41 (1H, d, J=8.3 Hz, H(7)), 7.36 (1H, dd, J=8.3,
2.0 Hz, H(7)), 7.26 (2H, m, aryl), 7.10 - 7.19 (3H, m, aryl), 3.95 - 4.04 (1H, m, H(3)),
3.26 (1H, dd, J=13.6, 5.6 Hz, H(4)), 3.12 (1H, dd, J=13.6, 9.4 Hz, H(4)), 3.02 - 3.09
(1H, m, H(12)), 2.90 - 2.98 (1H, m, H(12)), 2.37 - 2.46 (2H, m, H(14)), 1.49 - 1.61
(2H, m, H(13));
13C NMR (151 MHz, DMSO-d6) δ ppm 167.08 C(2), 141.53 C(15),
134.68 C(6), 133.21, 132.70, 132.15, 128.76, 128.28, 127.39, 125.76, 51.97 C(3), 38.25
C(15), 33.79 C(4), 32.26 C(14), 30.31 C(13); HRMS calcd for C18H21Cl2N2O: 351.1031
(M+H), found: 351.1039.
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(R)-2-Amino-3-(2,4-dichlorophenyl)-N -(3,4-dihydroxyphenethyl)-
propanamide hydrochloride (93)
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N -Boc protected amide 89 (177 mg, 0.38 mmol) was dissolved in dry diethyl ether
(10 mL). Hydrogen chloride was bubbled through the solution with vigorous stirring
for 35 min. The precipitate was filtered by gravity filtration through filter paper in a
funnel that was on top of a flask of boiling ether 93 (147 mg, 95%) as a white solid,
m.p. (decomp. 175 ℃); [α]25
D
c=1 methanol: -57.3°; νmax (cm
−1): 2967 (OH/NH3),
1664 (C=O); 1H NMR (600 MHz, DMSO-d6) δ ppm 8.86 (1H, s, H(20)/H(21)), 8.76
(1H, s, H(21)/H(20)), 8.57 (3H, br.s, 3H(5)), 8.53 (1H, t, J=5.6 Hz, H(1)), 7.61 (1H, d,
J=2.2 Hz, H(10)), 7.39 (1H, dd, J=8.3, 2.2 Hz, H(8)), 7.34 (1H, d, J=8.3 Hz, H(7)),
6.63 (1H, d, J=8.0 Hz, H(15)), 6.58 (1H, d, J=2.2 Hz, H(19)), 6.35 (1H, dd, J=8.0,
2.2 Hz, H(16)), 3.91 (1H, dd, J=8.6, 6.1 Hz, H(3)), 3.14 - 3.25 (2H, m, H(4),H(12)), 3.03
- 3.14 (2H, m, H(4),H(12)), 2.39 - 2.46 (1H, m, H(13)), 2.33 - 2.39 (1H, m, H(13));
13C
NMR (151 MHz, DMSO-d6) δ ppm 167.10 C(2), 145.16 C(17)/C(18), 143.69 C(18)/C(17),
134.73 C(6), 133.26, 132.77, 132.04, 129.69, 128.81, 127.43, 119.14, 115.98, 115.59,
51.95 C(3), 40.74 C(12), 34.24 C(13), 33.94 C(4); HRMS calcd for C17H19N2Cl2O3:
369.0772 (M+H), found: 369.0777.
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(R)-2-Amino-3-(2,4-dichlorophenyl)-N -(2-(6-hydroxy-2H-indol-3--
yl)ethyl)propanamide hydrochloride (94)
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N -Boc protected amide 90 (158 mg, 0.3 mmol) was dissolved in dry diethyl ether
(10 mL). Hydrogen chloride was bubbled through the solution with vigorous stirring
for 35 min. The precipitate was filtered by gravity filtration through filter paper in
a funnel that was on top of a flask of boiling ether 94 (105 mg, 0.24 mmol, 79%) as a
white solid, m.p. (decomp. 150℃); [α]25
D
c=1 methanol: -47.2°; 1H NMR (600 MHz,
DMSOd6) δ ppm 10.57 (1H, br.s, H(17)), 8.50 - 8.66 (5H, m, aryl), 7.61 (1 H, s), 7.33
- 7.36 (2H, m, aryl), 7.12 (1H, d, J=8.6 Hz, aryl), 7.00 (1H, d, J=1.9 Hz, aryl),
6.80 (1H, d, J=2.4 Hz, aryl), 6.60 (1H, dd, J=8.6, 2.4 Hz, aryl), 3.90 - 3.97 (1H,
m, H(3)), 3.28 - 3.35 (1H, m, H(11)), 3.16 - 3.25 (2H, m, H(11),H(4)), 3.12 (1 H, dd,
J=13.7, 8.7 Hz, H(4)), 2.52 - 2.67 (2H, m, H(14));
13C NMR (151 MHz, DMSO-d6)
δ ppm 167.09 C(2), 150.27 C(20), 134.74 C(6), 133.26, 132.76, 132.05, 130.79, 128.81,
127.70, 127.41, 123.19, 111.73, 111.34, 110.26, 102.08, 52.01 C(3), 33.95 C(4), 24.92
C(14);HRMS calcd for C19H20 N3Cl2O2: 392.0933 (M+H), found: 392.0936.
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(R)-2-Amino-3-(2,4-dichlorophenyl)propanoic acid hydrochloride (95)
OH
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N -Boc-(R)-2,4-dichlorophenylalanine (134 mg, 0.4 mmol) was dissolved in dry di-
ethyl ether (15 mL). Hydrogen chloride was bubbled through the solution with vigor-
ous stirring for 140 min. The precipitate was filtered by gravity filtration through
filter paper in a funnel that was on top of a flask of boiling ether 95 (89 mg, 82%)
as a white solid, 1H NMR (500 MHz, DMSO-d6) δ ppm 13.35 - 14.24 (1H, m, H(1)),
8.55 - 8.76 (3H, m, H(5)), 7.61 (1H, d, J= 2.0 Hz, H(10)), 7.48 (1H, d, J=8.3 Hz,
H(8)), 7.41 (1H, dd, J=8.3, 2.0 Hz, H(7)), 4.03 (1H, t, J=7.5 Hz, H(3)), 3.25 (2H,
d, J=7.5, H(4));
13C NMR (126 MHz, DMSO-d6) δ ppm 169.88 C(2), 134.52 C(6),
133.31, 132.78, 132.27, 128.81, 127.52, 51.58 C(3), 33.11 C(4);
(R)-2-Amino-1-(5-aminoisoindolin-2-yl)-3-(2,4-dichlorophenyl)propan-1-
one hydrochloride 97
N 1
2
O 3
4
NH2.HCl5
6
11
10
9
8
7
ClCl
19
1813
12
17
1615
14
H2N
20
N -Boc protected amide 136 (100 mg, 0.22 mmol) was dissolved in dry diethyl ether
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(20 mL). Hydrogen chloride was bubbled through the solution with vigorous stirring
for 30 min and the precipitate was filtered The precipitate was filtered by gravity
filtration through filter paper in a funnel that was on top of a flask of boiling ether
97 (20 mg, 22%) as a white solid, 1H NMR (600 MHz, D2O, 2 rotamers) δ ppm 7.39
- 7.44 (1H, m, aryl), 7.13 - 7.35 (5H, m, aryl), 4.63 (1H, m, H(12)/H(19)), 4.08 (1H, t,
J=15.0 Hz, H(4)), 3.38 (1H, ddd, J=13.7, 6.1, 3.0 Hz H(4)), 3.27 (1H, ddd, J=13.7,
9.0, 2.5 Hz, H(4)).
13C NMR (126 MHz, D2O, 2 rotamers) δ ppm 167.72 C(2), 167.69
C(2), 137.61, 137.35, 136.62, 136.42, 135.08, 135.05, 134.77, 134.76, 133.04, 130.34,
130.30, 129.98, 129.79, 129.74, 128.12, 124.80, 124.57, 123.10, 122.92, 117.99, 117.71,
52.61 C(12)/C(19), 52.46 C(12)/C(19), 52.24 C(19)/C(12), 52.14 C(19)/C(12), 50.98 C(4),
50.96 C(4), 34.30 C(3); HRMS calcd for C18H20N2Cl2O: 350.0952 (M+H), found:
350.0951.
(R)-2-(2-Amino-3-(2,4-dichlorophenyl)propanoyl)-N -methylisoindoline-
5-carboxamide hydrochloride (98)
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N -Boc protected amide 130 (45 mg, 0.09 mmol) was dissolved in diethyl ether (5
mL) and dichloromethane (4 mL) and hydrogen chloride was bubbled through the
solution with vigorous stirring for 2 h. The solvent was evaporated to give 98 (37
mg, 95%) as a white solid, m.p. decomp (190 ℃) ; 1H NMR (600 MHz, CD3OD,
2 rotamers) δ ppm 7.64 - 7.82 (2H, m, aryl), 7.46 (1H, s, aryl), 7.24 - 7.44 (3H,
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m, aryl), 4.98 - 5.08 (1H, m, H(12)/H(19)), 4.85 (1H, d, J=16.2 Hz, H(19)/H(12)),
4.68 (1H, d, J=16.2 Hz, H(19)/H(12)), 4.82 - 4.93 (1H, m, H(12)/H(19)), 4.21 (1H, t,
J=13.0 Hz, H(3)), 3.38 (2 H, d, J=6.8 Hz, H(4)), 2.94 (3H, s, 3 x 3H(26));
13C NMR
(151 MHz, CD3OD, 2 rotamers) δ ppm 170.24 C(2), 170.14 C(2), 168.16 C(20), 168.15
C(20), 140.51, 140.20, 137.43, 137.07, 136.44, 135.93, 135.40, 135.20, 134.48, 132.12,
130.64, 129.08, 128.30, 128.15, 124.21, 124.07, 122.98, 122.86, 53.57 C(12)/C(19),
53.48 C(12)/C(19), 53.27 C(19)/C(12), 53.17 C(19)/C(12), 52.14 C(3), 52.11 C(3), 35.31
C(4), 35.27 C(4), 27.15 C(22); HRMS calcd for C19H20N3Cl2O2: 392.0927 (M+H),
found: 392.0933.
(R)-N -(2-(2-Amino-3-(2,4-dichlorophenyl)propanoyl)isoindolin-5-yl)-
acetamide hydrochloride (99)
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N -Boc protected amide 138 (84 mg, 0.17 mmol) was dissolved in dry diethyl ether
(10 mL) and dichloromethane (10 mL). Hydrogen chloride was bubbled through
the solution with vigorous stirring for 150 min. The precipitate was filtered by
gravity filtration through filter paper in a funnel that was on top of a flask of
boiling ether 99 (65 mg, 89%) as a cream solid, m.p. (decomp. 200 ℃); [α]26
D
methanol: -28.8°; νmax (cm
−1): 2861 (NH3), 1651 (C=O), 1649 (C=O);
1H NMR
(500 MHz, chloroform-d, 2 rotamers) δ ppm 10.25 (1H, d, J=4.5 Hz, H(20)), 8.63
(3H, d, J=4.1 Hz, 3H(5)), 7.67 (1H, d, J=18.4 Hz, aryl), 7.61 (1H, t, J=2.3 Hz,
aryl), 7.42 - 7.50 (2H, m, aryl), 7.39 (1H, ddd, J=8.3, 3.8, 2.3 Hz, aryl), 7.21
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(1H, m, aryl), 4.99 (1H, m, J=13.9 Hz, H(12)/H(19)), 4.69 (1H, m, J=16.2 Hz,
H(19)/H(12)), 4.50 (1H, m, J=16.2 Hz, H(19)/H(12)), 4.32 - 4.42 (1H, m, H(3)), 4.22
(1H, m, J=13.9 Hz, H(12)/H(19)), 3.27 (2H, s, H(4)), 2.04 (3H, s, H(22));
13C NMR (126
MHz, chloroform-d, 2 rotamers) δ ppm 168.44 C(2)/C(21), 166.48 C(21)/C(2), 166.46
C(21)/C(2), 139.15, 139.08, 136.26, 135.64, 134.64, 134.61, 133.61, 133.59, 133.11,
133.10, 131.58, 129.99, 129.42, 128.90, 127.69, 123.14, 122.89, 118.63, 118.60, 113.29,
112.93, 52.24 C(12)/C(19), 51.84 C(12)/C(19), 51.79 C(19)/C(12), 51.36 C(19)/C(12), 49.98
C(3), 33.36 C(4), 33.25 C(4), 24.02 C(22), 24.01 C(22). HRMS calcd for C19H20N3Cl2O2:
392.0933 (M+H), found: 392.0938.
5-Bromophthalic acid (102)218,254
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To a solution of phthalic anhydride (17.76 g, 120 mmol) and sodium hydroxide (9.6
g, 240 mmol) in water (80 mL) was added bromine (12 mL, 466 mmol) dropwise
with stirring over 4 h. The mixture was heated to 90℃ and allowed to reflux for 9 h.
The mixture was then cooled slowly and allowed to stand at 20 ℃ overnight before
cooling to 4 ℃ for 48 hand the crystalised solids were collected by filtration to give
the mono-sodium salt of 102 (13.56 g, 42%) as an off white solid, m.p. >295℃; The
filtrate was concentrated, acidified with hydrochloric acid (4M) and extracted into
ethyl acetate (50 mL), washed with brine and evaporated to give a small amount of
102 as a free acid, m.p. 157-158 ℃ (lit.254 m.p. 166 - 168 ℃); 1H NMR (600 MHz,
DMSO-d) δ ppm 8.27 (1H, d, J=2.4 Hz, H(6)), 8.09 (1H, d, J=8.4 Hz, H(3)), 7.74
(1H, dd, J=8.4, 2.4 Hz, H(2)).
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5-Bromophthalic anhydride (103)218
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Phthalic acid 102 (9.59 g, 35 mmol) was dissolved in thionyl chloride (60 mL) was
heated at reflux at 80 ℃ for 3 h. The solvent was evaporated and the residue was
recrystallised from ethyl acetate to give 103 as a white solid (5.63 g, 58%), m.p.
97-99 ℃ (lit.255 m.p. 104-106 ℃); 1H NMR (500 MHz, chloroform-d) δ ppm 8.15
(1H, d, J=1.4 Hz, H(2)), 8.04 (1H, dd, J=8.0, 1.4 Hz, H(6)), 7.88 (1H, d, J=8.0 Hz,
H(5));
13C NMR (126 MHz, chloroform-d) δ ppm 161.94 C(8)/C(10), 161.45 C(10)/C(8),
139.40 C(1), 132.95, 131.56, 129.86, 128.97, 126.96.
5-Bromoisoindoline-1,3-dione (104a)218
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5-Bromophthalic anhydride 103 (5.4 g, 24 mmol) was heated at reflux in formamide
(7.8 mL) for 2 h. The mixture was poured into ice/water and stirred for 1 h, the
precipitate was collected by filtration and dried in a desiccator to give 104a (5.31 g,
97%) as an off white solid, m.p. 232-235℃ (lit.256 m.p. 221℃); 1H NMR (500 MHz,
DMSO-d6) δ ppm 11.42 (1H, s, H(9)), 7.88 (1H, dd, J=7.9, 1.5 Hz, H(6)), 7.81 (1H,
d, J=1.5 Hz, H(2)), 7.63 (1H, d, J=7.9 Hz, H(5));
13C NMR (126 MHz, DMSO-d6) δ
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168.40 C(8)/C(10), 167.80 C(10)/C(8), 136.93, 134.52, 131.46, 127.78, 125.72, 124.77;
HRMS calcd for C15H12N2O2Br: 331.0082 (M+H), found: 331.0086.
2-Benzyl-5-bromoisoindoline-1,3-dione (104b)257
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To intermediate 103 (5.67 g, 24 mmol) in acetic acid (27 mL) was added benzylamine
(2.62 g, 24 mmol). The mixture was heated at reflux for 1 h before pouring into
ice-water (200 mL) and stirred for 1 h. The product was filtered off and dried in a
vacuum oven to give a white solid (6.84 g, 90%), m.p. 124.5 - 125 ℃; νmax (cm
−1):
1696 (C=O); 1H NMR (300 MHz, chloroform-d) δ ppm 7.96 (1H, d, J=1.7 Hz, H(3)),
7.82 (1H, dd, J=7.9, 1.7 Hz, H(1)), 7.69 (1H, d, J=7.9 Hz, H(6)), 7.36 - 7.48 (2H,
m, aryl), 7.25 - 7.36 (3H, m, aryl), 4.83 (2H, s, H(13));
13C NMR (75 MHz, DMSO-
d6) δ ppm 167.36 C(7)/C(9), 166.82 C(9)/C(7), 137.14, 136.16, 133.87, 130.75, 129.05,
128.88 C(16),C(18), 128.78 C(15),C(19), 128.11, 126.88, 124.88, 41.98 C(13).
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5-Bromo-2-(4-methoxybenzyl)isoindoline-1,3-dione (104c)
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To a solution of anhydride (103) (3.0 g, 13.0 mmol) in acetic acid (15 mL) was added
4-methoxybenzylamine (1.73 mL, 13.0 mmol) the mixture was heated at reflux for
2.5 h. The reaction mixture was then poured into cold water and the precipitate was
dried in a desiccator to give 104c (3.91g, 87%) as an off white solid, m.p. 116-117
℃; νmax (cm
−1): 1769 (C=O), 1710 (C=O); 1H NMR (300 MHz, chloroform-d) δ
ppm 7.93 (1H, d, J=1.7 Hz, H(4)), 7.81 (1H, dd, J=7.9, 1.7 Hz, H(2)), 7.67 (1H, d,
J=7.9 Hz, H(1)), 7.31 - 7.40 (2H, m, H(12),H(16)), 6.77 - 6.86 (2H, m, H(15),H(13)), 4.75
(2H, s, H(10)), 3.75 (3H, s, H(18));
13C NMR (75 MHz, chloroform-d) δ ppm 167.35
C(7)/C(9), 166.80 C(9)/C(7), 159.42 C(14), 137.04, 133.92, 130.81, 130.31 C(12),C(16),
128.94, 128.45, 126.79, 124.79, 114.16 C(13),C(15), 55.38 C(18), 41.42 C(10); HRMS
calcd for C16H12NO3: 344.9995 (M+H), found: 344.9998.
5-Bromo-6-nitroisoindoline-1,3-dione (105a)218
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Sulfuric acid (14.4 mL) was added slowly to fuming nitric acid (6.2 mL) at -10 ℃
with stiring, 104a (3.4 g, 15 mmol) was added portionwise with stiring to the
mixture at -10 ℃ then stirred at 20 ℃ for 16 h. The mixture was poured into a
water/ice bath, the mixture was made basic (pH 10) with sodium hydroxide (4 M)
and stirred for 30 min. The precipitate was collected and dried to give 105a (4.06
g, 70%) as a white solid , m.p. 201-203 ℃ (lit 215 - 216 ℃)258 1H NMR (500 MHz,
DMSO-d6) δ ppm 12.00 (1H, br.s, H(8)), 8.59 (1H, s, H(3)), 8.51 (1H, s, H(6));
13C
NMR (126 MHz, DMSO-d6) δ ppm 167.02 C(7)/C(9), 166.83 C(9)/C(7), 153.59 C(1),
135.94 C(4), 133.27, 129.15, 119.60, 119.24 C(2).
2-Benzyl-5-bromo-6-nitroisoindoline-1,3-dione (105b)218
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To imide 105a (500 mg, 1.8 mmol) and potassium carbonate (650 mg, 4.63 mmol)
in dimethylformamide (3.0 mL) was added benzyl bromide (330 mg, 2.8 mmol) was
added and the mixture stirred for 16 h at 20 ℃. The mixture was then diluted with
ethyl acetate (10 mL) and washed with water (3 x 10 mL), the aqueous fractions
were re-extracted with ethyl aetate (30 mL). The combined organic fractions were
washed with brine (50 mL), dried over magnesium sulfate and evaporated. The
residue was purified by column chromatography (40% dichloromethane 60% hexane)
to give 105b (580 mg, 87%) as a white solid, m.p. 149-152℃; 1H NMR (500 MHz,
chloroform-d) δ ppm 8.18 - 8.23 (1H, s, H(3)/H(6)), 8.13 - 8.17 (1H, s, H(6)/H(3)), 7.23
- 7.45 (5H, m, aryl), 4.86 (2H, s, H(14));
13C NMR (126 MHz, chloroform-d) δ ppm
165.09 C(7)/C(9), 164.93 C(9)/C(7), 135.40, 134.81, 131.92, 130.21, 129.02, 128.93,
128.81, 128.36, 120.99, 120.17, 42.52 C(14).
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5-Bromoisoindoline (106a)221
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Sodium borohydride (378 mg, 10 mmol) was added with stirring to (104a) (226 mg,
1.0 mmol) in tetrahydrofuran (10 mL). The suspension was cooled to -10 ℃ and
boron trifluoride diethyletherate (1.43 mL 11.6 mmol) was added dropwise before
and then heated at reflux at 70 ℃ for 16 h. The mixture was quenched drop-
wise with cold water (10 mL) and diluted with ethyl acetate (70 mL), the aqueous
layer was basified with sodium hydroxide (6 M) to pH 10. The organic layer was
washed with brine (20 mL) then dried over sodium sulfate and the solvent evap-
orated. The residue was dissolved in ethyl acetate (20 mL) and water was added
(10 mL). The aqueous layer was acidified with HCl (6 M) to pH 1.0. The aqueous
layer was extracted with ethyl acetate (2 x 20 mL). The combined organic layers
were washed with brine (30 mL) and dried (sodium sulfate) and the solvent was
evaporated. The residue was purified by column chromatography (94: 5: 1 ethyl
acetate:methanol:0.880 ammonia) to give 106a (108 mg, 54%) as a pale pink solid.
The literature221 describes this compound as a pale green oil, 1H NMR (500 MHz,
CD3OD) δ ppm 7.62 (1H, s, H(2)), 7.53 (1H, dd, J=8.1, 2.0 Hz, H(6)), 7.35 (1H,
d, J=8.1 Hz, H(5)), 4.65 (2H, s, H(2)/H(10)), 4.61 (2H, s, H(10)/H(8));
13C NMR
(126 MHz, CD3OD) δ ppm 138.30 C(1), 135.06 C(4), 132.96 C(3), 127.37 C(5)/C(6),
125.86 C(6)/C(5), 123.42 C(2), 51.64 C, 51.56 C. This compound degraded rapidly
and further steps were achieved without isolation of 106a
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2-Benzyl-5-bromoisoindoline (106b )
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To phthalimide 104b (2.0 g, 6.3 mmol) in dry tetrahydrofuran (100 mL), sodium
borohydride (3.29 g, 87 mmol) was added and the suspension was cooled to -10
℃. Borontrifluoride diethyletherate (12.0 mL 101 mmol) was added dropwise with
stiring and the mixture was stirred at 24℃ for 16 h. Excess sodium borohydride
and borontrifluoride diethyletherate was quenched with water (15 mL) at 0 ℃ and
the mixture was neutralised with saturated aqueous sodium hydrogen carbonate
solution then extracted with diethyl ether (3 x 50 mL). The organic layers were
washed with brine (100 mL), dried over magnesium sulfate and concentrated to
give a white solid which was dissolved in dichloromethane and passed through a
silica plug to give 106b (1.50 g, 82%) as a white solid, m.p. 104-108 ℃; νmax
(cm−1): 2379-2273 (NH+3 stretch);
1H NMR (500 MHz, chloroform-d) δ ppm 7.32
- 7.39 (6H, m, aryl), 7.30 (1H, s, aryl), 7.03 (1H, d, J=8.0 Hz, aryl), 4.23 - 4.47
(4H, m, H(7),H(9)), 4.08 - 4.20 (2H, m, H(10));
13C NMR (126 MHz, chloroform-d)
δ ppm 139.23, 135.96, 132.50 C(13),C(17), 131.71, 131.08, 129.28, 128.44 C(14),C(16),
125.94, 124.18, 121.70, 65.50 C(10), 64.32 C(7)/C(9), 64.20 C(9)/C(7); HRMS calcd for
C15H15NBr: 288.0388(M+H), found: 288.0390.
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5-Bromo-2-(4-methoxybenzyl)isoindoline (106c), and
5-bromo-2-(4-methoxybenzyl)-2H -isoindole, (113)
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To phthalimide 104c (2.0 g, 5.78 mmol) and sodium borohydride (2.25 g, 58 mmol)
in tetrahydrofuran (100 ml) was added borontrifluoride diethyletherate (4.5 mL,
63.6 mmol) dropwise with stirring at -10 ℃, the mixture was brought to 20 ℃ and
stirred for 16 h. Excess sodium borohydride and borontrifluoride diethyletherate
were quenched with water. The mixture was extracted with diethyl ether (3 x 30
mL), the combined organic layers were washed with brine and dried over magnesium
sulfate. The solvent was evaporated to give a yellow oil which was purified by silica
column chromatography (60% dichloromethane 40% hexane) to give 106c (620
mg, 33%) as a white solid; νmax (cm
−1): 2932, 2381, 2349, 2325; 1H NMR (500
MHz, chloroform-d) δ ppm 7.36 (1H, dd, J=8.0, 1.2 Hz, H(2)), 7.23 - 7.33 (3H,
m, aryl), 7.03 (1H, d, J=8.0 Hz, H(1)), 6.83-6.89 (2H, m, H(13),H(15)), 4.21 - 4.39
(4H, m, H(7),H(9)), 4.07 (2H, s, H(10)), 3.78 - 3.81 (3H, m, H(18));
13C NMR (126
MHz, chloroform-d) δ ppm 160.28 C(14), 139.31, 136.03, 133.80 C(12),C(16), 131.07,
125.97, 124.23, 123.82, 121.67, 113.78 C(13),C(15), 64.84 C(10), 64.11 C(7)/C(9), 63.97
C(9)/C(7), 55.40 C(18). This reaction had not gone to completion; a second, less polar
product was purified and identified as the isoindole intermediate. This compound is
interesting as it contains a 10 pi electron system - 1H NMR (500 MHz, chloroform-d)
7.64 - 7.67 (1H, m, aryl), 7.35 - 7.41 (1H, m, aryl), 7.08 - 7.14 (3H, m, aryl), 7.03
- 7.07 (1H, m, aryl), 6.96 (1H, dd, J=9.0, 1.7 Hz, aryl), 6.84 - 6.90 (2H, m, aryl),
5.26 (2H, s, 2H(10)), 3.80 (3H, s, 3H(18))
13C NMR (126 MHz, chloroform-d) δ ppm
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159.59 C14, 128.94 C12,C16 , 125.44, 124.28, 122.75, 121.70, 121.45, 114.68, 114.31
C13,C15, 111.80, 110.69, 55.40 C18, 54.47 C10.
tert-Butyl 5-bromoisoindoline-2-carboxylate 106d221
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Using an adapted literature221 procedure, 104a (4.52 g, 20 mmol) was dissolved in
dry tetrahydrofuran (150 mL), sodium borohydride (7.56 g, 200 mmol) was added
and the mixture was stirred at -10 ℃. Borontrifluoride diethyletherate (29.6 mL,
240 mmol) was added dropwise over 2 h. The mixture was then heated at reflux
for 16 h before quenching with 20 mL water at 0 ℃. The quenched reaction was
stirred for 30 min until all solids had dissolved before diluting with ethyl acetate (50
mL), the aqueous layer was basified to pH 10-12 with sodium hydroxide (4 M), and
washed with brine (pH 10). The organic layer was dried over sodium sulfate and
evaporated to give crude (106a). This was dissolved in dimethylformamide (50 mL),
di-tert-butyl dicarbonate (5.5 mL) and a few crystals of 4-dimethylaminopyridine
were added. The mixture was stirred for 16 h at 20 ℃, diluted with ethyl acetate
(25 mL) and washed with water (3 x 30 mL) and brine (1 x 30 mL) and then dried
over magnesium sulfate. The solvent was evaporated and the residue was purified by
column chromatography (10% diethyl ether 90% hexane) to give 106d (2.28 g, 38 %
over 2 steps) as a pink oil. The literature221 describes this compound as a pale yellow
solid, 1H NMR (500 MHz, chloroform-d) δ ppm 7.31 - 7.44 (2H, m aryl), 7.03 - 7.17
(1H, m aryl), 4.56 - 4.67 (4H, H(8),H(10)), 1.48 - 1.54 (9H, m, H(15),H(16),H(18));
13C
NMR (126 MHz, chloroform-d) δ ppm 154.39 C(11), 139.69, 139.32, 136.39, 136.04,
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126.10, 125.85 C, 124.41, 124.16, 122.83, 122.60, 121.19, 121.11, 80.01 C(14), 51.97
C(8)/C(10), 51.72 C(10)/C(8), 51.69 C(10)/C(8), 28.58 C(15),C(16),C17. HRMS calcd for
C13H16BrNO2: 297.0364 (M+H), found: 297.0362.
2-Benzyl-5-bromo-6-nitroisoindoline (107b)
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Phthalimide 105b (320 mg, 0.88 mmol) was dissolved in dry tetrahydrofuran (15
mL), sodium borohydride (333 mg, 8.8 mmol) was added and the suspension was
cooled to -10 ℃. Borontrifluoride diethyletherate (1.3 mL 10.3 mmol) was added
dropwise with stiring and the mixture was allowed to stir at rt for 16 h. Excess
sodium borohydride and boron trifluoride diethyletherate was quenched with water
(2.5 mL) and extracted with diethyl ether (20 mL) the organic layers were washed
with brine, dried over magnesium sulfate and concentrated to give a white solid
which was purified by silica column chromatography (chloroform) to give 107b as
a yellow/orange oil (128 mg, 43%), 1H NMR (600 MHz, chloroform-d) δ ppm 7.66
(1H, s, aryl), 7.52 (1H, s, aryl), 7.28 - 7.40 (6H, m, aryl), 3.96 (2H, s, 2H(7)/2H(9)),
3.94 (2H, s, 2H(9)/2H(7)), 3.91 (2H, s, H(10));
13C NMR (151 MHz, chloroform-d) δ
ppm 167.76 C(7)/C(9), 167.15 C(9)/C(7), 149.25 C(2), 136.59, 133.59, 128.77, 128.62,
128.51, 127.88, 121.45, 112.80, 109.01, 41.71 C(10); HRMS calcd for C15H14N2O2Br:
333.0239 (M+H), found: 333.0236.
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tert-Butyl 5-bromo-6-nitroisoindoline-2-carboxylate (107c)
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Sodium borohydride (3.04 g, 80 mmol) was added with stirring to phthalimide 105a
(2.17 g, 8.0 mmol) in tetrahydrofuran (15 mL). The mixture was cooled to -10℃ and
boron trifluoride diethyletherate (1.26 mL, 10.26 mmol) was added dropwise over 2
h. The mixture was heated to 70℃ for 16 h before quenching slowly with cold water
(15 mL). The mixture was stirred until all solids had dissolved. Aqueous sodium
hydroxide (20%, 20 mL) was added and the mixture stirred for 2 h, then extracted
with ethyl acetate (1 x 50 mL, 1 x 100 mL). The combined organic layers were washed
with basified brine (pH 12) and dried over sodium sulfate. After evaporation the
residue was dissolved in 15 mL dimethylformamide and di-tert-butyl dicarbonate
(2.2 mL, 9.6 mmol) was added. A few crystals of 4-dimethylaminopyridine were
added and the mixture was stirred at 20 ℃ for 16 h. The mixture was diluted with
ethyl acetate (50 mL) and washed with brine (4 x 30 mL) the organic layer was
dried over magnesium sulfate and the solvent evaporated. The residue was purified
by column chromatography (40% diethyl ether 60% hexane) to give 107c (654 mg,
24%) as a cream solid, 1H NMR (500 MHz, chloroform-d) δ ppm 7.68 - 7.80 (1H,
m, H(3)/H(6)), 7.53 - 7.67 (1H, m, H(6)/H(3)), 4.61 - 4.76 (4H, m, 2H(7),2H(9)), 1.46
- 1.53 (9H, m, 3 x 3H(16));
13C NMR (126 MHz, chloroform-d) δ ppm 154.07 C(12),
154.03 C(12), 149.38 C(8), 149.35 C(8), 143.61, 143.29, 138.39, 138.06, 129.37, 129.14,
120.33, 120.13, 113.66, 113.56, 80.65 C(15), 51.66 C(7)/C(9), 51.51 C(9)/C(7), 51.48
C(9)/C(7).
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5-Amino-2-benzyl-6-bromoisoindoline-1,3-dione (110)
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To a stirred solution of iron sulfate heptahydrate (4.64 g, 16.68 mmol) in water (10
mL) and 0.880 ammonia (10 mL) at 60℃ was added a solution of 2-benzyl-5-bromo-
6-nitroisoindoline-1,3-dione (105b) (376 mg, 1.39 mmol) in methanol (10 mL). The
mixture was heated at 60℃ for 1 h before being extracted with dichloromethane (2 x
30 mL) and the solvent was evaporated to give 110 (270 mg, 59%) as a yellow solid,
m.p. (decomp. 221 ℃); 1H NMR (600 MHz, chloroform-d) δ ppm 7.88 (1H, s, H(4)),
7.40 (2H, d, J=7.5 Hz, H(12),H(16)), 7.28 - 7.35 (3H, m, H(13),H(14),H(15)), 7.12 (1H, s,
H(1)), 4.82 (2H, br.s, H(18)), 4.79 (2H, s, H(10));
13C NMR (151 MHz, chloroform-d)
δ ppm 167.76 C(7)/C(9), 167.15 C(9)/C(7), 149.25, 136.59, 133.59, 128.77 C(12),C(16),
128.62 C(16),C(12), 128.51, 127.88, 121.45, 112.80, 109.01, 41.71 C(10), HRMS calcd
for C20H20N2O2Br: 331.0082 (M+H), found: 331.0086.
For 113 see 106c
Ethyl 3,4-dimethylbenzoate (115)259
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Following a literature259 procedure, 3,4-dimethylbenzoic acid (10.0 g, 66.6 mmol) was
dissolved in ethanol (200 mL) and sulfuric acid (3.0 mL) was added. The mixture
was heated to 65 ℃ for 6 h before being concentrated and the residue dissolved
in ethyl acetate (50 mL), washed with saturated sodium hydrogen carbonate (3 x
50 mL) and then with brine (50 mL) the organic layer was dried over magnesium
sulfate and the solvent evaporated to give 115 (20.9 g, 88%) as an orange oil and
used without further purification. 1H NMR (600 MHz, chloroform-d) δ ppm 7.81
(1H, s, H(6)), 7.77 (1H, d, J=7.9 Hz, H(3)), 7.15 (1H, d, J=7.9 Hz, H(2)), 4.35 (2H,
q, J=7.2 Hz, H(11)), 2.27 (6H, s, H(7),H(12)), 1.38 (3H, t, J=7.2 Hz, H(13));
13C NMR
(151 MHz, chloroform-d) δ ppm 166.93 C(8), 142.16, 136.68, 130.66, 129.68, 128.15,
127.22 C(aryl, 60.76 C(11), 20.03 C(7)/C(12), 19.72 C(12)/C(7), 14.45 C(13).
Ethyl 3,4-bis(bromomethyl)benzoate (117)
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Ethyl 3,4-dimethylbenzoate (115) (1.44 g, 8.1 mmol), N -bromosuccinimide (3.17
g, 17.8 mmol) and 2-2’azobis(isobutylnitrile) (10 mg, 0.06 mmol) were dissolved in
carbon tetrachloride (10 mL) and heated at reflux for 2 h. The mixture was cooled
to 20 ℃ and the precipitate filtered and washed with carbon tetrachloride. The
filtrate was evaporated to give 117 as an orange oil which was used without further
purification in the next step (3.28 g, 64% by NMR), 1H NMR (500 MHz, chloroform-
d) δ ppm 8.02 (1H, s, H(1)), 7.93 (1H, d, J=8.1 Hz, H(4)/H(5)), 7.41 (1H, d, J=8.1
Hz, H(5)/H(4)), 4.64 (4H, d, J=4.9 Hz, H(7)/H(8)), 4.26 - 4.42 (2H, m, H(14)), 1.26 -
1.44 (3H, s, H(15));
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1,2-Bis(bromomethyl)-4-nitrobenzene (118)259
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To 1,2-dimethyl-4-nitrobenzene (8.0 g, 53 mmol) in carbon tetrachloride (80 mL)
was added N -bromosucinnimide (18.8 g, 106 mmol) followed by 2-2’azobis(isobutyl-
nitrile) (100 mg, 0.6 mmol) and the mixture was heated at reflux for 18 h. The
precipitated solids were filtered and washed with carbon tetrachloride and the filtrate
was evaporated to give 118 as a yellow oil (13.7 g, 84%) which was used without
further purification, 1H NMR (500 MHz, chloroform-d) δ ppm 8.18 - 8.26 (1H, m,
H(5)), 8.11 (1H, d, J = 8.4 Hz, H(8)), 7.54 (1H, d, J = 8.4 Hz, H(7), 4.58 - 4.68 (4H,
m, 2H(1),2H(4)).
Ethyl 2-benzylisoindoline-5-carboxylate (119a)
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Ethyl 3,4-dimethylbenzoate (9.43 g, 53 mmol), N -bromosucinnimide (20.7 g 116
mmol) and benzoyl peroxide (0.8 g, 3.3 mmol) were dissolved in carbon tetrachlo-
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ride (40 mL) and heated at reflux for 44 h. The mixture was allowed to cool and
the repcipitated solids were removed by filtration. The solvent was evaporated and
the residue was dissolved in tetrahydrofuran (250 mL), triethylamine (14.7 mL, 106
mmol) was added and benzylamine (5.6 mL, 51 mmol) in tetrahydrofuran (30 mL)
was added very slowly with stirring. The mixture was stirred for 16 h and the precip-
itate was filtered and washed with tetrahydrofuran. The solvent was evaporated and
the residue was purified by column chromatography (7% ethyl acetate 93% dichloro-
methane) to give 119a (6.6 g, 43%) as a brown oil, νmax (cm
−1): 2920, 2850, 1716
(C=O); 1H NMR (500 MHz, chloroform-d) δ ppm 7.90 (1H, dd, J=7.8, 1.4 Hz, H(5)),
7.86 (1H, s, H(1)), 7.39 - 7.42 (2H, m, aryl), 7.2 - 7.43 (8H, m, J=7.3 Hz, aryl), 4.36
(2H, q, J=7.1 Hz, H(10)), 3.97 (4H, s, H(12),H(14)), 3.92 (2H, s, H(15)), 1.38 (3H, t,
J=7.2 Hz, H(11));
13C NMR (126 MHz, chloroform-d) δ ppm 166.74 C(7), 145.56
C(3), 140.64 C(2), 138.75 C(16), 129.38, 128.85, 128.64, 128.53, 127.34, 123.59, 122.25,
60.94 C(10)/C(12)/C14/C14/C15, 60.25 C(10)/C(12),C14/C15, 58.85 C(10)/C(12),C14/C15,
58.62 C(10)/C(12),C14/C15, 14.39 C(11).
Ethyl 2-(4-methoxybenzyl)isoindoline-5-carboxylate (119b)
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Crude ethyl 3,4-bis(bromomethyl)benzoate (117) (3.281 g, 64% by NMR, 6.2 mmol)
was dissolved in tetrahydrofuran (80 mL) and treated with triethylamine (4.6 mL,
32.6 mmol). 4-Methoxybenzylamine (2.1 mL, 16.1 mmol) was dissolved in tetrahy-
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drofuran (17.9 mL) and added dropwise to the solution with stiring and stiring was
continued for 16 h. The precipitate was filtered and washed with tetrahydrofuran
and the solvent was evaporated. The residue was purified by column chromatogra-
phy (50% hexane 50% diethylether) to give 119b (1.02 g, 40%) as a dark yellow
oil, 1H NMR (300 MHz, chloroform-d) δ ppm 7.91 (1H, dd, J=7.7, 0.9 Hz, H(5)),
7.86 (1H, s, H(1)), 7.32 (2H, d, J=8.7 Hz, H(17),H(21)), 7.23 (1H, d, J=7.7 Hz, H(4)),
6.90 (2H, d, J=8.7 Hz, H(18),H(20)), 4.37 (2H, q, J=7.1 Hz, H(10)), 3.94 (4H, s,
H(12),H(14)), 3.86 (2H, s, H(15)), 3.82 (3H, s, H(23)), 1.39 (2H, t, J=7.1 Hz, H(11));
13C NMR (75 MHz, chloroform-d) δ ppm 166.64 C(7), 158.78 C(19), 145.59, 140.65,
130.85, 129.85 C(17),C(21), 129.18, 128.47, 123.46, 122.13, 113.75 C(18),C(20), 60.81 C,
59.45 C(12)/C(14)/C(15), 58.63 C(14)/C(15)/C(12), 58.39 C(15)/C(12)/C(14), 55.21 C(23),
14.28 C(11); HRMS calcd for C19H22NO3: 312.1600 (M+H), found: 312.1599.
2-Benzyl-5-nitroisoindoline (120)259
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To sodium carbonate (20.2 g, 190 mmol) was added water (30 mL). The mixture
was briefly sonicated and acetone (60 mL) was added. Benzylamine was dissolved
in acetone (10 mL) and added to the stirred suspension over 3 h and the mixture
was stirred for 18 h. The mixture was concentrated before being extracted into
ethyl acetate (2 x 75 mL). The organic layers were then extracted with hydrochloric
acid (2 M, 3 x 75 mL) and the aqueous layers were neutralised with saturated
aqueous sodium hydrogen carbonate solution and the product was extracted into
ethyl acetate (2 x 50 mL) washed with brine and dried over magnesium sulfate. The
solvent was evaporated and the residue purified by column chromatography (20%
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ethyl acetate 80% hexane) to give 120 (1.17 g, 20%) as a yellow solid, m.p. 79.5-80
℃ (lit.227 77.5-78 ℃) ; νmax (cm
−1): 2809 (CH), 1516 (NO asym), 1340 (NO sym);
1H NMR (500 MHz, chloroform-d) δ ppm 8.09 (1H dd, J=8.4, 2.0 Hz, H(6)), 8.02
(1H, s, H(4)), 7.27 - 7.44 (6H, m, aryl), 3.99 (4H, d, J=1.6 Hz, H(2),H(9)), 3.93 (2H,
s, 2H(11));
13C NMR (126 MHz, chloroform-d) δ ppm 147.98 C(5), 147.55 C(8), 142.20
C(3), 138.48 C(12), 128.79 C(13),C(17), 128.63 C(14),C(16), 127.48 C(7), 122.94 C(4)/C(15),
122.76 C(15)/C(4), 117.80 C(6), 60.07 C(11), 58.56 C(2)/C(9), 58.38 C(9)/C(2).
2-Benzylisoindoline-5-carboxylic acid (125a)
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To isoindoline 106b (327 mg, 1.13 mmol) in tetrahydrofuran (7 mL) at -78 ℃ was
added n-BuLi in hexane (0.60 mL, 1.2 mmol) dropwise with stiring. The mixture
was stirred at -78 ℃ for 2 h after which gaseous carbon dioxide evolved from the
sublimation of dry ice was bubbled into the mixture for 2 h. The reaction was
quenched at 0 ℃ with water, and slightly acidified (pH 4-5) with hydrochloric acid
(1 M) to pH 2-3. The product was extracted into ethyl acetate (2 x 20 mL) and
the combined organic fractions were washed with brine (1 x 30 mL) before drying
over magnesium sulfate and evaporating. The residue was loaded onto a silica plug
in dichloromethane, washed with dichloromethane and eluted with 1% acetic acid
in dichloromethane. The solvent was evaporated to give 125a as a white solid (277
mg, 79%), m.p. (decomp 151 ℃); νmax (cm
−1): 3400 (OH), 2378, 2325, 2282, 1676
(C=O); 1H NMR (600 MHz, chloroform-d) δ ppm 7.99 (1H, d, J=7.9 Hz, H(2)), 7.88
(1H, s, H(4)), 7.32 - 7.41 (5H, m, aryl), 7.24 (1H, d, J=7.9 Hz, H(1)), 4.34 - 4.54 (4H,
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m, H(7),H(9)), 4.19 (2H, s, H(10));
13C NMR (151 MHz, chloroform-d) δ ppm 171.23
C(17), 142.98 C(6), 137.61, 132.55 C(12),C(16), 131.65, 130.41, 129.61, 129.37, 128.56
C(13),C(15), 124.44, 122.74, 65.66 C(10), 64.50 C(7)/C(9), 64.23 C(9)/C(7); HRMS calcd
for C16H15NO2: 254.1179 (M+H), found: 254.1179.
2-(4-Methoxybenzyl)isoindoline-5-carboxylic acid (125b)
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To isoindoline 106c (620 mg, 1.95 mmol) in tetrahydrofuran (12 mL) was added n-
BuLi (0.94 mL, 2.34 mmol) dropwise at -78℃. The mixture was stirred at -78℃ for
2 h then carbon dioxide evolved from sublimation of dry ice was bubbled through the
reaction for 2 h. The reaction was quenched at 0 ℃ with water and extracted into
diethyl ether before being slightly acidified (pH 4-5) with hydrochloric acid (2 M)
and extracted into ethyl acetate (2 x 30 mL) the ethyl acetate layers were combined
and dried over sodium sulfate to give 125b (539 mg, 98%) as a white solid, m.p.
(decomp. 175 ℃); νmax (cm
−1): 3122 br. (OH) 2379, 2283, 2223 1676 (C=O); 1H
NMR (600 MHz, chloroform-d) δ ppm 8.01 (1H, d, J=8.1 Hz, H(2)), 7.90 (1H, s,
H(4)), 7.25 - 7.31 (4H, m, aryl), 6.87 (1H, d, J=8.1 Hz, H(1)), 4.35 - 4.50 (4H, m,
H(7),H(9)), 4.13 (2H, s, H(10)), 3.80 (3H, s, H(21));
13C NMR (126 MHz, chloroform-d)
δ ppm 169.96 C(17), 160.33 C(14), 143.15, 137.74, 133.83 C(12),C(16), 130.45, 129.18,
124.48, 123.72, 122.84, 113.88 C(13),C(15), 64.99 C(10), 64.31 C(7),C(9), 63.99 C(9)/C(7),
55.42 C(21); HRMS calcd for C17H17NO3: 284.1290 (M+H), found: 284.1287.
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2-Benzyl-N -methylisoindoline-5-carboxamide (126a)
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Isoindoline 125a (506 mg, 2.0 mmol), N -(3-dimethylaminopropyl)-N ’-ethylcarbo-
diimide hydrochloride (767 mg, 4 mmol) and anhydrous hydroxybenzotriazole (540
mg, 4 mmol) were dissolved in dimethylformamide (6.0 mL) and the mixture was
stirred for 30 min. Methylamine in tetrahydrofuran (10 mL, 20 mmol) was added
and the mixture stirred for 16 h. The mixture was then diluted with ethyl acetate
(30 mL) and washed with water (3 x 30 mL) the aqueous fractions were re-extracted
with ethyl acetate (50 mL). The combined organic layers were washed with brine
(50 mL), dried over magnesium sulfate and evaporated. The residue was purified by
column chromatography (3% methanol 97% ethyl acetate) to give 126a (396 mg,
74%) as a white solid, m.p. (decomp. 141-143 ℃); νmax (cm
−1): 3324 (NH), 3022,
2892, 2806, 1655 (C=O); 1H NMR (600 MHz, chloroform-d) δ ppm 7.60 (1H, s, H(4)),
7.57 (1H, d, J=7.9 Hz, H(2)), 7.39 - 7.44 (2H, m, H(16),H(12)), 7.36 (2H, t, J=7.3 Hz,
H(13),H(15)), 7.27 - 7.32 (1H, m, H(14)), 7.22 (1H, d, J=7.9 Hz, H(1)), 6.10 (1H, br.s,
H(16)), 3.95 (4H, s, H(7)/H(9)), 3.92 (2H, s, H(10)), 3.00 (3H, d, J=4.5 Hz, H(20));
13C NMR (126 MHz, chloroform-d) δ ppm 168.38 C(17), 143.91 C(6), 140.90 C(5),
138.78 C(11), 133.57, 128.85 C(12),C(16), 128.53 C(13),C(15), 127.33, 125.67, 122.41,
121.12, 60.24 C(10), 58.74 C(7)/C(9), 58.68 C(9)/C(7), 26.90 C(20); HRMS calcd for
C17H19NO2: 267.1497, found: 267.1497.
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2-(4-Methoxybenzyl)-N -methylisoindoline-5-carboxamide (126b)
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Ethylester (119a), (400 mg, 1.28 mmol) and 40% aqueous methylamine (4 mL) were
sealed in a tube and stirred at 100℃ for 16 h. The reaction was allowed to cool to 20
℃ and the solvent evaporated. The residue was purified by colum chromatography
(5% methanol 95% ethyl acetate) to give 126b (288 mg, 75%) as a white solid.
Using N -(3-dimethylaminopropyl)-N ’-ethylcarbodiimide hydrochloride, isoindoline
125b (320 mg, 1.1 mmol) in dimethylformamide (5 mL), N -(3-dimethylaminopropyl)-
N ’-ethylcarbodiimide hydrochloride (499 mg, 2.6 mmol) and anhydrous hydroxyben-
zotriazole (351 mg, 2.6 mmol) were stirred at rt for 30 min. Methylamine in tetrahy-
drofuran (6.5 mL, 13 mmol) was added and the mixture stirred for 16 h. The mixture
was then diluted with ethyl acetate (30 mL) and washed with water (3 x 30 mL)
the aqueous fractions were re-extracted with ethyl acetate (50 mL), the combined
organic layers were washed with brine (50 mL), dried over magnesium sulfate and
evaporated. The residue was purified by column chromatography (3% methanol 97%
ethyl acetate to give 126b (295 mg, 86%) as a white solid, m.p. 138-140 ℃; νmax
(cm−1): 3273 (NH), 2934, 2892, 2803, 1633 (C=O); 1H NMR (600 MHz, chloroform-
d) δ ppm 7.49 - 7.66 (2H, m, H(2),H(4)), 7.30 (2H, d, J=8.7 Hz, H(12),H(16)), 7.17
(1H, d, J=8.1 Hz, H(1)), 6.88 (2H, d, J=8.7 Hz, H(13),H(15)), 6.33 (1H, d, J=3.0 Hz,
H(19)), 3.90 (4H, s, H(7),H(9)), 3.83 (2H, s, H(10)), 3.80 (3H, s, 3H(22)), 2.96 (3H, d,
J=4.7 Hz, 3H(20));
13C NMR (126 MHz, chloroform-d) δ ppm 168.46 C(17), 158.95
C(14), 144.08 C(6), 141.06 C(5), 133.57, 131.08, 130.03 C(12),C(16), 125.70, 122.44,
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121.19, 113.94 C(13),C(15), 59.65 C(10), 58.73 C(7)/C(9), 58.66 C(9)/C(7), 55.42 C(22),
26.97 C(20); HRMS calcd for C18H19N2O2: 297.1603 (M+H), found: 297.1602.
2-(4-Methoxybenzyl)isoindoline-5-carboxamide (127)
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To isoindoline 119b (746 mg, 2.40 mmol) in ethanol (4 mL) was slowly added
concentrated 0.880 ammonia (10 mL). The tube was sealed and heated to 100 ℃
for 16 h. The solvent was evaporated and the residue was purified by column chro-
matography (5% methanol 95% ethyl acetate) to give 127 (181 mg, 26%) as a
white solid, m.p. 177-178 ℃; νmax (cm
−1): 3347 br. (NH), 3198 br. (NH), 1662
(C=O); 1H NMR (500 MHz, CD3OD) δ ppm 7.73 (1H, dd, J=7.8, 1.5 Hz, H(7)),
7.71 (1H, s, H(9)), 7.26 - 7.34 (3H, m, H(6),H(15),H(19)), 6.90 (2H, d, J=8.7 Hz,
H(16),H(18)), 3.91 (4H, s, H(2),H(5)), 3.84 (2H, s, H(13)), 3.78 (3H, s, H(21));
13C
NMR (126 MHz, CD3OD) δ ppm 172.27 C(10), 160.65 C(17), 145.23, 141.56, 134.08,
131.51 C(15),C(19), 131.13, 127.92, 123.43, 122.71, 114.89 C(16),C(18), 60.37 C(13),
59.41 C(2)/C(5), 59.27 C(5)/C(2), 55.68 C(21); HRMS calcd for C17H19N2O2: 283.1447
(M+H), found: 283.1457.
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N -Methylisoindoline-5-carboxamide (128)
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126a (288 mg, 0.971.0 mmol) was disolved in methanol (10 mL) and 30% palla-
dium on carbon (50 mg) was added. A hydrogen balloon was attached and the
solution was stirred at 30 ℃, after 24 h Pearlman’s catalyst (50 mg) was added, and
the mixture was stirred for a further 48 h under hydrogen at 30 ℃. The mixture
was filtered through celite celite and the filtrate was concentrated to give a purple,
minty-smelling oil. This was purified by column chromatography (90% ethyl ac-
etate 6% methanol 4% 0.880 ammonia) to give 128 (48 mg, 28%) as a white solid.
Starting material (130 mg, 45%) was recovered. 1H NMR (600 MHz, CD3OD) δ
ppm 7.70 (1H, s, H(1)), 7.68 (1H, d, J=7.7 Hz, H(5)), 7.34 (1H, d, J=7.7 Hz, H(4)),
4.19 (4H, s, H(7),H(9)), 2.90 (3H, s, H(13));
13C NMR (126 MHz, CD3OD) δ ppm
170.64 C(10), 145.88 C(3), 142.67 C(2), 134.79, 127.41, 123.48, 122.31, 52.96 C(7)/C(9),
52.84 C(9)/C(7), 26.93 C(13); HRMS calcd for C10H13N2O: 177.1028 (M+H), found:
177.0988.
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tert-Butyl (R)-(3-(2,4-dichlorophenyl)-1-(5-(methylcarbamoyl)isoindolin-
2-yl)-1-oxopropan-2-yl)carbamate (130)
14
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To isoindoline 128 (48 mg, 0.27 mmol), N -Boc-(R)-2,4-dichlorophenylalanine (91
mg, 0.27 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (59 mg, 0.33 mmol)
and anyhdrous 1-hydroxybenzotriazole (55 mg, 0.41 mmol) in dimethylformamide
(3 mL) was added N,N -diisopropylethylamine (0.4 mL, 2.3 mmol), the mixture was
then stirred for 24 h at 20 ℃. The mixture was the diluted with ethyl acetate (20
mL) and washed with water (3 x 20 mL). The combined aqueous fractions were
re-extracted with ethyl acetate (3 x 20 mL) and the combined organic layers were
dried over magnesium sulfate and evaporated. The residue was purified by column
chromatography (94% ethyl acetate 6% methanol) (100 mg, 75%) and then recrys-
tallised from chloroform to yield 130) (48 mg, 36%), m.p. 167-168 ℃; νmax (cm
−1):
3550-3180 (br.) 2971, 2927, 2865, 1699 (NHC=O), 1639 (CHC=O), 1583; 1H NMR
(600 MHz, chloroform-d, 2 rotamers) δ ppm 7.62 - 7.72 (2H, m, aryl), 7.32 (1H, d,
J=1.7 Hz, aryl), 7.20 - 7.28 (1H, m, aryl), 7.15 - 7.18 (1H, m, aryl), 7.11 (1H, m,
J=1.7 Hz, aryl), 6.69 - 6.81 (1H, m, H(21)), 5.48 (1H, d, J=8.7 Hz, H(5)), 4.98 (1H,
d, J=14.3 Hz, H(12)/H(19)), 4.76 - 4.87 (2H, m, H(3),H(19)/H(12)), 4.57 - 4.68 (2H, m,
H(12),H(19)), 3.13 (1H, dd, J=13.7, 6.2 Hz, H(4)), 2.94 - 3.03 (4H, m, H(4),H(22)), 1.27
- 1.38 (9H, m, 3 x 3H(25));
13C NMR (151 MHz, chloroform-d, 2 rotamers) 170.39
C(2), 167.85 C(15), 155.22 C(23), 139.22, 139.10, 136.51, 136.30, 135.09, 134.79, 134.62,
133.73, 132.87, 132.84, 129.34, 127.16, 126.79, 126.72, 123.06, 122.96, 121.84, 121.80,
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80.08 C(24), 52.27 C(3), 52.19 C(12)/C(19), 52.16 C(12)/C(19), 51.08 C(19)/C(12), 51.05
C(19)/C(12), 36.54 C(4), 28.34 3C(2), 27.03 C(22); HRMS calcd for C24H28N3Cl2O4:
492.1433 (M+H), found: 492.1457.
2-Benzylisoindolin-5-amine (132)227
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Following an adapted literature227 procedure, 120 (515 mg, 2.0 mmol) was dissolved
in methanol (15 mL) 10% palladium on carbon (29 mg) was added and the mixture
stirred vigorously under an atmosphere of hydrogen for 1.5 h. The catalyst awas
removed by filtration through celite and the filtrate was concentrated to give 132
(445 mg, 89%) as a cream solid, m.p. 137-139 ℃ (Lit227 110-115 ℃); 1H NMR (500
MHz, chloroform-d) δ ppm 7.42 - 7.47 (2H, m, aryl), 7.26 - 7.40 (3H, m, aryl), 6.93
(1H, d, J=7.9 Hz, aryl), 6.47 - 6.54 (2H, m, aryl), 3.94 (2H, s, H(11)), 3.90 (4H,
s, 2H(1),2H(3));
13C NMR (126 MHz, chloroform-d) δ ppm 145.43, 141.63, 139.40,
130.47, 128.86, 128.40, 127.09, 122.96, 113.80, 109.40, 60.48 C(11), 59.14 C(1)/C(3),
58.58 C(3)/C(1).
248
Materials and Methods Simon O.R. Greenwood
N -(2-Benzylisoindolin-5-yl)acetamide (133)
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To a mixture of amine 132 (443 mg, 1.8 mmol) and triethylamine (1.5 mL, 10
mmol) in dichloromethane (15 mL) was added acetic anhydride (1.5 mL, 15.8 mmol)
dropwise and the mixture was stirred for 135 min at 22 ℃. The organic phase
was washed with saturated aqueous sodium hydrogen carbonate (4 x 30 mL) and
dried over magnesium sulfate before evaporating. The residue was purified by silica
column chromatography (ethyl acetate) to give 133 (425 mg, 88%) as a white solid,
1H NMR (500 MHz, chloroform-d) δ ppm 7.56 (1H, br.s, H(10)), 7.38 - 7.44 (3H,
m, aryl), 7.34 (2H, t, J=7.4, H(17),H(19)), 7.28 (1H, d, J=7.1 Hz, aryl), 7.17 (1H,
d, J=8.0 Hz, H(1)/H(2)), 7.07 (1H, d, J=8.0 Hz, H(2)/H(1)), 3.89 (4H, s, H(7),H(9)),
3.86 (2H, s, H(14)), 2.12 (3H, s, H(13));
13C NMR (126 MHz, chloroform-d) δ ppm
168.54 C(11), 141.23, 139.07, 136.79 C,136.30, 128.87 C(16),C(20), 128.49 C(17),C(19),
127.23, 122.63, 118.74, 114.65, 60.35 C(7)/C(9)/C(14), 59.08 C(9)/C(14)/C(7), 58.60
C(14)/C(7)/C(9), 24.57 C(13).
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Isoindolin-5-amine (134)259
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120 (200 mg, 0.79 mmol) was dissolved in a mixture of methanol (8 mL) and ethanol
(5 mL), 10% palladium on carbon (42 mg) was added and the suspension was stirred
vigorously under an atmosphere of hydrogen for 48 h. The catalyst was removed by
filtration through celite and the filtrate was concentrated and purified by column
chromatography (85% ethyl acetate 10% methanol 2% 0.880 ammonia) to give 134
(54 mg, 51%) as a pale brown solid, 1H NMR (500 MHz, CD3OD) δ ppm 6.97 (1H,
d, J=8.0 Hz, H(5)), 6.63 (1H, s, H(8)), 6.59 (1H, dd, J=8.0, 2.0 Hz, H(6)), 4.05 (4H, d,
J=5.5 Hz, H(1),H(3));
13C NMR (126 MHz, chloroform-d) δ ppm 147.99 C(7), 142.71
C(9), 131.14 C(4), 123.71 C(5), 115.92 C(6)/C(8), 110.47 C(8)/C(6), 53.03 C(1)/C(3),
52.46 C(3)/C(1); HRMS calcd for C8H10N2[M
+]: 134.0844, found: 134.0848.
N -(Isoindolin-5-yl)acetamide (135)
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To 133 (290 mg, 1.1 mmol), 30% palladium on carbon (20 mg) and Pearlman’s
catalyst (40 mg) under an inert atmosphere was added methanol (10 mL). The
mixture was then stirred vigorously under an atmosphere of hydrogen for 16 h at 30
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℃. The catalyst was removed by filtration through celite and the filtrate evaporated
to give 128 as a tan solid (207 mg,107%), m.p. 153-155 ℃; νmax (cm
−1): 3432 br.
(NH) 3296 (NH), 1673 (C=O); 1H NMR (600 MHz, CD3OD) δ ppm 7.53 (1H, s,
H(5)), 7.31 (1H, d, J=7.9 Hz, H(1)/H(2)), 7.19 (1H, d, J=7.9 Hz, H(2)/H(1)), 4.05 -
4.17 (4H, m, H(7),H(9)), 2.10 (3H, s, H(13));
13C NMR (151 MHz, chloroform-d) δ
ppm 171.59 C(11), 142.80 C(4)/C(6)/C(3), 139.00 C(4)/C(6)/C(3), 137.69 C(6)/C(3)/C(4),
123.49 C(1)/C(2)/C(5), 120.21 C(2)/C(5)/C(1), 115.40 C(5)/C(1)/C(2), 53.14 C(7)/C(9),
52.69 C(9)/C(7) 23.77 C(13). HRMS calcd for C10H12N2O: 177.1028 (M+H), found:
117.1031.
(R)-tert-Butyl (1-(5-aminoisoindolin-2-yl)-3-(2,4-dichlorophenyl)-1-
oxopropan-2-yl)carbamate
(136)
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134 (68 mg, 0.5 mmol) N -Boc-(R)-2,4-dichlorophenylalanine (201 mg, 0.6 mmol), 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (109 mg, 0.6 mmol) and anyhdrous 1-
hydroxybenzotriazole (122 mg, 0.6 mmol) in dimethylformamide (3.0 mL) was added
N,N -diisopropylethylamine (0.78 mL, 4.5 mmol), the mixture was then stirred for 16
h at 20℃. The mixture was the diluted with ethyl acetate (20 mL) and washed with
water (3 x 20 mL). The combined aqueous fractions were re-extracted with ethyl
acetate (3 x 20 mL) and the combined organic layers were washed with saturated
aqueous sodium hydrogen carbonate (2 x 20 mL) and brine (20 mL) before being
dried over magnesium sulfate and evaporated. The residue was purified by colum
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chromatography (25% ethyl acetate 75% hexane) to yield 136 (100 mg, 44%) as
a white solid, 1H NMR (500 MHz, chloroform-d, 2 rotamers) δ ppm 7.34 (1H, s,
H(10)), 7.10 - 7.20 (1H, m, aryl), 6.99 (1H, m, aryl), 6.44 - 6.67 (2H, m, aryl), 5.44
(1H, br.s, H(6)), 4.79 - 5.01 (2H, m, H(3)/H(12)/H(19)), 4.71 (1H, m, H(12)/H(19)),
4.48 - 4.63 (2H, m, H(12)/H(19)), 3.76 (2H, br.s, H(20)), 3.15 (1H, dd, J=13.7, 6.1
Hz, H(4)), 3.00 (1H, dd, J=13.7, 8.0 Hz, H(4)), 1.34 (9H, s, 3 x 3H(23));
13C NMR
(500 MHz, chloroform-d, 2 rotamers) δ ppm 170.15 (2), 170.06 C(2), 155.07 C(21),
155.04 C(21), 146.58, 146.38, 137.06, 137.01, 135.17, 135.14 , 133.55, 133.04, 132.85,
129.26, 127.02, 125.47, 123.60, 123.46, 115.20 C(14)/C(16), 114.94 C(14)/C(16), 108.94
C(16)/C(14), 108.75 C(16)/C(14), 79.79 C(22), 52.43 C(12)/C(19), 52.38 C(12)/C(19), 52.00
C(19)/C(12), 51.90 C(19)/C(12), 51.01 C(3), 36.64 C(4), 28.32 C(23); HRMS calcd for
C22Cl2H(26)N3O3: 450.1351, found: 450.1351.
tert-Butyl (R)-(1-(5-acetamidoisoindolin-2-yl)-3-(2,4-dichlorophenyl)-1-
oxopropan-2-yl)carbamate (138)
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To isoindoline 135 (100 mg, 0.58 mmol), N -Boc-(R)-2,4-dichlorophenylalanine (201
mg, 0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (109 mg, 0.6 mmol)
and anyhdrous 1-hydroxybenzotriazole (122 mg, 0.9 mmol) in dimethylformamide
(3 mL) was added N,N -diisopropylethylamine (0.8 mL, 4.5 mmol), the mixture was
then stirred for 24 h at 20 ℃. The mixture was the diluted with ethyl acetate
(20 mL) and washed with water (3 x 20 mL). The combined aqueous fractions
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were re-extracted with ethyl acetate (3 x 20 mL) and the combined organic lay-
ers were washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL)
and brine (20 mL) before being dried over magnesium sulfate and evaporated. The
residue was purified by silica column chromatography (ethyl acetate) to give 138
(143 mg, 52%) as a white solid, m.p. 196 - 197 ℃; νmax (cm
−1): 3281 (NH),
2920, 2850 (CH), 1703 (NHC=O), 1640 (CHC=O); 1H NMR (500 MHz, chloroform-
d, 2 rotamers) δ ppm 8.26, 8.08 (1H, br.s, aryl), 7.65, 7.50 (1H, s, aryl), 7.34
(1H, d, J=6.3 Hz, aryl), 7.00 - 7.21 (3H, m, aryl), 5.45 (1H, t, J=9.0 Hz, H(5)),
4.48 - 4.86 (5H, m, H(3),H(12),H(19)), 3.14 (1H, dd, J=13.6, 5.8 Hz, H(4)), 2.85 -
3.02 (1H, m, H(4)), 2.15 (3H, d, J=7.4 Hz, H(22)), 1.26 - 1.37 (9H, m, 3H(25));
13C NMR (126 MHz, chloroform-d, 2 rotamers) δ ppm 170.07 C(2)/C(21), 170.01
C(2)/C(21), 168.96 C(21)/C(2), 168.84 C(21)/C(2), 155.32 C(23), 155.18 C(23), 138.26,
138.08, 136.73, 136.54, 135.14, 133.73, 133.68, 132.84, 132.75, 131.28, 130.96, 129.32,
129.27, 127.09, 123.16, 123.07, 119.55, 119.35 C, 114.45, 114.32, 80.16 C(24), 80.05
C(24), 52.46 C(12)/C(19), 52.30 C(12)/C(19), 52.03 C(19)/C(12), 51.95 C(19)/C(12), 51.03
C(3), 36.62 C(4), 36.58 C(4), 28.32 3C(2), 24.53 C(22), 24.47 C(22); HRMS calcd for
C24H27N3Cl2O4: 4923.1457 (M+H), found: 492.1460.
1-(2-Benzylisoindolin-5-yl)-N -methylmethanamine (140)
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To amide 126a (255 mg, 0.96 mmol) in dry tetrahydrofuran was added lithium
aluminium hydride in tetrahydrofuran (1.5 mL, 1.5 mmol) dropwise at 0 ℃ with
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stirring under an atmosphere of nitrogen. The solution was allowed to reach 23 ℃
and stirred for 30 min. The mixture was heated at reflux for 19 h and additional
tetrahydrofuran was added (5 mL), after a further 7.5 h at reflux the mixture was
cooled to 0℃ and was quenched with water (1 mL). The product was extracted with
ethyl acetate (2 x 20 mL), washed with brine, dried over magnesium sulfate and the
solvent evaporated. the residue was purified by silica column chromatography (92%
ethyl acetate 5% methanol 2% ammonia .880) to give 140 (169 mg, 75%) as a
white solid, 1H NMR (500 MHz, chloroform-d) δ ppm 7.22 - 7.54 (5H, m, aryl),
7.02 - 7.21 (3H, m, aryl), 3.91 (6H, d, J=1.9 Hz, H(7),H(9),H(10)), 3.71 (2H, d,
J=1.9 Hz, H(13)), 2.33 - 2.53 (3H, m, H(12)), 1.47 - 1.85 (1H, br.s, H(11));
13C NMR
(126 MHz, chloroform-d) δ ppm 140.67 C(14), 139.21 C(3)/C(4), 138.66 C(4)/C(3),
128.86 C(15),C(19), 128.46 C(16),C(18), 127.18, 126.89, 122.34, 122.28, 60.40 C(13),
58.97 C(7)/C(9), 58.80 C(9)/C(7), 56.03 C(10), 35.88 C(12); HRMS calcd for C17H21N2:
253.1705, found: 253.1704.
tert-Butyl ((2-benzylisoindolin-5-yl)methyl)(methyl)carbamate(141)
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To amine 140 (169 mg, 0.67 mmol) in tert-butanol (2 mL) was added dropwise
with stirring, di-tert-butyl dicarbonate (161 mg, 0.74 mmol) in tert-butanol (1 mL).
the mixture was strired for 2.5 h and the solvent was evaporated. The residue was
purified by silica column chromatography (50% hexane 50% diethyl ether) to give
141 (138 mg, 58%) as a yellow oil, νmax (cm
−1): 3080 (CH), 2783 br. (NH), 1687
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(C=O); 1H NMR (500 MHz, chloroform-d, 2 rotamers) δ ppm 7.43 (2H, d, J=7.5
Hz, H(22),H(26)), 7.36 (2H, t, J=7.5 Hz, H(23),H(25)), 7.27 - 7.32 (1H, m, aryl), 7.14
(1H, d, J=7.2 Hz, aryl), 7.00 - 7.10 (2H, m, aryl), 4.34 - 4.46 (2H, m, H(10)), 3.92
(6H, d, J=2.3 Hz, H(7),H(9),H(20)), 2.64 - 2.94 (3H, m, 3H(12)), 1.40 - 1.62 (9H,
m, 3H(16));
13C NMR (126 MHz, chloroform-d, 2 rotamers) δ ppm 156.29 C(13),
155.89 C(13), 140.84, 139.44, 139.16, 136.84, 128.94, 128.89, 128.55, 127.29, 122.48,
79.82 C(15), 79.65 C(15), 60.43 C(20), 58.99 C(7)/C(9), 58.81 C(9)/C(7), 52.65 C(10),
51.94 C(10), 33.85 C(12), 28.62 3C(2); HRMS calcd for C22H28N2O): 352.2145 (M+H),
found: 352.2144.
tert-Butyl (isoindolin-5-ylmethyl)(methyl)carbamate (142)
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To 141 (315 mg, 0.89 mmol in methanol (5 mL) was added 30% palladium on carbon
(20 mg) and Pearlman’s catalyst (20 mg). The suspension was stirred vigorously
under an atmosphere of hydrogen for 24 h at 30 ℃. The catalyst was removed by
filtration through celite and the filtrate evaporated. The residue was purified by sil-
ica column chromatography (90% ethyl acetate 7% methanol 3% 0.880 ammonia) to
give 142 (161 mg, 69%) as a dark yellow oil, νmax (cm
−1): 2970 (CH), 1683 (C=O);
1H NMR 500 MHz, chloroform-d, 2 rotamers) δ ppm 7.16 (1H, d, J=7.5 Hz, aryl),
6.98 - 7.13 (2H, m, aryl), 4.38 (2H, s, H(10)), 4.17 (4H, s, H(7),H(9)), 2.68 - 2.89
(3H, m, H(12)), 2.45 - 2.61 (1H, m, H(8)), 1.45 (9H, s, H(17));
13C NMR (126 MHz,
chloroform-d, 2 rotamers) δ ppm 156.24 C(13), 155.87 C(13), 142.39, 140.94, 136.86,
126.48, 126.00, 122.39, 121.78, 121.29, 79.74 C(16), 79.68 C(16), 52.97 C(7)/C(9),
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52.81 C(9)/C(7), 52.58 C(10), 51.89 C(10), 33.90 C(12), 28.56 C(17); HRMS calcd for
C15H23N2O2: 263.1760, found: 263.1763.
tert-Butyl (R)-((2-(2-((tert-butoxycarbonyl)amino)-3-(2,4-dichloro-
phenyl)propanoyl)isoindolin-5-yl)methyl)(methyl)carbamate
(143)
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To isoindoline 142 (158 mg, 0.6 mmol), N -Boc-(R)-2,4-dichlorophenylalanine (201
mg, 0.6 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (131 mg, 0.72 mmol)
and anyhdrous 1-hydroxybenzotriazole (122 mg, 0.9 mmol) in dimethylformamide
(5 mL) was added N,N -diisopropylethylamine (0.89 mL, 5.12 mmol), the mixture
was then stirred for 24 h h at 20 ℃. The mixture was the diluted with ethyl ac-
etate (20 mL) and washed with water (3 x 20 mL). The combined aqueous fractions
were re-extracted with ethyl acetate (3 x 20 mL) and the combined organic lay-
ers were washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL)
and brine (20 mL) before being dried over magnesium sulfate and evaporated. The
residue was purified by silica column chromatography (50% ethyl acetate 50% hex-
ane) to give 143 (291 mg, 84%) as a white solid; νmax (cm
−1): 3294 br. (NH),
2973, 1690 (NHC=O), 1640 (CHC=O); 1H NMR (500 MHz, chloroform-d, mixture
of rotamers) δ ppm 7.34 - 7.40 (1H, m, aryl), 7.19 (5H, m, aryl), 5.35 (1H, d, J=9.0
Hz, H(5)), 5.01 (1H, d, J=13.6 Hz, H(12)/H(19)), 4.88 (1H, s, H(4)), 4.82 (1H, d,
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J=15.8 Hz, H(19)/H(12)), 4.58 - 4.71 (2H, m, H(12),H(19)), 4.42 (2H, s, H(20)), 3.17
(1H, dd, J=13.4, 6.0 Hz, H(4)), 3.04 (1H, dd, J=13.4, 7.9 Hz, H(4)), 2.81 (3H, s,
H(22)), 1.48 (9H, s, 3 x 3H(28)), 1.27 - 1.40 (9H, s, 3 x 3H(22));
13C NMR (126 MHz,
chloroform-d, mixture of rotamers) δ ppm 170.26 C(2), 155.08 C(23),C(26), 138.43,
138.18, 136.39, 136.33, 135.20, 134.89, 133.68, 132.99, 132.85, 129.35, 127.12, 127.32
br., 123.09, 122.93, 121.99 br., 79.95 C(24),C(27), 52.38 C(12)/C(19), 52.32 C(12)/C(19),
52.26 C(19)/C(12), 52.20 C(19)/C(12), 51.06 C(3), 36.73 C(4), 34.11 C(20), 34.07 C(20),
28.57 (3C25/3C28), 28.56 (3C28/3C25), 28.36 3C(2); HRMS calcd for C29H37N3O5:
577.2105, found: 577.2108.
(R)-2-Amino-3-(2,4-dichlorophenyl)-1-(5-((methylamino)methyl)-
isoindolin-2-yl)propan-1-one dihydrochloride (144)
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N -Boc protected amide 143 (291 mg, 0.5 mmol) was dissolved in dry diethyl ether
(10 mL). Hydrogen chloride was bubbled through the solution with vigorous stirring
for 1 h. The precipitate was filtered by gravity filtration through filter paper in a
funnel that was on top of a flask of boiling ether 144 (196 mg, 87%) as a cream
solid, [α]26
D
methanol: -34.2°; νmax (cm
−1): 3437 br. (NH3), 2789 br. (NH3), 1649
(C=O); 1H NMR (500 MHz, DMSO-d6) δ ppm 9.62 (2H, br.s, H(24)), 8.75 (3H, br.s,
H(6)), 7.60 (1H, t, J=1.9 Hz, aryl), 7.50 (3H, s, aryl), 7.37 - 7.42 (2H, m, aryl),
7.34 (1H, d, J=7.9 Hz, aryl), 5.09 (1H, m, J=17.3, 15.4 Hz, H(15)/H(22)), 4.74 (1H,
257
Materials and Methods Simon O.R. Greenwood
dd, J=16.2, 3.8 Hz, H(22)/H(15)), 4.54 (1H, dd, J=16.2, 4.5 Hz, H(22)/H(15)), 4.33
- 4.46 (1H, m, H(4)), 4.25 (1H, dd, J=15.4, 12.0 Hz, H(15)/H(22)), 4.07 (2H, br.s,
H(23)), 3.30 - 3.35 (1H, m, H(5)), 3.26 (1H, dd, J=13.6, 7.9 Hz, H(5));
13C NMR (151
MHz, DMSO-d6) δ ppm 166.59 C(2), 136.61, 136.28, 136.00, 135.61, 134.59, 134.56,
133.60, 133.58, 133.08, 133.07, 131.73, 131.67, 129.64, 129.55, 128.88, 127.69, 124.70,
124.43, 123.29, 123.04, 51.94 C(23), 51.59 C(5), 51.57 C(5), 50.80 C(15)/C(22), 50.76
C(15)/C(22), 50.03 C(22)/C(15), 49.97 C(22)/C(15), C, 33.32 C(5)/C(25), 33.28 C(5)/C(25),
31.77 C(25)/C(5), 31.72 C25/5; HRMS calcd for C19H22N3Cl2O2: 378.1140 (M+H),
found: 378.1144.
N -(2-Benzylisoindolin-5-yl)-2-phenylacetamide (145)
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Nitroisoindoline 120 (520 mg, 1.9 mmol) in methanol (10 mL) was stirred with
10% palladium on carbon (20 mg) under an atmosphere of hydrogen for 1 h. The
catalyst was removed by filtration through celite and the solvent was evaporated.
The residue was dissolved in dichloromethane and triethylamine (0.8 mL, 5.7 mmol)
was added. Phenylacetyl chloride (0.28 mL, 2.1 mmol) was added dropwise and
the solution was stirred for 1 h. The mixture was diluted with dichloromethane
(10 mL), washed with aqueous saturated sodium hydrogen carbonate, dried over
magnesium sulfate and the solvent evaporated. The residue was purified by silica
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column chromatography (75% ethyl acetate 25% hexane) to give 145 as a white
solid (368 mg, 54%), m.p. 150-152 ℃; 1H NMR (500 MHz, chloroform-d) δ ppm
7.27 - 7.45 (10H, m, aryl), 6.96 - 7.19 (3H, m, aryl), 3.88 (4H, s, H(2),H(5)), 3.86 (2H,
s, H(20)), 3.72 (2H, s, H(12));
13C NMR (126 MHz, chloroform-d) δ ppm 169.06 C(11),
141.21, 138.97, 136.50, 136.43, 134.55, 129.61, 129.31, 128.85, 128.48 C, 127.73,
127.24, 122.60, 118.56, 114.45, 60.32 C(20), 59.05 C(2)/C(5), 58.57 C(5)/C(2), 44.90
C12; HRMS calcd for C23H22N2O): 343.1810 (M+H), found: 343.1811.
N -(2-Benzylisoindolin-5-yl)-3-phenylpropanamide (146)
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Nitroisoindoline 120 (210 mg, 0.74 mmol) was dissolved in methanol and stirred
vigorously with 10% Pd/c catalyst under an atmosphere of hydrogen for 2 h. The
catalyst was removed by filtration through celite and the filtrate was evaporated
to give a cream solid (174 mg). This was dissolved in dichloromethane (10 mL),
triethylamine (0.31 mL, 2.2 mmol) was added and the solution was cooled to 0
℃ before dropwise addition of hydrocinnamoyl chloride (0.14 mL, 0.77 mmol), the
mixture was then stirred for 15 min at 20 ℃. The reaction was quenched with
the addition of water (5 mL) and the organic phase was washed with saturated
aqueous sodium hydrogen carbonate, dried over magnesium sulfate and the solvent
was evaporated. The crude residue was purified by column chromatography (25%
hexane 75% ethyl acetate) to give 146 (238 mg, 90%) as a cream solid, m.p. 138-
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139.5 ℃; νmax (cm
−1): 3286 br. (NH), 2782, 1665 (C=O); 1H NMR (500 MHz,
chloroform-d) δ ppm 7.39 - 7.44 (2H, m, aryl), 7.33 - 7.39 (3H, m, aryl), 7.27 - 7.32
(3H, m, aryl), 7.18 - 7.24 (3H, m, aryl), 7.11 (1H, dd, J=8.1, 1.5 Hz, H(2)), 7.05
(1H, d, J=8.1 Hz, H(1)), 3.90 (2H, s, H(21)), 3.87 (4H, s, 2H(7),2H(9)), 3.03 (2H, t,
J=7.7 Hz, 2H(12)), 2.62 (2H, t, J=7.7 Hz, 2H(14));
13C NMR (151 MHz, chloroform-
d) δ ppm 170.62 C(11), 141.23, 140.81, 139.09, 136.66, 136.33, 128.93, 128.75, 128.56,
128.53, 127.31, 126.49, 122.66, 118.84, 114.75, 60.40 C(21), 59.11 C(7)/C(9), 58.65
C(9)/C(7), 39.50 C(12), 31.73 C(14); HRMS calcd for C24H24N2O 356.2883, found:
356.1881.
N -(Isoindolin-5-yl)-2-phenylacetamide (147)
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N -benzylisoindoline 145 (368 mg, 1.03 mmol) was stirred in methanol (5 mL) with
30% palladium on carbon (37 mg) and Pearlmans’ catalyst (37 mg) and stirred
vigorously under an atmosphere of hydrogen for 22 h. The catalyst was removed
by filtration through celite and the solvent evaporated. The residue was purified by
silca column chromatography (85% ethyl acetate 10% methanol 5% 0.880 ammonia)
to give 147 (164 mg, 63%) as a white solid which degrades rapidly upon exposure
to air, 1H NMR (500 MHz, CD3OD) δ ppm 7.54 (1H, s, H(9)), 7.29 - 7.38 (5H, m,
aryl), 7.21 - 7.27 (1H, m, aryl), 7.19 (1H, d, J=7.9 Hz, aryl), 4.11 (4H, d, J=6.4 Hz,
H(2),H(5)), 3.65 (2H, s, H(12));
13C NMR (126 MHz, CD3OD) δ ppm 172.28 C(11),
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142.78, 138.96, 137.80, 136.87, 130.13, 129.60, 127.95, 123.53, 120.36, 115.53, 53.11
C(2)/C(5), 52.69 C(5)/C(2), 44.67 C(12).
N -(Isoindolin-5-yl)-3-phenylpropanamide (148)
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N -Benzylisoindoline146 (283 mg, 0.67 mmol), 30% palladium on carbon (30 mg)
and Pearlman’s catalyst (50 mg) and in methanol (12 mL) was stirred vigorously
at 30 ℃ under an atmosphere of hydrogen for 24 h. The catalyst was removed by
filtration through celite and the solvent evaporated. The residue was purified by
silica chromatography (85% ethyl acetate 10% methanol 5% ammonia .880) to give
the amine 148 (125 mg, 70%) as a cream solid, m.p. 137-138.5 ℃; νmax (cm
−1):
3200-3400 (NH), 3128-2576 (NH), 1658 (C=O); 1H NMR (600 MHz, CD3OD) δ
ppm 7.50 (1H, s, H(4)), 7.29 (1H, dd, J=8.1, 1.7 Hz, H(2)), 7.19 - 7.26 (4H, m, aryl),
7.10 - 7.18 (2H, m, aryl), 4.02 - 4.13 (4H, m, 2H(7),2H(9)), 2.96 (2H, t, J=7.7 Hz,
H(12)), 2.63 (2H, t, J=7.7 Hz, H(14));
13C NMR (151 MHz, chloroform-d) δ ppm
173.53 C(11), 142.78, 142.19, 138.92, 137.70, 129.53, 129.43, 127.27, 123.51, 120.35,
115.54, 53.15 C(7)/C(9), 52.72 C(9)/C(7), 39.83 C(12), 32.85 C(14). HRMS calcd for
C17H18N2O: 266.1414, found: 266.1417.
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tert-Butyl (R)-(3-(2,4-dichlorophenyl)-1-oxo-1-(5-(2-phenylacetamido)-
isoindolin-2-yl)propan-2-yl)carbamate (149)
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To isoindoline 147 (164 mg, 0.65 mmol), N -Boc-(R)-2,4-dichlorophenylalanine (217
mg, 0.65 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (142 mg, 0.78 mmol)
and anyhdrous 1-hydroxybenzotriazole (131 mg, 0.98 mmol) in dimethylformamide
(3 mL) was added N,N -diisopropylethylamine (0.96 mL, 5.53 mmol), the mixture
was then stirred for 24 h at 20 ℃. The mixture was then diluted with ethyl acetate
(20 mL) and washed with water (3 x 20 mL). The combined aqueous fractions were
re-extracted with ethyl acetate (2 x 20 mL) and the combined organic layers were
washed with brine (50 mL) before being dried over magnesium sulfate and evapo-
rated. The residue was purified by silica column chromatography (65% ethyl acetate
35% hexane) and recrystallised from ethyl acetate to give 149 (192 mg, 52%) as a
white solid, m.p. (223-224℃); [α]26
D
chloroform: 25.2°; νmax (cm
−1): 3292 br. (NH),
1687 (NHC=O), 1636 (CHC=O); 1H NMR (500 MHz, chloroform-d) δ ppm 7.52
(1H, br.s, H(14)), 7.38 - 7.46 (2H, m, aryl), 7.34 (4H, m, aryl), 7.06 - 7.22 (5H, m,
aryl), 5.33 (1H, d, J=8.35 Hz, H(5)), 4.94 (1H, d, J=12.93 Hz, H(12)/H(19)), 4.80
- 4.88 (1H, m, H(19)/H(12)), 4.71 - 4.80 (1H, m, H(19)/H(12)), 4.50 - 4.66 (2H, m,
H(12),H(19)), 3.74 (2H, s, H(22)), 3.15 (1H, dd, J=13.48, 6.23 Hz, H(4)), 2.92 - 3.08
(1H, m, H(4)), 1.60 (1H, br.s, H(20)), 1.28 - 1.44 (9H, m, 3 x 3H(31));
13C NMR (126
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MHz, chloroform-d) δ ppm 170.19 C(2), 169.29 C(21), 155.08 C(29), 137.69, 137.50,
136.87, 136.80, 135.18, 134.35, 133.71, 132.95, 132.91, 132.84, 131.76, 131.73, 129.62,
129.42, 129.34, 127.89, 127.12, 123.28, 123.17, 119.72, 119.56, 114.55, 114.45, 79.98
C(30), 52.40 C(12)/C(19), 52.07 C(19)/C(12), 51.07 C(3), 44.93 C(22), 36.73 C(4), 28.36
3C(2), HRMS calcd for C30H32N3Cl2O4: 568.1770 (M+H), found: 568.1746.
tert-Butyl (R)-(3-(2,4-dichlorophenyl)-1-oxo-1-(5-(3-phenylpropan-
amido)isoindolin-2-yl)propan-2-yl)carbamate (150)
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Isoindoline 148 (125 mg, 0.47 mmol), N -Boc-(R)-2,4-dichlorophenylalanine (156 mg,
0.47 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (80 mg, 0.52 mmol)
and anyhdrous 1-hydroxybenzotriazole (86 mg, 0.56 mmol) in dimethylformamide
(3 mL) was added N,N -diisopropylethylamine (0.67 mL, 4.0 mmol), the mixture
was then stirred for 24 h at 20 ℃. The mixture was the diluted with ethyl acetate
(20 mL) and washed with water (3 x 20 mL). The combined aqueous fractions were
re-extracted with ethyl acetate (2 x 20 mL) and the combined organic layers were
washed with brine (50 mL) before being dried over magnesium sulfate and evapo-
rated. The residue was purified by silica column chromatography (35% hexane 65%
ethyl acetate) to give 150 (143 mg, 52%) as a cream solid, m.p. 195-197 ℃; νmax
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(cm−1): 3424-3300 (NH), 1687 (NHC=O), 1638 (CHC=O); 1H NMR (600 MHz,
chloroform-d, mixture of rotamers) δ ppm 7.60 - 7.79 (1H, m, aryl), 7.41 - 7.54 (1H,
m, aryl), 7.27 - 7.40 (3H, m, aryl), 7.07 - 7.26 (6H, m, aryl), 6.97 (1H, d, J=7.5 Hz,
aryl), 5.35 - 5.46 (1H, m, H(5)), 4.52 - 4.85 (5H, m, H(3),H(12),H(19)), 3.12 - 3.20 (1H,
m, H(4)/H(22)), 3.02 - 3.11 (2H, m, H(4),H(22)), 2.88 - 3.02 (1H, m, H(22)/H(4)), 2.59 -
2.76 (2H, m, H(23)), 1.23 - 1.40 (9 H, m, 3 x 3H(32))
13C NMR (151 MHz, chloroform-
d, mixture of rotamers) δ ppm 170.89 C(2)/C(21), 170.71 C(2)/C(21), 170.13 C(21)/C(2),
170.01 C(21)/C(2), 155.32 C(30), 155.15 C(30), 140.78, 140.68, 137.91, 137.82, 136.85,
136.70, 135.20, 135.18, 133.78, 133.73, 132.91, 132.89, 132.78, 131.48, 131.12, 129.40,
129.34, 128.79, 128.52, 128.50, 127.15, 127.13, 126.54, 126.52, 123.25, 123.16, 119.58,
119.35, 114.55, 114.47, 80.19 C(31), 80.06 C(31), 52.48 C(12)/C(19), 52.32 C(12)/C(19),
52.07 C(19)/C(12), 52.03 C(19)/C(12), 51.01 C(4), 39.54 C(22), 36.77 C(23), 31.75 C(4),
31.63 C(4), 28.38 C(32); HRMS calcd for C31H33N3Cl2O4: 581.1843, found: 581.1843.
(R)-N -(2-(2-Amino-3-(2,4-dichlorophenyl)propanoyl)isoindolin-5-yl)-2-
phenylacetamide hydrochloride (151)
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N -Boc protected amide 149 (150 mg, 0.26 mmol) was dissolved in diethyl ether
(10 mL) and dichloromethane (15 mL) and hydrogen chloride was bubbled through
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the solution with vigorous stirring for 1 h. The precipitate was filtered by gravity
filtration through filter paper in a funnel that was on top of a flask of boiling ether
151 (125 mg, 95%) as a grey solid, m.p. (decomp. 130 ℃); [α]25
D
c=1 methanol:
-30.9°; νmax (cm
−1): 2858 br. (NH3), 1644 (C=O);
1H NMR (500 MHz, chloroform-
d mixture of rotamers) δ ppm 10.46 (1H, d, J=3.2 Hz, H(20)), 8.49 (3H, d, J=2.6
Hz, H(5)), 7.66 - 7.75 (1H, m, aryl), 7.62 (1H, d, J=1.1 Hz, aryl), 7.43 - 7.52 (2H,
m, aryl), 7.39 (1H, dt, J=8.3, 1.9 Hz, aryl), 7.33 - 7.37 (2H, m, aryl), 7.31 (2H,
t, J=7.5 Hz, aryl), 7.16 - 7.28 (2H, m, aryl), 4.93 - 5.05 (1H, m, H(12)/H(19)), 4.64
- 4.76 (1H, m, H(19)/H(12)), 4.45 - 4.58 (1H, m, H(19)/H(12)), 4.34 - 4.45 (1H, m,
H(3)), 4.17 - 4.30 (1H, m, H(12)/H(19)), 3.65 (2H, d, J=3.2 Hz, H(22)), 3.26 (2H, d,
J=6.8 Hz, H(4));
13C NMR (126 MHz, chloroform-d) δ ppm 169.29 C(2)/C(21), 166.50
C(21)/C(2), 166.47 C(21)/C(2), 139.06, 139.00, 136.31, 136.12, 136.11, 135.69, 134.62,
133.62, 133.59, 133.12, 131.55, 130.22, 129.66, 129.16, 129.15, 128.92, 128.29, 127.69,
126.53, 123.19, 122.93, 118.82, 118.75, 113.47, 113.15, 64.96, 52.25 C(12)/C(19), 51.86
C(12)/C(19), 51.76 C(12)/C(19), 51.36 C(12)/C(19), 49.99 C(3), 43.27 C(22), 40.04 C(22),
33.36 C(4), 33.28 C(4), HRMS calcd for C25H23N3Cl2O2: 468.1246 (M+H), found:
468.1236.
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(R)-N -(2-(2-Amino-3-(2,4-dichlorophenyl)propanoyl)isoindolin-5-yl)-3-
phenylpropanamide hydrochloride (152)
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150 (143 mg, 0.24 mmol) was dissolved in a mixture of diethyl ether (5 mL) and
dichloromethane (13 mL). hydrogen chloride was bubbled through the stirred solu-
tion for 1.5 h. The precipitate was filtered by gravity filtration through filter paper
in a funnel that was on top of a flask of boiling ether 152 (76 mg, 61%) as a white
solid, m.p. (decomp. 170 ℃) ; [α]26
D
methanol: -30.5°; νmax (cm
−1): 2855 br. (NH3),
1649 (C=O); 1H NMR (600 MHz, DMSO-d6, 2 rotamers) δ ppm 10.23 (1H, s, H(20)),
8.59 (3H, br.s, 3H(5)), 7.70 (1H, d, J=18.4 Hz, aryl), 7.63 (1H, t, J=2.4 Hz, aryl),
7.42 - 7.51 (2H, m, aryl), 7.38 - 7.42 (1H, m, aryl), 7.15 - 7.32 (6H, m, aryl), 5.02
(1H, d, J=13.7 Hz, H(12)/H(19)), 4.97 (1H, d, J=13.7 Hz, H(12)/H(19)), 4.72 (1H, d,
J=16.0 Hz, H(19)/H(12)), 4.69 (1H, d, J=16.0 Hz, H(19)/H(12)), 4.53 (1H, d, J=16.0
Hz, H(19)/H(12)), 4.49 (1H, d, J=16.0 Hz, H(19)/H(12)), 4.33 - 4.44 (1H, m, H(3)),
4.28 (1H, d, J=13.7 Hz, H(12)/H(19)), 4.22 (1H, d, J=13.7 Hz, H(12)/H(19)), 3.20 -
3.33 (2H, m, 2H(4)), 2.90 (2H, t, J=7.7 Hz, 2H(22)), 2.64 (2H, t, J=7.7 Hz, H(23));
13C NMR (151 MHz, DMSO-d6, 2 rotamers) δ ppm 170.54 C(2), 166.50 C(21), 166.47
C(21), 141.19, 139.06, 138.98, 136.31, 135.67, 134.65, 134.63, 133.62, 133.60, 133.13,
131.56, 130.04, 129.48, 128.93, 128.34, 128.29, 127.70, 125.97, 123.17, 122.92, 118.72,
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118.67, 113.38, 113.04, 52.27 C(12)/C(19), 51.86 C(12)/C(19), 51.78 C(19)/C(12), 51.36
C(19)/C(12), 50.00 C(3), 37.94 C(22), 37.91 C(22), 33.37 C(4), 33.28 C(4), 30.86 C(23);
HRMS calcd for C26H25N3Cl2O2: 481.1318 (M+H), found: 481.1319.
(S)-tert-Butyl (1-(3,4-dihydroisoquinolin-2(1H )-yl)-1-oxo-3-
phenylpropan-2-yl)carbamate (153)250
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To tetrahydroisoquinoline (0.13 mL, 1.0 mmol), N -Boc-(R)-phenylalanine (265 mg,
1.0 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg, 1.0 mmol) and
anyhdrous 1-hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethylformamide (3.0
mL) was added N,N -diisopropylethylamine (1.3 mL, 7.5 mmol), the mixture was
then stirred for 16 h at 20 ℃. The solvent was evaporated, the residue was disolved
in ethyl acetate (20 mL) and washed with water (2 x 20 mL). The combined aqueous
fractions were re-extracted with ethyl acetate (2 x 20 mL) and the combined organic
layers were washed with saturated aqueous sodium hydrogen carbonate (2 x 20
mL) and brine (20 mL) before being dried over magnesium sulfate and evaporated.
The residue was purified by silica column chromatography (25% ethyl acetate, 75%
hexane) to give 33 (221 mg, 58%) as a colourless oil, νmax (cm
−1): 3304 (NH),
1701 (NHC=O), 1637 (CHC=O); 1H NMR (500 MHz, chloroform-d, 2 rotamers) δ
ppm 6.97 - 7.30 (8H, m, aryl), 6.75 - 9.63 (1H, m, aryl), 5.52 - 5.66 (1H, m, H(5)),
4.83 - 5.00 (1H, m, H(3)), 4.73, 4.55 (J = 17.0 Hz), 4.48, 3.98 (J = 16.0 Hz, 2H,
H(12)) 3.09 - 3.85 (2H, m, 2H(20)), 2.91 - 3.05 (2H, m, H(4),H(19)), 2.26 - 2.80 (2H,
m, H(4),H(19)), 1.34 - 1.45 (9H, m, 3 x 3H(23));
13C NMR (126 MHz, chloroform-d, 2
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rotamers) δ ppm 170.77 C(2), 170.47 C(2), 155.15 C(21), 149.40 C(21), 136.49, 136.24,
134.55, 134.10, 132.79, 132.10, 129.51, 129.37, 128.65, 128.52, 128.3, 128.29, 126.96,
126.90, 126.86, 126.64, 126.60, 126.57, 126.31, 126.15, 79.78 C(22), 51.84 C(3), 51.61
C(3), 47.08, 44.55, 43.10, 40.61, 40.49, 40.24, 29.15 C(19), 28.43 C(23), 28.35 C(19);
HRMS calcd for C23H28N2O3+H
+: 381.2180, found: 381.2182.
(S)-tert-Butyl (1-(3,4-dihydroisoquinolin-2(1H )-yl)-3-(4-hydroxyphenyl)
-1-oxopropan-2-yl)carbamate (154)
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To tetrahydroisoquinoline (0.11 mL, 1.0 mmol), N -Boc-(S)-tyrosine (281 mg, 1.0
mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (182 mg, 1.0 mmol) and
anyhdrous 1-hydroxybenzotriazole (203 mg, 1.5 mmol) in dimethylformamide (3.0
mL) was added N,N -diisopropylethylamine (1.3 mL, 7.5 mmol), the mixture was
then stirred for 24 h at 20 ℃. The mixture was the diluted with ethyl acetate (20
mL) and washed with water (2 x 20 mL). The combined aqueous fractions were
re-extracted with ethyl acetate (2 x 20 mL) and the combined organic layers were
washed with saturated aqueous sodium hydrogen carbonate (2 x 20 mL) and brine
(20 mL) before being dried over magnesium sulfate and evaporated. The residue was
purified by silica column chromatography (20% ethyl acetate 80% dichloromethane)
to give 154 (220 mg, 55%) as a pale yellow solid, νmax (cm
−1): 3297 (NH), 1695
(NHC=O), 1628 (CHC=O); 1H NMR (500 MHz, chloroform-d, 2 rotamers) δ ppm
7.83, 7.65 (1H, s, H(21)) 6.81 - 7.20 (6H, m, aryl), 6.60 - 6.74 (2H, m, H(8),H(10)),
5.58 (1H, d, J=9.0 Hz, H(5)), 4.82 - 4.95 (1H, m, H(3)), 3.90 - 4.81 (2H, m, 2H(12)),
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3.60 - 3.80 (1H, m, H(20)), 3.50 - 3.61, 3.09-3.22 (1H, m, H(20)), 2.82 - 2.98 (2H, m,
H(4),H(19)), 2.63 - 2.80 (1H, m, H(4)), 2.38 (1H, m, H(19)), 1.42 (9H, s, 3 x 3H(24));
13C
NMR (126 MHz, chloroform-d, 2 rotamers) δ ppm 170.15 C(2), 170.86 C(2), 155.80
C(9)/C(22), 155.72 C(9)/C(22), 155.51 C(22)/C(9), 155.49 C(22)/C(9), 134.48, 134.07,
132.56, 132.04, 128.57, 130.56 C(7),C(11), 130.47 C(7),C(11), 128.32, 127.28, 127.12
126.99 126.73, 126.59, 126.44, 126.18, 115.58 C(8),C(10) 115.49 C(8)/C(10), 80.02
C(23), 52.06 C(3), 51.83 C(3), 47.20 C(12), 44.70 C(12), 43.21 C(20), 40.62 C(20), 39.48
C(4), 39.43 C(4) 29.14 C(19), 28.45 3C(2), 28.29 C(9); HRMS calcd for C23H28N2O4:
397.2127, found 397.2121.
N,3,4-Trimethylbenzamide (155)
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Ethyl 3,4-dimethylbenzoate (115) (534 mg, 4.37 mmol) and aqueous methylamine
(40%, 10 mL) were added to a tube which was then sealed. The mixture was stirred
for 16 h at 100 ℃. The mixture was cooled to 20 ℃ and the solvent evaporated.
The residue was then extracted into dichloromethane, washed with brine and dried
over magnesium sulfate. The solvent was then evaporated to give crude 155 as a
pale yellow solid (558 mg, 78%),1H NMR (600 MHz, chloroform-d) δ ppm 7.55 (1H,
s, H(3)), 7.48 (1H, d, J=7.9 Hz, H(6)/H(7)), 7.12 (1H, d, J=7.9 Hz, H(7)/H(6)), 6.58
(1H, br.s, H(9)), 2.96 (3H, d, J=4.9 Hz, H(12)), 2.26 (3H, s, H(10)/H(11)), 2.25 (3H,
s, H(11)/H(10));
13C NMR (151 MHz, DMSO-d6) δ ppm 168.79 C(1), 140.41, 136.88,
132.12, 129.74, 128.36, 124.43, 26.90 C(12), 19.88 C(10)/C(11), 19.82 C(11)/C(10).
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